



CURRICULUM VITAE

Guillermo Garcia-Manero, M.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Deputy Chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Chair, Faculty Senate, University of Texas MD Anderson Cancer Center, Houston, TX

Fellowship Program Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

Spain

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center

1515 Holcombe Boulevard

Unit Number: 428

Houston, TX 77030

Room Number: FC4.2042

Phone: 713-745-3428

Fax: 713-563-0289

EDUCATION

Degree-Granting Education

Colegio "Luis Vives", Palma de Mallorca, Spain, Bachillerato, 1985, Pre-Med

University of Zaragoza, School of Medicine, Zaragoza, Spain, MD, 1991, Medical Doctor

Postgraduate Training

Honorary Intern Student, University of Zaragoza, Department of Anatomical Pathology, Zaragoza, Spain, 1988-1991

Research Student, Royal Free Hospital School of Medicine, London, United Kingdom, 1989-1991

Clinical Internship and Residency, Thomas Jefferson University Hospital, Jefferson Medical College, Philadelphia, PA, 1993-1996

Clinical Fellowship, Hematology and Medical Oncology, Cardeza Foundation for Hematology Research & Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, PA, 1996-1999

CREDENTIALS

Board Certification

Internal Medicine, 1996

Medical Oncology, 1999, Recertification Date: 2016

Hematology Eligible, 1999

Licensures**Active**

Texas, TX, K9276, 2000-11/2022

Inactive

Spain, 1991

Pennsylvania, PA, MD-060834-L, 1996-12/2014

EXPERIENCE/SERVICE**Academic Appointments**

Assistant Professor, Division of Oncology, The University of Texas Health Science Center at Houston, Houston, TX, 8/1999-8/2002

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/1999-9/2005

Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Houston, TX, 6/2004-present

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2005-9/2010

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2010-present

Administrative Appointments/Responsibilities

Chief Fellow, Division of Hematology and Medical Oncology, Thomas Jefferson University, Philadelphia, PA, 1998-1999

Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2006-present

Deputy Chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2012-present

Co-Director, DNA Methylation Core, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013-2017

Fellowship Program Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2019-present

Other Appointments/Responsibilities

Emergency Room Physician, Omesa Medical Center, Palma de Mallorca, Spain, 1991-1992

Member, Memorial Hermann Hospital, Cancer Committee, Houston, TX, 8/1999-8/2002

Global MDS/AML Steering Committee, Celgene, Orlando, FL, 12/2010-present

Chair, Independent Data Monitoring Committee, GlaxoSmithKline, London, United Kingdom, 8/2011-present

Member, SWOG Leukemia Committee, Portland, OR, 2012-present

Institutional Grant Reviewer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013-present

Leader, MDS/AML Moon Shot Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013-present

Independent Data Monitoring Committee Member, GlaxoSmithKline, Billerica, MA, 6/2013-present

Chair, MDS Clinical Research Consortium, Rockville, MD, 1/2015-12/2016
Start-Up Funds Proposal Review, UT MD Anderson Cancer Center, Houston, TX, 3/2016
Chair, MDS Clinical Research Consortium, Rockville, MD, 1/2017-12/2018
Chair, Faculty Senate, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2019-5/2021
Member, American Association for the Advancement of Science, Houston, TX, 2/2021-present
Defense Chair for Dissertation, University of South Florida, Houston, TX, 11/2021
Defense Chair for Dissertation, University of Groningen, Houston, TX, 11/2021

Endowed Positions

Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/2015-present

Consultantships

Novartis, East Hanover, NJ, 2007-present
Celgene Corporation, Summit, NJ, 2007-present
Bristol-Myers Squibb, New York City, 2007-present
Merck & Co., Inc., Whitehouse Station, NJ, 2007-present
MEI Pharma, Inc., San Diego, CA, 2012-present
AstraZeneca Anifrolumab program, Gaithersburg, MD, Advisor to the Data Safety Monitoring Board, 9/2015
Incyte Corporation, Dallas, Texas, Advisory Board Member, 8/2016-2017

Military or Other Governmental Service

Spanish Armed Forces, Infantry Regiment Palma 47, Medical Corporal, 2/1992-11/1992

Institutional Committee Activities

MD Anderson International Spain Committee, Member, 4/2001-present
Clinical Research Committee I, Member, 6/2001-6/2004
Transfusion Committee, Member, 5/2002-present
DoCM Research Sub-Committee, Member, 9/2003-present
Division of Cancer Medicine Fellowship Committee, Member, 2/2005-2012
Clinical Research Committee II, Member, 6/2005-8/2006
Faculty Senate, Senator, 9/2005-9/2008
Institutional Biosafety Committee, Member, 2006
Institutional Research Grant Committee, Reviewer, 2007-present
Clinical Research Impact Committee, Member, 2008-present
MD Anderson Moon Shots Steering Committee, Member, 2012-present
Cancer Genetics and Epigenetics Core, Member, 2012-present
Technology Review Committee, Member, 10/2012-present
K12 Advisory Committee, Member, 12/2012-present
Multidisciplinary Research Advisory Committee (MRAC), Member, 3/2013-present
MD Anderson Mock Study Section, Member, 2014
Search Committee for Chair of the Department of Pathology, Member, 2014
Search Committee for GU Medical Oncology Research Faculty, Member, 2/2014-7/2014

Center for Inflammation and Cancer, Member, 5/2014-present
Division of Cancer Medicine Executive Meeting, Research faculty representative, 11/2014-present
Immunotherapy Executive Committee, Voting member, 2015-2017
Translational Research Strategic Planning--Therapeutic Discovery & Development Subcommittee, Member, 3/2015-present
ASCO Scientific Program Committee, Member, 1/2016-12/2017
Promotion and Tenure Committee, Member, 1/2016-2018
Faculty Senate, Senator, 2/2016-2019
Search Committee for Emergency Medicine Chair, Member, 4/2016-9/2016
MD Anderson Physician Advisory Board, Board Member, 8/2016-present
Bridge Funding Advisory Committee, Committee Member, 10/2016-present
The 2017 Charles A. LeMaistre Outstanding Achievement Award Committee, Member, 4/2017
Executive Committee of Faculty Senate, Member, 6/2017-5/2019
ASCO Scientific Program Committee, Leader, 1/2018-2019
Clinical Research Billing Compliance Subcommittee, Member, 9/2018-present
Presidential Advisory Council, Member, 2019-present
Moon Shot FIT RFA Steering Committee, Member, 3/2019-present
President's Advisory Council, Member, 9/2019-present
LeMaistre Award Committee, Committee Member, 2020-present
Strategic Position Management Committee, Committee Member, 2/2020-present
COVID-19 Core Leadership Team, Committee Member, 3/2020-present
EC Patient Flow, Member, 6/2020-present
UT System Faculty Advisory Council, Member, 9/2020-present
Institutional Conflict of Interest, Member, 9/2021-present

HONORS AND AWARDS

Research Student Award, University of Zaragoza, 1990
Fellowship, European Society of Human Genetics, 1991
Research Award for Clinical Trainees Program, National Institutes of Health, 1994
Winner, Oncology Research Competition, Delaware Valley Hematology Oncology Association, 1998
Career Development Award, American Society of Clinical Oncology, 2001
Physician-Scientist Program Scholar, The University of Texas MD Anderson Cancer Center, 2002
Faculty Educator of the Month, The University of Texas MD Anderson Cancer Center, 2007
Faculty Scholar Award, The University of Texas MD Anderson Cancer Center, 2008
Celgene Young Investigator Award for Clinical Research in Hematology, American Society of Hematology, 2009
Emil J. Frei, III Award for Excellence in Translational Research, The University of Texas MD Anderson Cancer Center, 2009
Robert M. Chamberlain Distinguished Mentor Award 2011 Nominee, MD Anderson Postdoctoral Association, 2011
Irwin H. Krakoff Award for Excellence in Clinical Research, The University of Texas MD Anderson Cancer Center, 2013

Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2014

Honorary Member, Royal Academy of Medicine of the Balearic Islands, 2015-2017

Best Mentor of the Year, University of Texas MD Anderson Cancer Center Fellowship Program, 2017-2018

The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, The University of Texas MD Anderson Cancer Center, 2018

John Mendelsohn Lifetime Achievement Award, The University of Texas MD Anderson Cancer Center, 2020

RESEARCH

Grants and Contracts

Funded

Program Leader, 5%, MDS/AML Moon Shot, The University of Texas MD Anderson Cancer Center, 9/1/2013-8/31/2022 (\$2,106,275/year)

Principal Investigator, 1%, 2013-0901: Phase 2 Study of SGI-110 in Patients with Higher Risk MDS, 11009, Astex, 11/10/2014-5/15/2022, \$332,500 (\$110,833/year)

Principal Investigator, 1%, 2015-0617: A phase 2, open-label, single-arm rollover study to evaluate long-term safety in subjects who participated in other Celgene sponsored CC-486 (oral azacitidine) clinical trials in solid tumors and hematological disorders, 3565, Celgene Corporation, 10/22/2015-9/29/2022, \$21,858 (\$21,858/year)

Co-Investigator, 1%, Therapeutic targeting of glutamine metabolism in MDS, R01CA206210, NIH/NCI, PI - Marina Konopleva, 4/1/2016-3/31/2022, \$2,135,685 (\$423,668/year)

Principal Investigator, 1%, 2017-0256: Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome, Novartis, 3/10/2017-1/5/2023, \$339,740 (\$339,740/year)

Principal Investigator, 1%, 2016-0343: A phase II study of the combination of azacitidine and pembrolizumab for patients with MDS, 13028436, Merck and Company, 5/3/2017-5/2/2022, \$512,241 (\$512,241/year)

Principal Investigator, 3%, 2016-0757: To assess and compare overall survival (OS) between guadecitabine and treatment choice (TC) in adults with, 53682, Abbvie, 5/24/2017-5/24/2022, \$543,222 (\$543,222/year)

Principal Investigator-MDACC, 4%, Targeting IRAK 1/4 in Myelodysplastic Syndromes, R01 DK113639, NIH/NIDDK, PI - Daniel Starczynowski, 8/7/2017-5/31/2022, \$53,310 (\$10,662/year)

Co-Investigator, 2018-0911: Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents, Jazz Pharmaceuticals, Inc., PI - Guillermo Montalban Bravo, 7/5/2018-7/4/2023

Co-Principal Investigator, 5%, Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen, R01CA235622, NIH/NCI, PI - Marina Konopleva, 9/1/2018-8/31/2023, \$348,757 (\$460,137/year)

Principal Investigator, 1%, 2018-0912: A Phase II Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes, Aprea Therapeutics, 12/21/2018-12/20/2025, \$1,190,937 (\$1,190,936/year)

Collaborator, 0.6 months, Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen, R01CA235622, NIH/NCI, PI - Marina Konopleva, 1/1/2019-12/31/2023, \$348,757

Principal Investigator, 1%, 2018-0919: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate 1) Myelodysplastic Syndromes (MDS), Astex Pharmaceuticals, 2/5/2019-2/4/2026, \$373,773 (\$41,946/year)

Principal Investigator, 3%, 2018-0179: A Phase 3, Open-Label, Random Study to Compare the Efficacy and Safety of Luspatercept (ACE 536) vs Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low, or Immediate Risk (MDS) in ESA Naive Subjects who require RBC Transfusions, Celgene, 2/12/2019-2/11/2026, \$124,063 (\$124,063/year)

Principal Investigator, 1%, 2019-0400: ASTX727-06: An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), Astex Pharmaceuticals, 7/24/2019-7/23/2026, \$66,734 (\$66,734/year)

Principal Investigator, 1%, 2019-0760: Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53 Mutant Myeloid Malignancies, Aprea Therapeutics, 11/11/2019-11/10/2026, \$355,722 (\$355,722/year)

Principal Investigator, 1%, 2019-1246: A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome, Curis, 5/1/2020-4/30/2023, \$292,857 (\$292,857/year)

Principal Investigator, 1%, 2020-0025: Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with (MDS), (CMML), or (AML), Astex Pharmaceuticals, 5/17/2020-5/16/2023, \$1,627,492

Principal Investigator, 1%, 2020-0128: STRATEGIC ALLIANCE: 2020-0128 ML42089 A phase I/II study of venetoclax in combination with ASTX727 (cedazuridine/decitabine) in treatment-naive high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), Genentech Inc., 6/18/2020-6/17/2023, \$255,938 (\$255,938/year)

Principal Investigator, 1%, 2020-0546 ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome, Forty Seven Inc., 8/11/2020-8/10/2023, \$1,171,700

Principal Investigator, 1%, 2020-0572 AT148002 A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELOYDYSPLASTIC SYNDROME (MDS), ALX Oncology, 8/31/2020-8/30/2023, \$1,141,709 (\$1,141,709/year)

Principal Investigator, 1%, 2020-0129 ML42088 A phase I/II study of venetoclax in combination with ASTX727 (cedazuridine/decitabine) in treatment-naïve high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), Genentech Inc., 10/5/2020-10/4/2023, \$255,938 (\$255,938/year)

Principal Investigator, 1%, 2020-0615: A Phase 1 Study of SEA-CD70 in Myeloid Malignancies, Seattle Genetics, 10/8/2020-10/7/2023, \$3,606,370

Principal Investigator, Astex Alliance Projects, Astex, 1/1/2021, \$15,000,000

Principal Investigator, 3%, 2020-1119: Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination with Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes, Aprea Therapeutics, 3/26/2021-3/25/2024, \$488,820 (\$488,820/year)

Principal Investigator, 2%, 2020-0183: A Phase Ib, Multicenter, Open-Label Platform Study of Select Drug Combinations in Adult Patients with Lower Risk (very low, low, or intermediate risk) Myelodysplastic Syndrome, Novartis, 4/13/2021-10/31/2024, \$491,896 (\$491,896/year)

Co-Principal Investigator, 2020-0487: Phase I/II Study of SP-2577 (Seclidemstat) in Combination with Azacitidine for patients with Myelodysplastic syndromes and Chronic

Myelomonocytic Leukemia, Salarius Pharmaceuticals LLC, PI - Guillermo Montalban Bravo, 6/1/2021-5/31/2023, \$880,000 (\$880,000/year)

Principal Investigator, 3%, 2021-0497: A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications, Karopharma, 7/2021-6/2024

Co-Principal Investigator, 2020-1117: Phase I Study of Fostamatinib, a SYK inhibitor, in patients with Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia who have failed therapy with Hypomethylating Agents, Rigel Pharmaceuticals, PI - Guillermo Montalban Bravo, 8/2021-7/2024, \$400,000

Principal Investigator, 1%, 2021-0144: A Phase 1/2 study of ALX148 in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML) (ASPEN-05), ALX Oncology, 8/3/2021-8/2/2024

Principal Investigator, 5%, Targeting IL1 beta in clonal cytopenia of undetermined significance and low risk myelodysplastic syndrome, Edward P. Evans Foundation, 9/1/2021-8/31/2024, \$545,454 (\$181,818/year)

Co-Principal Investigator, 1%, 2020-0895: Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination with Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes, Stemline Therapeutics, PI - Guillermo Montalban Bravo, 1/2022-1/2025

Principal Investigator, 3%, A Single-Arm, Open-Label, Phase II Study of Sabatolimab In Combination with Azacitidine and Venetoclax In Adult Participants with High or Very High Risk Myelodysplastic Syndrome (MDS) As Per IPSS-R Criteria, Novartis, 1/2022-1/2025

Principal Investigator, 3%, 2021-0110: Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multicenter) (STIMULUS MDS-US), Novartis, 2/2022-1/2025, \$303,527

Principal Investigator, An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes, MD Anderson, 4/15/2022-4/14/2024, \$250,000

Principal Investigator, 1%, 2019-0339: A Phase II, Open-Label, Study of Subcutaneous canakinumab, an Anti-IL-1 β Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, Novartis

Co-Investigator, 2019-1178: Phase I/II Study of Azacitidine in Combination with Quizartinib for patients with Myelodysplastic syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL mutations, Daiichi Sankyo, Inc., PI - Guillermo Montalban Bravo

Principal Investigator, 1%, 2020-0030: A phase II, multicenter, single arm safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy, Novartis, \$1,151,558 (\$1,151,558/year)

Principal Investigator, 1%, 2020-0180: A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (HR-MDS), Abbvie

Principal Investigator, 1%, 2020-0546: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome, Forty Seven Inc., \$863,810 (\$863,810/year)

Principal Investigator, 2%, 2020-0983: A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma, Incyte

Principal Investigator, Astex Strategic Alliance, Astex Pharmaceuticals (\$3,000,000/year)

Pending

Co-Investigator, 3%, Characterizing clonal evolution in MDS patients with HMA failure using longitudinal sequencing data and novel computational methods, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Ziyi Li, 9/1/2022-8/31/2025

Collaborator, 10%, Clinical Validation of Predictive Biomarkers of Response to Venetoclax-Based Therapy in Patients with Myelodysplastic Syndromes at the Time of Progression after Therapy with Hypomethylating Agents, NIH/NCI, PI - Simona Colla, 9/1/2022-8/31/2027, \$4,049,960 (\$499,995/year)

Principal Investigator, 6%, Specialized Center of Research: An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes, Leukemia and Lymphoma Society, 10/1/2022-9/30/2027, \$4,999,992

Other

N/A

Completed

Principal Investigator, 10%, Non salary support to develop a peptide based immunotherapy using EGFRvIII, NIH/NCI, 1998, \$50,000

Principal Investigator, 5%, Study of the role of the EGF receptor and GM-CSF receptor b chain receptor complex in prostate cancer, Association for the Cure of Prostate Cancer, 1998, \$50,000

Principal Investigator, 5%, Study of DNA-methylation in prostate cancer, Association for the Cure of Prostate Cancer, 2000, \$50,000

Principal Investigator, 10%, Immunotherapy using dinitrophenyl-modified autologous cell vaccines for patients with acute and chronic myelogenous leukemia, Ladies Leukemia League, 5/1/2000-5/1/2001, \$40,000

Principal Investigator, 10%, Peggy Howard Memorial Fund, 2001, \$82,000

Principal Investigator, 10%, Studies of DNA-methylation in acute lymphocytic leukemia, American Society of Clinical Oncology Career Development Award, 7/1/2001-6/1/2004, \$170,000

Principal Investigator, 80%, MDACC Physician-Scientist Program, 9/1/2002-8/1/2005, \$640,000

Co-Investigator, 20%, 1 P50 CA100632-01, NIH/NCI, PI - Hagop Kantarjian, M.D, 12/1/2002-11/30/2007, \$1,866,379

Collaborator, 10%, Epigenetic silencing and resistance to Imatinib mesylate in CML, CM020027, DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP), PI - Jean-Pierre Issa, M.D., 7/1/2003-7/31/2006, \$165,563

Principal Investigator, 20%, Cell Cycle Controlling Genes in Adult Acute Lymphoma, 5 R21 CA100067, NIH/NCI, 9/1/2003-8/31/2005, \$180,000 (\$90,000/year)

Principal Investigator, 10%, Phase I/II study of 5-aza-2'-deoxycytidine and valproic acid in patients with relapsed/refractory leukemias or myelodysplastic syndromes, 5R21CA105771, NIH/NCI, 9/1/2003-8/31/2005, \$410,000 (\$205,000/year)

Principal Investigator, 10%, Phase I/II study of 5-aza-2'-deoxycytidine and valproic acid in patients with relapsed/refractory leukemias or myelodysplastic syndromes, UTMDACC Institutional Research Grant, 5/1/2004-4/1/2006, \$50,000

Principal Investigator, 2004-0748: A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes, CS2004-00012427SP, Methygene, 12/2/2004-5/25/2009, \$112,107 (\$24,913/year)

Principal Investigator, 2004-0799: Phase I/II Study of the combination of 5-azacytidine with Valproic Acid and All-trans Retinoic acid in Patients with High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia, CS2005-00014148SP, Pharmion Corporation, 5/20/2005-12/20/2007, \$268,155 (\$53,631/year)

Project Leader, 9%, New Approaches to the Biology and Treatment of MDS, 5P01CA108631-05, NIH/NCI, PI - Hagop M. Kantarjian, 6/21/2005-5/31/2011, \$1,319,793 (\$112,912/year)

Investigator, 2005-0417: A dose and schedule finding study of azacitidine maintenance therapy after allogeneic hematopoietic stem cell transplantation for AML and MDS, CS2005-14936, Pharmion, PI - Marcos de Lima, 8/29/2005-11/17/2010, \$44,099 (\$979/year)

Principal Investigator, 5%, Epigenetic and therapeutic profiling of chronic lymphocytic leukemia, CLL Global Research Foundation, 10/1/2005-10/1/2007 (\$99,750/year)

Principal Investigator, 2005-0659: A phase I/II study of MGCD0103 (MG-0103) in combination with azacitidine in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia, CS2005-00015410SP, Methygene Inc., 10/13/2005-9/25/2011, \$355,399 (\$71,080/year)

Principal Investigator, Phase I Study of Low-Dose Azacitidine Combined with Valproic Acid in Patients with Advanced Cancers, CS2006-00015656JW, Pharmion Corporation, 3/9/2006-3/9/2010, \$54,400 (\$11,350/year)

Principal Investigator, 1%, 2005-0913: Phase 2 Study of Proteinase 3 PR1 Peptide Vaccine in MDS, CS2006-00016206LE, The Vaccine Company, 3/31/2006-3/31/2010, \$210,000 (\$52,500/year)

Project Leader, 1%, Role of Aberrant DNA Methylation in the Pathogenesis and Prognosis of Acute Lymphocytic Leukemia, P50 CA100632, NIH/NCI, PI - Issa, 9/15/2006-4/30/2007, \$25,600 (\$25,600/year)

Principal Investigator, 10%, Prognostic and Therapeutic Implications of Aberrant DNA Methylation In Acute Lymphocytic Leukemia, 6173-07, Leukemia and Lymphoma Society, 10/1/2006-9/30/2009, \$404,646 (\$134,882/year)

Principal Investigator, 1%, 2006-0474: A Phase II Study of MGCD0103 (MG-0103) in Patients with Acute Myelogenous Leukemia/High Risk MDS who are Elderly and have Previously Untreated Disease or who are Adult and have Relapsed/Refractory, CS2006-00018396JW, Methygene Inc., 10/11/2006-5/21/2009, \$346,600 (\$69,320/year)

Principal Investigator, 1%, 2006-0722: A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents, CS2007-00018704, Amgen, 12/8/2006-10/14/2010, \$2,371,875 (\$474,377/year)

Mentor, 1%, K12 CA088084, Paul Calabresi Clinical Oncology Award Program, PI - Tapan Kadia, 12/10/2006-8/31/2008 (\$82,000/year)

Principal Investigator, 1%, 2006-0784: An Open-Label Dose-Escalation Study to Assess the Safety and Bioavailability of Single Oral Doses of Azacitidine in Patients with Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML, or Solid Tumors, CS2007-00018852RG, Pharmion, 1/3/2007-1/31/2010, \$94,375 (\$31,458/year)

Principal Investigator, 2005-0895: Phase 1 Study of Low Dose 5-Aza-2-Deoxycytidine Administered Daily for 5 Days Every Other Week for Patients with Relapsed or Refractory Acute Lymphocytic Leukemia, The University of Texas MD Anderson Cancer Center (Commonwealth), 2/1/2007-1/31/2011, \$263,405 (\$133,649/year)

Principal Investigator, 1%, 2007-0201: A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes, CS2007-00020389RG, Merck and Company, 5/16/2007-1/12/2010, \$93,000 (\$31,000/year)

Project Leader, 1%, Global Gene Methylation Profile of CLL Patients and its Implication in Therapy, Chronic Lymphocytic Leukemia Foundation, PI - Weigang Tong, 6/1/2007-5/31/2008, \$50,000 (\$50,000/year)

Principal Investigator, 1%, Effects of the Combination of 5-azacytidine, Valproic Acid and ATRA on Malignant Cell, American Society of Clinical Oncology (ASCO), 7/1/2007-6/30/2008, \$47,500 (\$47,500/year)

Principal Investigator, 1%, 2007-0265: A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (CT), CS2007-00021062EB, Cyclacel, Ltd, 8/15/2007-8/31/2009, \$325,000 (\$81,250/year)

Principal Investigator, 1%, 2007-0405: A Phase I CT, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), CS2007-00021174JW, Pharmion Corporation, 8/28/2007-8/27/2012, \$2,160,094 (\$540,023/year)

Principal Investigator-MDACC, 5%, Highly Multiplexed Assays on the BioCD for Acute Lymphocytic Leukemia, 5R21CA125336-02, NIH/NCI, PI - David Nolte, 9/1/2007-8/31/2011, \$285,370 (\$38,961/year)

Co-Investigator, 1%, Randomized Study of Combined Epigenetic Therapy, 5R01-CA121104-05, NIH/NCI, PI - Jean-Pierre Issa, 9/1/2007-7/31/2012, \$690,000 (\$192,000/year)

Principal Investigator, 1%, 2008-0165: A Prospective, Non-Interventional Multicenter Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients (CT), CS2008-00022768JW, Novartis, 9/1/2007-9/30/2014, \$668,875 (\$95,553/year)

Principal Investigator, 10%, Phase I Study of 5-Aza-2'-Deoxycytidine in Acute Lymphocytic Leukemia, 5R21CA126457-02, NIH/NCI, 9/12/2007-8/31/2010, \$380,000 (\$12,589/year)

Principal Investigator, 1%, 2007-0763: A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza) vs. Single Agent MGCD0103 vs. Azacitidine in Combination with MGCD0103 for the Treatment of Elderly Subjects with Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic Syndrome (Clinical Trial), CS2008-00022468MA, Pharmion, 10/25/2007-1/28/2010, \$545,446 (\$148,482/year)

Principal Investigator, 1%, 2007-0528: A Phase I, Open-Label, Dose-Escalation Study of CC-11006 in Subjects with Low- or Intermediate-1- Risk Myelodysplastic Syndromes (MDS)-CT, CS2007-00021598RG, Celgene, 11/9/2007-11/2/2009, \$113,882 (\$56,941/year)

Principal Investigator, 1%, 2007-0835: Phase II study of Idarubicin, Cytarabine, and Vorinostat in patients with high-risk MDS and AML, CS2008-00022768, Merck and Company, 12/6/2007-12/31/2014, \$400,316 (\$57,188/year)

Principal Investigator, 1%, Assess Potency of JNJ-26481585 in Leukemia Cell Lines and Limited Number of Ex Vivo Samples, LS2008-00022206EB, Johnson & Johnson, 1/8/2008-1/31/2009, \$10,157 (\$10,157/year)

Investigator, 5%, CTEP study 2005-0031 (Garcia-Manero PI of clinical trial) Phase 1 Studies of Targeted Anti-Cancer Therapies, 5U01CA062461-17, NIH/NCI, PI - Razelle Kurzrock, 4/16/2008-1/7/2010, \$2,103,510 (\$420,702/year)

Principal Investigator, 1%, 2007-0848: A Phase 1 CT Dose Escalation Study of Oral SB939 when administered Thrice Weekly (every other day) for 3 weeks in a 4-week cycle in Patients with Advanced Malignancies, CS2008-00022769MA, S*Bio Pte Ltd, 6/6/2008-6/30/2016, \$1,108,160 (\$221,632/year)

Faculty mentor, 5%, Training Program in Biostatistics for Cancer Research, 5T32CA096520, NIH/NCI, PI - Gary Rosner, 8/1/2008-7/31/2013, \$1,259,160 (\$264,324/year)

Principal Investigator, 1%, 2007-0883: Randomized Open-Label Phase 4 Study of Low Dose DACOGEN for Injection (Decitabine) in Patients with Low or Intermediate-1 Risk

Myelodysplastic Syndromes (CT), CS2008-00023760LG, MGI Pharma, Inc., 8/6/2008-8/31/2013, \$1,247,980 (\$249,596/year)

Project Leader, 1%, Developmental Research Project "Histone deacetylase inhibitors in leukemia: understanding the molecular and clinical implications of their use", 5 P50 CA100632 07 DRP-10, NIH/NCI, PI - Jean-Pierre Issa, 9/1/2008-8/31/2010, \$46,321 (\$23,161/year)

Principal Investigator, 1%, 2008-0245: Phase I Study of the Histone-deacetylase Inhibitor JNJ-26481585, CS2008-00024072EB, Johnson & Johnson, 10/24/2008-10/23/2013, \$618,033 (\$123,607/year)

Principal Investigator, 1%, 2007-0713: Phase II Study LBH589 for Patients with Low or Intermediate-1 Myelodysplastic Syndrome, CS2008-00022469MA 01, Novartis, 5/1/2009-7/31/2011, \$439,733 (\$219,866/year)

Co-Investigator, 1%, 2008-0503: Randomized controlled study of post-transplant azacitidine for prevention of disease relapse, CS2009-00027148LG, Celgene, PI - Marcos de Lima, 5/8/2009-5/30/2014, \$633,662 (\$316,831/year)

Principal Investigator, 1%, 2009-0434: A Phase II CT Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML), CS2009-00029376JW, Novartis, 7/9/2009-3/31/2013, \$152,165 (\$50,722/year)

Principal Investigator, 1%, 2009-0129: A Phase 1 CT Study of Oral Argy-614 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome, CS2009-00027421JW, Array BioPharma, 7/21/2009-12/8/2014, \$340,565 (\$170,282/year)

Principal Investigator, 1%, 2007-0685: A Phase 2 Trial of Vorinostat in Combination with Azacitidine in Patients with Newly-Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome who are ineligible for other Leukemia Protocols. DRUG ONLY, CS2008-00022766/7, Merck and Company and Pharmion, 9/8/2009-7/20/2014

Principal Investigator-MDACC, 5%, Proteasome/HDAC Inhibition in Leukemia/MDS; Phase 1 Trial and Correlative Studies, 5RC2-CA148431-02, NIH/NCI, PI - Steve Grant, 9/30/2009-2/23/2012, \$351,672 (\$175,836/year)

Principal Investigator, 1%, 2010-0591: A phase 1b CT, dose-finding study of oral panobinostat (LBH589) in combination with idarubicin and cytarabine induction and high-dose cytarabine-based consolidation therapy in adult patients with AML, CS2011-0033860RG, Novartis, 10/7/2009-7/9/2012, \$130,463 (\$26,093/year)

Principal Investigator, 1%, 2010-0041: A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1risk) and transfusional iron overload (TELESTO), CS2010-00031986MA, Novartis, 10/7/2009-10/6/2014, \$3,079,270 (\$615,854/year)

Principal Investigator, 1%, 2009-0467: Phase I/II CT Study of the Combination of 5-azacitidine with Lenalidomide in patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML), CS2009-00029597MA, Celgene, 12/15/2009-12/14/2014, \$494,101 (\$247,050/year)

Principal Investigator, 1%, 2009-0619: A phase I/b, open-label, multi-center, dose-escalation study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML), CS2010-00029764JW 01, Novartis, 2/9/2010-4/30/2016, \$68,354 (\$27,342/year)

Principal Investigator, 1%, 2009-0965: Phase I Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra, TLK199 Tablets) In Combination with Lenalidomide (Revlimid) In Patients with Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS), CS2010-00031402MA, Telik, 3/18/2010-8/16/2012, \$364,164 (\$182,032/year)

Principal Investigator, 1%, Correlative Study for "A phase I/b, open-label, multi-center, dose-escalation study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in

adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML)" 2009-0619, LS2010-00031095JW, Novartis, 4/8/2010-12/31/2013, \$68,354 (\$39,060/year)

Principal Investigator, 1%, 2009-0788: A Phase 1 study evaluating the safety and pharmacokinetics of ABT-348 in subjects with Advanced Hematologic Malignancies, CS2010-00031401JW 01, Abbott, 4/9/2010-3/7/2013, \$725,614 (\$241,871/year)

Principal Investigator, 15%, Analysis of histone code alterations and JMJD3 using CHIP-seq in myelodysplastic syndromes, RP100202, Cancer Prevention & Research Institute of Texas (CPRIT), 5/1/2010-10/31/2013, \$738,580 (\$241,556/year)

Faculty Mentor, 1%, Research Training in Academic Medical Oncology, 5T32CA009666-17, NIH/NCI, PI - Waun Ki Hong, 5/3/2010-4/30/2015, \$1,763,940 (\$352,788/year)

Principal Investigator, 1%, 2009-0737: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Placebo in Subjects with Transfusion-Dependent Anemia due to IPSS Low or Intermediate-1 Risk, CS2010-00031288LG, Celgene, 5/21/2010-3/16/2015, \$1,336,900 (\$267,380/year)

Principal Investigator, 1%, 2009-1001: A Phase 3, Multicenter, Randomized, Open-Label Study of Azacitidine (Vidaza) Versus Conventional Care Regimens for the Treatment of Older Subjects with Newly Diagnosed Acute Myeloid Leukemia, CS2010-00032590LG 01, Celgene, 7/28/2010-9/29/2014, \$339,127 (\$113,042/year)

Principal Investigator, 1%, 2010-0209: A Phase II/III, Randomized Controlled Study to Assess the Efficacy and Safety of ON 01910. Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blast Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine, CS2010-00032168MA, Onconova Therapeutics, 10/28/2010-1/6/2016, \$1,732,458 (\$246,067/year)

Principal Investigator, 1%, 2010-0965: Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of PM01183 in Patients with Advanced Acute Leukemia, CS2011-00034740JW, PharmaMar USA, Inc., 3/15/2011-11/11/2016, \$297,499 (\$99,166/year)

Principal Investigator, 1%, DR09-0074: Amgen Project 2010, CS2011-00033861LG, Amgen, Inc., 5/9/2011-10/15/2013, \$56,000 (\$22,400/year)

Principal Investigator, 1%, 2010-0317: A Phase 1 Trial of PF-03084014 in Patients with Advanced Solid Tumor Malignancy and T-Cell Acute Lymphoblastic Leukemia, CS2010-32969, Pfizer, 6/30/2011-5/9/2014, \$719,830 (\$143,966/year)

Principal Investigator, 1%, 2011-0427: Phase II Study of SB1518 for Patients with Myelodysplastic Syndrome, CS2011-00035304JW, S*Bio Pte Ltd, 9/21/2011-6/12/2013, \$32,532 (\$6,506/year)

Principal Investigator, 1%, 2011-0548: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International -1-Risk Myelodysplastic Syndrome, CS2011-00035516JW, Johnson & Johnson, 10/6/2011-11/20/2012, \$477,489 (\$238,745/year)

Principal Investigator, 1%, 2011-0827: A Phase 1 Study of ARRY-614 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes, CS2011-00035833, Array Biopharma, Inc., 11/21/2011-8/12/2015, \$944,462 (\$472,231/year)

Principal Investigator, 1%, Preclinical modeling of OPN-305 in human myelodysplastic syndromes and acute myelogenous leukemia, CS2012-00036766RG, Opsona Therapeutics, 6/23/2012-6/22/2013, \$13,026 (\$13,026/year)

Co-Investigator, 4%, CA110791: Innate immunity dysregulation in myelodysplastic syndromes, W81XWH-12-1-0221, DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP), PI - Yue Wei, 9/30/2012-9/29/2015, \$200,000 (\$100,000/year)

Principal Investigator, 1%, 2012-0733: A Phase 3, Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Placebo plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes, 4005.31987C, Celgene Corporation, 12/21/2012-12/20/2020, \$181,865 (\$36,373/year)

Principal Investigator, 1%, 2012-0428: An Open-Label Randomized, Phase 2, Parallel Dose-Ranging Study of Sotatercept (ACE 011) for Treatment of Patients with Anemia and low or intermediate-1 risk MDS, 4005.31592C, Celgene Corporation, 12/26/2012-12/25/2019, \$82,912 (\$16,582/year)

Principal Investigator, 1%, 2012-0374: Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Refractory Patients with Leukemias Involving Translocations of the MLL, CS2012-00037037LG, Epizyme, Inc., 6/6/2013-6/5/2017, \$282,787 (\$56,557/year)

Principal Investigator, 1%, S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (1A) Versus 1A with Vorinostat (NSC-701852) (1A+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML), 26681, NIH/NCI, 6/12/2013-6/11/2018, \$120,000 (\$40,000/year)

Principal Investigator, 1%, 2013-0324: Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After Azacitidine or Decitabine, 8357, Onconova Therapeutics, 6/14/2013-2/23/2015, \$246,090 (\$49,218/year)

Principal Investigator, 5%, MDS Clinical Research Consortium, Aplastic Anemia & MDS International Foundation supported by the Evans Foundation, 6/28/2013-6/27/2018, \$1,350,000 (\$270,000/year)

Principal Investigator, 1%, 2013-0030: Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia, 8322, Onconova Therapeutics, 7/7/2013-7/6/2021, \$807,867 (\$161,573/year)

Principal Investigator, 1%, 2013-0321: A Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (MDS), 9566, MEI Pharma, Inc., 7/11/2013-7/10/2017, \$532,516 (\$106,503/year)

Principal Investigator, 1%, 2012-0562: Phase II Study of Subcutaneous Bortezomib for Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome, Millennium Pharmaceuticals, Inc., 8/7/2013-8/6/2016, \$420,210 (\$84,042/year)

Principal Investigator, 1%, 2013-0531: A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies, MK-3475-013-00, Merck, Sharp & Dohme Corporation, 12/20/2013-12/19/2020, \$1,119,063 (\$373,021/year)

Principal Investigator, 1%, Overcoming resistance to hypomethylating agents in myelodysplastic syndromes, Fundacion Ramon Areces, 1/1/2014-12/31/2016, \$100,000 (\$50,000/year)

Principal Investigator, 1%, Identification and characterization of targets for BiTE therapy in Myelodysplastic Syndrome, Amgen, 1/1/2014-12/31/2019, \$5,000,000 (\$500,000/year)

Principal Investigator, 1%, 2013-0873: A Phase II Simon Two-Stage of the Addition of Pracinostat to a Hypermethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone, MDS 15, MEI Pharma, Inc., 1/31/2014-10/16/2015, \$515,984 (\$257,992/year)

Principal Investigator, 1%, 2013-0012: Phase I Study of Ruxolitinib for Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome, INCB0018424, Incyte Corporation, 2/6/2014-2/5/2020, \$377,000 (\$125,667/year)

Principal Investigator, 1%, 2013-0596: A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination with Azacitidine in Elderly (Age > or equal 65 Years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML), MEI Pharma, Inc., 2/24/2014-2/23/2018, \$334,910 (\$111,636/year)

Principal Investigator, 1%, PA14-0131: Anti-leukemia effect of the combination of inosine monophosphate dehydrogenase (IMPDH), FujiFilm Corporation, 5/6/2014-5/5/2015, \$63,062 (\$63,062/year)

Principal Investigator, 1%, 2013-1041: A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents, 13850, MedImmune, 6/10/2014-6/9/2020, \$1,197,157 (\$239,431/year)

Principal Investigator, 1%, 2014-0089: A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS), 11274, Astex Therapeutics, 7/7/2014-3/29/2020, \$1,467,580 (\$489,193/year)

Principal Investigator, 1%, 2014-0014: A Phase 1/2a, Dose-Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies, 11582, FujiFilm, 7/11/2014-5/4/2019, \$919,560 (\$306,320/year)

Co-Investigator, 3%, Molecular pathogenesis of MDS, 5R01DK102759-02, NIH/NIDDK, PI - Starczynowski grant PI; Garcia-Manero MD Anderson PI, 8/15/2014-5/31/2017, \$17,256 (\$5,752/year)

Principal Investigator, 15%, Towards the cure of myelodysplastic syndrome: interfering with innate immunity alterations in human and mouse systems, RP140500, Cancer Prevention & Research Institute of Texas (CPRIT), 8/31/2014-2/28/2018, \$855,000 (\$285,000/year)

Principal Investigator, 1%, 2014-0451: An Open-label Rollover Study to Continue ARRY-614 Treatment in Patients Previously Treated With ARRY-614 in Clinical Studies Sponsored by Array BioPharma Inc., 12757, Array BioPharma, 10/20/2014-9/11/2019, \$16,660 (\$8,330/year)

Principal Investigator, 1%, 2014-0391: Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study Of The ERK 1/2 Inhibitor BVD-523 In Patients With Acute Myelogenous Leukemia Or Myelodysplastic Syndromes, 12067, BioMed Valley, 11/19/2014-8/28/2018, \$602,980 (\$200,993/year)

Principal Investigator, 1%, 2014-0432: A Prospective, Open Label Phase I/II Study To Assess The Safety And Efficacy Of Cycles Of Intravenously Infused Doses Of OPN-305 In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS), 12248, Opsona Therapeutics, 12/15/2014-12/14/2018, \$540,659 (\$180,219/year)

Collaborator, 3%, Stromal Interactions and Leukemic Risk in Myelodysplastic Syndromes, 1R21 CA195689-01, NIH/NCI, PI - Honami Naora, 4/6/2015-3/31/2017, \$250,000 (\$125,000/year)

Principal Investigator, 1%, 2015-0056: A Phase 2, International, Multicenter, Single-Arm, Open-Label Study To Evaluate The Efficacy And Safety Of CC-486 (Oral Azacitidine) In Subjects With Myelodysplastic Syndromes Who Fail To Achieve An Objective Response To Treatment w Azacitidine for injection or decitabine, 3087, Celgene, 6/18/2015-6/17/2021, \$258,118 (\$86,039/year)

Principal Investigator, 1%, 2015-0516: A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients with Relapsed Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome, 3379, Forma Therapeutics, 10/1/2015-8/4/2020, \$1,241,458 (\$413,819/year)

Principal Investigator, 1%, 2015-0360: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent, 3360, Onconova Therapeutics, 10/20/2015-6/24/2021, \$1,836,500 (\$918,250/year)

Principal Investigator, 1%, 2014-0930: Combination of nivolumab and ipilimumab with 5-azacitidine in patients with myelodysplastic syndromes (MDS), 3130, Bristol Myers Squibb, 12/1/2015-11/30/2024, \$256,000 (\$28,444/year)

Principal Investigator, 1%, 2014-0934: Phase II combination of lirilumab and nivolumab with 5-azacitidine in patients with myelodysplastic syndromes (MDS), 3132, Bristol Myers Squibb, 12/1/2015-11/30/2024, \$256,000 (\$28,444/year)

Principal Investigator, 1%, 2015-0984: A Phase 1/2 Study of Vadastuximab Talrine (SGN-CD33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS), 52001, Seattle Genetics, 3/17/2016-3/16/2019, \$581,337 (\$194,445/year)

Principal Investigator, 2%, 2016-0547: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia, H3 Biomedicine, Inc., 3/30/2016-3/29/2022, \$291,041 (\$95,959/year)

Principal Investigator, 1%, 2015-0297: A Phase 1b Study of the Safety and Pharmacology of MPDL3280A (Anti PDL-1 antibody) Administered Alone or in Combination with Azacitidine in Patients with Myelodysplastic Syndromes, CS2015-13015361, Genentech, 4/7/2016-6/6/2017, \$285,650 (\$1,482,825/year)

Principal Investigator, 1%, 2015-0979: A phase 3, double-blind, randomized study to compare the efficacy & safety of luspatercept (ACE-536) vs. placebo for the treatment of anemia due to ipss-r very low, or intermediate risk MDS in subjects w/ ring sideroblast, CS2016-00051933, Celgene Corporation, 5/31/2016-2/10/2019, \$251,014 (\$119,446/year)

Principal Investigator, 5%, Decitabine and dCTPase inhibitor combination: proof-of-concept studies in MDS, The University of Texas MD Anderson Cancer Center Sister Institute Network Fund, 7/1/2016-6/30/2018, \$100,000 (\$49,597/year)

Principal Investigator, 1%, 2016-0182: A Randomized Multi-center, Open-label, Phase 2 Study evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination w/(MEDI4736) in Previously Untreated Subjects w/Higher Risk MDS or in Elderly AML Subjects Not Eligible (HSCT), 52461, Celgene, 12/14/2016-12/13/2021, \$676,480 (\$150,651/year)

Principal Investigator, 2%, 2016-0587: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents, 53402, Astex Pharmaceuticals, Inc, 2/23/2017-1/30/2022, \$1,188,999 (\$205,485/year)

Principal Investigator, 1%, 2016-0969: A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) who are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment, 54008, Janssen Research and Development LLC, 5/19/2017-4/30/2020, \$164,549

Principal Investigator, 3%, 2016-0974: ' Phase I/II, open-label, 2 arm study to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of GSK2879552 administered alone or in combination with azacitidine, in adult subjects with IPSS-R high and

very high risk myelodysplastic syndromes (MDS) previous treated with hypomethylating agents (HMA), 13029044, GlaxoSmithKline, 6/26/2017-6/25/2020, \$385,145 (\$161,715/year)

Principal Investigator, 2%, 2016-0944: A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure, 54170, AbbVie, 10/13/2017-10/12/2021, \$225,989 (\$225,989/year)

Principal Investigator, 2017-0173: A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients 18 Years with Newly Diagnosed Acute Myeloid Leukemia Unfit for Standard Induction Chemotherapy, Helsinn Healthcare, 11/30/2017-11/29/2021, \$164,625 (\$164,625/year)

Principal Investigator, 2017-0886: A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), Astex Pharmaceuticals, 12/15/2017-12/14/2021, \$1,200,452 (\$462,943/year)

Principal Investigator, 2017-0887: F/U to the Open Label Phase I/II study OPN-305-106 (A Prospective, Open Label Phase I/II to assess Safety & Efficacy of Cycles of IV Infused OPN-305 in Second-line and First-line lower (Low and intermediate-1) risk (MDS)), Opsona Therapeutics Ltd, 2/13/2018-2/12/2023, \$106,070

Principal Investigator, 2018-0009: A Phase 1, Multicenter, open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients with Intermediate or High-Risk Myelodysplastic Syndrome, Amphivena Therapeutics, 3/31/2018-3/30/2021, \$123,413 (\$123,413/year)

Principal Investigator, 2018-0309: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms, H. Lee Moffitt Cancer Center, 7/9/2018-7/8/2025, \$19,397

Principal Investigator, 2018-0309: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms, Aprea Therapeutics, 7/9/2018-7/8/2025, \$13,909 (\$10,176/year)

Collaborator, UTMDACC Leukemia SPORC Development Award, PI - DiNardo, 9/1/2018-8/31/2019, \$12,499

Principal Investigator, 2019-0126: A Phase 3B, Open-Label, Single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials, Celgene, 9/18/2019-9/17/2026, \$5,000 (\$5,000/year)

Principal Investigator, 2019-0340: A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers, Janssen Research and Development, LLC, 11/8/2019-1/7/2022, \$51,793

Not Funded

Co-Investigator, 1%, DNA Methylation Pattern of Acute Lymphoid Leukemia in Adolescents and Young Adults, 1 RC1 CA147225-01, NIH/NCI, PI - Anna Franklin, M.D., 9/30/2009-9/29/2011, \$620,884 (\$304,870/year)

Co-Principal Investigator, 15%, Targeting Microenvironment-Related Resistance in adult acute lymphoblastic leukemia (ALL), RP101320, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Hagop M. Kantarjian, 8/1/2010-7/31/2015, \$10,273,459 (\$247,836/year)

Principal Investigator, 10%, Aberrant DNA Methylation as a Mechanism of Resistance in ALL, 1 R01 CA161019-01A1, NIH/NCI, 7/1/2011-6/30/2016, \$1,250,000 (\$250,000/year)

Co-Principal Investigator, 5%, Modulation of IL-6 signaling in myelodysplastic syndromes (MDS), Leukemia and Lymphoma Society, PI - Yue Wei, PhD, 10/1/2011-9/30/2014, \$526,593 (\$175,074/year)

Principal Investigator, 5%, Treating patients with AML/MDS that do not qualify for clinical trials, Leukemia and Lymphoma Society, 10/1/2011-9/30/2014, \$535,990 (\$179,556/year)

Principal Investigator, 10%, Targeting innate immunity alterations in myelodysplastic syndrome (PQ20), R21 000000-00, NIH/NCI, 7/1/2012-6/30/2014, \$275,000 (\$137,500/year)

Principal Investigator, 10%, A randomized clinical trial for patients with AML/MDS not fit for Chemotherapy, GRANT10976413, NIH/NCI, 9/1/2012-3/31/2015, \$750,000 (\$250,000/year)

Principal Investigator, 5%, Targeting of an innate immunity-like pathway in myelodysplastic syndrome, Leukemia and Lymphoma Society, 10/1/2012-9/30/2015, \$540,054 (\$180,018/year)

Principal Investigator, 10%, Innate Immunity Alterations in MDS, 1R01HL118107-01, NIH/NHLBI, 4/1/2013-3/31/2018, \$1,250,000 (\$250,000/year)

Principal Investigator, 10%, A randomized clinical trial for patients with AML/MDS not fit for chemotherapy, American Society of Hematology (ASH), 5/1/2013-4/30/2014, \$150,000 (\$150,000/year)

Principal Investigator, 15%, Targeting the histone demethylase JMJD3 and innate immunity deregulation in myelodysplastic syndromes, RP130080, Cancer Prevention & Research Institute of Texas (CPRIT), 6/1/2013-5/31/2016, \$1,322,583 (\$430,557/year)

Mentor, 1%, Role of deregulated innate immunity signaling in resistance to hypomethylating agent based therapy in myelodysplastic syndrome and acute myelogenous leukemia, Gabrielle's Angel Foundation, PI - Yue Wei, 11/1/2013-10/31/2016, \$202,500 (\$67,500/year)

Principal Investigator, 30%, Biology of MDS, 1P01HL117793-01, NIH/NHLBI, 4/1/2014-3/31/2019, \$10,987,025 (\$2,197,405/year)

Collaborator, 1%, An Observational Study on Symptoms and Health-Related Quality of Life of Patients with Myelodysplastic Syndromes, Aplastic Anemia and MDS International Foundation, PI - Carmelita P. Escalante, 7/1/2014-6/30/2016, \$54,000 (\$27,000/year)

Principal Investigator, 5%, Targeting immune checkpoints in hypomethylating failure myelodysplastic syndromes, Aplastic Anemia and MDS International Foundation, 7/1/2014-6/30/2016, \$54,000 (\$27,000/year)

Principal Investigator, 5%, Targeting Toll-like Receptor and innate immunity signaling in hypomethylating failure MDS, Aplastic Anemia and MDS International Foundation, 7/1/2014-6/30/2016, \$54,000 (\$27,000/year)

Principal Investigator, 10%, Targeting immune checkpoints in hypomethylating failure, LLS TRP, Leukemia and Lymphoma Society, 10/1/2014-9/30/2017, \$540,054 (\$180,018/year)

Co-Investigator, 5%, Targeting Toll-like Receptor and innate immunity signaling in hypomethylating failure MDS, LLS TRP, Leukemia and Lymphoma Society, PI - Yue Wei, 10/1/2014-9/30/2017, \$540,054 (\$180,018/year)

Principal Investigator, 5%, Blocking Innate Immune Signaling: Toward New Treatments for Myelodysplastic Syndromes, Golfers Against Cancer, 12/1/2014-11/30/2016, \$50,000 (\$25,000/year)

Principal Investigator, 10%, Clonal hematopoiesis as a predictive biomarker for the development of therapy-related myeloid neoplasms, EvansMDS Foundation, 9/1/2016-8/31/2019, \$1,800,000 (\$600,000/year)

Co-Investigator, 1%, Mechanisms of natural killer (NK) cell immune escape in myelodysplastic syndromes, 1 R21 CA222037-01, NIH/NCI, PI - Katy Rezvani, 9/1/2017-8/31/2019, \$275,000 (\$150,000/year)

Principal Investigator, 10%, Preventing therapy-related leukemia and myelodysplastic syndromes in Texas, RP180583, Cancer Prevention & Research Institute of Texas (CPRIT), 3/1/2018-2/28/2021, \$855,000 (\$285,000/year)

Principal Investigator, 10%, Preventing therapy-related leukemia and myelodysplastic syndromes, 1 R21 CA226203, NIH/NCI, 4/1/2018-3/31/2020, \$275,000 (\$129,500/year)

Principal Investigator, 2%, Dissecting pathogenic cooperation between KDM6B overexpression and TET2 loss in bone marrow failure, Department of Defense (DOD), 9/1/2019-8/31/2021, \$316,725

Co-Investigator, 5%, RNA mutations in human cancers, NIH/NCI, PI - George A. Calin, MD, PhD, 9/1/2019-8/31/2026, \$4,199,998 (\$599,999/year)

Protocols

Funded

Principal Investigator, Post-Remission Immunotherapy of Acute Myelogenous Leukemia with an Autologous Dinitrophenyl (DNP)-Modified Leukemia Cell Vaccine, DM99-337, 1999-2001, Thomas Jefferson University

Principal Investigator, Study of DNA Methylation in Acute Lymphoblastic Leukemia, LAB00-200, 2000-2013, None

Principal Investigator, A Phase 2, multicenter, open label study of the safety and efficacy of high-dose pulse administration of DN-101 (Calcitriol) in patients with myelodysplastic syndrome, DM02-711, 2003-2004, \$23,500, Novacea, Inc.

Principal Investigator, Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced Leukemias, ID03-0044, 2003-2006, \$144,030, ATON Pharma Inc.

Principal Investigator, Phase I/II Study of 5-aza-2'-Deoxycytidine And Valproic Acid In Patients With Relapsed/Refractory Leukemia Or Myelodysplastic Syndromes, 2003-0314, 2003-2006, \$30,000, MGI Pharma

Principal Investigator, HOX Gene Expression in MDS, LAB03-0990, PI - A. Thomas Look, 2003-2010, \$1,444,668 (\$292,357/year), NCI

Principal Investigator, Correlative Lab Study for "A Phase IA/II, Two-Arm, Multicenter, dose-Escalation Study of LBH589 Administered Intravenously on Two Dose Schedules in Adult Patients with Advanced Hematologic Malignancies, 2003-0968, 2004-2005, \$150,000, Novartis

Principal Investigator, A Phase I Study of MGCD0103 Given As A Three-Times Weekly Oral Dose In Patients With Leukemia Or Myelodysplastic Syndromes, 2004-0748, 2004-2009, \$94,351, MethylGene Inc.

Principal Investigator, Phase I/II Study of the combination of 5-azacytidine with Valproic Acid and All-trans Retinoic acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia, 2004-0799, 2005-2007, \$211,594, Pharmion

Principal Investigator, A Randomized Phase II Study of the Combination of 5-azacytidine with Valproic Acid Versus Low-Dose Ara-C in Patients with AML/MDS not Eligible for other Studies, 2005-0177, 2005-2008, None

Principal Investigator, Phase I study of low dose 5-aza-2'-deoxycytidine administered daily for 5 days every other week for patients with relapsed or refractory acute lymphocytic leukemia, 2005-0895, 2005-2010, \$404,646, MGI Pharma

Principal Investigator, A Phase I/II Study of MGCD0103 (MG-0103) in Combination with Azacitidine in Patients with High-Risk Myelodysplastic Syndrome or Acute Myelogenous Leukemia, 2005-0659, 2005-2011, \$355,399 (\$71,080/year), MethylGene

Principal Investigator, An Open-Label Dose-Escalation Study to Assess the Safety and Bioavailability of Single Oral Doses of Azacitidine in Patients with Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML), or Solid Tumors, 2006-0784, 2006-2008, \$188,065, Pharmion

Principal Investigator, A Phase II Study of MGCD0103 (MG-0103) In Patients with Acute Myelogenous Leukemia/High Risk MDS who are Elderly and have Previously Untreated Disease or who are Adult and have Relapsed/Refractory Disease, 2006-0474, 2006-2009, \$346,600, Methygene Inc.

Principal Investigator, Phase 2 Study of Proteinase 3 PR1 Peptide Vaccine in MDS, 2005-0913, 2006-2009, \$210,000 (\$52,500/year), The Vaccine Company

Principal Investigator, A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents, 2006-0722, 2006-2010, \$386,000, Amgen, Inc.

Co-Principal Investigator, Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA; NS 701852) in Combination with Idarubicin for Patients with Relapsed Leukemia, 2005-0031, 2006-2010 (\$420,702/year), NCI

Principal Investigator, A Phase I, Open-Label, Dose-Escalation Study of CC-11006 in Subjects with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS), 2007-0528, 2007-2009, \$104,900, Celgene Corporation

Principal Investigator, A Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes, 2007-0201, 2007-2010, \$173,000, Merck, Inc.

Principal Investigator, A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), 2007-0405, 2007-present, \$751,870, Pharmion

Principal Investigator, A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza) vs. Single Agent MGCD0103 vs. Azacitidine in Combination with MGCD0103 for the Treatment of Elderly Subjects with Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic Syndrome, 2007-0763, 2008-2010, \$1,263,075, Pharmion

Principal Investigator, A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (every other day) for 3 Weeks in a 4-Week Cycle in Patients with Advanced Malignancies, 2007-0848, 2008-2012, \$180,958, S*Bio

Principal Investigator, Phase I Study of the Histone-deacetylase Inhibitor JNJ-264818585 in Subjects with Advanced or Refractory Leukemia or Myelodysplastic Syndrome, 2008-0245, 2008-2012, \$668,875, Johnson & Johnson

Principal Investigator, Randomized Open-Label Phase 2 Study of Low Dose Dacogen (Decitabine) for Injections in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes, 2007-0883, 2008-2012, \$627,350, MGI Pharma Inc.

Principal Investigator, Phase II Study of LBH589 for Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome, 2007-0713, 2008-2013, \$320,900, Novartis Pharmaceuticals Corp.

Principal Investigator, A Prospective, Non-Interventional Multicenter Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients, 2008-0165, 2008-present, \$668,875, Novartis Pharmaceuticals Corp.

Principal Investigator, Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients with High-Risk MDS and AML, 2007-0835, 2008-present, \$400,316 (\$80,063/year), Merck, Inc.

Principal Investigator, A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or Secondary Acute Myelogenous Leukemia (AML), 2009-0434, 2009-2011, \$152,165 (\$50,722/year), Novartis

Principal Investigator, Phase I Study of Belinostat (PXD-101) and Bortezomib (VELCADE, PS-341) in Patients with Relapsed or Refractory Acute leukemia and Myelodysplastic Syndrome, 2009-0752, 2009-2012 (\$190,048/year), Massey Cancer Center, Millenium, TopoTarget

Principal Investigator, A Phase 2 Trial of Vorinostat in Combination with Azacitidine in Patients with Newly-Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome who are ineligible for other Leukemia Protocols, 2007-0685, 2009-present, Merck

Principal Investigator, A Phase I Study of Oral Array-614 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome, 2009-0129, 2009-present, \$340,565 (\$170,282/year), Array BioPharma, Inc.

Principal Investigator, Phase I/II Study of the Combination of 5-azacitidine with Lenalidomide in Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML), 2009-0467, 2009-present, Celgene

Principal Investigator, Phase II Trial of Vorinostat in Combination with Azacitidine in Patients with Newly-Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome who are ineligible for other Leukemia Protocols, 2007-0685, 2009-present, Merck, Inc. and Pharmion Corporation (DRUG ONLY)

Principal Investigator, A Phase 1 Trial of Pf-03084014 in Patients with Advanced Solid Tumor Malignancy and T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma, 2010-0317, 2010-2012, Pfizer

Principal Investigator, A Phase 1b, Dose-Finding Study of Oral Panobinostat (LBH589) in Combination with Idarubicin and Cytarabine Induction and High-Dose Cytarabine-Based Consolidation Therapy in Adult Patients less than or equal to 65 Years Old with Acute Myeloid Leukemia, 2010-0591, 2010-2012, Novartis

Principal Investigator, A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza) Versus Conventional Care Regimens for the Treatment of Older subjects with Newly Diagnosed Acute Myeloid Leukemia, 2009-1001, 2010-2012, Celgene

Principal Investigator, Phase I Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra, TLK199 Tablets) in Combination with Lenalidomide (Revlimid) in Patients with Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS), 2009-0965, 2010-2012, Telik

Principal Investigator, A Multi-Center, Randomized, Double-Blind, Placebo-controlled Clinical Trial of Deferasirox in Patients with Myelodysplastic Syndromes (low/int-1 risk) and Transfusional Iron Overload (TELESTO), 2010-0041, 2010-2019, Novartis

Principal Investigator, A Ph I/B, Open-Label, M/C, Dose-Escalation Study of Oral Panobinostat (LBH589) Administered with 5-Azacitidine (Vidaza Rx) in Adult Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML), 2009-0619, 2010-present, Novartis

Principal Investigator, A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Placebo in Subjects with Transfusion-Dependent Anemia due to IPSS Low or Intermediate-1 Risk, 2009-0737, 2010-present, Celgene

Principal Investigator, A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-348 in Subjects with Advanced Hematologic Malignancies, 2009-0788, 2010-present, Abbott

Principal Investigator, A Phase III, Randomized Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine, 2010-0209, 2010-present, Onconova Therapeutics Inc.

Principal Investigator, A Retrospective Correlative Study of Cytogenetics and Response to Lenalidomide in Patients with Myelodysplastic Syndrome, LAB10-0703, 2010-present, Celgene

Study Chairman, A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in

Anemic Subjects with International Prognostic Scoring System Low- or Intermediate-1-Risk, 2011-0548, 2011-2012, Janssen Research Foundation

Principal Investigator, Phase II Study of SB1518 for Patients with Myelodysplastic Syndrome, 2011-0427, 2011-2013, SBIO Pte, Ltd.

Principal Investigator, A Phase I Study of ARRY-614 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes, 2011-0827, 2011-present, Array

Study Chairman, Clofarabine plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) who have have been Relapsing after, or are Refractory to, Hypomethylator Therapy, 2011-0660, 2011-present, None (Not Unknown)

Principal Investigator, Open-Label Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of PM01183 in Patients with Advanced Acute Leukemia, 2010-0965, 2011-present, PharmaMar, S.A.U.

Study Chairman, A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Refractory Patients with Leukemias Involving Translo, 2012-0374, 2012-present, Epizyme, Inc.

Study Chairman, A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia, 2012-0733, 2012-present, Celgene

Study Chairman, A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies, 2013-0531, 2013-present, Merck Sharp and Dohme

Study Chairman, A PHASE II OPEN-LABEL, SINGLE-ARM, TWO-STAGE, MULTICENTER TRIAL OF PRACINOSTAT IN COMBINATION WITH AZACITIDINE IN ELDERLY (AGE $\geq$ 65 YEARS) PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML), 2013-0596, 2013-present, MEI Pharma, Inc.

Study Chairman, A Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (, 2013-0321, 2013-present, MEI Pharma, Inc.

Study Chairman, An open-label, randomized, Phase 2, parallel, dose-ranging, multicenter study of sotatercept for the treatment of patients with anemia and low- or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemia (CMML)., 2012-0428, 2013-present, Celgene

Study Chairman, PHASE I STUDY OF RUXOLITINIB FOR PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELOYDYSPLASTIC SYNDROME, 2013-0012, 2013-present, Incyte

Study Chairman, Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia, 2013-0030, 2013-present, Onconova Therapeutics, Inc.

Study Chairman, Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After Azacitidine or Decitabine, 2013-0324, 2013-present, Onconova Therapeutics

Study Chairman, Phase II Study of Subcutaneous Bortezomib for Patients with Low Or Intermediate-1 Risk Myelodysplastic Syndrome, 2012-0562, 2013, Millennium

Study Chairman, A PHASE II OPEN-LABEL, SINGLE-ARM, TWO-STAGE, MULTICENTER TRIAL OF PRACINOSTAT IN COMBINATION WITH AZACITIDINE IN ELDERLY (AGE $\geq$ 65

YEARS) PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML), 2013-0873, 2014-present, MEI Pharma, Inc.

Principal Investigator, A PHASE III, DOUBLE-BLIND, PLACEBOCONTROLLED,, 2017-0173, 2017-2020, \$205,979, Helsinn Healthcare SA

Unfunded

N/A

Patents and Technology Licenses

Patents

Board of Regents, The University of Texas System, Methods of Identifying and Treating Individuals Exhibiting NUP214-ABL1 Positive T-Cell Malignancies with Protein Tyrosine Kinase Inhibitors and Combinations thereof, United States, MDA08-004, Ref 008440.0123, Filed

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

U54 PRCC/MDACC Partnership for Excellence in Cancer Research, NIH, Member, 2003

State of Florida Cancer Research Grant Bankhead-Coley Cancer Research, Florida Biomedical Research Programs, Member, 2007-2010

Leukemia and Lymphoma Society of America, Translational Research Program, Reviewer, 2007-2012

German National Cancer Research Grant, German National Cancer Center, Ad Hoc Member, 2007

The V Foundation for Cancer Research, MD Anderson Cancer Center Translational Grant, Member, 2007

AMA Medical Student Grant, American Medical Association, Member, 2007-present

Paul Calabresi K12 Program, NCI, Member, 2007-present

Basic Cancer Research Sub-Committee American Association for Cancer Research, MD Anderson Cancer Center, Member, 2008

Israel Cancer Research Grant, The Israel Science Foundation, Member, 2008

National Health System of Scotland, National Health Service, Member, 2008

Pennsylvania State Health Research Formula Grants, Pennsylvania Department of Health, AACR Basic, Member, 2008-present

Basic Cancer Research Fellowship Scientific Review Committee, AACR, Member, 2009-2011

NCI Leukemia Steering Committee, NIH, Member, 2009-2014

Global Research Foundation, CLL, Reviewer, 2009

Grant Reviewer, NIH, Ad Hoc Member, 2009-present

Merit Review and Career Development Awards, Department of Veterans A, Reviewer, 2008/09 Council CLINR 6/1/09, 2009-present

Leukemia, AIRC - Italian Association for Cancer Research, Member, 2010-present

Peer Reviewed Cancer Research Program, DOD, Reviewer, 2011-2016

Competitive Research Program, National Research Foundation, Reviewer, 2011

Cancer Biomarkers, NIH, Mail Reviewer, 2012

Clinical research in hospital program in oncology, Republique Francaise Institut National du Cancer, Clinical Project Proposal Reviewer, 2012

Molecular and Hematology, NIH, Ad Hoc Member, 2012
Cancer Research UK, Drug Development, Ad Hoc Member, 2012-present
Scientific Review Committee, Taub Foundation Grants Program for MDS Research, Chair, 2013-present
Grant Reviewer, Research Grants Council of Hong Kong, Member, 2014
Lise Meitner-Postdoctoral proposal, Austrian Science Fund, Member, 2014
Grant reviewer, Genesis Oncology Trust, Member, 2015
Grant Reviewer, Austrian Science Fund, Ad Hoc Member, 2017
Grant Reviewer, AAMDS, Reviewer, 2018-present
2019 Specialized Center of Research (SCOR), Leukemia & Lymphoma Society, Reviewer, 2019
Grant Reviewer, AIRC Foundation for Cancer Research, Grant Reviewer, 2020-present
Grant Reviewer, Je-S, Grant Reviewer, 2021
R24 Application, NIAID, Reviewer, 2021-present
2022 Blood Cancer Discoveries Grant (BCDG) Program Grant Review Subcommittee, Leukemia and Lymphoma Society, Grant Reviewer, 2022
Grant Reviewer, EvansMDS Discovery Research Grant LOI Review, Grant Reviewer, 2022

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. García-Manero G. Chromosomal Fragile Sites and the enzyme DNA topoisomerase II. Graduation thesis, Faculty of Medicine, University of Zaragoza. Annals of the Faculty of Medicine of the University of Zaragoza, 11/1991.
2. García-Manero G, Dómine M. Daunomicine inhibits the catenation activity of the enzyme DNA topoisomerase II in an in vitro system. *Oncología (Spain)* 15:305-310, 1992.
3. Chowdhury ZA, Barsigian C, Chalupowicz GD, Bach TL, Garcia-Manero G, Martinez J. Colocalization of tissue transglutaminase and stress fibers in human vascular smooth muscle cells and human umbilical vein endothelial cells. *Exp Cell Res* 231(1):38-49, 2/1997. PMID: 9056410.
4. García-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. *Am J Hematol* 60(2):130-5, 2/1999. PMID: 9929105.
5. Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. *Hematol Oncol Clin North Am* 14(6):1381-96, x-xi, 12/2000. PMID: 11147229.
6. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. *Cancer* 92(2):406-13, 7/2001. PMID: 11466696.
7. Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. *Invest New Drugs* 19(1):13-20, 2001. PMID: 11291829.
8. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. *J Clin Oncol* 20(3):656-64, 2/2002. PMID: 11821445.
9. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. *Cancer* 94(7):2024-32, 4/2002. PMID: 11932905.

10. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. *Blood* 99(10):3547-53, 5/2002. PMID: 11986206.
11. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. *Cancer* 94(9):2416-25, 5/2002. PMID: 12015767.
12. Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. *Clin Cancer Res* 8(6):1897-903, 6/2002. PMID: 12060634.
13. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshour T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). *Leukemia* 16(6):1045-52, 6/2002. PMID: 12040436.
14. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. *Clin Cancer Res* 8(7):2217-24, 7/2002. PMID: 12114423.
15. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. *Clin Cancer Res* 8(7):2177-87, 7/2002. PMID: 12114418.
16. Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. *Clin Cancer Res* 8(7):2134-41, 7/2002. PMID: 12114413.
17. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. *Clin Cancer Res* 8(7):2167-76, 7/2002. PMID: 12114417.
18. Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. *Haematologica* 87(8):804-7, 8/2002. PMID: 12161355.
19. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. *Blood* 100(5):1590-5, 9/2002. PMID: 12176876.
20. Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). *Leukemia* 16(9):1888, 9/2002. PMID: 12200720.
21. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. *Haematologica* 87(10):1114-6, 10/2002. PMID: 12368170.
22. Shen L, Kondo Y, Issa JP, Garcia-Manero G. Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. *Blood* 100(9):3432-3; author reply 3433-4, 11/2002. PMID: 12412576.
23. Giles F, Garcia-Manero G, O'Brien S, Estey E, Kantarjian H. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. *Acta Haematol* 108(3):164-7, 2002. PMID: 12373091.
24. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to

- standard-dose therapy in patients with chronic myelogenous leukemia. *Blood* 101(2):473-5, 1/2003. PMID: 12393385.
25. Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. *Cancer* 97(3):695-702, 2/2003. PMID: 12548613.
26. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. *Cancer* 97(5):1234-41, 3/2003. PMID: 12599230.
27. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. *Blood* 101(5):1692-7, 3/2003. PMID: 12411300.
28. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. *Cancer* 97(6):1481-7, 3/2003. PMID: 12627513.
29. Tsimberidou AM, Medina J, Earl M, Sierra M, Shriki JE, Bueso-Ramos C, Giralt S, Beran M, Giles FJ, Garcia-Manero G. Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia. *Bone Marrow Transplant* 31(5):413-4, 3/2003. PMID: 12634736.
30. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. *J Clin Oncol* 21(6):1050-6, 3/2003. PMID: 12637470.
31. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. *Cancer* 97(7):1711-20, 4/2003. PMID: 12655528.
32. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. *Leuk Res* 27(4):301-4, 4/2003. PMID: 12531220.
33. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. *Cancer* 97(8):1920-8, 4/2003. PMID: 12673719.
34. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. *Blood* 101(10):4131-6, 5/2003. PMID: 12586619.
35. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. *J Clin Oncol* 21(9):1722-7, 5/2003. PMID: 12721247.
36. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. *Blood* 101(9):3413-5, 5/2003. PMID: 12522009.

37. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *Cancer* 97(9):2225-8, 5/2003. PMID: 12712475.
38. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. *Blood* 101(10):3794-800, 5/2003. PMID: 12560227.
39. Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. *Leuk Res* 27(6):475-9, 6/2003. PMID: 12648505.
40. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. *Leukemia* 17(6):1100-3, 6/2003. PMID: 12764375.
41. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. *Cancer* 97(11):2760-6, 6/2003. PMID: 12767088.
42. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. *Cancer* 97(12):3010-6, 6/2003. PMID: 12784336.
43. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. *Blood* 102(1):83-6, 7/2003. PMID: 12637317.
44. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. *Cancer* 98(3):522-8, 8/2003. PMID: 12879469.
45. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *Cancer* 98(6):1105-13, 9/2003. PMID: 12973833.
46. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. *Cancer* 98(5):888-93, 9/2003. PMID: 12942553.
47. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. *Cancer* 98(7):1430-7, 10/2003. PMID: 14508830.
48. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. *Leuk Res* 27(10):893-7, 10/2003. PMID: 12860008.
49. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. *Blood* 102(7):2379-86, 10/2003. PMID: 12791647.

50. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. *Cancer* 98(9):1905-11, 11/2003. PMID: 14584073.
51. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in mice by genomic hypomethylation". *Science* 302(5648):1153; author reply 1153, 11/2003. PMID: 14615517.
52. Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. *Expert Opin Investig Drugs* 12(12):1985-93, 12/2003. PMID: 14640942.
53. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. *Cancer* 98(12):2636-42, 12/2003. PMID: 14669283.
54. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. *Cancer Chemother Pharmacol* 52(6):449-52, 12/2003. PMID: 13680159.
55. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. *Leuk Res* 27(12):1077-83, 12/2003. PMID: 12921943.
56. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. *Blood* 101(1):97-100, 2003. PMID: 12393600.
57. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. *Cancer Chemother Pharmacol* 51(1):87-90, 2003. PMID: 12497211.
58. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. *Cancer* 100(3):581-9, 2/2004. PMID: 14745876.
59. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood* 103(5):1635-40, 3/2004. PMID: 14604977.
60. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. *Leuk Res* 28(4):373-8, 4/2004. PMID: 15109537.
61. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. *Blood* 103(8):2873-8, 4/2004. PMID: 15070658.
62. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JP. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. *Cancer Res* 64(7):2411-7, 4/2004. PMID: 15059893.

63. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. *Cancer* 100(7):1449-58, 4/2004. PMID: 15042679.
64. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. *J Clin Oncol* 22(7):1287-92, 4/2004. PMID: 15051776.
65. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyu Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. *Br J Haematol* 125(2):187-95, 4/2004. PMID: 15059141.
66. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. *Clin Cancer Res* 10(9):2908-17, 5/2004. PMID: 15131024.
67. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Patel G, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. *Clin Cancer Res* 10(10):3371-6, 5/2004. PMID: 15161691.
68. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. *Leuk Res* 28(6):657-60, 6/2004. PMID: 15120945.
69. Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. *Cancer* 100(12):2592-7, 6/2004. PMID: 15197801.
70. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. *Blood* 103(12):4396-407, 6/2004. PMID: 14551133.
71. Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. *Leuk Res* 28(9):991-4, 9/2004. PMID: 15234578.
72. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. *Blood* 104(7):1979-88, 10/2004. PMID: 15198956.
73. Hennessy B, Giles F, Cortes J, O'Brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. *Am J Hematol* 77(3):209-14, 11/2004. PMID: 15495258.
74. Grosso D, Filicko J, Garcia-Manero G, Beardell F, Brunner J, Cohn J, Ferbér A, Martinez J, Mookerjee B, Rose L, Tice D, Wagner JL, Capizzi R, Flomenberg N. Cytoprotection in acute myelogenous leukemia (AML) therapy. *Semin Oncol* 31(6 Suppl 18):67-73, 12/2004. PMID: 15726527.
75. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. *Clin Cancer Res* 10(1 Pt 1):88-95, 2004. PMID: 14734456.

76. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. *Clin Cancer Res* 10(1 Pt 1):68-75, 2004. PMID: 14734453.
77. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. *Blood* 105(3):940-7, 2/2005. PMID: 15486072.
78. Murai M, Toyota M, Satoh A, Suzuki H, Akino K, Mita H, Sasaki Y, Ishida T, Shen L, Garcia-Manero G, Issa JP, Hinoda Y, Tokino T, Imai K. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. *Br J Cancer* 92(6):1165-72, 3/2005. PMCID: PMC2361956.
79. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. *Blood* 105(6):2281-6, 3/2005. PMID: 15572595.
80. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. *J Clin Oncol* 23(12):2805-12, 4/2005. PMID: 15728224.
81. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. *Clin Cancer Res* 11(9):3425-32, 5/2005. PMID: 15867244.
82. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. *Cancer* 103(10):2099-108, 5/2005. PMID: 15830345.
83. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. *Leuk Res* 29(6):649-52, 6/2005. PMID: 15863204.
84. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. *J Clin Oncol* 23(18):4070-8, 6/2005. PMID: 15767647.
85. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. *J Clin Oncol* 23(17):3948-56, 6/2005. PMID: 15883410.
86. Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, Rosner G, Garcia-Manero G. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. *J Clin Oncol* 23(17):3932-9, 6/2005. PMID: 15851765.
87. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. *Leuk Res* 29(7):739-48, 7/2005. PMID: 15927669.
88. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. *Cancer* 104(3):541-6, 8/2005. PMID: 15977212.
89. Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, Pierce S, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of a cell cycle regulatory

- pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. *Leuk Res* 29(8):881-5, 8/2005. PMID: 15978938.
90. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. *Cancer* 104(3):547-54, 8/2005. PMID: 15973664.
 91. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. *Clin Cancer Res* 11(18):6615-24, 9/2005. PMID: 16166440.
 92. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. *Clin Cancer Res* 11(21):7817-24, 11/2005. PMID: 16278404.
 93. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. *Clin Lymphoma Myeloma* 6(3):234-9, 11/2005. PMID: 16354329.
 94. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon-alpha (IFN-a) Therapy for Patients with Essential Thrombocythemia (ET): Final Results of a Phase II Study Initiated in 1986. *Cancer* 103(12):2551-2557, 2005.
 95. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. *Cancer* 106(2):337-45, 1/2006. PMID: 16353201.
 96. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients $\geq$ 50 years. *Blood* 108(1):45-51, 1/2006. PMID: 16403905.
 97. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. *Cancer* 106(2):346-52, 1/2006. PMID: 16342165.
 98. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. *Blood* 107(2):480-2, 1/2006. PMID: 16195326.
 99. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. *Blood* 107(3):880-4, 2/2006. PMID: 16123215.
 100. Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Kantarjian H, Estey E. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. *Leuk Res* 30(3):362-3, 3/2006. PMID: 16168477.
 101. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. *Cancer* 106(5):1090-8, 3/2006. PMID: 16435386.
 102. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. *Cancer* 106(6):1306-15, 3/2006. PMID: 16463391.

103. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. *Cancer* 106(7):1569-80, 4/2006. PMID: 16502413.
104. Soper SA, Brown K, Ellington A, Frazier B, Garcia-Manero G, Gau V, Gutman SI, Hayes DF, Korte B, Landers JL, Larson D, Ligler F, Majumdar A, Mascini M, Nolte D, Rosenzweig Z, Wang J, Wilson D. Point-of-care biosensor systems for cancer diagnostics/prognostics. *Biosens Bioelectron* 21(10):1932-42, 4/2006. PMID: 16473506.
105. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. *Cancer Res* 66(10):5495-503, 5/2006. PMID: 16707479.
106. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. *Cancer* 106(9):1974-84, 5/2006. PMID: 16583431.
107. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. *Blood* 107(9):3469-73, 5/2006. PMID: 16373661.
108. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. *Cancer* 106(12):2645-51, 6/2006. PMID: 16688777.
109. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. *Cancer* 107(1):125-35, 7/2006. PMID: 16700034.
110. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'Brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. *Leuk Res* 30(7):813-22, 7/2006. PMID: 16478631.
111. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'Brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. *Br J Haematol* 134(1):58-60, 7/2006. PMID: 16803568.
112. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. *Clin Cancer Res* 12(15):4628-35, 8/2006. PMID: 16899611.
113. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. *Blood* 108(4):1174-82, 8/2006. PMID: 16895868.
114. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. *Leukemia* 20(8):1452-3, 8/2006. PMID: 16728980.
115. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival Benefit with Imatinib Mesylate versus Interferon Alpha-Based Regimens in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. *Blood* 108(6):1835-40, 9/2006. PMID: 16709931.
116. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. *Leukemia* 20(10):1767-73, 10/2006. PMID: 16855631.
117. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. *Blood* 108(8):2811-3, 10/2006. PMID: 16809614.

118. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. *Blood* 108(10):3271-9, 11/2006. PMCID: PMC1895437.
119. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. *Cancer* 106(1):120-7, 2006. PMID: 16331634.
120. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. *Mod Pathol* 20(1):54-62, 1/2007. e-Pub 11/2006. PMID: 17143258.
121. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. *Cancer* 109(2):248-55, 1/2007. PMID: 17154172.
122. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. *Blood* 109(1):52-7, 1/2007. e-Pub 8/2006. PMID: 16882708.
123. Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. *Expert Opin Pharmacother* 8(1):65-73, 1/2007. PMID: 17163808.
124. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. *Cancer* 109(2):265-73, 1/2007. PMID: 17133405.
125. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. *Leuk Lymphoma* 48(2):283-9, 2/2007. PMID: 17325887.
126. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. *Cancer* 109(7):1355-9, 2/2007. PMID: 17326049.
127. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. *Cancer* 109(6):1133-7, 2/2007. PMID: 17315156.
128. Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, Garcia-Manero G. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. *Oncogene* 26(10):1439-48, 3/2007. e-Pub 8/2006. PMID: 16936778.
129. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. *Cancer* 109(5):899-906, 3/2007. PMID: 17236224.
130. Bumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis. *Cancer Res* 67(5):1997-2005, 3/2007. PMID: 17332327.
131. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given

- prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. *Blood* 109(8):3214-8, 4/2007. e-Pub 1/2007. PMID: 17209054.
132. Hoshino K, Quintás-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. *Leukemia* 21(5):906-11, 5/2007. e-Pub 3/2007. PMID: 17344919.
 133. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. *Blood* 109(11):4679-85, 6/2007. e-Pub 2/2007. PMID: 17299097.
 134. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. *Br J Haematol* 138(2):213-6, 7/2007. PMID: 17593028.
 135. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP. Effect of cytarabine and decitabine in combination in human leukemic cell lines. *Clin Cancer Res* 13(14):4225-32, 7/2007. PMID: 17634552.
 136. Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. *J Pathol* 212(4):402-10, 8/2007. PMID: 17503411.
 137. Yanada M, Huang X, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. *Br J Haematol* 138(4):555-7, 8/2007. e-Pub 6/2007. PMID: 17593249.
 138. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Blood* 110(8):2991-5, 10/2007. e-Pub 7/2007. PMID: 17625066.
 139. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. *Blood* 110(7):2302-8, 10/2007. e-Pub 6/2007. PMID: 17596541.
 140. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. *Cancer* 110(9):2012-8, 11/2007. PMID: 17849460.
 141. Cortes J, Quintás-Cardama A, Garcia-Manero G, O'Brien S, Jones D, Faderl S, Ebarb T, Giles F, Thomas D, Kantarjian H. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. *Cancer* 110(9):2000-6, 11/2007. PMID: 17849425.
 142. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. *Blood* 110(12):4005-11, 12/2007. e-Pub 9/2007. PMID: 17785585.
 143. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. *Cancer* 110(12):2756-60, 12/2007. PMID: 17948909.
 144. Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia. *Hematology Am Soc Hematol Educ Program* 2007:405-11, 2007. PMID: 18024658.
 145. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. *J Clin Oncol* 26(2):196-203, 1/2008. PMID: 18182662.

146. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? *Cancer* 112(4):837-45, 2/2008. PMID: 18085610.
147. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. *Blood* 111(3):1060-6, 2/2008. e-Pub 10/2007. PMID: 17962510.
148. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. *Leukemia* 22(3):538-43, 3/2008. e-Pub 12/2007. PMID: 18079733.
149. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Relapse and death during first remission in acute myeloid leukemia. *Haematologica* 93(4):633-4, 4/2008. PMID: 18379012.
150. Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. *Leukemia* 22(5):965-70, 5/2008. e-Pub 4/2008. PMCID: PMC4369783.
151. Quintás-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. *Leukemia* 22(6):1117-24, 6/2008. e-Pub 4/2008. PMID: 18401417.
152. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. *Cancer* 112(11):2341-51, 6/2008. PMID: 18398832.
153. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. *Leukemia* 22(6):1095-105, 6/2008. e-Pub 3/2008. PMID: 18323801.
154. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. *Clin Cancer Res* 14(12):3906-15, 6/2008. PMID: 18559612.
155. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. *Blood* 112(1):53-5, 7/2008. e-Pub 4/2008. PMCID: PMC4081375.
156. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. *Blood* 112(3):516-8, 8/2008. e-Pub 5/2008. PMCID: PMC4082324.
157. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. *Leukemia* 22(8):1529-38, 8/2008. e-Pub 6/2008. PMID: 18528427.
158. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. *Blood* 112(4):981-9, 8/2008. e-Pub 5/2008. PMCID: PMC4081529.
159. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. *Leukemia* 22(9):1680-4, 9/2008. e-Pub 6/2008. PMID: 18548103.
160. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine

- versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood* 112(5):1638-45, 9/2008. e-Pub 6/2008. PMCID: PMC4081352.
161. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. *Cancer* 113(6):1351-61, 9/2008. PMCID: PMC4188533.
 162. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. *Cancer* 113(6):1338-43, 9/2008. PMID: 18629842.
 163. Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. *Leuk Res* 32(10):1505-9, 10/2008. e-Pub 4/2008. PMCID: PMC4182927.
 164. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P, NCCN Myelodysplastic Syndromes Panel. Myelodysplastic syndromes. *J Natl Compr Canc Netw* 6(9):902-26, 10/2008. PMID: 18926100.
 165. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. *Clin Cancer Res* 14(19):6296-301, 10/2008. PMCID: PMC2582814.
 166. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. *Blood* 112(13):4839-4842, 12/2008. e-Pub 9/2008. PMCID: PMC4186640.
 167. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. *Cancer* 113(11):3186-91, 12/2008. PMCID: PMC4188532.
 168. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E. Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. *J Clin Oncol* 26(35):5684-5688, 12/2008. e-Pub 10/2008. PMID: 18955453.
 169. Stone R, Sekeres M, Garcia-Manero G, Lyons RM. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. *Clin Adv Hematol Oncol* 6(12):1-15, 12/2008. PMID: 19385003.
 170. Kadia TM, Garcia-Manero G. Role of epigenetic therapy in myelodysplastic syndrome. *Expert Rev Hematol* 1(2):161-74, 12/2008. PMCID: PMC3833719.
 171. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. *Cancer* 113(11):3181-5, 12/2008. PMCID: PMC4126078.
 172. Jain N, Hubbard J, Vega F, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous Remission of Acute Myeloid Leukemia: Report of Three Cases and Review of the Literature. *Clinical Leukemia* 2(1):64-67, 2008.
 173. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. *Cancer* 115(1):101-6, 1/2009. PMCID: PMC4180242.
 174. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. *J Clin Oncol* 27(4):504-510, 2/2009. e-Pub 12/2008. PMID: 19075265.

175. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. *Blood* 113(9):1892-8, 2/2009. e-Pub 12/2008. PMCID: PMC2651008.
176. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. *J Hematop* 2(1):2-8, 3/2009. e-Pub 11/2008. PMCID: PMC2713495.
177. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. *Blood* 113(10):2154-2160, 3/2009. e-Pub 12/2008. PMCID: PMC4081392.
178. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. *Nat Genet* 41(4):385-386, 4/2009. e-Pub 3/2009. PMCID: PMC3676425.
179. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. *J Clin Oncol* 27(10):1637-43, 4/2009. e-Pub 2/2009. PMID: 19224852.
180. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. *Blood* 113(21):5058-5063, 5/2009. e-Pub 3/2009. PMCID: PMC4081366.
181. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. *Cancer* 115(9):1899-905, 5/2009. e-Pub 2/2009. PMCID: PMC4086213.
182. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. *Oncologist* 14(5):489-96, 5/2009. e-Pub 4/2009. PMID: 19365094.
183. De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. *Bone Marrow Transplant* 43(11):839-843, 6/2009. e-Pub 1/2009. PMID: 19151791.
184. Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. *Leuk Res* 33(6):837-9, 6/2009. e-Pub 11/2008. PMCID: PMC4422052.
185. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. *Blood* 113(25):6330-7, 6/2009. e-Pub 8/2008. PMCID: PMC2943753.
186. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. *Blood* 114(1):144-7, 7/2009. e-Pub 5/2009. PMCID: PMC2710942.
187. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic

- anemia and myelodysplastic syndrome. *Leukemia* 23(7):1297-1302, 7/2009. e-Pub 2/2009. PMID: PMC4217203.
188. Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, Douer D, Garcia-Manero G, Liang G, Yang AS. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. *Int J Cancer* 125(3):723-729, 8/2009. e-Pub 2/2009. PMID: PMC4086885.
189. Stone R, Sekeres M, Garcia-Manero G. Evolving strategies in the treatment of MDS and AML. *Clin Adv Hematol Oncol* 7(8):1-14; quiz 2 p following 14, 8/2009. PMID: 19927982.
190. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. *J Clin Oncol* 27(23):3842-8, 8/2009. e-Pub 6/2009. PMID: 19528372.
191. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. *Cancer* 115(16):3709-3718, 8/2009. e-Pub 6/2009. PMID: PMC4388415.
192. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. *Leukemia* 23(9):1605-13, 9/2009. e-Pub 4/2009. PMID: PMC2950785.
193. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. *Cancer* 115(20):4737-44, 10/2009. e-Pub 7/2009. PMID: PMC4199225.
194. Hoshino K, Quintás-Cardama A, Radich J, Dai H, Yang H, Garcia-Manero G. Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. *Leuk Res* 33(10):1361-6, 10/2009. e-Pub 5/2009. PMID: PMC3833718.
195. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. *J Clin Oncol* 27(28):4760-6, 10/2009. e-Pub 8/2009. PMID: 19720904.
196. Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? *Cancer* 115(22):5202-9, 11/2009. e-Pub 8/2009. PMID: PMC2783477.
197. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. *Leukemia* 23(12):2275-80, 12/2009. e-Pub 9/2009. PMID: PMC4217206.
198. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. *Cancer* 115(23):5490-8, 12/2009. e-Pub 8/2009. PMID: PMC4458381.
199. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. *Cancer* 115(24):5746-51, 12/2009. e-Pub 9/2009. PMID: PMC2794953.
200. Garcia-Manero G. Progress in myelodysplastic syndromes. *Clin Lymphoma Myeloma* 9 Suppl 3:S286-92, 2009. PMID: 19778854.

201. Lakshmikuttyamma A, Takahashi N, Pastural E, Torlakovic E, Amin HM, Garcia-Manero G, Voralia M, Czader M, DeCoteau JF, Geyer CR. RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression. *J Hematol Oncol* 2(1):28, 2009. e-Pub 7/2009. PMID: 19895616.
202. Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. *Expert Rev Anticancer Ther* 10(1):9-22, 1/2010. PMID: 20014881.
203. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. *J Clin Oncol* 28(2):285-91, 1/2010. e-Pub 11/2009. PMID: 19895616.
204. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). *Br J Haematol* 148(3):386-93, 2/2010. e-Pub 11/2009. PMID: 19895616.
205. Jones D, Yao H, Romans A, Dando C, Pierce S, Borthakur G, Hamilton A, Bueso-Ramos C, Ravandi F, Garcia-Manero G, Kantarjian H. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. *Genes Chromosomes Cancer* 49(2):182-91, 2/2010. e-Pub 11/2009. PMID: 19895616.
206. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. *Blood* 115(6):1131-6, 2/2010. e-Pub 12/2009. PMID: 19895616.
207. Tong WG, Wei Y, Stevenson W, Kuang SQ, Fang Z, Zhang M, Arts J, Garcia-Manero G. Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. *Leuk Res* 34(2):221-8, 2/2010. e-Pub 8/2009. PMID: 19682743.
208. Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, Wang ZZ, Garcia-Manero G. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. *Blood* 115(12):2412-9, 3/2010. e-Pub 1/2010. PMID: 19895616.
209. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. *Leuk Lymphoma* 51(3):475-480, 3/2010. e-Pub 1/2010. PMID: 19895616.
210. Strom SS, Estey E, Outshoorn UM, Garcia-Manero G. Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients. *Leuk Lymphoma* 51(4):598-605, 4/2010. e-Pub 2/2010. PMID: 19895616.
211. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. *J Clin Oncol* 28(11):1856-62, 4/2010. e-Pub 3/2010. PMID: 19895616.
212. Wang SA, Jabbar K, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. *Leukemia* 24(4):740-7, 4/2010. e-Pub 1/2010. PMID: 20072149.
213. Chandra P, Luthra R, Zuo Z, Yao H, Ravandi F, Reddy N, Garcia-Manero G, Kantarjian H, Jones D. Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. *Am J Clin Pathol* 133(5):686-93, 5/2010. PMID: 20395514.
214. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. *Cancer* 116(9):2174-9, 5/2010. e-Pub 2/2010. PMID: 19895616.

215. Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of pericardial effusions in patients with leukemia. *Cancer* 116(10):2366-71, 5/2010. e-Pub 3/2010. PMCID: PMC3833724.
216. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. *Clin Lymphoma Myeloma Leuk* 10(3):205-10, 6/2010. PMCID: PMC3726276.
217. Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells. *J Cell Mol Med* 14(6B):1777-92, 6/2010. e-Pub 6/2009. PMCID: PMC3444523.
218. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. *J Clin Oncol* 28(16):2755-60, 6/2010. e-Pub 4/2010. PMID: 20421540.
219. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. *Leuk Res* 34(6):752-6, 6/2010. e-Pub 10/2009. PMCID: PMC4082769.
220. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. *Cancer* 116(11):2673-81, 6/2010. PMCID: PMC4216809.
221. Garcia-Manero G. Update on treatments for patients with myelodysplastic syndrome. *Clin Adv Hematol Oncol* 8(6):407-9, 6/2010. PMID: 20733550.
222. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. *Br J Haematol* 150(1):72-82, 7/2010. e-Pub 4/2010. PMCID: PMC4124904.
223. Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. *Drugs* 70(11):1381-94, 7/2010. PMID: 20614946.
224. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garriss R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. *J Clin Oncol* 28(24):3880-9, 8/2010. e-Pub 7/2010. PMCID: PMC2940403.
225. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. *Br J Haematol* 150(3):303-12, 8/2010. e-Pub 6/2010. PMCID: PMC4105000.
226. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. *Epigenetics* 5(6):499-508, 8/2010. e-Pub 8/2010. PMCID: PMC3322493.
227. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. *Leuk Lymphoma* 51(8):1478-84, 8/2010. PMCID: PMC4188823.
228. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. *Cancer* 116(16):3830-4, 8/2010. PMCID: PMC4295788.

229. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. *Clin Cancer Res* 16(15):3923-32, 8/2010. e-Pub 6/2010. PMID: PMC4113507.
230. Quintás-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. *Nat Rev Clin Oncol* 7(8):433-44, 8/2010. e-Pub 6/2010. PMID: 20551943.
231. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garriss R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. *Blood* 116(12):2070-7, 9/2010. e-Pub 5/2010. PMID: PMC4081177.
232. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound {beta}-phenylethyl isothiocyanate. *Blood* 116(15):2732-41, 10/2010. e-Pub 6/2010. PMID: PMC3324257.
233. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. *Blood* 116(17):3163-70, 10/2010. e-Pub 7/2010. PMID: PMC3324162.
234. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. *Autophagy* 6(7):976-8, 10/2010. e-Pub 10/2010. PMID: 20729640.
235. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. *Blood* 116(22):4422-9, 11/2010. e-Pub 7/2010. PMID: PMC4081299.
236. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. *Cancer* 116(22):5272-8, 11/2010. e-Pub 7/2010. PMID: 20665501.
237. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H. Characteristics and outcome of patients with acute myeloid leukemia refractory to one cycle of high dose cytarabine-based induction chemotherapy. *Blood* 116(26):5818-23; quiz 6153, 12/2010. e-Pub 10/2010. PMID: PMC4081278.
238. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. *Cancer* 116(24):5568-74, 12/2010. e-Pub 8/2010. PMID: PMC4332768.
239. de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. *Cancer* 116(23):5420-31, 12/2010. e-Pub 7/2010. PMID: 20672358.
240. Garcia-Manero G. Prognosis of myelodysplastic syndromes. *Hematology Am Soc Hematol Educ Program* 2010:330-7, 2010. PMID: 21239815.
241. Vigil CE, Martin-Santos T, Garcia-Manero G. Safety and efficacy of azacitidine in myelodysplastic syndromes. *Drug Des Devel Ther* 4:221-9, 2010. e-Pub 9/2010. PMID: PMC2948932.
242. Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. *BMC Med Genet* 11:163, 2010. e-Pub 11/2010. PMID: PMC2992491.

243. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespi T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MÁ, Valencia A, Florensa L, Sanz GF, Haase D, Solé F. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. *Leukemia* 25(1):110-20, 1/2011. e-Pub 9/2010. PMID: 20882045.
244. Garcia-Manero G. Nontransplantation options for patients with myelodysplastic syndromes. *Biol Blood Marrow Transplant* 17(1 Suppl):S9-10, 1/2011. PMID: 21195318.
245. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. *Cancer* 117(1):110-5, 1/2011. e-Pub 8/2010. PMID: PMC4287232.
246. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. *Clin Lymphoma Myeloma Leuk* 11(1):54-9, 2/2011. PMID: 21454191.
247. Quintás-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. *Leukemia* 25(2):226-35, 2/2011. e-Pub 11/2010. PMID: 21116282.
248. Garcia-Manero G, Fenaux P. Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes. *J Clin Oncol* 29(5):516-23, 2/2011. e-Pub 1/2011. PMID: PMC3056493.
249. Cortes J, Quintás-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. *Cancer* 117(3):572-80, 2/2011. e-Pub 9/2010. PMID: PMC4312759.
250. Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. *Am J Hematol* 86(2):237-8, 2/2011. PMID: PMC3652683.
251. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. *Blood* 117(6):1822-7, 2/2011. e-Pub 10/2010. PMID: PMC4081281.
252. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. *Cancer* 117(6):1236-44, 3/2011. e-Pub 10/2010. PMID: PMC4061136.
253. Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, Garcia-Manero G, Miranda RN. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. *Leuk Res* 35(3):351-7, 3/2011. e-Pub 8/2010. PMID: 20691474.
254. Santos FP, Kantarjian H, Garcia-Manero G, Ravandi F. The Search for Better Prognostic Models in Myelodysplastic Syndromes. *Curr Hematol Malig Rep* 6(1):13-21, 3/2011. e-Pub 12/2010. PMID: PMC4206196.
255. Wei Y, Gañán-Gómez I, Salazar-Dimicoli S, McCay SL, Garcia-Manero G. Histone methylation in myelodysplastic syndromes. *Epigenomics* 3(2):193-205, 4/2011. PMID: PMC3758889.
256. Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes:

- associations and prognostic implications. *Clin Lymphoma Myeloma Leuk* 11(2):237-41, 4/2011. e-Pub 4/2011. PMCID: PMC4120264.
257. Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. *J Clin Oncol* 29(15):1963-70, 5/2011. e-Pub 4/2011. PMID: 21519021.
258. Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. *Expert Opin Drug Metab Toxicol* 7(5):661-72, 5/2011. e-Pub 4/2011. PMID: 21500965.
259. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. *J Clin Oncol* 29(16):2240-6, 6/2011. e-Pub 5/2011. PMCID: PMC3107743.
260. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med* 364(26):2496-506, 6/2011. PMCID: PMC3159042.
261. Mallo M, Luño E, Sanzo C, Cervera J, Haase D, Schanz J, García-Manero G, del Cañizo C, Sanz GF, Solé F. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. *Leuk Res* 35(6):834-6, 6/2011. e-Pub 1/2011. PMID: 21269692.
262. Bumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. *Expert Opin Investig Drugs* 20(6):823-9, 6/2011. e-Pub 5/2011. PMID: 21554162.
263. Garcia-Manero G. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. *Am J Hematol* 86(6):490-8, 6/2011. PMID: 21594886.
264. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. *J Clin Oncol* 29(18):2507-13, 6/2011. e-Pub 5/2011. PMID: 21555694.
265. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. *J Clin Oncol* 29(18):2521-7, 6/2011. e-Pub 5/2011. PMCID: PMC3675699.
266. Zuo Z, Calin GA, de Paula HM, Medeiros LJ, Fernandez MH, Shimizu M, Garcia-Manero G, Bueso-Ramos CE. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. *Blood* 118(2):413-5, 7/2011. e-Pub 5/2011. PMCID: PMC3293748.
267. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. *Am J Hematol* 86(7):546-9, 7/2011. e-Pub 4/2011. PMID: 21509801.
268. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. *J Clin Oncol* 29(23):3173-8, 8/2011. e-Pub 7/2011. PMID: 21747082.
269. Al-Ameri A, Cherry M, Garcia-Manero G, Quintás-Cardama A. Standard therapy for patients with myelodysplastic syndromes. *Clin Lymphoma Myeloma Leuk* 11(4):303-13, 8/2011. PMID: 21816368.
270. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. *Blood* 118(17):4690-3, 10/2011. e-Pub 8/2011. PMCID: PMC4081364.

271. De Yao JT, Al-Ameri A, Garcia-Manero G, Quintás-Cardama A. Infrequent Presentations of Mucormycosis in Patients With Myelodysplastic Syndrome and Acute Leukemia: Case Series and Review of Literature. *Clin Lymphoma Myeloma Leuk* 11(5):446-51, 10/2011. e-Pub 8/2011. PMID: 21820986.
272. Garcia-Manero G. Integrating care for patients with lower risk myelodysplastic syndrome. *Semin Oncol* 38(5):658-66, 10/2011. PMID: 21943672.
273. Garcia-Manero G. Introduction: advances in myelodysplastic syndromes. *Semin Oncol* 38(5):612, 10/2011. PMID: 21943666.
274. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Blood* 118(17):4541-6; quiz 4759, 10/2011. e-Pub 7/2011. PMCID: PMC3291489.
275. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint? *Clin Lymphoma Myeloma Leuk* 11(5):421-6, 10/2011. e-Pub 8/2011. PMCID: PMC3215673.
276. Garcia-Manero G. Treatment of higher-risk myelodysplastic syndrome. *Semin Oncol* 38(5):673-81, 10/2011. PMID: 21943674.
277. Wood SM, Meyers CA, Faderl S, Kantarjian HM, Pierce SA, Garcia-Manero G. Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Am J Hematol* 86(11):950-2, 11/2011. e-Pub 9/2011. PMID: 21919036.
278. Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE. Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response? *J Clin Oncol* 29(32):4260-5, 11/2011. e-Pub 10/2011. PMCID: PMC3221527.
279. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. *J Clin Oncol* 29(31):4088-95, 11/2011. e-Pub 10/2011. PMID: 21969505.
280. Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. *Cancer* 117(22):5085-93, 11/2011. e-Pub 4/2011. PMCID: PMC4324753.
281. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. *Am J Hematol* 87(1):127-9, 1/2012. e-Pub 11/2011. PMCID: PMC4085038.
282. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. *Blood* 119(2):569-72, 1/2012. e-Pub 11/2011. PMID: 22096241.
283. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. *Cancer* 118(3):722-8, 2/2012. e-Pub 7/2011. PMCID: PMC4180241.
284. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G, Huang P. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. *Cell Res* 22(2):399-412, 2/2012. e-Pub 8/2011. PMCID: PMC3257361.
285. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. *Am J Hematol* 87(3):317-8, 3/2012. e-Pub 1/2012. PMCID: PMC4221258.

286. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. *Blood* 119(9):1981-7, 3/2012. e-Pub 1/2012. PMCID: PMC3311242.
287. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. *J Clin Oncol* 30(8):820-9, 3/2012. e-Pub 2/2012. PMID: 22331955.
288. Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. *Blood* 119(19):4524-6, 5/2012. e-Pub 3/2012. PMCID: PMC3362365.
289. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. *Br J Haematol* 157(3):312-20, 5/2012. e-Pub 2/2012. PMCID: PMC3924750.
290. Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA. Notch pathway activation induces neuroblastoma tumor cell growth arrest. *Pediatr Blood Cancer* 58(5):682-9, 5/2012. e-Pub 7/2011. PMCID: PMC3264695.
291. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. *Cancer* 118(10):2665-73, 5/2012. e-Pub 10/2011. PMCID: PMC4060157.
292. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. *Cancer* 118(11):2879-88, 6/2012. e-Pub 10/2011. PMID: 22038701.
293. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthakur G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. *Invest New Drugs* 30(3):1107-15, 6/2012. e-Pub 4/2011. PMCID: PMC4205950.
294. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. *J Clin Oncol* 30(18):2204-10, 6/2012. e-Pub 5/2012. PMID: 22585696.
295. Lu H, Marengo MF, Mihu CN, Garcia-Manero G, Suarez-Almazor ME. Rare Case of Septic Arthritis Caused by *Candida krusei*: Case Report and Literature Review. *J Rheumatol* 39(6):1308-9, 6/2012. PMID: 22661427.
296. Sampath D, Garcia-Manero G. Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. *Leuk Lymphoma* 53(6):1013-4, 6/2012. PMID: 22506546.
297. Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. *Cancer* 118(12):3116-22, 6/2012. e-Pub 2/2012. PMCID: PMC3370116.
298. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M,

- Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. *Cancer* 118(14):3556-64, 7/2012. e-Pub 12/2011. PMID: 22139909.
299. Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. *J Clin Oncol* 30(19):2340-7, 7/2012. e-Pub 5/2012. PMID: 22585703.
300. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. *Am J Hematol* 87(7):692-701, 7/2012. PMID: 22696212.
301. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell* 22(2):153-66, 8/2012. PMID: PMC3422513.
302. Tang G, Jorgensen LJ, Zhou Y, Hu Y, Kersh M, Garcia-Manero G, Medeiros LJ, Wang SA. Multi-color CD34(+) progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. *Leuk Res* 36(8):974-81, 8/2012. e-Pub 5/2012. PMID: 22626984.
303. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 12(4):244-51, 8/2012. e-Pub 4/2012. PMID: PMC3859239.
304. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. *Cancer* 118(18):4471-7, 9/2012. e-Pub 1/2012. PMID: PMC3907176.
305. Strom SS, Oum R, Elhor Gbeto KY, Garcia-Manero G, Yamamura Y. De novo acute myeloid leukemia risk factors: A Texas case-control study. *Cancer* 118(18):4589-96, 9/2012. e-Pub 2/2012. PMID: 22297571.
306. Sikkema AH, den Dunnen WF, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJ, Kampen KR, Hoving EW, Kamps WA, Diks SH, Peppelenbosch MP, de Bont ES. EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. *Neuro Oncol* 14(9):1125-35, 9/2012. e-Pub 6/2012. PMID: PMC3424207.
307. Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, LaFave LM, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM. Loss of the tumor suppressor BAP1 causes myeloid transformation. *Science* 337(6101):1541-6, 9/2012. e-Pub 8/2012. PMID: 22878500.
308. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. *Cancer* 118(18):4462-70, 9/2012. e-Pub 1/2012. PMID: PMC3913560.
309. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. *Blood* 120(12):2454-65, 9/2012. e-Pub 6/2012. PMID: PMC4425443.

310. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. *J Clin Oncol* 30(27):3376-82, 9/2012. e-Pub 8/2012. PMCID: PMC3438234.
311. Bumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. *Leukemia* 26(11):2428-31, 11/2012. e-Pub 6/2012. PMCID: PMC3981542.
312. Takahashi K, Yabe M, Shapira I, Pierce S, Garcia-Manero G, Varma M. Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. *Leuk Res* 36(11):1376-9, 11/2012. e-Pub 8/2012. PMID: 22917767.
313. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. *Cancer* 118(22):5550-9, 11/2012. e-Pub 5/2012. PMCID: PMC3416961.
314. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. *Lancet Oncol* 13(11):1096-104, 11/2012. e-Pub 10/2012. PMCID: PMC4004358.
315. Garcia-Manero G. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. *Best Pract Res Clin Haematol* 25(4):427-35, 12/2012. e-Pub 10/2012. PMID: 23200539.
316. Quintás-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. *Blood* 120(24):4840-5, 12/2012. e-Pub 10/2012. PMCID: PMC3952725.
317. Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). *J Hematol Oncol* 5:18, 2012. e-Pub 4/2012. PMCID: PMC3416694.
318. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. *Am J Hematol* 88(1):56-9, 1/2013. e-Pub 10/2012. PMCID: PMC4085099.
319. Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. *Leuk Lymphoma* 54(2):321-8, 2/2013. e-Pub 11/2012. PMID: 22906162.
320. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients with advanced myeloid malignancies. *Haematologica* 98(2):217-21, 2/2013. e-Pub 8/2012. PMCID: PMC3561428.
321. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. *Biol Blood Marrow Transplant* 19(2):214-20, 2/2013. e-Pub 9/2012. PMCID: PMC4106407.
322. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giral S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. *Am J Hematol* 88(3):198-200, 3/2013. e-Pub 1/2013. PMCID: PMC4085133.

323. Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintás-Cardama A. Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk* 13(2):139-43, 4/2013. e-Pub 12/2012. PMID: PMC4114759.
324. Li Y, Lin P, Ge Y, Garcia-Manero G. Myelodysplastic syndromes should be renamed as myelodysplastic neoplasms. *Leuk Res* 37(4):463-4, 4/2013. e-Pub 1/2013. PMID: 23347902.
325. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine. *Clin Lymphoma Myeloma Leuk* 13(2):131-8, 4/2013. e-Pub 12/2012. PMID: PMC4098775.
326. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. *Leukemia* 27(4):836-42, 4/2013. e-Pub 11/2012. PMID: PMC4181539.
327. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38 α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. *Leukemia* 27(4):977-80, 4/2013. e-Pub 9/2012. PMID: 23032694.
328. Attieh Y, Geng QR, Dinardo CD, Zheng H, Jia Y, Fang ZH, Gañán-Gómez I, Yang H, Wei Y, Kantarjian H, Garcia-Manero G. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. *Blood* 121(19):4009-11, 5/2013. PMID: 23660862.
329. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. *Am J Hematol* 88(5):365-9, 5/2013. e-Pub 3/2013. PMID: PMC4089101.
330. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study. *Clin Lymphoma Myeloma Leuk* 13(3):292-5, 6/2013. e-Pub 12/2012. PMID: PMC3860181.
331. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood* 121(23):4655-62, 6/2013. e-Pub 4/2013. PMID: PMC3674666.
332. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. *Br J Haematol* 161(5):659-66, 6/2013. e-Pub 3/2013. PMID: PMC4068703.
333. Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J. The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. *Clin Lymphoma Myeloma Leuk* 13(3):302-6, 6/2013. e-Pub 1/2013. PMID: PMC4160838.
334. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M. Myelodysplastic syndromes: clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 11(7):838-74, 7/2013. PMID: PMC4000017.
335. Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. *J Clin Oncol* 31(20):2548-53, 7/2013. e-Pub 6/2013. PMID: 23733767.
336. Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Lee SJ, Horowitz MM, Greenberg PL, Tallman MS, DiPersio JF, Bunjes D, Weisdorf DJ, Cutler C.

- Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. *J Clin Oncol* 31(21):2662-70, 7/2013. e-Pub 6/2013. PMID: PMC3825320.
337. Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy. *Clin Lymphoma Myeloma Leuk* 13(4):435-40, 8/2013. e-Pub 6/2013. PMID: PMC4114766.
 338. Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor? *Int J Cancer* 133(3):534-43, 8/2013. e-Pub 2/2013. PMID: PMC3904286.
 339. Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 13(4):477-84, 8/2013. e-Pub 6/2013. PMID: PMC3752280.
 340. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. *Eur J Cancer Care (Engl)* 22(5):605-11, 9/2013. e-Pub 5/2013. PMID: PMC3745781.
 341. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 13 Suppl 2:S276-81, 9/2013. e-Pub 8/2013. PMID: PMC4101888.
 342. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Res* 23(9):1446-61, 9/2013. e-Pub 6/2013. PMID: PMC3759721.
 343. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. *Clin Lymphoma Myeloma Leuk* 13 Suppl 2:S289-94, 9/2013. e-Pub 8/2013. PMID: PMC4120258.
 344. DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G, Rytting M. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. *Am J Hematol* 88(9):784-9, 9/2013. e-Pub 7/2013. PMID: PMC3947930.
 345. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganai-Gomez I, Kantarjian H, Garcia-Manero G. Toll-like receptor alterations in myelodysplastic syndrome. *Leukemia* 27(9):1832-40, 9/2013. e-Pub 6/2013. PMID: PMC4011663.
 346. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. *Am J Hematol* 88(10):831-7, 10/2013. e-Pub 7/2013. PMID: PMC3923606.

347. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. *Blood* 122(16):2807-11, 10/2013. e-Pub 7/2013. PMID: PMC3798995.
348. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. *Leukemia* 27(10):2081-3, 10/2013. e-Pub 6/2013. PMID: 23774633.
349. Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Mike Makrigiorgos G. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. *Leukemia* 27(10):2077-81, 10/2013. e-Pub 5/2013. PMID: PMC3967719.
350. Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD. Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. *Clin Lymphoma Myeloma Leuk* 13(5):559-67, 10/2013. e-Pub 6/2013. PMID: PMC3775947.
351. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. *Clin Lymphoma Myeloma Leuk* 13(5):592-6, 10/2013. e-Pub 6/2013. PMID: PMC4120256.
352. Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, Bueso-Ramos C, Verstovsek S, Garcia-Manero G, Medeiros LJ, Wang SA. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. *Ann Hematol* 92(10):1335-43, 10/2013. e-Pub 5/2013. PMID: PMC4190057.
353. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia (AML). *Am J Hematol* 88(11):961-6, 11/2013. e-Pub 9/2013. PMID: PMC4110914.
354. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganán-Gómez I, Ebert B, Levine R, Kantarjian H, Garcia-Manero G. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. *Leukemia* 27(11):2177-86, 11/2013. e-Pub 3/2013. PMID: 23538751.
355. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. *Leuk Res* 37(11):1461-7, 11/2013. e-Pub 8/2013. PMID: PMC4205589.
356. Gañán-Gómez I, Wei Y, Yang H, Boyano-Adánez MC, García-Manero G. Oncogenic functions of the transcription factor Nrf2. *Free Radic Biol Med* 65C:750-764, 12/2013. e-Pub 6/2013. PMID: 23820265.
357. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. *Am J Hematol* 88(12):1024-9, 12/2013. e-Pub 9/2013. PMID: PMC3849405.
358. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. *Clin Lymphoma Myeloma Leuk* 13(6):693-9, 12/2013. e-Pub 9/2013. PMID: PMC3835390.
359. Yamamura Y, Oum R, Gbitto KY, Garcia-Manero G, Strom SS. Dietary Intake of Vegetables, Fruits, and Meats/Beans as Potential Risk Factors of Acute Myeloid Leukemia: A Texas Case-Control Study. *Nutr Cancer* 65(8):1132-40, 2013. e-Pub 10/2013. PMID: 24168094.

360. Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Bumber Y, Garcia-Manero G. Epigenetic inactivation of notch-hes pathway in human B-cell acute lymphoblastic leukemia. *PLoS One* 8(4):e61807, 2013. e-Pub 4/2013. PMCID: PMC3637323.
361. Bashir Q, William BM, Garcia-Manero G, de Lima M. Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. *Rev Bras Hematol Hemoter* 35(2):126-33, 2013. PMCID: PMC3672123.
362. Lepore I, Dell'Aversana C, Pilyugin M, Conte M, Nebbioso A, De Bellis F, Tambaro FP, Izzo T, Garcia-Manero G, Ferrara F, Irminger-Finger I, Altucci L. HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b. *PLoS One* 8(12):e83018, 2013. e-Pub 12/2013. PMCID: PMC3859623.
363. Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D, Loh ML, Wu WS, Rodig SJ, Garcia-Manero G, Kantarjian HM, Look AT. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. *Elife* 2:e00825, 2013. e-Pub 7/2013. PMCID: PMC3713455.
364. Dimicoli S, Wei Y, Bueso-Ramos C, Yang H, Dinardo C, Jia Y, Zheng H, Fang Z, Nguyen M, Pierce S, Chen R, Wang H, Wu C, Garcia-Manero G. Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes. *PLoS One* 8(8):e71120, 2013. e-Pub 8/2013. PMCID: PMC3744562.
365. Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH, Patel K, Medeiros LJ, Garcia-Manero G, Wang SA. Application of the International Prognostic Scoring System-Revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. *Leukemia* 28(1):185-9, 1/2014. e-Pub 6/2013. PMID: 23787392.
366. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. *Am J Hematol* 89(1):97-108, 1/2014. PMID: 24464505.
367. Garcia-Manero G. Reply to T. Radivoyevitch et Al. *J Clin Oncol* 32(1):61, 1/2014. e-Pub 11/2013. PMID: 24248690.
368. Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. *Cytotherapy* 16(1):90-100, 1/2014. e-Pub 10/2013. PMCID: PMC4124936.
369. Lyons RM, Marek BJ, Paley C, Esposito J, Garbo L, DiBella N, Garcia-Manero G. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. *Leuk Res* 38(2):149-54, 2/2014. e-Pub 11/2013. PMID: 24314590.
370. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. *Cancer Chemother Pharmacol* 73(3):495-501, 3/2014. e-Pub 1/2014. PMCID: PMC4148903.
371. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garriss R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. *Am J Hematol* 89(3):282-7, 3/2014. PMCID: PMC4196860.
372. Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis. *Clin Lymphoma Myeloma Leuk* 14(2):93-7, 4/2014. e-Pub 11/2013. PMCID: PMC4098769.
373. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giral S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. *Am J Hematol* 89(4):395-8, 4/2014. e-Pub 3/2014. PMCID: PMC4140180.

374. Stevenson WS, Best OG, Przybylla A, Chen Q, Singh N, Koleth M, Pierce S, Kennedy T, Tong W, Kuang SQ, Garcia-Manero G. DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia. *Leukemia* 28(4):787-93, 4/2014. e-Pub 9/2013. PMID: 24045499.
375. Kplola Y, Gbita E, Garcia-Manero G, Strom SS. Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes. *Cancer Causes Control* 25(4):425-35, 4/2014. e-Pub 1/2014. PMID: 24463789.
376. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. *Leukemia* 28(4):958-61, 4/2014. e-Pub 1/2014. PMID: PMC3981947.
377. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplastic syndrome and chronic myelomonocytic leukemia post clofarabine failure. *Ther Adv Hematol* 5(2):29-34, 4/2014. PMID: PMC3949300.
378. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics. *Clin Lymphoma Myeloma Leuk* 14(2):163-71, 4/2014. e-Pub 1/2014. PMID: PMC4167660.
379. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. *Clin Lymphoma Myeloma Leuk* 14(2):155-162.e1, 4/2014. e-Pub 12/2013. PMID: PMC3959284.
380. Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line. *Leukemia* 28(5):1142-5, 5/2014. e-Pub 12/2013. PMID: PMC4215634.
381. Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, Miranda RN, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Luthra R, Khoury JD. BRAF Kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with Wild-Type RAS. *Am J Hematol* 89(5):499-504, 5/2014. e-Pub 2/2014. PMID: PMC4207363.
382. Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the Revised-IPSS for patients with myelodysplastic syndromes. *Am J Hematol* 89(5):509-16, 5/2014. e-Pub 2/2014. PMID: PMC4221257.
383. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis. *Clin Lymphoma Myeloma Leuk* 14(3):223-30, 6/2014. e-Pub 11/2013. PMID: PMC4096861.
384. Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvalo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. *Leuk Lymphoma* 55(6):1431-4, 6/2014. e-Pub 11/2013. PMID: PMC4105975.
385. Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, Dennison B, Sekeres MA. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. *Cancer* 120(11):1670-6, 6/2014. e-Pub 2/2014. PMID: 24577838.
386. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. *Leukemia* 28(6):1280-8, 6/2014. e-Pub 11/2013. PMID: PMC4032802.

387. Liu X, Robinson SN, Setoyama T, Tung SS, D'Abundo L, Shah MY, Yang H, Yvon E, Shah N, Yang H, Konopleva M, Garcia-Manero G, McNiece I, Rezvani K, Calin GA, Shpall EJ, Parmar S. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. *Bone Marrow Transplant* 0(6):793-9, 6/2014. e-Pub 4/2014. PMCID: PMC4080423.
388. Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z. Interaction Between Myelomonocytic and Lymphoid Cells in a Patient with Acute MyeloMonocytic Leukemia and Chronic Lymphocytic Leukemia. *Leuk Lymphoma* 55(6):1425-7, 6/2014. e-Pub 1/2014. PMCID: PMC4204466.
389. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated Nucleophosmin-1 (NPM1) in patients with Acute Myeloid Leukemia (AML) in remission and relapse. *Leuk Lymphoma* 55(6):1337-44, 6/2014. e-Pub 10/2013. PMCID: PMC4143910.
390. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. *Leukemia* 28(7):1543-5, 7/2014. e-Pub 2/2014. PMCID: PMC4091714.
391. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. *Cancer* 120(14):2142-9, 7/2014. e-Pub 4/2014. PMCID: PMC4124083.
392. Tang G, Zhang L, Fu B, Hu J, Lu X, Hu S, Patel A, Goswami M, Khoury JD, Garcia-Manero G, Medeiros LJ, Wang SA. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. *Am J Hematol* 89(8):813-8, 8/2014. e-Pub 5/2014. PMCID: PMC4354712.
393. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents. *Leuk Lymphoma* 55(8):1925-9, 8/2014. e-Pub 2/2014. PMCID: PMC4139917.
394. Garcia-Manero G, Gartenberg G, Steensma DP, Schipperus MR, Breems DA, de Paz R, Valcárcel D, Kranenburg B, Reddy M, Komrokji RS. A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome. *Am J Hematol* 89(9):E156-62, 9/2014. e-Pub 6/2014. PMID: 24888488.
395. Bravo GM, Lee E, Merchan B, Kantarjian HM, García-Manero G. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. *Br J Haematol* 166(5):646-59, 9/2014. e-Pub 6/2014. PMID: 24903747.
396. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 14(5):401-10, 10/2014. e-Pub 5/2014. PMCID: PMC4167474.
397. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. *Am J Hematol* 89(10):964-8, 10/2014. e-Pub 7/2014. PMCID: PMC4431614.
398. Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood* 124(17):2705-12, 10/2014. e-Pub 9/2014. PMCID: PMC4208285.

399. Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. *Br J Haematol* 167(3):356-65, 11/2014. e-Pub 7/2014. PMCID: PMC4198465.
400. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garriss R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). *Cancer* 120(23):3660-8, 12/2014. e-Pub 7/2014. PMCID: PMC4239168.
401. Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors - single institution experience. *Leuk Lymphoma* 55(12):2879-86, 12/2014. e-Pub 9/2013. PMCID: PMC4127158.
402. Shah S, Loghavi S, Garcia-Manero G, Khoury JD. Discovery of imatinib-responsive FIP1L1-PDGFR α mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. *J Hematol Oncol* 7:26, 2014. e-Pub 3/2014. PMCID: PMC3994268.
403. Gañán-Gómez I, Wei Y, Yang H, Pierce S, Bueso-Ramos C, Calin G, Boyano-Adánez Mdel C, García-Manero G. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF- κ B activation and enhances erythroid differentiation arrest. *PLoS One* 9(4):e93404, 2014. e-Pub 4/2014. PMCID: PMC3972113.
404. DiNardo CD, Tang G, Pemmaraju N, Wang SA, Pike A, Garcia-Manero G, Cortes J, Bueso-Ramos C, Kantarjian HM. Acute Myeloid Leukemia With t(10;11): A Pathological Entity With Distinct Clinical Presentation. *Clin Lymphoma Myeloma Leuk* 15(1):47-51, 1/2015. e-Pub 6/2014. PMCID: PMC4849878.
405. Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, Ravandi F. Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. *Am J Hematol* 90(1):27-30, 1/2015. e-Pub 10/2014. PMCID: PMC4276516.
406. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. *Lancet Haematol* 2(1):e12-20, 1/2015. e-Pub 12/2014. PMCID: PMC4936479.
407. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 15(2):110-4, 2/2015. e-Pub 7/2014. PMCID: PMC4294996.
408. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. *Am J Hematol* 90(2):120-4, 2/2015. e-Pub 11/2014. PMCID: PMC4447180.
409. Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. *Cancer* 121(4):556-61, 2/2015. e-Pub 10/2014. PMCID: PMC4320000.
410. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The Effect of Decitabine Dose Modification and Myelosuppression on

- Response and Survival in Patients With Myelodysplastic Syndromes. *Leuk Lymphoma* 56(2):1-21, 2/2015. e-Pub 7/2014. PMID: PMC4297591.
411. Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannon Z, List A, Kantarjian H, Komrokji R. A Phase 1 Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate 1 Risk Myelodysplastic Syndromes. *Clin Cancer Res* 21(5):985-94, 3/2015. e-Pub 12/2014. PMID: PMC4348327.
 412. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 15(3):171-6, 3/2015. e-Pub 9/2014. PMID: PMC4344906.
 413. Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjan JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF, MDS/MPN International Working Group. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. *Blood* 125(12):1857-65, 3/2015. e-Pub 1/2015. PMID: PMC4915792.
 414. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. *Br J Haematol* 168(5):646-53, 3/2015. e-Pub 10/2014. PMID: PMC4323735.
 415. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. *Leuk Res* 39(3):348-54, 3/2015. e-Pub 12/2014. PMID: 25573287.
 416. Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C, National comprehensive cancer network. Myelodysplastic syndromes, version 2.2015. *J Natl Compr Canc Netw* 13(3):261-72, 3/2015. PMID: PMC4696005.
 417. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, DeZern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. *Cancer* 121(6):876-82, 3/2015. e-Pub 11/2014. PMID: PMC4378905.
 418. Zuo Z, Maiti S, Hu S, Loghavi S, Calin GA, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Cooper LJ, Bueso-Ramos CE. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. *Mod Pathol* 28(3):373-82, 3/2015. e-Pub 9/2014. PMID: 25216221.
 419. Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a cd22 monoclonal antibody. *Am J Hematol* 90(3):193-6, 3/2015. e-Pub 1/2015. PMID: 25407953.
 420. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. *Leuk Lymphoma* 56(4):1-8, 4/2015. e-Pub 8/2014. PMID: PMC4326620.
 421. Montalban-Bravo G, Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. *Leukemia* 29(4):760-9, 4/2015. e-Pub 8/2014. PMID: 25142817.

422. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *Am J Hematol* 90(4):276-81, 4/2015. e-Pub 3/2015. PMCID: PMC4376596.
423. Jabbour E, Garcia-Manero G. Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes. *Leuk Lymphoma* 56(5):1-26, 5/2015. e-Pub 2/2015. PMID: 25058371.
424. Cabrero M, Jabbour E, Ravandi F, Bohannon Z, Pierce S, Kantarjian HM, Garcia-Manero G. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. *Leuk Res* 39(5):520-4, 5/2015. e-Pub 3/2015. PMCID: PMC4826042.
425. Daver N, Thomas D, Ravandi F, Cortes J, Garriss R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. *Haematologica* 100(5):653-61, 5/2015. e-Pub 2/2015. PMCID: PMC4420214.
426. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Cortes J, Estrov Z. Incidence of and risk factors for acute myeloid leukemia involvement of the central nervous system. *Leuk Lymphoma* 56(5):1-19, 5/2015. e-Pub 11/2014. PMCID: PMC4417664.
427. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. *Leuk Lymphoma* 56(5):1-12, 5/2015. e-Pub 11/2014. PMCID: PMC4417657.
428. Estécio MR, Maddipati S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, Pierce SA, Bohannon Z, Borthakur G, Kantarjian H, Garcia-Manero G. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. *Br J Haematol* 169(3):344-51, 5/2015. e-Pub 1/2015. PMCID: PMC4762375.
429. Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. *Cancer Cell* 27(5):644-57, 5/2015. PMCID: PMC4596059.
430. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. *J Hematol Oncol* 8(1):45, 5/2015. e-Pub 5/2015. PMCID: PMC4431603.
431. Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. *Br J Haematol* 169(4):595-7, 5/2015. e-Pub 11/2014. PMCID: PMC4414662.
432. Yabe M, Tang G, Garcia-Manero G, Loghavi S, Lu X, Miranda RN, Medeiros LJ, Kantarjian HM, Bueso-Ramos CE, Khoury JD. Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. *Clin Lymphoma Myeloma Leuk* 15 Suppl:S85-90, 6/2015. PMID: 26297286.
433. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 15(6):358-63, 6/2015. e-Pub 12/2014. PMCID: PMC4457594.
434. Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES. EphB1 Suppression in Acute Myeloid

- Leukemia: Regulating the DNA Damage Control System. *Mol Cancer Res* 13(6):982-92, 6/2015. e-Pub 5/2015. PMCID: PMC4983719.
435. Gañán-Gómez I, Bohannan ZS, Garcia-Manero G. p38 MAPK in MDS. *Aging (Albany NY)* 7(6):346-7, 6/2015. PMCID: PMC4505155.
 436. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. *Blood Cancer J* 5:e333, 7/2015. e-Pub 7/2015. PMCID: PMC4526779.
 437. Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. *Am J Hematol* 90(7):E134-5, 7/2015. e-Pub 3/2015. PMCID: PMC4948743.
 438. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. *Leukemia* 29(7):1458-69, 7/2015. e-Pub 3/2015. PMCID: PMC4857136.
 439. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. *Cancer* 121(14):2375-82, 7/2015. e-Pub 3/2015. PMID: 25809968.
 440. Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies. *Clin Lymphoma Myeloma Leuk* 15(7):433-438.e2, 7/2015. e-Pub 2/2015. PMCID: PMC4509631.
 441. Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). *Leukemia* 29(7):1502-13, 7/2015. e-Pub 2/2015. PMID: 25721895.
 442. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. *Am J Hematol* 90(8):732-6, 8/2015. e-Pub 5/2015. PMCID: PMC4612499.
 443. Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G. Chronic myelomonocytic leukemia: Forefront of the field in 2015. *Crit Rev Oncol Hematol* 95(2):222-42, 8/2015. e-Pub 3/2015. PMCID: PMC4859155.
 444. Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS, MDS Clinical Research Consortium. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better? *Am J Hematol*. e-Pub 8/2015. PMCID: PMC4751065.
 445. Shen Q, Ouyang J, Tang G, Jabbour EJ, Garcia-Manero G, Routbort M, Konoplev S, Bueso-Ramos C, Medeiros LJ, Jorgensen JL, Wang SA. Flow Cytometry Immunophenotypic Findings in Chronic Myelomonocytic Leukemia and Its Utility in Monitoring Treatment Response. *Eur J Haematol* 95(2):168-76, 8/2015. e-Pub 4/2015. PMID: 25354960.
 446. Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase

- inhibitor, in patients with hematologic malignancies. *Invest New Drugs* 33(4):870-80, 8/2015. e-Pub 5/2015. PMID: 25933833.
447. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. *Br J Haematol* 170(4):590-3, 8/2015. e-Pub 2/2015. PMCID: PMC4977576.
 448. Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, Ozeck M, Aster JC, Kuo F, Huang D, Lira PD, McLachlan KR, Kern KA, Garcia-Manero G, Martinelli G. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. *Blood Cancer J* 5:e350, 9/2015. e-Pub 9/2015. PMCID: PMC4648526.
 449. Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. *Haematologica* 100(9):1117-30, 9/2015. PMCID: PMC4800699.
 450. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. *Am J Hematol* 90(9):769-73, 9/2015. e-Pub 7/2015. PMCID: PMC4546505.
 451. Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. *Clin Lymphoma Myeloma Leuk* 15(9):556-62, 9/2015. e-Pub 6/2015. PMCID: PMC4837956.
 452. Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. *Am J Hematol* 90(9):831-41, 9/2015. PMID: 26294090.
 453. Falantes JF, Garcia-Manero G. Does the concept of lower-risk myelodysplastic syndrome need to be revisited? *Leuk Res* 39(10):1003-5, 10/2015. e-Pub 6/2015. PMID: 26198376.
 454. Loghavi S, Al-Ibraheemi A, Zuo Z, Garcia-Manero G, Yabe M, Wang SA, Kantarjian HM, Yin CC, Miranda RN, Luthra R, Medeiros LJ, Bueso-Ramos CE, Khoury JD. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. *Br J Haematol* 171(1):91-9, 10/2015. e-Pub 6/2015. PMCID: PMC5577911.
 455. Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, Bailey SL, Bhavsar EB, Chan B, Colla S, Corson L, Feala J, Fekkes P, Ichikawa K, Keaney GF, Lee L, Kumar P, Kunii K, MacKenzie C, Matijevic M, Mizui Y, Myint K, Park ES, Puyang X, Selvaraj A, Thomas MP, Tsai J, Wang JY, Warmuth M, Yang H, Zhu P, Garcia-Manero G, Furman RR, Yu L, Smith PG, Buonamici S. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. *Cell Rep* 13(5):1033-45, 11/2015. e-Pub 10/2015. PMID: 26565915.
 456. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannon Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. *Lancet Oncol* 16(15):1547-55, 11/2015. e-Pub 9/2015. PMCID: PMC4816046.
 457. Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS, MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? *Am J Hematol* 90(11):1036-40, 11/2015. PMID: 26284571.
 458. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid

- leukemia patients over the last one and a half decade. *Am J Hematol* 90(11):1065-70, 11/2015. e-Pub 9/2015. PMCID: PMC4618182.
459. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. *Leuk Res* 39(12):1367-74, 12/2015. e-Pub 10/2015. PMCID: PMC4822515.
 460. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garriss R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Cancer* 121(23):4158-64, 12/2015. e-Pub 8/2015. PMCID: PMC4666803.
 461. Cogle CR, Scott BL, Boyd T, Garcia-Manero G. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Oncologist* 20(12):1404-12, 12/2015. e-Pub 10/2015. PMCID: PMC4679081.
 462. Yang H, Maddipati S, Quesada A, Bohannan Z, Cabrero Calvo M, Colla S, Wei Y, Estecio M, Wierda W, Bueso-Ramos C, Garcia-Manero G. Analysis of class I and II histone deacetylase gene expression in human leukemia. *Leuk Lymphoma* 56(12):1-8, 2015. e-Pub 5/2015. PMCID: PMC4762655.
 463. Laille E, Shi T, Garcia-Manero G, Cogle CR, Gore SD, Hetzer J, Kumar K, Skikne B, MacBeth KJ. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. *PLoS One* 10(8):e0135520, 2015. e-Pub 8/2015. PMCID: PMC4546409.
 464. Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine. *Biomed Res Int* 2015:497597, 2015. e-Pub 1/2015. PMCID: PMC4310492.
 465. Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. *Leukemia* 30(1):243-7, 1/2016. e-Pub 5/2015. PMID: 25975189.
 466. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. *Biol Blood Marrow Transplant* 22(1):47-53, 1/2016. e-Pub 9/2015. PMCID: PMC4892364.
 467. Chamseddine AN, Jabbour E, Kantarjian HM, Bohannan ZS, Garcia-Manero G. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. *Curr Oncol Rep* 18(1):4, 1/2016. PMID: 26700507.
 468. Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. *Leukemia* 30(2):268-73, 2/2016. e-Pub 9/2015. PMCID: PMC4790089.
 469. Roboz GJ, Montesinos P, Selleslag D, Wei A, Jang JH, Falantes J, Voso MT, Sayar H, Porkka K, Marlton P, Almeida A, Mohan S, Ravandi F, Garcia-Manero G, Skikne B, Kantarjian H. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. *Future Oncol* 12(3):293-302, 2/2016. e-Pub 1/2016. PMCID: PMC5684733.

470. DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes J, Kantarjian H. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). *Am J Hematol* 91(2):227-32, 2/2016. PMID: 26799610.
471. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. *Br J Haematol* 172(3):392-400, 2/2016. e-Pub 10/2015. PMCID: PMC4826052.
472. Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG. Outcomes for patients with Chronic Lymphocytic Leukemia (CLL) and Acute leukemia or myelodysplastic syndrome. *Leukemia* 30(2):325-30, 2/2016. e-Pub 8/2015. PMCID: PMC4794262.
473. Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS, MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. *Leuk Res* 41:43-7, 2/2016. e-Pub 12/2015. PMCID: PMC4986515.
474. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. *Oncotarget* 7(12):14172-87, 3/2016. e-Pub 2/2016. PMCID: PMC4924706.
475. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. *Clin Lymphoma Myeloma Leuk* 16(3):163-168.e2, 3/2016. e-Pub 11/2015. PMCID: PMC4804759.
476. Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R, MDS Clinical Research Consortium. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. *Leukemia* 30(3):649-57, 3/2016. e-Pub 10/2015. PMCID: PMC4775363.
477. Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. *Oncotarget* 7(12):14251-8, 3/2016. e-Pub 2/2016. PMCID: PMC4924712.
478. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannon Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultonwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. *Br J Haematol* 173(1):161-5, 4/2016. e-Pub 6/2015. PMID: 26105212.
479. Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. *Leukemia* 30(4):889-96, 4/2016. e-Pub 10/2015. PMCID: PMC4832070.
480. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. *Leukemia* 30(4):980-4, 4/2016. e-Pub 7/2015. PMCID: PMC4733599.
481. Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero G, Thomas D, Pierce S, Verstovsek S, Borthakur G, Cortes J. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute

- Myeloid Leukemia (AML). *Clin Lymphoma Myeloma Leuk* 16(4):213-222.e2, 4/2016. e-Pub 1/2016. PMID: PMC4811701.
482. Huang L, Garcia-Manero G, Jabbour E, Goswami M, Routbort MJ, Medeiros LJ, Jorgensen JL, Wang SA. Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. *J Clin Pathol*. e-Pub 4/2016. PMID: 27083210.
 483. Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. *Lancet Oncol* 17(4):496-508, 4/2016. e-Pub 3/2016. PMID: 26968357.
 484. Cabrero M, Wei Y, Yang H, Ganán-Gómez I, Bohannon Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. *Leuk Res* 44:1-7, 5/2016. e-Pub 2/2016. PMID: 26970171.
 485. Hong M, Hao S, Patel KP, Kantarjian HM, Garcia-Manero G, Yin CC, Medeiros LJ, Lin P, Lu X. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. *Cancer Genet* 209(5):205-14, 5/2016. e-Pub 4/2016. PMID: 27134073.
 486. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. *Cancer* 122(12):1871-9, 6/2016. e-Pub 3/2016. PMID: 26990290.
 487. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA, MDS Clinical Research Consortium. The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes at the Time of Hypomethylating Agent Failure. *Haematologica* 101(6):e224-7, 6/2016. e-Pub 3/2016. PMID: PMC5013943.
 488. DiNardo CD, Bannan SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). *Clin Lymphoma Myeloma Leuk* 16(7):417-428.e2, 7/2016. e-Pub 4/2016. PMID: PMC4925265.
 489. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garriss R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood* 128(4):504-7, 7/2016. e-Pub 5/2016. PMID: PMC4965905.
 490. Huang A, Ju HQ, Liu K, Zhan G, Liu D, Wen S, Garcia-Manero G, Huang P, Hu Y. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. *Cancer Lett* 377(2):149-57, 7/2016. e-Pub 4/2016. PMID: 27132990.
 491. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantaji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. *Cancer* 122(14):2186-96, 7/2016. e-Pub 5/2016. PMID: 27142181.
 492. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid

- leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. *Cancer*. e-Pub 7/2016. PMCID: PMC5269552.
493. Sanford D, Garcia-Manero G, Jorgensen J, Konoplev S, Pierce S, Cortes J, Kantarjian H, Ravandi F. CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. *Leuk Lymphoma* 57(8):1-4, 8/2016. e-Pub 1/2016. PMID: 26726757.
 494. Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. *BMC Cancer* 16:652, 8/2016. e-Pub 8/2016. PMCID: PMC4991094.
 495. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. *Blood*. e-Pub 8/2016. PMID: 27535995.
 496. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. *Am J Hematol* 91(8):819-23, 8/2016. e-Pub 6/2016. PMID: 27178680.
 497. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. *Haematologica* 101(8):e324-7, 8/2016. e-Pub 5/2016. PMCID: PMC4967581.
 498. Chamseddine AN, Cabrero M, Wei Y, Ganon-Gomez I, Colla S, Takahashi K, Yang H, Bohannon ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. *Clin Lymphoma Myeloma Leuk* 16 Suppl:S67-73, 8/2016. PMID: 27521329.
 499. Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL. Time-dependent changes in mortality and transformation risk in MDS. *Blood* 128(7):902-10, 8/2016. e-Pub 6/2016. PMCID: PMC5161006.
 500. Chihara D, Masarova L, Newberry KJ, Maeng H, Ravandi F, Garcia-Manero G, Ferrajoli A, Cortes J, Kantarjian H, Verstovsek S. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. *Leuk Res* 48:1-5, 9/2016. e-Pub 6/2016. PMID: 27416326.
 501. Tamamyian GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. *Cancer* 122(18):2857-66, 9/2016. e-Pub 5/2016. PMCID: PMC5014667.
 502. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with

- chronic myeloid leukemia in chronic phase. *Cancer* 122(21):3336-3343, 11/2016. e-Pub 8/2016. PMID: PMC5073019.
503. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. *Clin Lymphoma Myeloma Leuk* 16(11):616-624, 11/2016. e-Pub 8/2016. PMID: 27601000.
 504. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garriss RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. *Cancer* 122(23):3650-3656, 12/2016. e-Pub 8/2016. PMID: 27479888.
 505. Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. *Blood* 128(24):2819-2823, 12/2016. e-Pub 10/2016. PMID: PMC5159704.
 506. Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to AML induction chemotherapy. *Am J Hematol* 91(12):1221-1226, 12/2016. e-Pub 8/2016. PMID: PMC5118152.
 507. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. *Cancer* 122(24):3812-3820, 12/2016. e-Pub 8/2016. PMID: 27508525.
 508. Garcia-Manero G, Almeida A, Giagounidis A, Platzbecker U, Garcia R, Voso MT, Larsen SR, Valcarcel D, Silverman LR, Skikne B, Santini V. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. *BMC Hematol* 16:12, 2016. e-Pub 5/2016. PMID: PMC4855808.
 509. Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Wang SA. Myelodysplastic Syndromes Following Therapy with Hypomethylating Agents (HMAs): Development of Acute Erythroleukemia May Not Influence Assessment of Treatment Response. *Leuk Lymphoma* 57(4):1-19, 2016. e-Pub 3/2016. PMID: 26293512.
 510. Zhang C, Suo J, Katayama H, Wei Y, Garcia-Manero G, Hanash S. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. *Clin Proteomics* 13:14, 2016. e-Pub 7/2016. PMID: PMC4932764.
 511. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. *Am J Hematol* 92(1):7-11, 1/2017. e-Pub 12/2016. PMID: PMC5361214.
 512. Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias - (de novo and blast phase CML). *Am J Hematol* 92(1):E3-E4, 1/2017. e-Pub 11/2016. PMID: PMC5551407.
 513. Alfonso A, Montalban-Bravo G, Garcia-Manero G. Current management of patients with chronic myelomonocytic leukemia. *Curr Opin Oncol* 29(1):79-87, 1/2017. e-Pub 11/2016. PMID: 27849645.
 514. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K,

- Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. *Cancer* 123(2):294-302, 1/2017. e-Pub 9/2016. PMCID: PMC5321541.
515. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 15(1):60-87, 1/2017. PMID: 28040720.
 516. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. *Lancet Oncol* 18(1):100-111, 1/2017. e-Pub 12/2016. PMCID: PMC5405697.
 517. Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. *Leukemia* 31(2):318-324, 2/2017. e-Pub 10/2016. PMID: 27795561.
 518. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. *Cancer* 123(4):609-616, 2/2017. e-Pub 10/2016. PMCID: PMC5293656.
 519. Montalban-Bravo , Takahashi K, Garcia-Manero G. Decitabine in TP53-Mutated AML. *N Engl J Med* 376(8):796-7, 2/2017. PMID: 28229579.
 520. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. *Cancer* 123(3):426-435, 2/2017. e-Pub 9/2016. PMCID: PMC5258784.
 521. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. *Cancer* 123(4):629-637, 2/2017. e-Pub 10/2016. PMID: 27741352.
 522. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. *Blood* 129(5):572-581, 2/2017. e-Pub 12/2016. PMCID: PMC5290985.
 523. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. *Cancer* 123(3):459-467, 2/2017. e-Pub 10/2016. PMCID: PMC5321542.
 524. Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, Salomonis N, Geiger H, Zheng Y, Starczynowski DT. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. *Nat Immunol* 18(2):236-245, 2/2017. e-Pub 12/2016. PMCID: PMC5423405.
 525. Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L,

- Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. *Transfusion* 57(2):289-295, 2/2017. e-Pub 11/2016. PMCID: PMC5309168.
526. Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, Salamonis N, Geiger H, Zheng Y, Starczynowski DT. Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. *Nat Immunol* 18(4):474, 3/2017. PMCID: PMC5505686.
 527. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. *Blood* 129(10):1275-1283, 3/2017. e-Pub 12/2016. PMCID: PMC5413297.
 528. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garriss R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. *Am J Hematol* 92(3):238-243, 3/2017. e-Pub 2/2017. PMCID: PMC5495018.
 529. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garriss R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. *Am J Hematol* 92(3):279-285, 3/2017. e-Pub 2/2017. PMID: 28052371.
 530. Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. *Leuk Lymphoma* 58(4):1-6, 4/2017. e-Pub 8/2016. PMCID: PMC5521009.
 531. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. *Am J Hematol* 92(4):351-358, 4/2017. e-Pub 2/2017. PMCID: PMC5439522.
 532. Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML, or AML with 30% blasts. *Leukemia*. e-Pub 5/2017. PMID: 28546581.
 533. Nebbioso A, Carafa V, Conte M, Tambaro FP, Abbondanza C, Martens J, Nees M, Benedetti R, Pallavicini I, Minucci S, Garcia-Manero G, Iovino F, Lania G, Ingenito C, Belsito Petrizzi V, Stunnenberg HG, Altucci L. c-Myc modulation & acetylation is a key HDAC inhibitor target in cancer. *Clin Cancer Res* 23(10):2542-2555, 5/2017. e-Pub 6/2016. PMID: 27358484.
 534. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. *Blood* 129(18):2584-2587, 5/2017. e-Pub 2/2017. PMCID: PMC5418636.
 535. Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes. *Cancer* 123(6):994-1002, 5/2017. e-Pub 1/2017. PMCID: PMC5432122.

536. Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Richards PD, DiBella N, Garcia-Manero G. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. *Leuk Res* 56:88-95, 5/2017. e-Pub 1/2017. PMID: 28242540.
537. Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium. *Leukemia* 31(6):1391-1397, 6/2017. e-Pub 1/2017. PMID: 28111463.
538. Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. *Blood Adv* 1(15):1031-1036, 6/2017. e-Pub 6/2017. PMCID: PMC5728325.
539. DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA, Evans MDS Clinical Research Consortium. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). *Leuk Lymphoma* 58(6):1-7, 6/2017. e-Pub 10/2016. PMCID: PMC5394924.
540. Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. *Mol Cancer Ther* 16(6):1133-1144, 6/2017. e-Pub 3/2017. PMCID: PMC5457713.
541. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. *Am J Hematol* 92(6):E114-E117, 6/2017. e-Pub 4/2017. PMID: 28295472.
542. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. *Leukemia* 31(7):1659, 7/2017. e-Pub 3/2017. PMID: 28338082.
543. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma*:1-8. e-Pub 7/2017. PMID: 28718728.
544. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. *Cancer*. e-Pub 7/2017. PMID: 28708931.
545. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. *Am J Hematol* 92(7):674-682, 7/2017. e-Pub 6/2017. PMCID: PMC5580683.
546. Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganon-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. *Cancer Cell* 32(1):88-100.e6, 7/2017. e-Pub 6/2017. PMCID: PMC5593798.

547. Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. *Am J Hematol* 92(7):599-606, 7/2017. e-Pub 5/2017. PMID: PMC5553721.
548. Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. *Appl Immunohistochem Mol Morphol*. e-Pub 7/2017. PMID: 28682832.
549. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. *Cancer*. e-Pub 7/2017. PMID: 28743165.
550. Hidalgo-López JE, Kanagal-Shamanna R, Quesada AE, Thakral B, Hu Z, Mitsuhashi T, Yabe M, Garcia-Manero G, Bueso-Ramos CE. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints. *Clin Lymphoma Myeloma Leuk* 17S:S16-S25, 7/2017. PMID: 28760297.
551. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. *Leuk Lymphoma*:1-13. e-Pub 7/2017. PMID: 28679300.
552. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. *Blood Adv* 1(17):1312-1323, 7/2017. e-Pub 7/2017. PMID: PMC5727976.
553. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. *Cancer* 123(16):3050-3060, 8/2017. e-Pub 4/2017. PMID: PMC5544569.
554. Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. *Cancer*. e-Pub 8/2017. PMID: 28841236.
555. Yang H, Fang Z, Wei Y, Bohannon ZS, Gañán-Gómez I, Pierola AA, Paradiso LJ, Iwamura H, Garcia-Manero G. Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. *Leuk Res* 59:85-92, 8/2017. e-Pub 5/2017. PMID: 28599189.
556. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. *Clin Lymphoma Myeloma Leuk*. e-Pub 8/2017. PMID: 28927784.
557. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garriss R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. *JAMA Oncol*. e-Pub 8/2017. PMID: 28859185.
558. Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in

- hypomethylating agent-treated acute myeloid leukemia. *Leuk Lymphoma*:1-4. e-Pub 8/2017. PMID: 28838278.
559. Kanagal-Shamanna R, Hidalgo Lopez JE, Milton DR, Kim HR, Zhao C, Zuo Z, Janania Martinez M, Stingo F, Lee J, Luthra R, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. *Am J Hematol* 92(8):E168-E171, 8/2017. e-Pub 5/2017. PMID: 28456995.
 560. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. *Blood* 130(13):1514-1522, 9/2017. e-Pub 8/2017. PMCID: PMC5620419.
 561. Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. *Eur J Haematol*. e-Pub 9/2017. PMID: 28926144.
 562. Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. *J Cutan Pathol*. e-Pub 9/2017. PMID: 28885734.
 563. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. *Am J Hematol* 92(9):924-928, 9/2017. e-Pub 7/2017. PMID: 28556489.
 564. Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. *Am J Hematol* 92(9):845-850, 9/2017. e-Pub 6/2017. PMID: 28494506.
 565. Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. *Leuk Lymphoma* 58(9):1-6, 9/2017. e-Pub 2/2017. PMCID: PMC5478443.
 566. Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. *Haematologica* 102(10):1661-1670, 10/2017. e-Pub 6/2017. PMCID: PMC5622850.
 567. Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naïve patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. *Lancet Oncol* 18(10):1317-1326, 10/2017. e-Pub 8/2017. PMID: 28844816.
 568. Ju HQ, Zhan G, Huang A, Sun Y, Wen S, Yang J, Lu WH, Xu RH, Li J, Li Y, Garcia-Manero G, Huang P, Hu Y. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. *Leukemia* 31(10):2143-2150, 10/2017. e-Pub 1/2017. PMCID: PMC5629368.
 569. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhurairi A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. *Leuk Lymphoma*:1-11. e-Pub 10/2017. PMID: 28972430.

570. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garriss R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. *Cancer* 123(19):3717-3724, 10/2017. e-Pub 6/2017. PMID: 28608976.
571. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. *Haematologica* 102(10):1709-1717, 10/2017. e-Pub 7/2017. PMCID: PMC5622855.
572. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment. *Blood* 130(19):2084-2091, 11/2017. e-Pub 8/2017. PMID: 28835440.
573. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. *Leuk Lymphoma*:1-5. e-Pub 11/2017. PMID: 29119847.
574. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience. *Am J Hematol* 92(12):1295-1302, 12/2017. e-Pub 9/2017. PMID: 28850699.
575. Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtmann SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. *Blood Cancer J* 7(12):644, 12/2017. e-Pub 12/2017. PMCID: PMC5802598.
576. Byun HM, Eshaghian S, Douer D, Trent J, Garcia-Manero G, Bhatia R, Siegmund K, Yang AS. Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia. *Open Med (Wars)* 12:76-85, 2017. e-Pub 5/2017. PMCID: PMC5444343.
577. Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. *Leukemia* 32(1):241-244, 1/2018. e-Pub 9/2017. PMID: 28919634.
578. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garriss R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. *Am J Hematol* 93(1):91-99, 1/2018. e-Pub 11/2017. PMID: 29047158.
579. Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. *Am J Hematol* 93(1):129-147, 1/2018. PMID: 29214694.
580. Alhurairi A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. *Am J Hematol* 93(1):84-90, 1/2018. e-Pub 11/2017. PMID: 29027261.
581. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L,

- Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. *Am J Hematol* 93(2):277-285, 2/2018. e-Pub 11/2017. PMID: 29134664.
582. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. *Oncotarget* 9(11):9714-9727, 2/2018. e-Pub 1/2018. PMCID: PMC5839396.
 583. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. *Lancet Oncol* 19(2):240-248, 2/2018. e-Pub 1/2018. PMID: 29352703.
 584. Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. *Lancet Haematol* 5(2):e63-e72, 2/2018. e-Pub 1/2018. PMID: 29331635.
 585. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. *Am J Hematol* 93(3):401-407, 3/2018. e-Pub 12/2017. PMID: 29218851.
 586. Zhang H, Li HS, Hillmer EJ, Zhao Y, Chrisikos TT, Hu H, Wu X, Thompson EJ, Clise-Dwyer K, Millerchip KA, Wei Y, Puebla-Osorio N, Kaushik S, Santos MA, Wang B, Garcia-Manero G, Wang J, Sun SC, Watowich SS. Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis. *Proc Natl Acad Sci U S A* 115(10):E2311-E2319, 3/2018. e-Pub 2/2018. PMCID: PMC5878002.
 587. Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'Brien S, Kantarjian H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. *Am J Hematol* 93(3):371-374, 3/2018. e-Pub 12/2017. PMID: 29178361.
 588. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. *Cancer* 124(6):1160-1168, 3/2018. e-Pub 12/2017. PMCID: PMC5851790.
 589. Montalban-Bravo G, Garcia-Manero G, Jabbour E. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. *Curr Opin Hematol* 25(2):146-153, 3/2018. PMID: 29266015.
 590. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. *Blood* 131(16):1820-1832, 4/2018. e-Pub 1/2018. PMCID: PMC5909764.
 591. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological

- malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. *Lancet Haematol* 5(4):e136-e146, 4/2018. e-Pub 3/2018. PMID: 29550383.
592. Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. *Leukemia* 32(5):1094-1105, 5/2018. e-Pub 2/2018. PMID: 29487386.
 593. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. *Int J Hematol* 107(6):689-695, 6/2018. e-Pub 2/2018. PMID: 29464484.
 594. Gur HD, Loghavi S, Garcia-Manero G, Routbort M, Kanagal-Shamanna R, Quesada A, Khogeer H, Pierce S, Medeiros LJ, Kantarjian H, Khoury JD. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. *Am J Surg Pathol* 42(6):799-806, 6/2018. PMID: 29596070.
 595. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. *J Clin Oncol* 36(18):1788-1797, 6/2018. e-Pub 4/2018. PMCID: PMC6008108.
 596. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. *Cancer* 124(12):2534-2540, 6/2018. e-Pub 4/2018. PMID: 29645075.
 597. Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, Löwenberg B, Tallman MS. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. *Blood* 131(24):2661-2669, 6/2018. e-Pub 5/2018. PMCID: PMC6265654.
 598. Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. *Ann Hematol* 97(7):1183-1191, 7/2018. e-Pub 3/2018. PMID: 29557496.
 599. DiNardo CD, Routbort MJ, Bannan SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. *Cancer* 124(13):2704-2713, 7/2018. e-Pub 4/2018. PMID: 29682723.
 600. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. *Nat Commun* 9(1):2670, 7/2018. e-Pub 7/2018. PMCID: PMC6039465.
 601. Kurt H, Zheng L, Kantarjian HM, Tang G, Ravandi-Kashani F, Garcia-Manero G, Gong Z, Amin HM, Konoplev SN, Routbort MJ, Han X, Wang W, Medeiros LJ, Hu S. Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. *Mod Pathol* 31(7):1141-1154, 7/2018. e-Pub 2/2018. PMID: 29449681.
 602. Migdady Y, Barnard J, Al Ali N, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations

- in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. *Clin Lymphoma Myeloma Leuk* 18(8):528-532, 8/2018. e-Pub 5/2018. PMID: 29937400.
603. Garcia-Manero G. Secondary primary cancers before and after myeloid neoplasia: a two-way street. *Lancet Haematol* 5(8):e328-e329, 8/2018. PMID: 30075831.
 604. Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. *Blood Adv* 2(15):1807-1816, 8/2018. PMCID: PMC6093727.
 605. Patnaik MM, Tefferi A, Garcia-Manero G. Blast-phase chronic myelomonocytic leukemia: more than just semantics. *Leukemia* 32(9):2093-2094, 9/2018. e-Pub 8/2018. PMID: 30087420.
 606. Garcia-Manero G, Scott BL, Cogle CR, Boyd TE, Kambhampati S, Hetzer J, Dong Q, Kumar K, Ukrainskyj SM, Beach CL, Skikne BS. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. *Leuk Res* 72:79-85, 9/2018. e-Pub 8/2018. PMID: 30114559.
 607. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. *Lancet Haematol* 5(9):e411-e421, 9/2018. e-Pub 8/2018. PMID: 30115541.
 608. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. *Leuk Lymphoma* 59(9):2238-2241, 9/2018. e-Pub 1/2018. PMID: 29338567.
 609. Almeida A, Fenaux P, Garcia-Manero G, Goldberg SL, Gröpper S, Jonasova A, Vey N, Castaneda C, Zhong J, Beach CL, Santini V. Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. *Leuk Lymphoma* 59(9):2135-2143, 9/2018. e-Pub 1/2018. PMID: 29322849.
 610. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. *Am J Hematol* 93(9):1136-1141, 9/2018. e-Pub 8/2018. PMID: 30028037.
 611. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. *Blood* 132(16):1664-1674, 10/2018. e-Pub 9/2018. PMCID: PMC6265645.
 612. Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. *Clin Lymphoma Myeloma Leuk* 18(10):658-663.e2, 10/2018. e-Pub 6/2018. PMID: 30001986.
 613. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. *Cancer* 124(20):4044-4055, 10/2018. e-Pub 10/2018. PMID: 30307611.
 614. Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes:

- Analysis from the International Working Group for Prognosis of MDS. *Leuk Res* 73:51-57, 10/2018. e-Pub 9/2018. PMID: 30219650.
615. Garcia-Manero G. Improving Prognostic Tools for Patients With Myelodysplastic Syndromes. *Mayo Clin Proc* 93(10):1340-1342, 10/2018. PMID: 30286827.
 616. Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganon-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero G. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. *Blood Adv* 2(19):2491-2504, 10/2018. PMCID: PMC6177657.
 617. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF- κ B activation. *Leuk Res* 73:78-85, 10/2018. e-Pub 9/2018. PMID: 30245189.
 618. Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. *Am J Hematol* 93(10):1245-1253, 10/2018. e-Pub 9/2018. PMID: 30051599.
 619. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. *Cancer Med* 7(11):5457-5469, 11/2018. e-Pub 10/2018. PMCID: PMC6246941.
 620. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. *Cancer* 124(21):4192-4201, 11/2018. e-Pub 10/2018. PMID: 30307606.
 621. Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. *Leukemia* 32(11):2512-2518, 11/2018. e-Pub 4/2018. PMCID: PMC6202273.
 622. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. *Blood* 132(19):2100-2103, 11/2018. e-Pub 9/2018. PMCID: PMC6236463.
 623. Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, Zhang J, Heffernan TP, Gera S, Kovacs JJ, Marszalek JR, Bristow C, Yan Y, Garcia-Manero G, Kantarjian H, Vassiliou G, Futreal PA, Donehower LA, Takahashi K, Goodell MA. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. *Cell Stem Cell* 23(5):700-713.e6, 11/2018. PMCID: PMC6224657.
 624. Abaza Y, Cortes J, Ravandi F, Kadia T, Garcia-Manero G, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G. Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. *Am J Hematol* 93(11):E357-E360, 11/2018. e-Pub 9/2018. PMID: 30074261.
 625. Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garriss R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. *Lancet Haematol* 5(12):e618-e627, 12/2018. PMID: 30501869.
 626. Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA. Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. *Cancer* 124(24):4601-4609, 12/2018. e-Pub 10/2018. PMID: 30289970.

627. Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, Kadia T, Brandt M, Maduik R, Kantarjian H, Borthakur G. Response kinetics and factors predicting survival in core-binding factor leukemia. *Leukemia* 32(12):2698-2701, 12/2018. e-Pub 6/2018. PMID: 29884905.
628. Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. *Adv Exp Med Biol* 995:97-116, 2018. PMID: 30539507.
629. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. *Am J Hematol* 94(1):74-79, 1/2019. e-Pub 11/2018. PMID: 30328139.
630. Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. *Nat Commun* 10(1):244, 1/2019. e-Pub 1/2019. PMCID: PMC6335421.
631. Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? *Blood Cancer J* 9(2):7, 1/2019. e-Pub 1/2019. PMCID: PMC6335405.
632. Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. *J Clin Oncol* 37(1):7-11, 1/2019. e-Pub 11/2018. PMCID: PMC6354773.
633. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. *Leuk Lymphoma* 60(1):37-48, 1/2019. e-Pub 5/2018. PMCID: PMC6226369.
634. Burgos S, Montalban-Bravo G, Fuente L, Jabbour EJ, Kanagal-Shamanna R, Soltysiak KA, Garcia-Manero G, Mela-Osorio MJ. Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. *Medicine (Baltimore)* 98(1):e14011, 1/2019. PMCID: PMC6344201.
635. Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultonwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R, International Working Group for MDS Molecular Prognostic Committee. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. *Leukemia*. e-Pub 1/2019. PMID: 30635634.
636. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia:

- a randomised phase 2 trial. *Lancet Haematol* 6(1):e29-e37, 1/2019. e-Pub 12/2018. PMID: 30545576.
637. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. *J Hematol Oncol* 12(1):1, 1/2019. e-Pub 1/2019. PMCID: PMC6318861.
 638. Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. *Leuk Lymphoma*:1-7. e-Pub 2/2019. PMID: 30773968.
 639. Escalante CP, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E, Garcia-Manero G. Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. *Cancer Med* 8(2):543-553, 2/2019. e-Pub 1/2019. PMCID: PMC6382725.
 640. Garcia-Manero G. Highlights in Myelodysplastic Syndromes From the 60th American Society of Hematology Annual Meeting: Commentary. *Clin Adv Hematol Oncol* 17 Suppl 5(2):16-19, 2/2019. PMID: 31730587.
 641. Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. *Blood Adv* 3(4):508-518, 2/2019. PMCID: PMC6391673.
 642. Othus M, Sekeres MA, Nand S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey E. Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. *Leukemia* 33(2):371-378, 2/2019. e-Pub 10/2018. PMCID: PMC6367029.
 643. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. *Hematol Oncol* 37(1):96-102, 2/2019. e-Pub 12/2018. PMCID: PMC6386594.
 644. Othus M, Estey EH, Garcia-Manero G, Wood BL, Stirewalt DL, Godwin JE, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB. Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. *Leukemia* 33(2):554-558, 2/2019. e-Pub 10/2018. PMCID: PMC6367002.
 645. Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. *Blood Adv* 3(6):851-861, 3/2019. PMCID: PMC6436011.
 646. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. *Cancer*. e-Pub 3/2019. PMID: 30861111.
 647. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. *Cancer Discov* 9(3):370-383, 3/2019. e-Pub 11/2018. PMCID: PMC6397669.

648. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganon-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. *Blood Adv* 3(6):922-933, 3/2019. PMCID: PMC6436014.
649. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 19(3):142-148.e1, 3/2019. e-Pub 12/2018. PMID: 30635233.
650. Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres MA, Steensma DP, Glogou S. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. *Blood* 133(10):1020-1030, 3/2019. e-Pub 11/2018. PMID: 30404811.
651. Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. *Lancet Haematol* 6(4):e194-e203, 4/2019. PMID: 30926081.
652. Garcia-Manero G, Almeida A, Fenaux P, Gattermann N, Giagounidis A, Goldberg SL, Ozawa K, Weaver J, Santini V. Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. *Clin Lymphoma Myeloma Leuk* 19(4):213-219.e4, 4/2019. e-Pub 12/2018. PMID: 30770308.
653. You X, Jiang W, Lu W, Zhang H, Yu T, Tian J, Wen S, Garcia-Manero G, Huang P, Hu Y. Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis. *Cancer Commun (Lond)* 39(1):17, 4/2019. e-Pub 4/2019. PMCID: PMC6449955.
654. Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. *Cancer* 125(7):1091-1100, 4/2019. e-Pub 12/2018. PMCID: PMC6561101.
655. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. *Int J Hematol* 109(5):545-552, 5/2019. e-Pub 3/2019. PMID: 30830579.
656. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. *Leuk Lymphoma*:1-9. e-Pub 5/2019. PMID: 31125272.
657. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. *Cancer* 125(10):1665-1673, 5/2019. e-Pub 1/2019. PMID: 30668890.
658. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. *Cancer* 125(9):1470-1481, 5/2019. e-Pub 11/2018. PMCID: PMC6467779.

659. Bataller A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G. The role of TGF β in hematopoiesis and myeloid disorders. *Leukemia* 33(5):1076-1089, 5/2019. e-Pub 2/2019. PMID: 30816330.
660. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. *Cancer*. e-Pub 5/2019. PMID: 31150121.
661. Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. *Lancet Haematol* 6(6):e317-e327, 6/2019. e-Pub 5/2019. PMID: 31060979.
662. Chekouo T, Stingo FC, Class CA, Yan Y, Bohannon Z, Wei Y, Garcia-Manero G, Hanash S, Do KA. Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes. *Stat Methods Med Res*:962280219852721. e-Pub 6/2019. PMID: 31172886.
663. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. *Cancer* 125(11):1855-1866, 6/2019. e-Pub 2/2019. PMID: 30811597.
664. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. *Am J Hematol*. e-Pub 6/2019. PMID: 31237017.
665. Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannion SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 Mutations in Myeloid Neoplasms are Associated with Male Gender, TP53 Mutations and High-Risk Disease. *Am J Hematol* 94(7):757-766, 7/2019. e-Pub 5/2019. PMID: 30963592.
666. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. *Am J Hematol* 94(7):E188-E190, 7/2019. e-Pub 4/2019. PMCID: PMC6566858.
667. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. *Cancer*. e-Pub 7/2019. PMID: 31310323.
668. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. *Lancet Haematol*. e-Pub 8/2019. PMID: 31400961.
669. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVd) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia

- chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. *Cancer* 125(15):2579-2586, 8/2019. e-Pub 4/2019. PMID: PMC6625850.
670. Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, Pudipeddi M, Nidarmarthy S, Vaddi K, Kantarjian H. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. *Haematologica*. e-Pub 9/2019. PMID: 31558670.
 671. Tanaka T, Morita K, Wang F, Little L, Gumbs C, Matthews J, DiNardo CD, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Garcia-Manero G, Futreal PA, Takahashi K. Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). *Blood* 134(Supplement_1):17, 11/2019. PMID: 31724013.
 672. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. *Blood* 134(Supplement_1):47, 11/2019. PMID: 31723997.
 673. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. *Cancer Med* 8(15):6559-6565, 11/2019. e-Pub 9/2019. PMID: PMC6825993.
 674. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garriss R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. *Am J Hematol* 94(12):1388-1395, 12/2019. e-Pub 10/2019. PMID: 31595534.
 675. Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. *JCO Precis Oncol* 3, 2019. e-Pub 9/2019. PMID: PMC6818517.
 676. Tian T, Li J, Li Y, Lu YX, Tang YL, Wang H, Zheng F, Shi D, Long Q, Chen M, Garcia-Manero G, Hu Y, Qin L, Deng W. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification. *Theranostics* 9(13):3768-3779, 2019. e-Pub 5/2019. PMID: PMC6587355.
 677. Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Gai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. *N Engl J Med* 382(2):140-151, 1/2020. PMID: 31914241.
 678. Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer RL, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR. Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. *JCO Oncol Pract*:JOP1900133. e-Pub 1/2020. PMID: 32048933.
 679. Yalniz FF, Berdeja JG, Maris MB, Lyons RM, Reeves JA, Essell JH, Patel P, Sekeres M, Hughes A, Mappa S, Garcia-Manero G. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. *Br J Haematol* 188(3):404-412, 2/2020. e-Pub 8/2019. PMID: 31468521.
 680. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP,

- Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. *Blood Adv* 4(3):482-495, 2/2020. PMID: PMC7013259.
681. Garcia-Manero G. Highlights in myelodysplastic syndromes from the 61st American Society of Hematology Annual Meeting: commentary. *Clin Adv Hematol Oncol* 18 Suppl 5(2):18-22, 2/2020. PMID: 33843920.
 682. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. *Cancer* 126(4):765-774, 2/2020. e-Pub 11/2019. PMID: 31742675.
 683. Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K, Ganan-Gomez I, Yang H, Soltysiak KA, Kanagal-Shamanna R, Do KA, Kantarjian HM, Garcia-Manero G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. *Leuk Lymphoma*:1-7. e-Pub 2/2020. PMID: 32036728.
 684. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. *Am J Hematol*. e-Pub 2/2020. PMID: 32112433.
 685. Abou Dalle I, Kantarjian H, Bannan SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful Lenalidomide Treatment in High Risk Myelodysplastic Syndrome with Germline DDX41 Mutation. *Am J Hematol* 95(2):227-229, 2/2020. e-Pub 8/2019. PMID: 31400013.
 686. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garriss R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. *Am J Hematol* 95(2):144-150, 2/2020. e-Pub 11/2019. PMID: 31682008.
 687. Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G, TELESTO Study Investigators. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. *Ann Intern Med*. e-Pub 3/2020. PMID: 32203980.
 688. Sasaki K, Kantarjian H, Wierda W, Ravandi F, Daver N, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Z, Konopleva M, Ohanian M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garriss R, Cortes J, O'Brien S, Ingram A, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. *Am J Hematol*. e-Pub 3/2020. PMID: 32170867.
 689. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. *Cancer*. e-Pub 3/2020. PMID: 32125707.
 690. Xie W, Tang G, Wang E, Kim Y, Cloe A, Shen Q, Zhou Y, Garcia-Manero G, Loghavi S, Hu AY, Wang S, Bueso-Ramos CE, Kantarjian HM, Medeiros LJ, Hu S. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? *Ann Hematol* 99(3):487-500, 3/2020. e-Pub 1/2020. PMID: 32006151.
 691. Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien K, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. *Leukemia* 34(3):872-881, 3/2020. e-Pub 11/2019. PMID: PMC7056563.

692. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. *Blood Adv* 4(8):1690-1699, 4/2020. PMID: 32330243.
693. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. *Cancer* 126(7):1448-1459, 4/2020. e-Pub 1/2020. PMID: 31999850.
694. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. *Cancer* 126(7):1502-1511, 4/2020. e-Pub 1/2020. PMID: 31999839.
695. Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells RA, McCloskey J, Odenike O, DeZern A, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian HM, Oganessian A, Azab M, Savona MR. Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML. *Blood*. e-Pub 4/2020. PMID: 32285126.
696. Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. *Leuk Lymphoma*:1-11. e-Pub 4/2020. PMID: 32264726.
697. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. *Blood Adv* 4(8):1670-1677, 4/2020. PMID: 32324887.
698. Muto T, Walker CS, Choi K, Hueneman K, Smith MA, Gul Z, Garcia-Manero G, Ma A, Zheng Y, Starczynowski DT. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. *Nat Immunol* 21(5):535-545, 5/2020. e-Pub 4/2020. PMID: 32313245.
699. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. *Blood Cancer J* 10(5):47, 5/2020. e-Pub 5/2020. PMCID: PMC7198507.
700. Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. *Blood Cancer J* 10(5):61, 5/2020. e-Pub 5/2020. PMCID: PMC7250857.
701. Montalban-Bravo G, Garcia-Manero G. MDS/MPN-RS-T justified inclusion as a unique disease entity? *Best Pract Res Clin Haematol* 33(2):101147, 6/2020. e-Pub 1/2020. PMID: 32460979.
702. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. *Haematologica*. e-Pub 6/2020. PMID: 32499238.

703. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. *Leukemia*. e-Pub 6/2020. PMID: 32561839.
704. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia. *Am J Hematol*. e-Pub 6/2020. PMID: 32557828.
705. Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. *Leukemia*. e-Pub 6/2020. PMID: 32595214.
706. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. *Lancet Haematol* 7(7):e523-e533, 7/2020. PMID: 32589978.
707. Navada SC, Garcia-Manero G, Odchimar-Reissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtmann SM, Silverman LR. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. *Leuk Res* 94:106369, 7/2020. e-Pub 5/2020. PMID: 32442785.
708. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultonwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. *Blood* 136(2):157-170, 7/2020. PMID: 32347921.
709. DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannan SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. *Epigenetics*:1-10. e-Pub 8/2020. PMID: 32856987.
710. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. *Leukemia* 34(9):2489-2492, 9/2020. e-Pub 2/2020. PMID: 32099037.
711. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. *Mod Pathol* 33(9):1678-1689, 9/2020. e-Pub 4/2020. PMID: 32238878.

712. Garcia-Manero G. Highlights in myelodysplastic syndromes from the 2020 American Society of Clinical Oncology Annual Meeting and the 25th European Hematology Association Congress: commentary. *Clin Adv Hematol Oncol* 18 Suppl 14(9):20-23, 9/2020. PMID: 33843881.
713. Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. *Clin Lymphoma Myeloma Leuk* 20(9):e597-e605, 9/2020. e-Pub 3/2020. PMID: 32303488.
714. Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. *Haematologica Online* ahead of print, 9/2020. e-Pub 9/2020. PMID: 33054123.
715. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirida WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. *Lancet Haematol* 7(10):e724-e736, 10/2020. e-Pub 9/2020. PMID: PMC7549397.
716. Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. *Br J Haematol* 191(1):e10-e13, 10/2020. e-Pub 7/2020. PMID: 32686139.
717. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. *Cancer*. e-Pub 10/2020. PMID: 33119202.
718. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. *Nat Commun* 11(1):5327, 10/2020. e-Pub 10/2020. PMID: PMC7577981.
719. Angelucci E, Greenberg P, Izquierdo M, Garcia-Manero G. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes. *Ann Intern Med* 173(7):595-596, 10/2020. PMID: 33017548.
720. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *J Hematol Oncol* 13(1):132, 10/2020. e-Pub 10/2020. PMID: PMC7542942.
721. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. *Blood Adv* 4(21):5580-5588, 11/2020. PMID: PMC7656915.
722. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N,

- Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Sherry Pierce RN, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. *Am J Hematol*. e-Pub 11/2020. PMID: 33156969.
723. Lachowiec C, Bannan S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. *Am J Hematol* 95(11):E313-E315, 11/2020. e-Pub 9/2020. PMID: 32804409.
 724. Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management. *Am J Hematol* 95(11):1399-1420, 11/2020. e-Pub 8/2020. PMID: 32744763.
 725. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. *Am J Hematol* 95(11):1288-1295, 11/2020. e-Pub 8/2020. PMID: 32681739.
 726. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. *Leukemia* 34(11):2914-2924, 11/2020. e-Pub 6/2020. PMID: 32546726.
 727. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. *Blood Adv* 4(22):5681-5689, 11/2020. PMCID: PMC7686900.
 728. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerewinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. *Nat Commun* 11(1):5996, 11/2020. e-Pub 11/2020. PMCID: PMC7677309.
 729. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 20(11):e871-e882, 11/2020. e-Pub 6/2020. PMID: 32792304.
 730. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes. *Am J Hematol*. e-Pub 11/2020. PMID: 33180322.
 731. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). *Am J Hematol* 95(12):E326-E329, 12/2020. e-Pub 10/2020. PMID: 32886803.
 732. Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmiecik M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. *Leuk Lymphoma*:1-14. e-Pub 12/2020. PMID: 33356689.

733. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. *Leuk Lymphoma* 61(13):1-8, 12/2020. e-Pub 8/2020. PMID: 32755333.
734. Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. *Leuk Lymphoma* 61(12):1-10, 12/2020. e-Pub 7/2020. PMCID: PMC8424781.
735. Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. *Front Immunol* 11:590494, 2020. e-Pub 1/2021. PMCID: PMC7859512.
736. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. *Front Oncol* 10:582213, 2020. e-Pub 1/2021. PMCID: PMC7878971.
737. Malek AE, Gutierrez C, Mulanovich VE, Botdorf J, Chemaly RF, Shah S, McCall BM, Melancon JT, McConn KK, Borjan J, Raad II, Burger JA, Garcia-Manero G, Adachi JA. Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts. *Mediterr J Hematol Infect Dis* 12(1):e2020044, 2020. e-Pub 7/2020. PMCID: PMC7340251.
738. Garcia-Manero G, Diez-Campelo M, Vellenga E, Jacoby MA, Merchan B, Breems D, Cortelezzi A, Doronin V, Gomez V, Beckers M, Porta MGD, Varsos H, Xiu L, DeAngelis N, Nnane I, Rose E, van Eygen K. Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes. *Am J Hematol*. e-Pub 1/2021. PMID: 33448430.
739. Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korb G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. *J Clin Oncol*:JCO2002341. e-Pub 1/2021. PMID: 33449813.
740. Garcia-Manero G. Highlights in myelodysplastic syndromes from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. *Clin Adv Hematol Oncol* 19 Suppl 5(1):20-23, 1/2021. PMID: 33843866.
741. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. *Cancer*. e-Pub 1/2021. PMID: 33449377.
742. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. *Leuk Lymphoma* 62(1):1-5, 1/2021. e-Pub 9/2020. PMID: 32955970.
743. Komrokji RS, Al Ali NH, Sallman D, Padron E, DeZern AE, Barnard J, Roboz GJ, Garcia-Manero G, List A, Steensma DP, Sekeres MA. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS

- Clinical Research Consortium. *Cancer Med* 10(2):447-453, 1/2021. e-Pub 12/2020. PMCID: PMC7877342.
744. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. *Blood Cancer J* 11(2):41, 2/2021. e-Pub 2/2021. PMCID: PMC7900255.
 745. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *J Hematol Oncol* 14(1):34, 2/2021. e-Pub 2/2021. PMCID: PMC7901199.
 746. Fang H, Yabe M, Zhang X, Kim Y, Wu X, Wei P, Chi S, Zheng L, Garcia-Manero G, Shao L, Yuan J, Shen Y, Zheng G, Tang G, Wang W, Loghavi S, Shen Q, Yuan Y, He R, Chen D, Medeiros LJ, Hu S. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. *Mod Pathol*. e-Pub 2/2021. PMID: 33558656.
 747. Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. *Am J Hematol*. e-Pub 2/2021. PMID: 33639000.
 748. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. *J Immunother Cancer* 9(2), 2/2021. PMCID: PMC7919586.
 749. Moseley A, Othus M, Garcia-Manero G, Appelbaum FR, Erba HP, Walter RB. Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. *Leuk Lymphoma*:1-7. e-Pub 2/2021. PMID: 33560164.
 750. Montalban-Bravo G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, Class CA, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. *Leuk Res* 101:106511, 2/2021. e-Pub 1/2021. PMID: 33517186.
 751. Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ, Yang X, Zhou Y, Platzbecker U, Steensma DP, Wolff JE, Fenaux P. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. *Leuk Res* 104:106555. e-Pub 3/2021. PMID: 33705966.
 752. Othus M, Garcia-Manero G, Godwin J, Weick J, Stirewalt D, Appelbaum F, Erba H, Estey E. Associations between complete remission and 2- to 3-year survival following 7?+?3 induction for acute myeloid leukemia. *Leuk Lymphoma*:1-6. e-Pub 3/2021. PMID: 33719833.
 753. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. *Blood Cancer J* 11(3):52, 3/2021. e-Pub 3/2021. PMCID: PMC7936977.
 754. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M,

- Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. *Cancer*. e-Pub 3/2021. PMID: 33740268.
755. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. *Blood Cancer Discov* 2(2):125-134, 3/2021. e-Pub 12/2020. PMCID: PMC7935111.
 756. Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Gai V, Oliva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. *J Clin Oncol*:JCO2002619. e-Pub 3/2021. PMID: 33764805.
 757. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. *Am J Hematol* 96(3):282-291, 3/2021. e-Pub 12/2020. PMID: 33264443.
 758. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. *Haematologica*. e-Pub 4/2021. PMID: 33853292.
 759. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. *Leukemia*. e-Pub 4/2021. PMID: 33846541.
 760. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). *Am J Hematol*. e-Pub 4/2021. PMID: 33811786.
 761. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. *Cancer*. e-Pub 4/2021. PMID: 33914911.
 762. Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ, Yang X, Zhou Y, Platzbecker U, Steensma DP, Wolff JE, Fenaux P. Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [*Leukemia Res*. 104 March (2021)]. *Leuk Res*:106581. e-Pub 4/2021. PMID: 33896620.
 763. Lachowiec CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K,

- Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. *Blood Adv* 5(8):2173-2183, 4/2021. PMID: 33885753.
764. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. *Am J Hematol*. e-Pub 4/2021. PMID: 33901324.
 765. Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. *Leuk Lymphoma* 62(4):909-917, 4/2021. e-Pub 12/2020. PMID: 33283580.
 766. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. *Cancer*. e-Pub 4/2021. PMID: 33823073.
 767. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garriss R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. *Cancer*. e-Pub 4/2021. PMID: 33793964.
 768. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. *Blood Adv* 5(7):1876-1883, 4/2021. PMCID: PMC8045494.
 769. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. *Nat Commun* 12(1):2823, 5/2021. e-Pub 5/2021. PMCID: PMC8110810.
 770. Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. *Clin Lymphoma Myeloma Leuk* 21(5):338-344, 5/2021. e-Pub 1/2021. PMID: 33597098.
 771. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. *Nat Commun* 12(1):2607, 5/2021. e-Pub 5/2021. PMCID: PMC8110775.
 772. Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver NG, Pierce SR, Jabbour EJ, Kadia TM, DiNardo CD, Garcia-Manero G, Qazilbash MH, Konopleva MY, Kantarjian HM. Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm. *Blood*. e-Pub 6/2021. PMID: 34098573.
 773. Tanaka T, Morita K, Wang F, Loghavi S, Furudate K, Sasaki Y, Little LD, Gumbs CE, Matthews J, Daver NG, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA,

- Futreal A, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). *Blood*. e-Pub 6/2021. PMID: 34115096.
774. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. *Leukemia*. e-Pub 6/2021. PMID: 34135465.
 775. Quesada AE, Luthra R, Jabbour E, Patel KP, Khoury JD, Tang Z, Alvarez H, Mallampati S, Garcia-Manero G, Montalban-Bravo G, Medeiros LJ, Kanagal-Shamanna R. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. *Cold Spring Harb Mol Case Stud* 7(3), 6/2021. e-Pub 6/2021. PMID: 34117074.
 776. Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérrola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. *Leukemia*. e-Pub 6/2021. PMID: 34172893.
 777. Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. *Int J Lab Hematol* 43(3):426-432, 6/2021. e-Pub 11/2020. PMID: 33220019.
 778. Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. *Leuk Lymphoma*:1-9. e-Pub 8/2021. PMID: 34380367.
 779. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. *Blood Adv* 5(16):3163-3173, 8/2021. PMID: PMC8405193.
 780. Volpe VO, Garcia-Manero G, Komrokji RS. Myelodysplastic Syndromes: A New Decade. *Clin Lymphoma Myeloma Leuk*. e-Pub 8/2021. PMID: 34544674.
 781. Komrokji R, Melody M, Al Ali N, Chan O, Klimek V, Ball BJ, Sekeres MA, Lucas G, Maciejewski JP, Sallman DA, Padron E, Kuykendall A, Lasho T, Al-Kali A, Naqvi K, Steensma DP, Garcia-Manero G, Patnaik MM. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. *Leuk Lymphoma*:1-6. e-Pub 8/2021. PMID: 34448437.
 782. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. *Lancet Haematol* 8(8):e552-e561, 8/2021. PMID: 34329576.
 783. Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garriss R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. *Cancer* 127(18):3381-3389, 9/2021. e-Pub 6/2021. PMID: 34138471.

784. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad FG, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia TM, Garcia-Manero G, Garriss R, O'Brien SM, Jabbour EJ. Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience. *Blood Adv.* e-Pub 9/2021. PMID: 34525185.
785. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. *Blood Cancer J* 11(9):162, 9/2021. e-Pub 9/2021. PMCID: PMC8481264.
786. Abbas H, Alaniz Z, Mackay SG, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour EJ, Garcia-Manero G, Konopleva MY, Andreeff M, Daver NG. Single-cell Polyfunctional Proteomics of CD4 Cells from Patients with AML Predicts Responses to Anti-PD-1-based therapy. *Blood Adv.* e-Pub 9/2021. PMID: 34555853.
787. DiNardo CD, Lachowicz CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. *J Clin Oncol* 39(25):JCO2003736, 9/2021. e-Pub 5/2021. PMCID: PMC8407653.
788. Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. *Cancer* 127(20):3761-3771, 10/2021. e-Pub 6/2021. PMID: 34171128.
789. Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. *Cancer* 127(19):3552-3565, 10/2021. e-Pub 6/2021. PMID: 34161603.
790. Garcia-Manero G, Döhner H, Wei AH, La Torre I, Skikne B, Beach CL, Santini V. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. *Clin Lymphoma Myeloma Leuk.* e-Pub 10/2021. PMID: 34758945.
791. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. *Cancer* 127(19):3541-3551, 10/2021. e-Pub 6/2021. PMID: 34182597.
792. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. *Am J Hematol.* e-Pub 10/2021. PMID: 34716921.
793. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. *Nat Commun* 12(1):6071, 10/2021. e-Pub 10/2021. PMCID: PMC8524723.
794. Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. *Cancer.* e-Pub 10/2021. PMID: 34614211.
795. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM,

- Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. *Leuk Lymphoma*:1-4. e-Pub 10/2021. PMID: 34668451.
796. Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. *Leukemia* 35(11):3282-3286, 11/2021. e-Pub 4/2021. PMCID: PMC8550958.
 797. Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganon-Gomez I, Groarke EM, Gutierrez-Rodriguez F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Hematopoiesis under telomere attrition at the single-cell resolution. *Nat Commun* 12(1):6850, 11/2021. e-Pub 11/2021. PMCID: PMC8617077.
 798. Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routhort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. *Mod Pathol*. e-Pub 11/2021. PMID: 34775472.
 799. Garcia-Manero G, Mufti Obe GJ, Fenaux P, Buckstein RJ, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. *Blood*. e-Pub 11/2021. PMID: 34758066.
 800. Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, Maciejewski JP, Haferlach T, Sekeres MA. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. *J Clin Oncol* 39(33):JCO2002810, 11/2021. e-Pub 8/2021. PMID: 34406850.
 801. Chien KS, Kim K, Noguerras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. *Br J Haematol* 195(3):378-387, 11/2021. e-Pub 8/2021. PMID: 34340254.
 802. Oliva EN, Platzbecker U, Fenaux P, Garcia-Manero G, LeBlanc TW, Patel BJ, Kubasch AS, Sekeres MA. Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. *Blood Rev* 50:100851, 11/2021. e-Pub 5/2021. PMID: 34088518.
 803. Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Sallman D. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)? *Leuk Lymphoma* 62(11):1-6, 11/2021. e-Pub 6/2021. PMID: 34114922.
 804. Oliva EN, Platzbecker U, Garcia-Manero G, Mufti GJ, Santini V, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P. Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. *J Clin Med* 11(1), 12/2021. e-Pub 12/2021. PMCID: PMC8745777.
 805. Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. *Ann Hematol* 100(12):2957-2960, 12/2021. e-Pub 8/2021. PMID: 34350483.
 806. Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian

- H, Curti A. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. *Front Oncol* 11:656218, 2021. e-Pub 5/2021. PMCID: PMC8143531.
807. Abbas HA, Reville PK, Jiang X, Yang H, Reuben A, Im JS, Little L, Sinson JC, Chen K, Futreal A, Garcia-Manero G. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. *Front Immunol* 12:659625, 2021. e-Pub 4/2021. PMCID: PMC8072464.
 808. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. *Acta Haematol* 144(2):1-13, 2021. e-Pub 5/2020. PMCID: PMC7270066.
 809. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver NG, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SR, Qazilbash MH, Konopleva MY, Kantarjian HM. Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD. *Blood Adv.* e-Pub 1/2022. PMID: 35061885.
 810. Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. *J Hematol Oncol* 15(1):12, 1/2022. e-Pub 1/2022. PMCID: PMC8800349.
 811. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garriss R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. *Leukemia.* e-Pub 2/2022. PMID: 35132195.
 812. Tian T, Zhang S, Luo B, Yin F, Lu W, Li Y, Huang K, Liu Q, Huang P, Garcia-Manero G, Wen S, Hu Y. Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library. *J Med Chem* 65(4):3597-3605, 2/2022. e-Pub 2/2022. PMID: 35148084.
 813. Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. *Leukemia.* e-Pub 2/2022. PMID: 35220402.
 814. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. *J Natl Compr Canc Netw* 20(2):106-117, 2/2022. PMID: 35130502.
 815. Venugopal S, Borthakur G, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva MY, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. *Blood Adv.* e-Pub 2/2022. PMID: 35201293.
 816. Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. *Am J Hematol* 97(3):329-337, 3/2022. e-Pub 1/2022. PMCID: PMC8884919.
 817. Garcia-Manero G, Ribrag V, Zhang Y, Farooqui M, Marinello P, Smith BD. Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study. *Leuk Lymphoma*:1-9. e-Pub 3/2022. PMID: 35244520.

818. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Levenson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. *Nat Med* 28(3):557-567, 3/2022. e-Pub 3/2022. PMCID: PMC8938266.
819. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. *Am J Hematol*. e-Pub 3/2022. PMID: 35357036.
820. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. *Leuk Lymphoma*:1-10. e-Pub 4/2022. PMID: 35442137.
821. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. *Blood Adv* 6(7):2207-2218, 4/2022. PMCID: PMC9006291.
822. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. *Leukemia*. e-Pub 4/2022. PMID: 35411096.
823. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. *Nat Commun* 13(1):1970, 4/2022. e-Pub 4/2022. PMID: 35413951.
824. Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. *Leukemia* 36(4):1189-1192, 4/2022. e-Pub 1/2022. PMID: 34975158.
825. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. *Cancer*. e-Pub 4/2022. PMID: 35452134.
826. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. *Am J Hematol*. e-Pub 4/2022. PMID: 35384048.
827. DiNardo CD, Garcia-Manero G, Kantarjian HM. Time to blur the blast boundaries. *Cancer* 128(8):1568-1570, 4/2022. e-Pub 2/2022. PMID: 35133004.
828. Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent Cytoreduction for Newly Diagnosed

- AML patients Allows Acquisition of Pretreatment Genomic Data and Enrollment on Investigational Clinical Trials. *Am J Hematol*. e-Pub 4/2022. PMID: 35413152.
829. Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. *Am J Hematol* 97(5):574-582, 5/2022. e-Pub 2/2022. PMID: 35150150.

Invited Articles

1. Garcia-Manero G, Domine M, Delgado C, Cunningham JM, Francis GE. The polymerase chain reaction (PCR): a new technique for the molecular study of cancer. *Oncologia* 15:501-516, 1991.
2. Sorensen SC, García-Manero G, Mastrangelo MJ, Soltan A. Does lymph node dissection still have a role in cancer therapy? *Semin Oncol* 24(3):xxxiii-xxxiv, xxxix, xli-xlii, xlv, 6/1997. PMID: 9208880.
3. Garcia-Manero G, Schuster SJ, Agha ME. Should autologous or allogeneic stem-cell therapy be a part of consolidation therapy for all cases of adult acute myelogenous leukemia? *Semin Oncol* 26(1):xvi-xvii, xxi-xxii, 2/1999. PMID: 10073556.
4. Garcia-Manero G, Issa J-P. CpG island methylation in cancer. *Cancer Research Alert* 1:133-144, 2000.
5. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. *Hematol Oncol Clin North Am* 15(1):163-205, 2/2001. PMID: 11253606.
6. Garcia-Manero G, Keating MJ, O'Brien S. Fludarabine, cyclophosphamide, and rituximab in chronic lymphocytic leukemia. *Biological Therapy of Lymphoma* 4:7-9, 2001.
7. Garcia-Manero G, Talpaz M, Kantarjian HM. Current therapy of chronic myelogenous leukemia. *Intern Med* 41(4):254-64, 4/2002. PMID: 11993784.
8. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. *Rev Clin Exp Hematol* 6(2):142-60; discussion 200-2, 6/2002. PMID: 12196213.
9. Garcia-Manero G Kantarjian H. Imatinib mesylate in accelerated-phase Philadelphia chromosome positive chronic myelogenous leukemia. *American Journal Oncology Review* 1:208-228, 2002.
10. Garcia-Manero G Kantarjian H. Treatment innovations in chronic myelogenous leukemia. *Hematologia (Argentina) suppl* II:19-25, 2002.
11. Garcia-Manero G Kantarjian H. Treatment innovations in chronic myelogenous leukemia. *Oncology Special* 5:139-143.3, 2002.
12. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. *Cancer* 98(3):437-57, 8/2003. PMID: 12879460.
13. Garcia-Manero G, Glantz M. Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults? *Expert Rev Neurother* 4(4 Suppl):S25-31, 7/2004. PMID: 15853552.
14. Garcia-Manero G. Alteraciones epigeneticas en leucemias agudas. *Haematologia* 1:44, 2004.
15. Garcia-Manero G. Avances en leucemia linfocitica cronica. *Haematologia* 1:34, 2004.
16. Garcia-Manero G. Front line therapy for patients with chronic myelogenous leukemia in chronic phase in the year 2004. *Haematologica* 89:57-61, 2004.
17. Garcia-Manero G. on DNA Hypomethylation in the Treatment of MDS. *Clinical Advances in Hematology & Oncology* 4(4):3, 2004.
18. Garcia-Manero G, Gore SD. Future directions for the use of hypomethylating agents. *Semin Hematol* 42(3 Suppl 2):S50-9, 7/2005. PMID: 16015506.
19. Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. *Cancer Invest* 23(7):635-42, 2005. PMID: 16305991.
20. Garcia-Manero G, Saba HI. Decitabine in myelodysplastic syndromes: viewpoints. *Drugs* 66(7):959-60, 2006. PMID: 16740015.
21. Garcia-Manero G. Recent Advances in the Treatment of MDS. A review of selected presentations from the 48th Annual Meeting of the American Society of Hematology,

- December 9-12, 2006, Orlando, Florida. Clin Adv Hematol Oncol 5(3 Suppl 6):1-13; quiz 15-6, 3/2007. PMID: 17519888.
22. Atallah E, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol 5(7):544-52, 7/2007. PMID: 17679928.
 23. Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol 5(11):1-9, 11/2007. PMID: 18185491.
 24. Garcia-Manero G. Histone Deacetylases: Transcriptional regulation and other cellular functions. Br J Cancer 96(7):1153, 2007.
 25. Garcia-Manero G. Recent advances in the treatment of MDS. Clinical Advances in Hematology & Oncology 3(6):1-16, 2007.
 26. Garcia-Manero, G. Using combination therapy to improve control: DNA methylation and HDAC inhibition. The Promise of Epigenetic Therapy:14-18, 2007.
 27. Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest 26(2):208-216, 3/2008. PMID: 18259954.
 28. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113(7 Suppl):1933-52, 10/2008. PMCID: PMC4392892.
 29. Garcia-Manero G. Advances in MDS Management. Medical Progress 7(11):15-16, 11/2008.
 30. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 20(6):705-10, 11/2008. PMCID: PMC3873866.
 31. Kim H, Garcia-Manero G. Management of Myelodysplastic Syndromes: Just the Beginning. Oncology (Williston Park) 22(12):1360-1368, 11/2008. PMID: 19320068.
 32. Garcia-Manero G. All MDS Patients Are Not the Same. Clinical Advances in Hematology & Oncology 6(12):8-10, 12/2008.
 33. Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol 41(1):72-80, 1/2009. e-Pub 10/2008. PMCID: PMC3833715.
 34. Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol 46(1):24-32, 1/2009. PMCID: PMC3833728.
 35. Garcia-Manero G. Improving survival in myelodysplastic syndromes. Lancet Oncol 10(3):223-232, 3/2009. PMID: 19261248.

Editorials

1. Garcia-Manero G. Prognostic implications of epigenetic silencing of p15INK4B in acute promyelocytic leukemia. Leukemia 17(5):839-40, 5/2003. PMID: 12750694.
2. Garcia-Manero, G. Methylation, aging and pediatric acute lymphocytic leukemia. Leukemia 17:2063-2064, 2003.

Other Articles

N/A

Abstracts

1. Garcia-Manero G, Schuster SJ, Martinez J. Myeloproliferative diseases with bone marrow fibrosis complicated by pulmonary hypertension. Blood 90:292b, 1997.
2. Garcia-Manero G, Moscatello DK, Wong AJ. Association of a growth factor receptor and a cytokine receptor in a prostate cancer cell line. Blood 92(Suppl 1):205a, 1998.
3. Garcia-Manero G, et al. Combination of ethylol (amifostine) with idarubicin and ara-c for the induction treatment of AML. Blood 92:216b, 1998.
4. Flomenberg N, Garcia-Manero G, Grosso D, et al. High complete response rate and normal organ cytoprotection using dose escalation idarubicin and amifostine in high risk patients with acute myelogenous leukemia. Blood 94:299a, 1999.
5. Garcia-Manero G. Molecular detection of vancomycin resistant enterococci genotypes using polymerase chain reaction in patients admitted to a bone marrow transplantation unit. Blood 94:367b, 1999.
6. Faderl S, Kantarjian H, O'Brien S, Cortes J, Thomas D, Giles F, Freireich E, Koller C, Estey E, Beran M, Garcia-Manero G, Williams M. A broad exploratory trial of campath-1h in the treatment of acute leukemias. Blood 96:324a, 2000.

7. Garcia-Manero G, O'Brien S, Cortes J, Giles F, Faderl S, Lerner S, Albitar M, Kantarjian H, Keating M. Combination fludarabine, cyclophosphamide, rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). *Blood* 96:757a, 2000.
8. Garcia-Manero G, Daniel J, Pierce S, Kornblau S, Kantarjian H, Issa J. CpG island methylation profile in acute lymphocytic leukemia (ALL). *Blood* 96:102a, 2000.
9. Flomenberg N, Grosso D, Beardell F, Brunner J, Cohn J, Ferber A, Flicko J, Friedman A, Garcia-Manero G, Martinez J, Rose L, Tice D, Wagner J, Capizzi R. High complete remission rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML. *Blood* 96:211b, 2000.
10. Flomenberg N, Garcia-Manero G, Grosso D, Beardell F, Brunner J, Cohn J, Flicko J, Friedman A, Martinez J, Rose L, Tice D, Capizzi R. High CR rate & normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML. *Proceedings of the American Society of Clinical Oncology* 19:12a (#37), 2000.
11. Giles F, Cortes J, Thomas D, DeJager R, Garcia-Manero G, Jeha S, Kantarjian H. Phase I study of exatecan mesylate (DX-8951f), a novel topoisomerase I (topo 1) inhibitor. *Blood* 96:121a, 2000.
12. Faderl S, Thomas D, Cortes J, Giles F, Garcia-Manero G, O'Brien S, Koller C, Keating M, Cabanillas F, Sarris A, Grigsby V, Plunkett W, Kantarjian H. Phase I study of tezacitabine, an antimetabolite deoxycytidine analog, in patients with relapsed and refractory hematologic malignancies. *Blood* 96:724a, 2000.
13. Quackenbush R, Verstovsek S, Lin H, Xie S, Garcia-Manero G, Guo J, Talpaz M, Kantarjian H, Arlinghaus R. The low levels of P230 BCR-ABL expression that are typically seen in patients with neutrophilic-chronic myelogenous leukemia do not transform 32 D cells. *Blood* 96:351a, 2000.
14. Martins JT, Garcia-Manero G, Daniel J, Kantarjian H, Issa JP. 06-methylguanine-dna-methyltransferase (MGMT) is infrequently methylated in acute lymphocytic leukemia (ALL). *Blood* 98:180b, 2001.
15. Gharibyan V, Jiao L, Shen L, Kantarjian H, Garcia-Manero G, Issa JP. ABL methylation in chronic myelogenous leukemia (CML) spreads from a methylation center normally present in the 5 prime region of the CpG island. *Blood* 98:147a, 2001.
16. Tsimberidou A, Thomas D, Faderl S, Cortes J, Garcia-Manero G, O'Brien S, Albitar M, Kantarjian H, Keating M, Giles F. Alternating cyclophosphamide, vincristine, liposomal daunorubicin (DaunoXome), and dexamethasone (hCVXD) with methotrexate (MTX), and ara-C (A) regimen plus rituximab and GM-CSF in patients with refractory chronic lymphocytic leukemia (CLL) or richter's syndrome (RS). *Blood* 98:294b, 2001.
17. Faderl S, Thomas D, O'Brien S, Giles F, Koller C, Beran M, Williams M, Garcia-Manero G, Kantarjian H, Keating M. An exploratory study of the combination of monoclonal antibodies campath-1h and rituximab in the treatment of CD52- and CD20- positive chronic lymphoid disorders. *Blood* 98:365a, 2001.
18. Giles F, Thomas D, Cortes J, Garcia-Manero G, Kornblau S, Waddelow T, Kantarjian H. An ursodiol and methylprednisone (MP) regimen does not reduce mylotarg-associated hepatic veno-occlusive disease (VOD) in patients with acute myeloid leukemia (AML) not receiving stem cell transplantation (SCT). *Blood* 98:721a, 2001.
19. Thomas D, Cortes J, Giles F, Faderl S, Rios MB, Issa JP, Garcia-Manero G, Koller C, Talpaz M, Kantarjian H. Combination of hyper-CVAD with gleevec for Philadelphia (Ph)- positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast crisis (CML-BP). *Blood* 98:803a, 2001.
20. Kantarjian H, Arlinghaus RB, Quackenbush RC, Guo JQ, Cortes J, Giles F, Garcia-Manero G, Thomas D, Faderl S, Ford JM, Talpaz M. Competitive quantitative polymerase chain reaction (CQPCR) studies in Philadelphia chromosome positive chronic phase myelogenous leukemia (Ph + CML CP) on imatinib mesylate (STI571) therapy. *Blood* 98:614a, 2001.
21. Garcia-Manero G, Jeha S, Williamson J, Daniel J, Gold D, Rosner G, Albitar M, Kantarjian H, Issa JP. DNA methylation in pediatric acute lymphocytic leukemia (ALL): no distinct differences compared to adult patterns. *Blood* 98:318a, 2001.

22. Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian H, Issa JP. DNA-methylation patterns at relapse in acute lymphocytic leukemia (ALL): simultaneous hypermethylation of p15 and p16. *Blood* 98:314a, 2001.
23. Garcia-Manero G, Bueso-Ramos C, Daniels J, Williamson J, Kantarjian H, Issa JP. DNA-methylation patterns at relapse in acute lymphocytic leukemia (ALL): simultaneous hypermethylation of p15 and p16. *Proceedings of the American Association of Cancer Research:Poster A-11*, 2001.
24. Cortes J, O'Brien S, Beran M, Koller C, Garcia-Manero G, Giles F, Kantarjian H. Efficacy of topoisomerase I inhibitor, 9-nitro-20-(S)-camptothecin (9-NC RFS2000) in chronic myelomonocytic leukemia (CMML) and high-risk myelodysplastic syndromes (MDS). *Blood* 98:621a, 2001.
25. Estey E, Giles F, Cortes J, Thomas D, Garcia-Manero G, Faderl S, O'Brien S, Kantarjian H. Gemtuzumab ozogomycin (Mylotarg) in untreated acute promyelocytic leukemia (APL). *Blood* 98:766a, 2001.
26. Garcia-Manero G, Daniels J, Mannari R, Chen XQ, Kantarjian H, Issa J-P. HOXA5 is hypermethylated at a high frequency and density in human leukemias. *Proceedings of the American Association of Cancer Research* 42:poster 1859, 2001.
27. Kantarjian HM, Cortes J, O'Brien S, Giles F, Thomas D, Garcia-Manero G, Faderl S, Rios MB, Shan J, Hayes K, Keating MJ, Freireich E, Talpaz M. Imatinib mesylate (STI571) therapy of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in early chronic phase (ph + CML early CP). *Blood* 98:137a, 2001.
28. Garcia-Manero G, Kwari M, Cortes J, Faderl S, Giles F, O'Brien S, Koller C, Quackenbush R, Andreeff M, Beran M, Kantarjian H, Berd B, Estey E. Immunotherapy with autologous cell vaccine in patients with acute myelogenous leukemia (AML) in second remission. *Blood* 98:212b, 2001.
29. Mannari R, Kantarjian H, Garcia-Manero G, Cortes J, Beran M, Issa JP. Methylation analysis in patients with CML treated with the hypomethylating drug decitabine. *Proceedings of the American Association of Cancer Research* 42:poster 3809, 2001.
30. Dai D, Shen LL, Habib N, Garcia-Manero G, Issa J-P. Methylation profiling in liver metastasis of colon cancer. *Proceedings of the American Association of Cancer Research:Poster A-33*, 2001.
31. Issa JP, Garcia-Manero G, Mannari R, Thomas D, Giles F, Cortes J, Estey E, Kantarjian H. Minimal effective dose of the hypomethylating agent decitabine in hematopoietic malignancies. *Blood* 98:594a, 2001.
32. Cortes J, Kurzrock R, O'Brien S, Thomas D, Faderl S, Garcia-Manero G, Wright J, Sonnichsen D, Cooper M, Estey E, Kantarjian H. Phase I study of farnesyl transferase inhibitor (FTI), bms-214662, in patients with refractory or relapsed acute leukemias. *Blood* 98:594a, 2001.
33. Faderl S, Garcia-Manero G, Thomas D, Cortes J, O'Brien S, Giles F, Koller C, Beran M, Verstovsek S, Kwari M, Gandhi V, Plunkett W, Kantarjian H. Phase I study of tezacitabine (FMdC) in patients with relapsed and refractory hematologic malignancies. *Blood* 98:595a, 2001.
34. Giles F, Garcia-Manero G, O'Brien S, Estey E, Kantarjian H. Phase II study of Mylotarg plus Troxatyl in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). *Blood* 98:212b, 2001.
35. Giles F, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Waddelow T, Talpaz M, Kantarjian H, Estrov Z. Phase II study of pegylated intron in patients essential thrombocythemia (ET). *Blood* 98:629a, 2001.
36. Kurzrock R, Cortes J, Ryback ME, Thibault A, Faderl S, Estey E, Garcia-Manero G, Giles F, Thomas D, O'Brien S, Talpaz M, Kantarjian H. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. *Blood* 98:848a, 2001.
37. Giles F, Feldman E, Cortes J, Faderl S, Larson R, Mamus S, Thomas D, Garcia-Manero G, O'Brien S, Beran M, Talpaz M, Kantarjian H. Phase II study of troxatyl in patients with chronic myeloid leukemia in blastic phase (CML-BP). *Blood* 98:258b, 2001.

38. Thomas D, Cortes J, O'Brien S, Garcia-Manero G, Kurzrock R, Giles F, Faderl S, Thibault A, Rybak ME, Kantarjian H. R115777, a farnesyl transferase inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia (CML). *Blood* 98:727a, 2001.
39. Kantarjian H, Cortes J, Garcia-Manero G, Thomas D, Yazji S, Bivins C, Jolivet J, Giles F. Randomized phase I/II study of troxacitabine combined with topotecan, ara-C or idarubicin in patients with leukemia. *Proceedings of the American Society of Clinical Oncology* 20:224b, 2001.
40. Kantarjian H, Cortes J, O'Brien S, Faderl S, Thomas D, Giles F, Garcia-Manero G, Albitar M, Andreeff M, Kornblau SM, Rios MB, Shan J, Beran M, Koller C, Resta D, Capdeville R, Estey E, Keating M, Freireich E, Talpaz M. Results if imatinib mesylate (STI571) in Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (ph + CML-CP) post interferon alpha (IFN) failure. *Blood* 98:260b, 2001.
41. Kantarjian H, Cortes J, O'Brien S, Giles F, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Issa JP, Thomas D, Capdeville R, Talpaz M. Results if imatinib mesylate (STI571), a bcr-able tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (ph + CML-BP). *Blood* 98:260b, 2001.
42. Kantarjian HM, O'Brien S, Cortes J, Giralt S, Rios MB, Shan J, Giles F, Thomas D, Faderl S, de Lima M, Arlinghaus R, Garcia-Manero G, Issa JP, Resta D, Capdeville R, Talpaz M. Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT). *Blood* 98:137a, 2001.
43. Thomas D, Cortes J, Giles F, Faderl S, O'Brien S, Garcia-Manero G, Keating M, Cabanillas F, Kantarjian H. Rituximab and hyper-CVAD for adult burkitt's (BL) or burkitt's-like (BLL) leukemia or lymphoma. *Blood* 98:804a, 2001.
44. Chen XQ, Ahuja N, Shen LL, Mannari R, Garcia-Manero G, Issa J-P. THBS2 promoter Hypermethylation and silencing in cancer. *Proceedings of the American Association of Cancer Research* 42:poster 2560, 2001.
45. Thomas D, Cortes J, Giles F, O'Brien S, Faderl S, Koller C, Beran M, Issa JP, Garcia-Manero G, Estey E, Pierce S, Andreeff M, Kornblau S, Keating M, Kantarjian H. The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia. *Blood* 98:590a, 2001.
46. Kantarjian H, O'Brien S, Cortes J, Faderl S, Giles F, Thomas D, Garcia-Manero G, Albitar M, Rios MB, Shan J, Issa JP, Resta D, Capdeville R, Keating MJ, Freireich EJ, Talpaz M. Treatment of accelerated phase of Philadelphia chromosome-positive chronic myelogenous leukemia (ph + CML AP) with imatinib mesylate (STI571). *Blood* 98:141a, 2001.
47. Cortes J, Talpaz M, O'Brien S, Garcia-Manero G, Thomas D, Faderl S, Capdeville R, Kantarjian H. Treatment of chronic myeloid leukemia (CML) with STI571 in patients age > 60 years. *Blood* 98:256b, 2001.
48. Garcia-Manero G, Talpaz M, Giles F, Cortes J, O'Brien S, Faderl S, Thomas D, Rios MB, Kantarjian H. Treatment of Philadelphia chromosome positive chronic phase myelogenous leukemia (ph + CML) with pegylated interferon alpha 2b (peg-ifn/sch54031) and low-dose cytosine arabinoside (ara-C). *Blood* 98:258b, 2001.
49. Thomas DA, O'Brien S, Faderl S, Fayad L, Garcia-Manero G, Wierda W, Verstovsek S, Kornblau S, Pierce S, Kantarjian H, Keating M. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphomas (MZL) with single agent rituximab. *Blood* 98:134a, 2001.
50. Giles F, Faderl S, Thomas D, Cortes J, Jeha S, Garcia-Manero G, Douer D, Levine A, Estey E, Beran M, O'Brien S, Koller C, Andreeff M, Kantarjian H. Troxatyl plus topotecan, ara-C, or idarubicin in patients with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or blastic-phase chronic myeloid leukemia (CML-BP): a randomized phase I/II study. *Blood* 98:594a, 2001.
51. Garcia-Manero G, O'Brien S, Cortes J, Faderl S, Giles F, Albitar M, Lerner S, Kantarjian H, Keating M. Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). *Blood* 98:633a, 2001.

52. Cortes J, Kantarjian H, Garcia-Manero G, Thomas D, Yazji S, Bivins C, Jolivet J, Giles F. A phase II study of troxacitabine, a novel nucleoside analog, in patients with leukemia. *Proceedings of the American Society of Clinical Oncology* 20:304a, 2002.
53. Kornblau S, Womble M, Qiu YH, Cade J, Thomas D, Cortes J, Garcia-Manero G, Jackson CE, Andreeff M. A Prospective Study of Apoptosis Related Proteins BCL2, Bax, PKCa, ERK2 & perk in AML. *Blood* 100:329a, 2002.
54. Borthakur G, Estey E, Kantarjian H, Koller C, Giles F, Garcia-Manero G, Cortes J. A randomized trial of interferon alfa (IFN) and granulocyte macrophage colony stimulating factor (GM-CSF) versus IFN and cytarabine (Ara-C) versus idarubicin (Ida) and ara-c for maintenance therapy in acute myelogenous leukemia (AML), refractory anemia with excess of blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEB-T) in first complete remission (CR). *Blood* 100:261b, 2002.
55. Garcia-Manero G, Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian H, Issa JP. Aberrant DNA Methylation of a Cell Cycle Regulatory Pathway Composed of P73, P15 and P57KIP2 Identifies Adult Patients (pts) with Philadelphia (Ph) Chromosome Negative Acute Lymphocytic Leukemia (ALL) and Poor Prognosis. *Blood* 100:755a, 2002.
56. Shen L, Toyota M, Daniels S, Obata T, Imai K, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of P57KIP2 is frequent in primary and relapsed adult acute lymphocytic leukemia (ALL). *Proceedings of the American Association for Cancer Research* 43:1119, 2002.
57. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Adaptive randomization of idarubicin and ara-C (IA) ± interleukin (IL11) in patients with newly diagnosed (ND) acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS). *Blood* 100:264b, 2002.
58. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Faderl S, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome (Ph) negative metaphases appearing during treatment with imatinib mesylate in patients (pts) with Ph positive chronic myeloid leukemia (CML) in chronic phase (CP). *Blood* 100:368a, 2002.
59. Cortes J, Gandhi V, Plunkett W, Keating M, Faderl S, O'Brien S, Giles F, Garcia-Manero G, Thomas D, Du M, Davis J, Craig A, Estey E, Kantarjian H. Clofarabine {2-chloro-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl) adenine} is active for patients with refractory or relapsed acute leukemias, myelodysplastic syndromes (MDS) and chronic myeloid leukemia in blast phase (CML-BP). *Blood* 100:197a, 2002.
60. Faderl S, Thomas D, O'Brien S, Wierda W, Kantarjian H, Garcia-Manero G, Giles F, Koller C, Beran M, Ferrajoli A, Lerner S, Keating M. Combined use of alemtuzumab and rituximab in patients with relapsed and refractory chronic lymphoid malignancies – an update of the MD Anderson experience. *Blood* 100:206a, 2002.
61. Garcia-Manero G, Faderl S, Giles F, Verstovsek S, Beran M, Andreeff M, Cortes J, Thomas D, Koller C, Pierce S, Ouzonian S, Kantarjian H, Estey E. Double induction (DI) chemotherapy for patients (pts) with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). *Blood* 100:342a, 2002.
62. Tsimberidou A, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Feasibility of mylotarg, fludarabine, ara-c and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia (AML). *Blood* 100:339a, 2002.
63. Estey E, Cortes J, Garcia-Manero G, Thomas D, Faderl S, Verstovsek S, Pierce S, O'Brien S, Beran M, Kantarjian H, Giles F. Further observations on use of gemtuzumab ozogamycin (GO) and all-trans retinoic acid (ATRA) in untreated APL: median additional 8 months of follow-up. *Blood* 100:340a, 2002.
64. Kantarjian H, Cortes J, O'Brien S, Giles F, Thomas D, Faderl S, Garcia-Manero G, Rios MB, Letvak L, Bochinski K, Shan J, Talpaz M. High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph + CML-CP). *Proceedings of the American Society of Clinical Oncology* 21:261a, 2002.

65. Cortes J, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Rios M, Thomas D, Ferrajoli A, Verstovsek S, Faderl S, Letvak L, Bochinski K, Kantarjian H. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with imatinib at 400 mg or 800 mg daily. *Blood* 100:95a, 2002.
66. Cortes J, Talpaz M, Giles F, O'Brien S, Rios M, Thomas D, Garcia-Manero G, Verstovsek S, Kantarjian H. High-dose imatinib mesylate (STI571, Gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon-alpha (IFN) induces molecular remissions. *Blood* 100:164a, 2002.
67. Cortes J, Talpaz M, Giles F, Rios MB, Thomas D, Garcia-Manero G, O'Brien S, Verstovsek S, Kantarjian H. High-dose, imatinib mesylate (STI571, Gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon-alpha (IFN). *Proceedings of the American Society of Clinical Oncology* 21:262a, 2002.
68. Mattiuzzi G, Riehl T, Pierce S, Rex J, Cortes J, Giles F, Garcia-Manero G, Verstovsek S, Malekshamran K, Kantarjian H, Estey E. Intravenous itraconazole (ITRA) versus caspofungin (CASPO) for prophylaxis of invasive fungal infections (IFI) in patients (PTS) with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). *Blood* 100:332a, 2002.
69. Estey E, Kantarjian H, Cortes J, Thomas D, Verstovsek S, Pierce S, Garcia-Manero G, Faderl S, Keating M, Beran M, Giles F. Is the absence of circulating blasts a valid criterion for CR in AML? *Blood* 100:88a, 2002.
70. Thomas D, Cortes J, Garcia-Manero G, Faderl S, O'Brien S, Pierce S, Verstovsek S, Giles F, Andreeff M, Kornblau S, Letvak L, Kantarjian H. Minimal residual disease (MRD) after hyper-cvad and imatinib mesylate (STI571) for Philadelphia (Ph) positive adult acute lymphoblastic leukemia (ALL). *Blood* 100:764a, 2002.
71. Tsimberidou A, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Mylotarg, fludarabine, ara-c and cyclosporine (MFAC) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS). *Blood* 100:339a, 2002.
72. Tsimberidou A, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with cd33-positive primary resistant or relapsed acute myeloid leukemia (AML). *Blood*:339a, 2002.
73. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, Beran M, Keating M, O'Brien S, Kantarjian H, Giles F. Nonleukemic granulocytic sarcoma (GS) in a single institution: frequency, presentation and clinical outcome. *Blood* 100:243b, 2002.
74. Apostolidou E, Garcia-Manero G, Cortes J, Thomas D, Andreeff M, Keating M, Tallman M, Kantarjian H, Giles F. Phase I study of OSI-211, a novel liposomal topoisomerase 1 (Topo 1) inhibitor, in patients with refractory leukemia. *Blood* 100:262b, 2002.
75. Cortes J, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Pate O, Zaknoen S, Kantarjian H. Pilot study of SCH 66336 (Lonafarnib) a farnesyl transferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to imatinib. *Blood* 100:164a, 2002.
76. El-Zimaity MMT, Kantarjian H, Talpaz M, Garcia-Manero G, O'Brien S, Giles F, Verstovsek S, Ferrajoli A, Rios MB, Hayes K, Cortes J. Response to imatinib in patients with chronic myeloid leukemia (CML) with variant Philadelphia chromosome (Ph). *Blood* 100:788a, 2002.
77. Thomas D, Cortes J, Giles F, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Pierce S, Keating M, Cabanillas F, Kantarjian H. Rituximab and hyper-cvad for adult burkitt's (BL) or burkitt's like (BLL) leukemia or lymphoma. *Blood* 100:763a, 2002.
78. Tsao A, Kantarjian H, Thomas D, Giles F, Issa JP, Cortes J, Garcia-Manero G, Huh YO, Shen Y, Yang Y, Albitar M, Estey E. Surface antigen expression in acute leukemias – association with patient and disease characteristics and with outcome. *Blood* 100:253b, 2002.
79. Cortes J, Giles F, O'Brien S, Talpaz M, Thomas D, Keating M, Garcia-Manero G, Faderl S, Estey E, Letvak L, Bochinski K, Kantarjian H. Treatment with imatinib mesylate in patients

- with refractory or relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS) or myeloproliferative disorders (MPD). *Blood* 100:800a, 2002.
80. Alvarez RH, Kantarjian H, Faderl S, Giles F, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. A phase II study of imatinib, idarubicin and low dose of cytarabine in patients (pts) with chronic myeloid leukemia (CML) in blastic phase (BP). *Proceedings of the American Society of Clinical Oncology* 22:617, 2003.
81. Canalli A, Yang H, Jeha S, Albitar M, Shen L, Hocino K, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA Methylation of a Cell Cycle Regulatory Pathway Composed of p73, p15, and p57KIP2 Is an Infrequent Event in Pediatric Acute Lymphocytic Leukemia (ALL) and May Explain Prognostic Differences with Adult Patients (pts). *Blood* 102:30a, 2003.
82. Giles F, Kantarjian H, Cortes J, Tsimberidou A, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Andreeff M, O'Brien S, Beran M, Estey E. Adaptive Randomized Study of Idarubicin and Cytarabine (IA) Alone or with Interleukin 11 (IL-11) as Induction therapy in Patients Aged 50 or above with Untreated Acute Myeloid Leucemia (AML) or High-Risk Myelodysplastic Syndromes (HR-MDS). *Blood* 102:30a, 2003.
83. Quintas-Cardama A, Kantarjian H, O'Brien S, Vu K, Garcia-Manero G, Giles F, Rios MB, Talpaz M, Cortes J. Administration of G-CSF (Filgrastim, Neopogen) for Imatinib Mesylate (Gleevec)-Induced Neutropenia in Chronic Phase Chronic Myeloid Leucemia (CML) Patients (pts) Is Safe and Facilitates the Achievement of Cytogenetic Responses. *Blood* 102:30a, 2003.
84. Estey E, Faderl S, Giles F, Thomas D, Ferrajoli A, Wierda W, Verstovsek S, Garcia-Manero G, Kantarjian H. All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO) to Minimize or Eliminate Chemotherapy in Untreated APL. *Blood* 102:30a, 2003.
85. Estey E, Giles F, Cortes J, Garcia-Manero G, Faderl S, Verstovsek S, Wierda W, Thomas D, Rytting M, Kantarjian H. Application of successful but intensive, children's AML protocol to adults. *Proceedings of the American Society of Clinical Oncology* 22:587, 2003.
86. Cortes J, O'Brien S, Talpaz M, Luthra R, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Ferrajoli A, Wierda W, Thomas D, Faderl S, Kantarjian H. Clinical Significance of Molecular Response in Chronic Myelogenous Leukemia (CML) after Imatinib Mesylate (Gleevec) Therapy: Low Levels of Residual Disease Predict for Response Duration. *Blood* 102:30a, 2003.
87. Yang AS, Garcia-Manero G, Kantarjian H, Issa J-P. Combined bisulfite restriction analysis of Alu repeats to detect demethylation in patients treated with 5-aza-2'-deoxycytidine. *Proc AACR* 44:940, 2003.
88. Faderl S, Albitar M, Wierda W, Ferrajoli A, Manshouri T, Garcia-Manero G, O'Brien S, Thomas D, Kantarjian H, Browning M, Keating M. Continuous I.V. Infusión (C.I.) Followed by Subcutaneous (S.C.) Alemtuzumab Plus Rituximab is Active in Patients with Relapsed/Refractory Chronic Lymphoproliferative Disorders (LPD). *Blood* 102:30a, 2003.
89. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Hayes K, Glassman A, Rios MB, Shan J, Cortes J. Deletion of Derivative Chromosome 9 Has No Prognostic Impact on Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate (Gleevec). *Blood* 102:30a, 2003.
90. Hoshino K, Yang H, Canalli A, Sanchez-Gonzalez B, Donato N, Kantarjian H, Issa JP, Garcia-Manero G. DNA Methylation of the Protein-Tyrosine Phosphatase SHP1in Philadelphia (Ph) Chromosome Positive Chronic Myelogenous Leukemia (CML). *Blood* 102:30a, 2003.
91. Garcia-Manero G, Bumber Y, Mannari R, Vilaything J, Youssef E, Yang H, Estey E, Strom S, Kantarjian H, Issa J-P. DNA Methylation Profiling of Patients (PTS) with Myelodysplastic Syndromes (MDS) Identified Methylation of RIL as an Independent Marker of Poor Prognosis. *Proceedings of the American Society of Clinical Oncology* 22:578, 2003.
92. Wierda W, O'Brien S, Ferrajoli A, Faderl S, Kornblau S, Andreeff M, Koller C, Garcia-Manero G, Thomas D, Kantarjian H, Keating M. Early Analysis of Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab for Relapsed and Refractory Patients with CLL. *Blood* 102:30a, 2003.

93. Faderl S, Kantarjian H, Estey E, Verstovsek S, Garcia-Manero G, Kwari M, Callander N, Emanuel P, Piro L, Keck J, Jameson A, Patel K, Brown G, Estrov Z. Hematologic Improvement Following Treatment with TLK199 (A Novel Glutathione Analog Inhibitor of GST P1-1) in Myelodysplastic Syndrome (MDS): Interim Results of a Phase 1-2^a Study. *Blood* 102:30a, 2003.
94. Cortes J, Talpaz M, Garcia-Manero G, Giles F, O'Brien S, Rios MB, Verstovsek S, Faderl S, Thomas D, Koller C, Wierda W, Andreeff M, Letvak L, Salvado A, Kantarjian H. High Rates of Major Cytogenetic Response in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Early Chronic Phase Treated with High-Dose Imatinib 800 mg Daily. *Blood* 102:30a, 2003.
95. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Lerner S, Wang X, Thomas D, Garcia-Manero G, Cortes J, Kantarjian H, Keating M. Improved Survival in Patients with Relapsed – Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination. *Blood* 102:30a, 2003.
96. Cabanillas M, Mattiuzzi G, Weiser M, Ossa G, Fowler E, Pierce S, Kantarjian H, Garcia-Manero G, Thomas D. Incidence of Invasive Fungal Infections (IFI) in Patients (pts) Receiving Hyper-CVAD. *Blood* 102:30a, 2003.
97. Saba R, Jwied M, Quintas-Cardama A, Talpaz M, Giles F, Cortes J, Keating M, Estey E, O'Brien S, Garcia-Manero G, Kantarjian H, Freireich E, Verstovsek S. Interferon alpha therapy for Patients with Essential Thrombocythemia: Final Results of Phase II Study Initiated in 1986. *Blood* 102:30a, 2003.
98. Wierda W, Garcia-Manero G, O'Brien S, Faderl S, Lerner S, Albitar M, Plunkett W, Giles F, Cortes J, Keating M. Molecular remissions in patients with relapsed or refractory CLL treated with combined fludarabine, cyclophosphamide, and rituximab. *Proceedings of the American Society of Clinical Oncology* 22:581, 2003.
99. Verstovsek S, Lawhorn K, Giles F, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Koller C, Beran M, Talpaz M, Freireich E, Kantarjian H. PEG Intron Therapy for Patients with Myeloproliferative Diseases (MPD): Interim Analysis of Phase II Study. *Blood* 102:30a, 2003.
100. Giles F, Tallman M, Garcia-Manero G, Cortes J, Thomas D, Wierda W, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian H. Phase I and Pharmacokinetic Study of OSI-211, a Liposomal Formulation of Lurtotecan, a Topoisomerase 1 Inhibitor, in Patients with Advanced Leukemia. *Blood* 102:30a, 2003.
101. Cortes J, Garcia-Manero G, O'Brien S, Hernandez I, Rackoff W, Faderl S, Thomas D, Talpaz M, Kantarjian H. Phase I Study of a Imatinib and Tipifarnib (Zarnestra, R115777) in Patients with Chronic Myeloid Leukemia in Chronic Phase Refractory to Imatinib. *Blood* 102:30a, 2003.
102. Giles F, Cortes J, Thomas D, Verstovsek S, Garcia-Manero G, Faderl S, Ferrajoli A, Hagey A, Gordon G, Kantarjian H. Phase I Study of ABT-751, a Novel Tubulin-Binding Agent, in Patients with Refractory Hematological Malignancies. *Blood* 102:30a, 2003.
103. Garcia-Manero G, Canalli A, Wierda W, Cortes J, O'Brien S, Cupo A, Secrist AP, Davis J, Faderl S, Giles F, Chiao J, Richon V, Issa JP. Phase I Study of Oral suberoylanilide Hydroxamic Acid (SAHA) in Patients (pts) with Advanced Leukemias or Myelodysplastic Syndromes (MDS). *Blood* 102:30a, 2003.
104. Cortes J, O'Brien S, Verstovsek S, Thomas D, Giles F, Garcia-Manero G, Murgo A, Newman R, Rios MB, Talpaz M, Kantarjian H. Phase I Study of Subcutaneous (SC) Homoharringtonine (HHT) for Patients (pts) with Chronic Myelogenous Leukemia (CML). *Blood* 102:30a, 2003.
105. Alvarado Y, Kantarjian H, Cortes J, Verstovsek S, Faderl S, Garcia-Manero G, Tsimberidou A, Sznol M, Giles F. Phase I study of VNP4010M, a novel alkylating agent in patients with refractory hematologic malignancies. *Proceedings of the American Society of Clinical Oncology* 22:585, 2003.
106. Issa JP, Garcia-Manero G, Talpaz M, Cortes J, Giles F, Verstovsek S, Faderl S, O'Brien S, Morris G, Kantarjian H. Phase II Study of 5-aza-2'-Deoxycytidine (decitabine) in Patients (pts) with Philadelphia (Ph) Chromosome Positive Chronic Myelogenous Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate. *Blood* 102:30a, 2003.

107. Yang H, Hocino K, Canalli A, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Garcia-Manero G. Preclinical Studies of the Combination of the Hypomethylating Agent 5-aza-2'-Deoxycytidine (Decitabine) and the Histone Deacetylase Inhibitor (HDI) Valproic Acid (VPA) in Leukemic Cell Systems. *Blood* 102:30a, 2003.
108. Tsimberidou A, Estey E, Cortes J, Verstovsek S, Faderl S, Thomas D, Wierda W, Garcia-Manero G, Kantarjian H, Giles F. Randomized comparison of idarubicin and ara-C (IA)+-interleukin (IL11) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS). *Proceedings of the American Society of Clinical Oncology* 22:585, 2003.
109. Thomas D, Garcia-Manero G, Cortes J, O'Brien S, Jeha S, Andreeff M, Kornblau S, Letvak L, Talpaz M, Kantarjian H. Results of intensive chemotherapy with hyper-CVAD and imatinib mesylate in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). *Proceedings of the American Society of Clinical Oncology* 22:588, 2003.
110. Bumber Y, Kondo Y, Chen X, Shen LL, Garcia-Manero G, Youssef E, Issa J-P. RIL, a LIM domain protein and candidate 5q31 tumor suppressor gene frequently silenced by methylation in cancer and sensitizes colorectal cell to apoptosis. *Proc AACR* 44:942, 2003.
111. Ossa G, Hennessy B, Cortes J, Giles F, Medina J, Ferrajoli A, Garcia-Manero G, Faderl S, O'Brien S, Kantarjian H, Verstovsek S. Systemic Mastocytosis: A Review of MD Anderson Experience. *Blood* 102:30a, 2003.
112. Hoshino K, Yang H, Canalli A, Sanchez-Gonzalez B, Donato N, Kantarjian H, Issa JP, Garcia-Manero G. The Transcription Factor JunB Is Not Methylated in Philadelphia (Ph) Chromosome Positive Chronic Myelogenous Leukemia (CML). *Blood* 102:30a, 2003.
113. Thomas D, Faderl S, Cortes J, O'Brien S, Giles F, Garcia-Manero G, Keating M, Kornblau S, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Kantarjian H. Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). *Blood* 102:30a, 2003.
114. Thomas D, Cortes J, Giles F, O'Brien S, Faderl S, Garcia-Manero G, Beran M, Koller C, Andreeff M, Kornblau S, Keating M, Kantarjian H. Update of the Modified Hyper-CVAD Regimen in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL). *Blood* 102:30a, 2003.
115. Ault P, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Cortes J. Use of darbepoetin alfa for the treatment of anemia occurring during imatinib therapy for CML: Preliminary evidence of safety and efficacy. *Proceedings of the American Society of Clinical Oncology* 22:613, 2003.
116. Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, Koller C, O'Brien S, Plunkett W, Garcia-Manero G, Jackson E, Kantarjian H, Andreeff M. 2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES). *Blood* 104(11) (#4764), 11/2004.
117. Cortes J, Garcia-Manero G, O'Brien S, Hernandez I, Rackoff W, Faderl S, Thomas D, Ferrajoli A, Talpaz M, Kantarjian H. A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy. *Blood* 104(11) (#1011), 11/2004.
118. Yee K, Garcia-Manero G, Thomas D, Ravandi-Kashani F, Verstovsek S, Andreeff M, Dancy J, Giles F. A Phase II Study of Temsirolimus (CCI-779) in Patients with Advanced Leukemias. *Blood* 104(11):4523, 11/2004.
119. Hoshino K, Yang H, Santos-Malave C, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA Methylation of the Src Tyrosine Kinase Hck Is a Frequent Event in Human Leukemia and May Predict for Poor Prognosis in Adult Acute Lymphocytic Leukemia (ALL). *Blood* 104(11) (#1542), 11/2004.
120. Shikami M, Konopleva M, Samudio I, Hoshino K, Garcia-Manero G, Kojima K, Tsao T, McQueen T, Andreeff M. ARTS, a Pro-Apoptotic Mitochondrial Septin-Like Protein That Binds to XIAP, Is Silenced in Acute Lymphoblastic and Primitive Acute Myeloblastic Leukemia Cells. *Blood* 104(11) (#3378), 11/2004.
121. Oki Y, Estey E, Kantarjian H, Cortes J, Faderl S, O'Brien S, Koller C, Beran M, Keating M, Pierce S, Garcia-Manero G. Characteristics and Prognosis of Patients (pts) with Acute

- Megakaryocytic Leukemia (AMeGL) Treated at MD Anderson Cancer Center Since 1987. Blood 104(11) (#3003), 11/2004.
122. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Garcia-Manero G, Giles F, Shan J, Verstovsek S, Rios MB, Kantarjian H. Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy. Blood 104(11) (#272), 11/2004.
123. Faderl S, Gandhi V, Verstovsek S, Cortes J, Ravandi-Kashani F, Beran M, Garcia-Manero G, Koller C, O'Brien S, Ferrajoli A, Estrov Z, Kwari M, Plunkett W, Kantarjian H. Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (pts) = Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 104(11) (#875), 11/2004.
124. Kantarjian H, Ravandi F, O'Brien S, Giles F, Faderl S, Garcia-Manero G, Davis J, Estey E, Issa JP. Decitabine Low-Dose Schedule (100 mg/m²/course) in Myelodysplastic Syndrome (MDS). Blood 104(11) (#1437), 11/2004.
125. Hoshino K, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Detection of Aberrant DNA Methylation in Acute Lymphocytic Leukemia (ALL) Using a Real-Time Polymerase Chain Reaction (PCR) Assay. Blood 104(11) (#998), 11/2004.
126. Issa JP, Gharibyan V, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian H. Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia. Blood 104(11) (#2956), 11/2004.
127. Gonzalez-Sanchez B, Hoshino K, Bueso-Ramos C, Yang H, Youssef E, Bumber Y, Santos-Malave C, Garcia-Manero G. In Vitro Effects of the Combination of Idarubicin (IDA) with Suberoylanilide Hydroxamic Acid (SAHA) or Valproic Acid (VPA) in Leukemia Cell Lines. Blood 104(11) (#1173), 11/2004.
128. Oki Y, Jabbour E, Kantarjian H, Estey E, Cortes J, Faderl S, Pierce S, Zhou X, Bekele BN, Garcia-Manero G. Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome. Blood 104(11) (#4530), 11/2004.
129. Cortes J, O'Brien S, Garcia-Manero G, Faderl S, Shan J, Verstovsek S, Rios MB, Talpaz M, Kantarjian H. Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era? Blood 104(11) (#1014), 11/2004.
130. Jabbour E, Kantarjian H, Jones D, O'Brien S, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate – P-Loop Mutations Are Not Associated with Worse Outcome. Blood 104(11) (#1007), 11/2004.
131. Thomas D, Cortes J, Faderl S, O'Brien S, Beran M, Koller C, Garcia-Manero G, Younes A, Fayad L, Wierda W, Pierce S, Giles F, Kantarjian H. Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma. Blood 104(11) (#3297), 11/2004.
132. Verstovsek S, Lawhorn K, Giles F, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Beran M, Talpaz M, Kantarjian H. PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study. Blood 104(11) (#1517), 11/2004.
133. Faderl S, Ferrajoli A, Wierda W, Verstovsek S, Ravandi-Kashani S, Garcia-Manero G, Estey E, Thomas D, Kornblau S, Kwari M, Gandhi V, Kantarjian H. Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML). Blood 104(11) (#1809), 11/2004.
134. Giles F, Fischer T, Cortes J, Beck J, Ravandi-Kashani F, Garcia-Manero G, Kantarjian H, Peng B, Rae P, Laird G, Sharma S, Dugan M, Albitar M, Bhalla KA. Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies. Blood 104(11) (#1802), 11/2004.
135. Estey E, Wang X, Thall P, Pierce S, Koller C, Faderl S, Verstovsek S, Cortes J, Garcia-Manero G, Kantarjian H. Plausibility of Delaying Induction Therapy in Untreated AML. Blood 104(11) (#879), 11/2004.

136. Beran M, Verstovsek S, Kornblau S, Estey E, Giles F, Garcia-Manero G, Kantarjian H. Prolonged Administration of Arsenic Trioxide (Trisenox®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study. *Blood* 104(11) (#4731), 11/2004.
137. Garcia-Manero G, Kantarjian HM, Gonzalez-Sanchez B, Faderl S, Verstovsek S, Ravandi F, Rytting M, Cortes J, Wierda W, Hoshino K, Yang H, Santos-Malave C, Fiorentino J, Jabbour E, Rosner G, Issa JP. Results of a Phase I/II Study of the Combination of 5-aza-2-deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia. *Blood* 104(11) (#263), 11/2004.
138. Cortes J, Talpaz M, O'Brien S, Garcia-Manero G, Ravandi-Kashani F, Giles F, Faderl S, Wierda W, Shan J, Rios MB, Kantarjian H. Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib. *Blood* 104(11) (#1006), 11/2004.
139. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Kantarjian H. Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL). *Blood* 104(11) (#393), 11/2004.
140. Yang H, Hoshino K, Canalli A, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Garcia-Manero G. Additive effect of the combination of 5-aza-2'-deoxycytidine and valproic acid in leukemia cell systems. *Proc AACR:abs* 4435, 2004.
141. Qin T, Youssef E, Yang A, Garcia-Manero G, Issa JP. Antagonistic effect of 1-beta-D-arabinofuramosylcytosine and 5-aza-2'-deoxycytidine in human leukemic cells through regulation of DNA methylation. *Proc AACR:abs* 1601, 2004.
142. Faderl S, Gandhi V, Giles F, Estey E, Garcia-Manero G, O'Brien S, Wierda W, Kwari M, Craig A, Kantarjian H. Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ³ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). *Proceedings of the American Society of Clinical Oncology* 23:6609, 2004.
143. Donato N, Ji Y, Koyu H, Kantarjian H, Talpaz M, Garcia-Manero G. Control of Bcr-ABL activation by SHP-1: role in chronic myelogenous leukemia disease progression and imatinib resistance. *Proc AACR:abs* 2422, 2004.
144. Yang A, Doshi K, Mannari R, Garcia-Manero G, Kantarjian H, Issa JP. DNA methylation changes in leukemia patients treated with 5-aza-2'-deoxycytidine. *Proc AACR:abs* 1599, 2004.
145. Bumber Y, Kondo Y, Shen LL, Ahmed S, Yang A, Garcia-Manero G, Issa JP. Hypermethylation of glycine N-methyltransferase promoter in cancer cell lines and primary AML samples. *Proc AACR:abs* 4189, 2004.
146. Cabanillas M, Mattiuzzi G, Thomas D, Vu K, Ossa G, Garcia-Manero G, Cortes J, Giles F, O'Brien S, Kantarjian H. Invasive fungal infections (IFI) in patients (pts) receiving hyper-CVAD. *Proceedings of the American Society of Clinical Oncology* 23:6727, 2004.
147. Sanchez-Gonzalez B, Yang H, Hoshino K, Garcia-Manero G. La combinacion de idarrubicina con inhibidores de la deacetilacion de histones posse actividad antileucemica in vitro. *Haematologica* 89:10 (C-22), 2004.
148. Giles F, Verstovsek S, Cortes J, Faderl S, Garcia-Manero G, Ravandi-Kashami F, Kornblau S, Gerson S, Sznol M, Kantarjian H. Phase I study of NVP40101M (101M) and AraC in patients (pts) with refractory leukemia. *Proceedings of the American Society of Clinical Oncology* 23:6617, 2004.
149. Garcia-Manero G, Issa JP, Cortes J, Koller C, O'Brien S, Estey E, Canalli A, Chiao J, Richon V, Kantarjian H. Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS). *Proceedings of the American Society of Clinical Oncology* 23:3027, 2004.
150. Hoshino K, Yang H, Canalli A, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Donato N, Garcia-Manero G. The protein-tyrosine phosphatase SHP1 is downregulated with disease progression in Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML), an effect not mediated by DNA methylation. *Proc AACR:abs* 4436, 2004.

151. Rytting M, Sanchez-Gonzalez B, Fiorentino J, McDonald L, Yan H, Issa JP, Kantarjian H, Garcia-Manero G. A Phase I/II Study of 5-AZA-2' deoxycytidine combined with valproic acid in patients with Leukemia: A pediatric subset analysis. *Pediatric Blood and Cancer* 45(4), 10/2005.
152. Quintas-Cardama A, Kantarjian H, Ravandi F, Garcia-Manero G, O'Brien S, Wierda W, Faderl S, Cortes J. A Pilot Trial of Imatinib, Low-Dose Cytarabine (ara-C) and Idarubicin (Ida) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Myeloid Blastic (BP). *Blood* 106(11) (#4840), 11/2005.
153. Cortes J, Talpaz M, O'Brien S, Ravandi F, Verstovsek S, Garcia-Manero G, Koller C, Andreeff M, Estrov Z, Kantarjian H. A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP). *Blood* 106(11) (#1084), 11/2005.
154. Yang H, Hoshino K, Xiao L, Rosner G, Garcia-Manero G. Aberrant DNA Methylation of a Cell Cycle Regulatory Pathway Composed of p73, p15 and P57kip2 is Associated with Poor Prognosis in Adult Patients with Philadelphia Chromosome Negative Acute Lymphocytic Leukemia (ALL). *Blood* 106(11) (#481), 11/2005.
155. Faderl S, Thomas D, Garcia-Manero G, Ravandi F, Beran M, Rytting M, Koller C, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, Vu K, Jarmon R, Kantarjian H. Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage. *Blood* 106(11) (#1840), 11/2005.
156. Kornblau S, Bunker D, Lemker E, Estrov Z, Faderl S, Verstovsek S, Cortes J, Garcia-Manero G, Koller C, Ravandi-Kashani F, Andreeff M, Jackson CE, Chen W, Petersdorf S, Estey E, Appelbaum F. Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study. *Blood* 106(11) (#405), 11/2005.
157. Thomas D, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles F, Verstovsek S, Wierda W, Pierce S, Shan J, Brandt M, Hagemeister F, Cabanillas F, Keating M, Kantarjian H. Chemo-Immunotherapy with Hyper-CVAD Plus Rituximab for Adult Burkitt's and Burkitt's Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL). *Blood* 106(11) (#149), 11/2005.
158. Jabbour E, Kantarjian H, O'Brien S, Verstovsek S, Garcia-Manero G, Rios MB, Cortes J. Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Imatinib Mesylate (IM) Therapy in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase. *Blood* 106(11) (#1090), 11/2005.
159. Estey E, Garcia-Manero G, Giles F, Cortes J, O'Brien S, Kantarjian H. Clinical Relevance of CRp in Untreated AML. *Blood* 106(11) (#541), 11/2005.
160. Faderl S, Ravandi F, Ferrajoli A, Garcia-Manero G, Estrov Z, Thomas D, O'Brien S, Verstovsek S, Wierda W, Cortes J, Giles F, Kwari M, Jarmon R, Kantarjian H. Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) > 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood* 106(11) (#2804), 11/2005.
161. Faderl S, Ferrajoli A, Wierda W, Ravandi F, Estrov Z, Verstovsek S, Thomas D, Garcia-Manero G, Kwari M, Kantarjian H. Clofarabine Combination in Acute Myeloid Leukemia (AML) Salvage: A Dose-Finding Phase I Study of Clofarabine Plus Idarubicin and Clofarabine/Idarubicin Plus Cytarabine (ara-C). *Blood* 106(11) (#2803), 11/2005.
162. Faderl S, Ferrajoli A, Wierda W, Ravandi F, O'Brien S, Garcia-Manero G, Thomas D, Browning M, Keating M. Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). *Blood* 106(11) (#2963), 11/2005.
163. Auki E, Kantarjian H, O'Brien S, Rios MB, Ravandi F, Verstovsek S, Garcia-Manero G, Shan J, Cortes J. Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP). *Blood* 106(11) (#1103), 11/2005.

164. Kantarjian H, O'Brien S, Giles F, Ravandi-Kashani F, Faderl S, Garcia-Manero G, Davis J, Issa JP. Decitabine Low-Dose Schedules (100 mg/m²/Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules. *Blood* 106(11) (#2522), 11/2005.
165. Cortes J, Garcia-Manero G, O'Brien S, Verstovsek S, Estrov Z, Giles F, Ravandi F, Wright J, Kantarjian H. Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). *Blood* 106(11) (#2796), 11/2005.
166. Garcia-Manero G, Yang H, Sanchez-Gonzalez B, Verstovsek S, Ferrajoli A, Keating M, Andreeff M, O'Brien S, Cortes J, Wierda W, Faderl S, Koller C, Davis J, Morris G, Issa JP, Frankel S, Richon V, Fine B, Kantarjian H. Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA) in Patients with Leukemia and Myelodysplastic Syndrome. *Blood* 106(11) (#2801), 11/2005.
167. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Ravandi F, Faderl S, Estrov Z, Cortes J, O'Brien S, Fiorentino J, Issa JP. Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2'-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia. *Blood* 106(11) (#408), 11/2005.
168. Han X, Garcia-Manero G, McDonnell T, Lozano G, Medeiros LJ, Rosner G, Hayes K, Bueso-Ramos C. MDMX is Widely Expressed in Adult Pre-Cursor B Cell B Acute Lymphoblastic Leukemia and is a Potential Therapeutic Target. *Blood* 106(11) (#3280), 11/2005.
169. Garcia-Manero G, Minden M, Estrov Z, Verstovsek S, Fiorentino J, Kantarjian H. Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS). *Blood* 106(11) (#4639), 11/2005.
170. Thomas D, Faderl S, Cortes J, O'Brien S, Giles F, Garcia-Manero G, Kornblau S, Andreeff M, Beran M, Verstovsek S, Pierce S, Letvak L. Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). *Blood* 106(11) (#1830), 11/2005.
171. Yee K, Cortes J, Garcia-Manero G, Verstovsek S, Ferrajoli S, Wierda W, Thomas D, Faderl S, Kina I, O'Brien S, Sznol M, Giles F. Phase I Study of Triapine and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS). *Blood* 106(11) (#4925), 11/2005.
172. Oki Y, Kantarjian H, O'Brien S, Verstovsek S, Gharibyan V, Cortes J, Morris G, Garcia-Manero G, Issa JP. Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML). *Blood* 106(11) (#1099), 11/2005.
173. Jabbour E, Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome—Predictive Prognostic Models for Outcome. *Blood* 106(11) (#1846), 11/2005.
174. Wierda W, O'Brien S, Ferrajoli A, Faderl S, Koller C, Giles F, Cortes J, Thomas D, Ravandi F, Garcia-Manero G, Andreeff M, Lerner S, Kantarjian H, Keating M. Salvage Therapy with Combined Cyclophosphamide [C] , Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. *Blood* 106(11) (#719), 11/2005.
175. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo L, Cortes J. Secondary Leukemia after Imatinib Mesylate (IM) Therapy for Chronic Myelogenous Leukemia (CML). *Blood* 106(11) (#4862), 11/2005.
176. Borthakur G, Kantarjian H, Estey E, Verstovsek S, Garcia-Manero G, Cortes J. Study of Intra-Venous Homoharringtonine (HHT) in the Treatment of Myelodysplastic Syndrome (MDS). *Blood* 106(11) (#4903), 11/2005.
177. Thomas D, Cortes J, O'Brien S, Faderl S, Ravandi F, Garcia-Manero G, Giles F, Beran M, Koller C, Wierda W, Verstovsek S, Ferrajoli A, Kornblau S, Keating M, Andreeff M, Kantarjian H. Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL). *Blood* 106(11) (#1831), 11/2005.
178. O'Brien S, Issa JP, Ravandi-Kashani F, Giles F, Faderl S, Garcia-Manero G, Davis J, Estey E, Kantarjian H. Decitabine low-dose schedule (100mg/m²/course) in myelodysplastic

- syndrome (MDS). Comparison of 3 different dose schedules. *Proceedings of the American Society of Clinical Oncology* 23:6545, 2005.
179. Tsimberidou AM, O'Brien S, Wierda W, Garcia-Manero G, Lerner S, Keating M. Effects of immunotherapy on survival and progression-free survival in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma. *Proceedings of the American Society of Clinical Oncology* 23:6583, 2005.
180. Oki Y, Kantarjian H, Davis J, Ravandi-Kashani F, Vertovsek S, Cortes J, Garcia-Manero G, Issa JP. Hypomethylation induction in MDS after treatment with decitabine at three different doses. *Proceedings of the American Society of Clinical Oncology* 23:6546, 2005.
181. Han X, McDonnell TJ, Lozano G, Garcia-Manero G, Medeiros LJ, Rassidakis GS, Bueso-Ramos C. MDMX is widely expressed in adult pre-B acute lymphocytic leukemia (ALL) and is a potential therapeutic target. *Modern Pathology* 18:1081, 2005.
182. Freireich E, Kantarjian H, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II study of EL625, a p53 antisense oligonucleotide, and chemotherapy in refractory and relapsed acute myelogenous leukemias (AML). *Proceedings of the American Society of Clinical Oncology* 23:6617, 2005.
183. Faderl S, Favandi-Kashani F, Ferrajoli A, Estrov Z, Wierda W, Verstovsek S, Garcia-Manero G, Estey E, Kwari M, Kantarjian H. Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) $\geq$ 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML). *Proceedings of the American Society of Clinical Oncology* 23:6627, 2005.
184. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Verstovsek S, Ravandi F, Rytting M, Cortes J, Yang H, Fiorentino J, Ronser G, Issa JP. Results of a phase I/II study of the combination of 5-aza-2'-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome. *Proceedings of the American Society of Clinical Oncology* 23:6544, 2005.
185. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Thomas D, Kornblau S, Estey E, Nemri M, Cortes J, Giles F, Verstovsek S. A Phase II Study of Azacitidine (VidazaTM) for Patients with Myelofibrosis (MF). *Blood* 108(11) (#2706), 11/2006.
186. Choi SH, Byun H-M, Jiang JY, Garcia-Manero G, Yang AS. Changes in DNA Methylation of Repetitive Elements during the Progression of Chronic Myelogenous Leukemia. *Blood* 108(11) (#4302), 11/2006.
187. Tam CA, Giles F, Cortes J, Garcia-Manero G, Estey E, Kantarjian H, Verstovsek S. Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder. *Blood* 108(11) (#2705), 11/2006.
188. Atallah E, Kantarjian H, Cortes J, Pierce S, Estey E, Garcia-Manero G, Thomas D, Ravandi-Kashani F, Giles F, Verstovsek S. Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup. *Blood* 108(11) (#2612), 11/2006.
189. Loboda A, Fantin VR, Bueso-Ramos CE, Randolph S, Hardwick JS, Ricker JL, Richon VM, Issa JP, Kantarjian HM, Frankel SR, Garcia-Manero G. Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial. *Blood* 108(11) (#2320), 11/2006.
190. Jabbour E, Kantarjian H, Ravandi-Kashani F, Garcia-Manero G, O'Brien S, Cortes J. Clinical Significance of Loss of Chromosome Y (-Y) in Patients with Chronic Myeloid Leukemia (CML): Is It Clonal Evolution? *Blood* 108(11) (#2117), 11/2006.
191. Quintas-Cardama A, Kantarjian HM, Nicaise C, Garcia-Manero G, O'Brien S, Ravandi-Kashani F, Faderl S. Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL[®]): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy. *Blood* 108(11) (#2163), 11/2006.
192. Jabbour E, O'Brien S, Ravandi-Kashani F, Cortes J, Borthakur G, Verstovsek S, Garcia-Manero G, Giles F, Zanoria L, Davisson J, Issa JP, Kantarjian H. Decitabine Induces High

- Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML). *Blood* 108(11) (#2655), 11/2006.
193. Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O'Brien S, Verstovsek S, Garcia-Manero G, Newman BA, Giles F, Issa JP, Kantarjian H. Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy. *Blood* 108(11) (#518), 11/2006.
194. Quintas-Cardama A, Kantarjian HM, Jones D, Garcia-Manero G, O'Brien S, Shan J, Ravandi-Kashani F, Wierda W, Cortes. Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM). *Blood* 108(11) (#432), 11/2006.
195. Garcia-Manero G, Bueso-Ramos C, Xiao L, Hoshino K, Rosner G, Pierce S, Yang H. Detection of Residual p73 DNA Methylation Predicts for Shorter Disease Free and Overall Survival in Patients (pts) with Philadelphia (Ph) Chromosome Negative Acute Lymphocytic Leukemia (ALL) in Remission. *Blood* 108(11) (#2333), 11/2006.
196. Jabbour E, Jones D, Kantarjian H, O'Brien S, Garcia-Manero G, Giles F, Wierda W, Cortes J. Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI). *Blood* 108(11) (#750), 11/2006.
197. Estey EH, Garcia-Manero G, Giles F, Kantarjian H. Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age $\geq$ 60 with Newly-Diagnosed AML. *Blood* 108(11) (#1965), 11/2006.
198. Alvarez RH, Kantarjian H, Garcia-Manero G, Estrov Z, Ravandi-Kashani F, Verstovsek S, Giles F, O'Brien S, Koller CA, Faderl S, Thomas D, Wright JJ, Cortes J. Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). *Blood* 108(11) (#1999), 11/2006.
199. Quintas-Cardama A, Tong W, Manshouri T, Cools J, Gilliland DG, Kantarjian HM, Cortes J, Garcia-Manero G. Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines. *Blood* 108(11) (#710), 11/2006.
200. Aoki T, Kantarjian H, O'Brien S, Talpaz M, Giles F, Verstovsek S, Wierda W, Salavado A, Letvak L, Garcia-Manero G, Jones D, Luthra R, Shan J, Cortes J. High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML. *Blood* 108(11) (#2143), 11/2006.
201. Quintas-Cardama A, Kantarjian HM, Ravandi-Kashani F, Garcia-Manero G, O'Brien S, Verstovsek S, Koller CA, Pate O, Cortes J. Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF. *Blood* 108(11) (#2207), 11/2006.
202. Vu KD, Thomas D, Hubbard JC, Faderl S, Cortes J, Cabanillas ME, Garcia-Manero G, O'Brien S, Kantarjian H. Incidence of Venothromboembolism (VTE) in Patients (pts) with Acute Lymphocytic Leukemia (ALL), Burkitt's Leukemia/Lymphoma (BL) or Lymphoblastic Leukemia (LL). *Blood* 108(11) (#4534), 11/2006.
203. Soriano AO, Champlin R, McCormick G, Giral S, Thall P, Komanduri K, Qazilbash M, Garcia-Manero G, De Lima M. Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study. *Blood* 108(11) (#3668), 11/2006.
204. Byun HM, Eshaghian S, Jiang JY, Choi SH, Ramezani L, Douer D, Garcia-Manero G, Issa JP, Yang D, Trent J, Yang AS. Methylation Profiling of Three Homogeneous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST). *Blood* 108(11) (#736), 11/2006.
205. Giles F, Bergstrom DA, Garcia-Manero G, Kornblau S, Andreeff M, Kantarjian H, Jones D, Freedman SJ, Verstovsek S. MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2)

- Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD). *Blood* 108(11) (#4893), 11/2006.
206. Giles F, Freedman SJ, Xiao A, Borthakur G, Garcia-Manero G, Wierda W, Kornblau SM, O'Brien S., Bergstrom DA, Rizzieri DA. MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL. *Blood* 108(11) (#1967), 11/2006.
 207. Garcia-Manero G, Yang AS, Giles F, Faderl S, Ravandi F, Cortes J, Newsome, WM, Issa JP, Patterson TA, Dubay M, Li Z, Kantarjian H, Martell RE. Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML). *Blood* 108(11) (#1954), 11/2006.
 208. Thomas D, Kantarjian HM, Jorgensen JL, Faderl S, Cortes J, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Koller CA, Beran M, Kornblau SM, Andreeff M, Jones D, O'Brien S. Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). *Blood* 108(11) (#1861), 11/2006.
 209. Thomas D, Kantarjian HM, Cortes J, Faderl S, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Andreeff M, Letvak LA, Jones D, Champlin R, O'Brien. Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). *Blood* 108(11) (#284), 11/2006.
 210. Mattiuzzi GN, Cortes JE, Faderl S, Cabanillas ME, Giles FJ, O'Brien S, Garcia-Manero G, Kantarjian H. Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections. *Blood* 108(11) (#4483), 11/2006.
 211. Jabbour E, Kantarjian H, Koller CA, Faderl S, Ferrajoli A, Richie MA, Garcia-Manero G, Cortes J, Estrov Z, Ravandi-Kashani F, Giles F, Verstovsek S. PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study. *Blood* 108(11) (#3636), 11/2006.
 212. Giles FJ, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ferrajoli A, Garcia-Manero G, Thomas D, Wierda W, Verstovsek S. Phase I Study of XL-119, a Rebecamycin Analog, in Patients with Refractory Hematological Malignancies. *Blood* 108(11) (#1969), 11/2006.
 213. Thomas DA, Kantarjian H, Heffner L, Stock W, Garcia-Manero G, Faderl S, Ferrajoli A, Giles F, Wierda W, Ravandi-Kashani F, Choy G, Berk GI, O'Brien S. Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL). *Blood* 108(11) (#4539), 11/2006.
 214. Quintas-Cardama A, Kantarjian HM, Munden R, Talpaz M, Bruzzi J, O'Brien S, Garcia-Manero G, Nicaise C, Cortes J. Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure. *Blood* 108(11) (#2164), 11/2006.
 215. Tsimberidou AM, Kantarjian HM, Keating MJ, O'Brien S, Wen S, Cortes J, Giles F, Koller CA, Garcia-Manero G, Pierce S, Brandt M, Freireich EJ, Estey EH. Prognostic Significance of β -2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients. *Blood* 108(11) (#802), 11/2006.
 216. Takahashi N, Pastural E, Lowsky R, Torlakovic E, Czader M, Garcia-Manero G, Amin HM, Geyer CR, DeCoteau J. RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines. *Blood* 108(11) (#2134), 11/2006.
 217. Soriano AO, Yang H, Tong W, Faderl S, Wierda W, Andreeff M, Estrov Z, Ouzounian S, Clavell J, Kantarjian H, Issa JP, Garcia-Manero G. Significant Clinical Activity of the Combination of 5-Azacitidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study. *Blood* 108(11) (#160), 11/2006.
 218. Jabbour E, Kantarjian HM, Cortes J, Wierda W, Ferrajoli A, Faderl S, O'Brien S, Ravandi-Kashani F, Verstovsek S, Garcia-Manero G, Davisson J, Giles F, Shan J, Issa JP. Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in

- Patients with Higher Risk Myelodysplastic Syndrome (MDS). *Blood* 108(11) (#2652), 11/2006.
219. Aribi AM, Kantarjian H, Ault P, Koller CA, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The Effect of Interleukin-11 (Oprelvekin, Neumega®) on Thrombocytopenia Associated with Tyrosine Kinase Inhibitors (TKI) in Patients with Chronic Myeloid Leukemia (CML). *Blood* 108(11) (#2148), 11/2006.
220. Shan J, Kantarjian H, Pierce S, Estey E, Garcia-Manero G. A new prognostic score for patients with lower-risk myelodysplastic syndrome (MDS) allows the identification of a subset of patients with poor prognosis. *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7076), 5/2007.
221. Ward MR, Stoltz ML, Etter JB, Patton LM, Garcia-Manero G, Sharma S. An oral dosage formulation of azacitidine: A pilot pharmacokinetic study. *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7084), 5/2007.
222. Solh MM, Kantarjian H, O'Brien S, Giles F, Faderl S, Garcia-Manero G, Rios M, Shan J, Cortes J, Ravandi-Kashani F. Central nervous system (CNS) leukemia alter imatinib mesylate therapy for chronic myelogenous leukemia (CML). *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7042), 5/2007.
223. Soriano AO, Braitheh F, Garcia-Manero G, Camacho LH, Hong D, Moulder S, Ng C, Kurzrock R. Combination of 5-azacytidine (5-AZA) and valproic acid (VPA) in advanced solid cancers: A phase I study. *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#3547), 5/2007.
224. Issa J, Saba HI, Garcia-Manero G, Shan J, Kantarjian HM. Decitabine in older patients with acute myelogenous leukemia (AML). *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7021), 5/2007.
225. O'Brien S, Garcia-Manero G, Ravandi F, Borthakur G, Issa J, Giles F, Kantarjian H, Estey. Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7059), 5/2007.
226. Yang H, Thomas DA, Rytting ME, Zweidler-McKay PA, Brown DL, Kantarjian H, Garcia-Manero G. Phase I study of frequent low-dose administration of decitabine, alone or in combination with hyperCVAD, in relapsed or refractory acute lymphocytic leukemia (ALL). *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7072), 5/2007.
227. Plunkett W, Garcia-Manero G, Faderl S, Cortes J, Boone P, Hilbe C, Green S, Chiao JH, Kantarjian H. Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromes. *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7063), 5/2007.
228. Garcia-Manero G, Yang AS, Klimek V, Luger S, Newsome WM, Berman N, Patterson T, Maroun C, Li Z, Ward R, Martell R. Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7059), 5/2007.
229. Alvarado Y, Kantarjian H, Freireich EJ, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II doping study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML). *Proceedings from the annual American Society of Clinical Oncology* 25(18s) (#7070), 5/2007.
230. Estey E, Sun Z, Rowe J, Faderl S, Cassileth P, Sartiano G, Tartaglia A, Garcia-Manero G, Cripe L, Bennett J, Kantarjian H, Tallman M. A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), MD Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development. *Blood* 110(11) (#298), 11/2007.
231. de Lima M, Padua L, Giralt S, Hosing C, Komanduri K, Qazilbash M, Shpall EJ, Thall P, Qureshi S, McCormick G, Tong W, Popat U, Soriano A, Champlin R, Garcia-Manero G. A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine

- (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. *Blood* 110(11) (#3012), 11/2007.
232. Kadia TM, Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, Verstovsek S, Newsome W, Zwiebel J, Egorin M, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. *Blood* 110(11) (#1842), 11/2007.
 233. Tsimberidou AM, Kantarjian H, O'Brien S, Garcia-Manero G, Koller C, Jones D, Pierce S, Brandt M, Keating M, Estey E. All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As₂O₃) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL). *Blood* 110(11) (#1834), 11/2007.
 234. Garcia-Manero G, Quesada AS, Maddipati S, Kuang SQ, Tong W, Wierda WG, Bueso-Ramos CM, Yang H. Analysis of Class I and II Histone Deacetylase Fails To Identify a Human Leukemia Specific Expression Profile. *Blood* 110(11) (#2130), 11/2007.
 235. Jain N, Mattiuzzi GN, Cortes J, Cassat J, Garcia-Manero G, Ravandi-Kashani F, Pierce S, Borthakur G, O'Brien S, Kantarjian HM. Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline "Targeted Therapy". *Blood* 110(11) (#2858), 11/2007.
 236. Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger J, Verstovsek S, Garcia-Manero G, Cortes J. Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2. *Blood* 110(11) (#1939), 11/2007.
 237. Jabbour E, Kantarjian H, Jones D, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs). *Blood* 110(11) (#1947), 11/2007.
 238. Wierda WG, O'Brien S, Ferrajoli A, Faderl S, Koller C, Estrov Z, Garcia-Manero G, Verstovsek S, Browning M, Lerner S, Keating M. Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. *Blood* 110(11) (#628), 11/2007.
 239. Wierda WG, O'Brien S, Faderl S, Ferrajoli A, Garcia-Manero G, Burger J, Schlette E, Abruzzo L, Lerner S, Keating M. Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL. *Blood* 110(11) (#2065), 11/2007.
 240. Jabbour E, Giral S, Kantarjian H, Garcia-Manero G, Shpall E, Kebriaei P, Silva LDP, Champlin R, de Lima M. Efficacy of Azacytidine (5-AC) Given as Maintenance or Salvage Therapy for Patients (pts) with Acute Leukemia Post Allogeneic Stem Cell Transplantation (HSCT). *Blood* 110(11) (#3013), 11/2007.
 241. Cortes J, O'Brien S, Jabbour E, Ferrajoli A, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Thomas M, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). *Blood* 110(11) (#29), 11/2007.
 242. Kuang SQ, Fang ZH, Lopez G, Tong W, Yang H, Garcia-Manero G. Eph Receptor Tyrosine Kinases and Ephrin Ligands Are Epigenetically Inactivated in Acute Lymphoblastic Leukemia and Are Potential New Tumor Suppressor Genes in Human Leukemia. *Blood* 110(11) (#2128), 11/2007.
 243. Delmonte, Jr. J, Kantarjian HM, Garcia-Manero G, Estrov Z, Ravandi F, Verstovsek S, O'Brien S, Koller CA, Faderl S, Thomas DA, Wright JJ, Cortes J. Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. *Blood* 110(11) (#441), 11/2007.
 244. Tong W, Wierda WG, Bekele N, Kuang SQ, Keating MJ, Garcia-Manero G. Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia. *Blood* 110(11) (#492), 11/2007.

245. Kuang SQ, Tong W, Yang H, Lee MK, Fang ZH, Jelinek J, Issa JP, Garcia-Manero G. Genome-Wide Identification of Aberrant Promoter Associated CpG Island Methylation in Acute Lymphoblastic Leukemia. *Blood* 110(11) (#2127), 11/2007.
246. Faderl S, Thomas DA, Ravandi F, Garcia-Manero G, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, O'Brien S, Vu K, Kwari M, Bretz J, Kantarjian HM. Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). *Blood* 110(11) (#4324), 11/2007.
247. Rytting M, Verstovsek S, Garcia-Manero G, Ravandi-Kashani F, Pierce S, Estey E. Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML). *Blood* 110(11) (#1851), 11/2007.
248. Yanada M, Garcia-Manero G, Ravandi F, Faderl S, Kantarjian H, Estey E. Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival. *Blood* 110(11) (#1852), 11/2007.
249. Borthakur G, Garcia-Manero G, Faderl S, Estrov Z, Verstovsek S, Hood M, Kantarjian H. Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities. *Blood* 110(11) (#1459), 11/2007.
250. Thomas DA, Kantarjian HM, Ravandi F, Faderl S, Garcia-Manero G, Wierda W, Ferrajoli A, Verstovsek S, Jones D, Letvak L, Champlin R, Cortes J, O'Brien S. Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). *Blood* 110(11) (#9), 11/2007.
251. Fava C, Kantarjian HM, Jabbour E, Rios MB, Garcia-Manero G, O'Brien S, Cortes J. Long-Term Significance of Achieving a Major Cytogenetic Response (MCyR) without a Complete Hematologic Response (CHR) among Patients (pts) with Chronic Myeloid Leukemia (CML) in Advanced Phase Treated with Second Generation Tyrosine Kinase Inhibitors (TKI). *Blood* 110(11) (#1944), 11/2007.
252. Schanz J, Estey E, Steidl C, Germing U, Hildebrandt B, Garcia-Manero G, Kantarjian HM, Haase D. Multivariate Analysis Suggests That the Prognostic Impact of Poor Cytogenetics Is Potentially Underestimated in the IPSS. *Blood* 110(11) (#248), 11/2007.
253. Haase D, Estey EH, Steidl C, Germing U, Garcia-Manero G, Kantarjian HM, Schanz J. Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS. *Blood* 110(11) (#247), 11/2007.
254. Silva LDP, de Lima M, Kantarjian H, Champlin R, Faderl S, Giral S, Kebriaei P, Davisson J, Estey E, Garcia-Manero G, Issa JP, Ravandi F. Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2'-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome. *Blood* 110(11) (#1468), 11/2007.
255. Lim Z, Ho AYL, Samuel J, Hayden J, Garcia-Manero G, Mufti GJ. Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine. *Blood* 110(11) (#1449), 11/2007.
256. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, Cortes J, Richie MA, Borthakur G, Verstovsek S. Pegylated Interferon-alfa-2a (PEG-IFN- α -2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study. *Blood* 110(11) (#3542), 11/2007.
257. Garcia-Manero G, Thomas D, Rytting M, Zweidler-McKay P, Estrov Z, Brown DL, Yang G, Kantarjian H, O'Brien S. Phase I Study of 5-aza-2'-Deoxycytidine, Alone or in Combination with Hyper-CVAD, in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL). *Blood* 110(11) (#2826), 11/2007.
258. Kantarjian H, Garcia-Manero G, Faderl S, Cortes J, Estrov Z, Boone P, Stuart I, Westwood R, Green S, Chiao JH, Plunkett W. Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS). *Blood* 110(11) (#884), 11/2007.
259. Ravandi F, Faderl S, Thomas D, Burger J, Koller C, Garcia-Manero G, Morris G, Torma R, Kantarjian H, Issa JP. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. *Blood* 110(11) (#897), 11/2007.

260. Garcia-Manero G, Yang AS, Klimek V, Cortes J, Ravandi F, Newsome WM, Dumouchel J, Dubay M, Li Z, Maroun C, Laille E, Kantarjian H, Martell RE, Luger S. Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). *Blood* 110(11) (#444), 11/2007.
261. Verstovsek S, Tefferi A, Kornblau S, Thomas D, Cortes J, Ravandi-Kashani F, Garcia-Manero G, Kantarjian H. Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. *Blood* 110(11) (#3543), 11/2007.
262. Verstovsek S, Ayalew T, Jorge C, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Thomas D, Kantarjian H. Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. *Blood* 110(11) (#3551), 11/2007.
263. Quintás-Cardama A, Tefferi A, Thomas D, Cortes J, Ravandi F, Faderl S, Garcia-Manero G, Borthakur G, Bell N, Byrne C, Kantarjian H, Verstovsek S. Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis. *Blood* 110(11) (#3545), 11/2007.
264. Ravandi F, Issa JP, Faderl S, Garcia-Manero G, Hood M, Jorgensen J, Lee M, O'Brien S, Estey E, Borthakur G, Ferrajoli A, Verstovsek S, Cortes J, Kantarjian H. Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission. *Blood* 110(11) (#2859), 11/2007.
265. Faderl S, Garcia-Manero G, Gandhi V, Ravandi F, Borthakur G, Thomas DA, Ferrajoli A, Estrov Z, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome. *Blood* 110(11) (#1455), 11/2007.
266. Borthakur G, Kantarjian H, Garcia-Manero G, Pierce S, Estey E. Salvage Therapy with Standard Dose Cytarabine Is Appropriate for Patients with Acute Myelogenous Leukemia Refractory to Front-Line Therapy with Hypomethylating Agents. *Blood* 110(11) (#4382), 11/2007.
267. Alvarado Y, Kantarjian H, Faderl S, Burger J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). *Blood* 110(11) (#1932), 11/2007.
268. Kantarjian H, Garcia-Manero G, O'Brien S, Estrov Z, Ravandi F, Cortes J, Shan J, Davisson J, Issa JP. Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen. *Blood* 110(11) (#115), 11/2007.
269. Verma D, Kantarjian H, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure. *Blood* 110(11) (#2949), 11/2007.
270. Kuang S, Ling X, Sanchez-Gonzalez B, Yang H, Garcia-Manero G. The Cyclin-Dependent Kinase Inhibitor p57KIP2 Functions as a Tumor Suppressor Gene in Human Leukemia. *Blood* 106(11) (#1604), 11/2007.
271. Verma D, Thomas D, O'Brien S, Faderl S, Koller C, Pierce S, Estey E, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen. *Blood* 110(11) (#2832), 11/2007.
272. Kadia TM, Kantarjian H, Verstovsek S, Newman B, Garcia-Manero G, Borthakur G. Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS. *Blood* 110(11) (#1463), 11/2007.
273. Estey E, Issa JP, Garcia-Manero G, Faderl S, Kantarjian H. Use of Post-Treatment Clinical Data To Predict Response to Decitabine. *Blood* 110(11) (#1448), 11/2007.
274. Garcia-Manero G. Epigenetic Therapy of High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia. *Cancer Investigation* 25(Supplement 1), 2007.

275. Tong W, Kuang SQ, Wierda WG, Garcia-Manero G. Global Gene Methylation of CLL Patients and its Implication in Therapy. American Association of Cancer Research (#1112), 2007.
276. Kuang SQ, Yang H, Jelinek J, Tong W, Issa JP, Garcia-Manero G. Identification of Novel Differentially Methylated Markers in Adult Acute Lymphocytic Leukemias. American Association for Cancer Research (#1131), 2007.
277. Quintas-Cardama A, Manshour T, Tong W, Kantarjian H, Cortes J, Garcia-Manero G. The Dual ABL/SRC Inhibitors Dasatinib, SKI-606, and INNO-406 are Potent Inhibitors of T Cell Acute Lymphoblastic Leukemia Cell Lines Expressing the NUP214-ABL1 Fusion Kinase. American Association for Cancer Research (#1825), 2007.
278. Skikne BS, Ward MR, Nasser A, Aukerman L, Garcia-Manero G. A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). Proceedings of the Annual American Society of Clinical Oncology 26(15s):394s (#7091), 5/2008.
279. Conley AP, Stevenson W, Pierce S, Cortes JE, O'Brien SM, Ravandi F, Kantarjian HM, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome (MDS). Proceedings of the Annual American Society of Clinical Oncology 26(15s):395s (#7096), 5/2008.
280. Borthakur G, Kantarjian HM, O'Brien SM, Jones D, Koller C, Nicaise C, Garcia-Manero G, Ferrajoli A, Cortes JE. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Proceedings of the Annual American Society of Clinical Oncology 26(15s):375s (#7013), 5/2008.
281. Cortes JE, O'Brien SM, Ferrajoli A, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Letvak L, Kantarjian HM. Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP). Proceedings of the Annual American Society of Clinical Oncology 26(15s):376s (#7016), 5/2008.
282. Garg RJ, Shah N, Garcia-Manero G, Faderl S, Cortes JE, Koller C, Beran M, Borthakur G, Kantarjian HM, Ravandi F. Phase II study of thymoglobulin, cyclosporine and G-CSF for initial treatment of aplastic anemia and low risk myelodysplastic syndrome. Proceedings of the Annual American Society of Clinical Oncology 26(15s):395s (#7093), 5/2008.
283. Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian HM, Estey E. Prognostic significance of blood counts at time of complete remission in acute myeloid leukemia. Proceedings of the Annual American Society of Clinical Oncology 26(15s):391s (#7078), 5/2008.
284. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Estey E. Randomized comparison of "neutropenic" and non-neutropenic diet in pts undergoing remission induction therapy for AML. Proceedings of the Annual American Society of Clinical Oncology 26(15s):385s (#7052), 5/2008.
285. Jain N, Kantarjian HM, Garcia-Manero G, Borthakur G, Ebarb T, Cortes JE. Synthetic tumor-specific breakpoint peptide vaccine in patients (pts) with chronic myeloid leukemia (CML) and minimal residual disease: A phase II trial. Proceedings of the Annual American Society of Clinical Oncology 26(15s):386s (#7056), 5/2008.
286. Santos FPS, Faderl S, Garcia-Manero G, Koller C, Beran M, Borthakur G, Bueso-Ramos C, Keating M, Cortes J, Kantarjian H, Ravandi F. Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the MD Anderson Cancer Center. Blood 112(11):342-343, 11/2008.
287. Tong W, Wei Y, Stevenson W, Kuang SQ, Arts J, Garcia-Manero G. Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor. Blood 112(11):910-911, 11/2008.
288. Santos F P.S, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Kornblau S, Ravandi F, Wierda W, Cortes J. Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML). Blood 112(11):1104, 11/2008.

289. Ravandi F, Cortes J, Faderl S, Garcia-Manero G, O'Brien S, Brandt M, Lang M, Zhang W, Luthra R, Jones D, Levis M, Konopleva M, Andreeff M, Kantarjian H. Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years. *Blood* 112(11):285, 11/2008.
290. Quintas-Cardama A, Kantarjian H, Thomas DA, Garcia-Manero G, Borthakur G, Bell N, Byrne C, Verstovsek S. Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis. *Blood* 112(11):247, 11/2008.
291. Borthakur G, Estrov Z, Garcia-Manero G, Williams B, Wathen JK, Konopleva M, Burger J, Ferrajoli A, George S, Kantarjian H. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. *Blood* 112(11):1026, 11/2008.
292. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List AF, Fenaux P, Garcia-Manero G. Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS). *Blood* 112(11):236, 11/2008.
293. Kantarjian H, Giles F, Greenberg P, Paquette R, Wang E, Gabrilove J, Garcia-Manero G, Gray J, Hu K, Franklin J. Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine. *Blood* 112(11):89, 11/2008.
294. Cortes J, O'Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G, Garcia-Manero G, Letvak L, Kantarjian H. Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). *Blood* 112(11):170, 11/2008.
295. Kuang S, McKay PZ, Yang H, Fang ZH, Tong W, Garcia-Manero G. Epigenetic Inactivation of Notch Signaling Target Genes HES in B Cell Acute Lymphoblastic Leukemia. *Blood* 112(11):1157, 11/2008.
296. Maddipati SC, Bueso-Ramos C, Yang H, Fernandez M, Kuang S, Stevenson W, Wei Y, Pierce S, Garcia-Manero G. Epigenetic Silencing of the RUNX3 Gene by Promoter Hypermethylation in Patients with Myeloid Leukemia. *Blood* 112(11):1148, 11/2008.
297. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy. *Blood* 112(11):1015, 11/2008.
298. Tong W, Kuang SQ, Wierda W, Keating MJ, Garcia-Manero G. Identification of Multiple Promoter Associated CpG Islands Commonly Methylated in Both Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) Using Novel Genome-Wide Microarray Technique: Implications for Common Primordial Molecular Pathways in Lymphoid Leukemias. *Blood* 112(11):789, 11/2008.
299. Kantarjian H, Pierce S, Garcia-Manero G, Cortes J, Faderl S, Ravandi F. Increase in the Incidence of Secondary Acute Myeloid Leukemia (2-AML): A Single Institution Experience Over 20 Years. *Blood* 112(11):533, 11/2008.
300. Henderson JD, O'Brien SM, Wang X, Faderl S, Ferrajoli A, Garcia-Manero G, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ, Wierda WG. Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patient with CLL Receiving Salvage Treatment. *Blood* 112(11):723, 11/2008.
301. Wierda WG, O'Brien SM, Wang X, Faderl SH, Ferrajoli A, Garcia-Manero G, Cortes J, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ. Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy. *Blood* 112(11):729, 11/2008.
302. de Lima M, de Padua Silva L, Giral S, Komaduri K, Andersson BS, Hosing C, Qazilbash M, Shpall E, Thall P, Zhang W, McCormick G, Wang X, Popat U, Soriano A, Alousi A, Champlin R, Garcia-Manero G. Maintenance Therapy with Low-Dose Azacitidine(AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. *Blood* 112(11):414, 11/2008.

303. Verma D, Kantarjian HM, Rios MB, O'Brien S, Ault P, Burton EM, Estrov Z, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Cortes J. Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies. *Blood* 112(11):740, 11/2008.
304. Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Estrov Z, Thomas D, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian H. Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS). *Blood* 112(11):89, 11/2008.
305. Thomas DA, Katarjian H, Faderl S, Wierda W, Garcia-Manero G, Ferrajoli A, Burger J, Cortes J, Koller C, Borhakur G, Estrov Z, Knopleva M, O'Brien S. Outcome after Frontline therapy with the Modified Hyper-CVAD Regime with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). *Blood* 112(11):674, 11/2008.
306. Fava C, Blamble D, O'Brien S, Garcia-Manero G, Pierce S, Kantarjian H, Borthakur G. Outcome of First Salvage Therapy in core Binding Factor Associated Acute Myelogenous Leukemia Is Less Than Optimal. *Blood* 112(11):1014, 11/2008.
307. Jabbour E, Garcia-Manero G, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure. *Blood* 112(11):585-586, 11/2008.
308. Quintas-Cardama A, Kantarjian HM, Borhakur G, Faderl S, Garcia-Manero G, Wierda W, Burton EM, Cortes J. Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy. *Blood* 112(11):735, 11/2008.
309. Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian H, Lancet J. Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy. *Blood* 112(11):1026, 11/2008.
310. Issa J-P, Castoro R, Ravandi-Kashani F, Faderl S, Huang X, Estey E, Borhakur G, Morris G, Garcia-Manero G, Kantarjian H. Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine vs. Decitabine and Valproic Acid in MDS and AML. *Blood* 112(11):91, 11/2008.
311. Borthakur G, de Lima M, Kantarjian H, Xiao L, de Padua Silva L, Garcia-Manero G, Giralt S, Ravandi-Kashani F, Pierce S, Champlin R. Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations. *Blood* 112(11):1134, 11/2008.
312. Wei Y, Kadia T, Tong W, O'Brien S, Viallet J, Garcia-Manero G. The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways. *Blood* 112(11):577, 11/2008.
313. Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS? *Blood* 112(11):580, 2008, 11/2008.
314. Jabbour E, Faderl S, Ravandi F, Konopleva M, Verstovsek S, Cortes J, Wierda W, Newsome WM, Yang H, Kantarjian H, Garcia-Manero G. Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). *Journal of Clinical Oncology* 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):327s (#7004), 2/2009.
315. Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Courtre S, Stock W, Borthakur G, Chiao J, Kantarjian H. A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. *Journal of Clinical Oncology* 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):361s (#7021), 5/2009.
316. Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia (AML) in adolescents and young

- adults (AYA): The MD Anderson Cancer Center experience. *Journal of Clinical Oncology* 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):368s, 5/2009.
317. Verma D, Kantarjian H, Jones D, Borthakur G, Garcia-Manero G, Thomas DA, Verstovsek S, Rios M, Cortes J. Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance. *Journal of Clinical Oncology* 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):363s (#7030), 5/2009.
318. Naqvi K, Oh J, Garcia-Manero G, Pierce S, Suarez-Almazor ME. Comorbidities and prognosis of myelodysplastic syndromes. *Journal of Clinical Oncology* 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):376s, 5/2009.
319. Batty G, Kantarjian H, Issa JP, Garcia-Manero G, Pierce S, O'Brien S, Jabbour E, Cortes J, Ravandi F. Feasibility of hypomethylating therapy in patients with renal insufficiency. *Journal of Clinical Oncology* 27(15S, Part I of II) (#7089), 5/2009.
320. Ravandi-Kashani F, Cortes J, Faderl S, Jones D, Byrd A, Brandt M, Garcia-Manero G, Levis M, Andreeff M, Kantarjian H. Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML). *Journal of Clinical Oncology* 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):360s (#7018), 5/2009.
321. Sampat KR, Garcia-Gutierrez V, Rossi A, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia. *Journal of Clinical Oncology* 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):372s (#7067), 5/2009.
322. Laille E, Ward R, Nasser A, Stoltz M, Cogle C, Gore S, Skikne BS, Garcia-Manero G. The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). *Journal of Clinical Oncology* 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):377s (#7087), 5/2009.
323. MacBeth KJ, Laille E, Ning Y, Cogle CR, Skikne B, Gore SD, Garcia-Manero G, Ward MR. A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML): Results from a Phase I Study. *Blood* 114 (#1772), 11/2009.
324. Angelucci E, Bowen D, Magalhaes SMM, Lawniczek T, Douma S, Jakobs P, Garcia-Manero G. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Deferasirox (Exjade(R)) in Patients with Low/Intermediate-1 Risk MDS and Transfusional Iron Overload. *Blood* 114 (#4854), 11/2009.
325. Garcia-Manero G, Khoury HJ, Borthakur G, Ravandi F, Kadia T, Estrov Z, Jabbour E, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Freeman B, Simmons H, Ptaszynski M, Kantarjian H. A Phase I Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias. *Blood* 114 (#2047), 11/2009.
326. Garcia-Manero G, Gore SD, Skikne B, Cogle CR, Ning Y, MacBeth KJ, Laille E, Ward MR. A Phase I Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML). *Blood* 114 (#117), 11/2009.
327. Garcia-Manero G, Thomas D, Rytting M, Zweidler-McKay PA, Yang H, Fang Z, Kuang S, Dara S, O'Brien S, Kantarjian HM. A Phase I Study of Dose-Dense 5-Aza-2'-Deoxycytidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL). *Blood* 114 (#2030), 11/2009.
328. Garcia-Manero G, Couriel DR, Tambaro FP, Gabrail N, Nadeem A, Kadia T, Jabbour E, Borthakur G, Faderl S, Newsome W, Yang H, Chen K, Stein K, Kantarjian H. A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS). *Blood* 114 (#119), 11/2009.
329. Kim H, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cortes J, Ravandi F, Wierda WG, Estrov Z, Faderl S, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome. *Blood* 114 (#3796), 11/2009.

330. Kantarjian HM, Garcia-Manero G, Luger S, Venugopal P, Maness LJ, Wetzler M, Stock W, Coutre S, Borthakur G, Chiao J. A Randomized Phase 2 Study of Sapacitabine, an Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse. *Blood* 114 (#1061), 11/2009.
331. Garcia-Manero G, Luger S, Venugopal P, Maness LJ, Wetzler M, Altman J, Claxton DF, Strickland S, Faderl S, Chiao J, Kantarjian HM. A Randomized Phase 2 Study of Sapacitabine, an Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents. *Blood* 114 (#1758), 11/2009.
332. Mattiuzzi G, Kantarjian H, Ho J, Garcia-Manero G, Cortes J. Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts. *Blood* 114 (#3102), 11/2009.
333. Ayoubi M, Thomas DA, Kantarjian H, O'Brien S, Ravandi F, Garcia-Manero G, Verstovsek S, Rytting M, Borthakur G, Kadia T, Kornblau SM, Andreeff M, Feliu J, Faderl S. Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase. *Blood* 114 (#2031), 11/2009.
334. Mattiuzzi G, Amin HM, Kantarjian H, Garcia-Manero G, Cortes J. Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. *Blood* 114 (#1611), 11/2009.
335. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, de Lima M, Pierce S, Brandt M, Borthakur G, Ferrajoli A, Wierda WG, Koller CA, Kantarjian HM. Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy. *Blood* 114 (#1038), 11/2009.
336. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau SM, Andreeff M, Garriss R, Keating MJ, O'Brien S. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). *Blood* 114 (#836), 11/2009.
337. Badoux XC, Keating M, O'Brien S, Kadia T, Ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger JA, Wierda WG. Chemoimmunotherapy with Cyclophosphamide, Fludarabine, Alemtuzumab and Rituximab (CFAR) is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia. *Blood* 114 (#3431), 11/2009.
338. Kadia T, Kornblau SM, Kantarjian H, Faderl S, Jones D, Garcia-Manero G, Borthakur G, Koller C, Verstovsek S, Pierce S, Cortes J, Ravandi F. Clinical Characterization and Proteomic Consequences of Mutated RAS in Acute Myeloid Leukemia. *Blood* 114 (#509), 11/2009.
339. Martell RE, Garcia-Manero G, Younes A, Ewer M, Daher IN, Drouin M, Hunt W, Lortie K, Wilhelm J, Besterman JM. Clinical Development of MGCD0103, an Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy. *Blood* 114 (#4756), 11/2009.
340. Garcia-Manero G, Marek BJ, Lyons RM, Martinez-Lopez N, Paley C, Greenberg PL. Clinical parameters in 391 Iron-Overloaded Patients with Lower-Risk MDS Enrolled in a Prospective, Non-Interventional Multicenter Registry. *Blood* 114 (#4834), 11/2009.
341. Parikh SA, Kantarjian H, Garcia-Manero G, Jabbour E, Kadia T, Ravandi F, Ferrajoli A, Estrov Z, Feliu J, Faderl S. Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs). *Blood* 114 (#2058), 11/2009.
342. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Pierce S, Lei X, Suarez-Allmazor ME. Comorbidities and Myelodysplastic Syndromes. *Blood* 114 (#2789), 11/2009.
343. Jabbour E, Kantarjian H, Parikh SA, Thomas D, Kadia T, Garcia-Manero G, Borthakur G, Pierce S, Brandt M, Cortes J, Verstovsek S. Comparison of Thalidomide and Lenalidomide for the Treatment of Patients (pts) with Myelofibrosis (MF). *Blood* 114 (#2901), 11/2009.

344. Rosinski SL, Ravandi F, Faderl S, Garcia-Manero G, Pierce S, Kantarjian HM, Estey EH. Count Recovery in AML Patients Achieving a Complete Response. *Blood* 114 (#2062), 11/2009.
345. Castoro RJ, Raynal NJ, Huang X, Bueso-Ramos CE, Garcia-Manero G, Kantarjian HM, Issa JPJ. DNA Methylation and Gene Expression Analysis in a Phase II Randomized Study of Decitabine vs. Decitabine Plus Valproic Acid in MDS and AML. *Blood* 114 (#3808), 11/2009.
346. Greenberg PL, Garcia-Manero G, Moore MR, Damon LE, Roboz GJ, Wei Y, Kantarjian H, Franklin JL. Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine. *Blood* 114 (#1769), 11/2009.
347. Thomas DA, Faderl S, O'Brien S, Wierda WG, Ravandi F, Garcia-Manero G, Verstovsek S, Kornblau SM, Fayad L, Cortes J, Kantarjian HM. Favorable Outcome for Lymphoblastic Lymphoma (LL) after Frontline Therapy with the Hyper-CVAD Regimens: An Update. *Blood* 114 (#4099), 11/2009.
348. Pemmaraju N, Kantarjian HM, Ravandi F, Garcia-Manero G, Borthakur G, Parikh SA, Konopleva M, Kornblau SM, Andreeff M, O'Brien S, Cortes J. FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact on Survival According to FLT3 Status. *Blood* 114 (#1026), 11/2009.
349. Wei Y, Chen R, Bueso-Ramos CE, Wang H, Song X, Wang J, Yao H, Nguyen M, Fernandez M, Yang H, Garcia-Manero G. Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF- κ B signalling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS). *Blood* 114 (#291), 11/2009.
350. Santos FPS, Kantarjian H, Kadia T, Bivins C, O'Brien S, Ravandi F, Cortes J, Garcia-Manero G, Faderl S, Pierce S, Jabbour E. High Prevalence of FLT3-ITD Mutations in Patients (pts) with Acute Myeloid Leukemia (AML) who Present with Central Nervous System (CNS) Relapse. *Blood* 114 (#1020), 11/2009.
351. Vigil C, Cortes J, Kantarjian HM, Garcia-Manero G, Lancet JE, List AF. Hypomethylating Therapy for the Treatment of Acute Erythroleukemia Patients. *Blood* 114 (#2069), 11/2009.
352. Fang Z, Kuang S, Yang H, Garcia-Manero G. Lack of IKZF1 Aberrant DNA Methylation in Acute Lymphocytic Leukemia. *Blood* 114 (#982), 11/2009.
353. Kadia T, Estrov Z, Ravandi F, Koller CA, Borthakur G, Jabbour E, Faderl S, Pierce S, Cortes J, Kantarjian HM, Garcia-Manero G. Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated on Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid. *Blood* 114 (#2074), 11/2009.
354. Santos FPS, Schlette E, Kantarjian H, Sargent R, Garcia-Manero G, Verstovsek S, Kadia T, Jabbour E, Pierce S, Borthakur G. Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients. *Blood* 114 (#2775), 11/2009.
355. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes J, O'Brien S, Gandhi V, Plunkett W, Byrd AL, Kwari M, Kantarjian H. Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome. *Blood* 114 (#118), 11/2009.
356. Dayyani F, Kantarjian HM, O'Brien S, Pierce S, Faderl S, Garcia-Manero G, Cortes-Franco J, Ravandi F. Outcome of Therapy-Related Acute Promyelocytic Leukemia (t-APL) with or without Arsenic Trioxide (ATO) as a Component of Frontline Therapy. *Blood* 114 (#1050), 11/2009.
357. Badoux XC, Keating M, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Abruzzo LV, Wierda WG. Patients with Relapsed CLL and 17p Deletion by FISH have very Poor Survival Outcomes. *Blood* 114 (#1248), 11/2009.
358. Al-Kali A, Jones D, Cortes J, Faderl S, Ao X, Garcia-Manero G, Borthakur G, Konopleva M, Brandt M, Andreeff M, Kantarjian H, Ravandi F. Patterns of Molecular Response to and Relapse after Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML). *Blood* 114 (#2079), 11/2009.
359. Borthakur G, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, Thomas DA, Kadia T, Williams B, George S, Kantarjian H. Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome--Outcome in Previously Untreated Patients. *Blood* 114 (#1053), 11/2009.

360. Garcia-Manero G, Tambaro FP, Bekele BN, Jabbour E, Ravandi F, Yang H, Borthakur G, Kadia T, Cortes J, Faderl S, Konopleva M, Pierce S, Burger JA, Estrov Z, O'Brien S, Thomas D, Newsome W, Kantarjian H. Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). *Blood* 114 (#1055), 11/2009.
361. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure. *Blood* 114 (#509), 11/2009.
362. Tong WG, Kadia T, Borthakur G, Jabbour E, Pierce S, Shan J, Cortes-Franco J, Ravandi F, Wierda W, Thomas D, Kantarjian H, Garcia-Manero G. Prognostic Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score. *Blood* 114 (#3819), 11/2009.
363. Hu Y, Chen G, Jia Y, Zhang H, Huang P, Bhalla KN, Keating M, Garcia-Manero G. The Combination of PEITC (Phenethyl Isothiocyanate) with a Histone Deacetylase Inhibitor (HDACi) has Synergistic Antileukemia Activity by Overcoming a Redox-Mediated Resistance Pathway. *Blood* 114 (#1739), 11/2009.
364. Garg RJ, Kantarjian H, Agarwal M, Ravandi F, Borthakur G, Kornblau SM, Ferrajoli A, Garcia-Manero G, O'Brien S, Cortes J. The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) who Fail Both All-Trans-retinoic Acid (ATRA) and Arsenic Trioxide (ATO). *Blood* 114 (#4143), 11/2009.
365. Ottmann OG, Fenaux P, Lubbert M, DeAngelo DJ, Garcia-Manero G, Bhalla KN, Sekeres MA, Ludicke F, Weber HJ, Winiger IJ. A phase 1b study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). *Journal of Clinical Oncology* 28(15S):51s (#TPS282), 5/2010.
366. Garcia-Manero G, Luger SM, Venugopal P, Maness LJ, Wetzler M, Altman JK, Claxton D, Strickland SA, Chiao JH, Kantarjian H. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. *Journal of Clinical Oncology* 28(15S):494s (#6528), 5/2010.
367. Jabbour E, Kantarjian H, Garcia-Manero G, Ravandi Kashani F, Borthakur G, Estrov Z, Gandhi V, Byrd A, Kwari M, Faderl S. A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS). *Journal of Clinical Oncology* 28(15S):488s (#6504), 5/2010.
368. Jabbour E, Kantarjian H, Garcia-Manero G, Ravandi-Kashani F, Borthakur G, Estrov Z, Gandhi V, Byrd A, Kwari M, Faderl S. A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS). *Journal of Clinical Oncology* 28(15S):488s (#6504), 5/2010.
369. Faderl S, Ravandi Kashani F, Borthakur G, Kadia TM, Jabbour E, Garcia-Manero G, Brandt M, Pierce S, Kantarjian H. Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison. *Journal of Clinical Oncology* 28(15S):499s (#6551), 5/2010.
370. Ayoubi M, Kantarjian H, Cortes JE, Faderl S, Garcia-Manero G, Wen S, Fiorentino J, Huang X, Luthra R, Ravandi Kashani F. Dynamic of morphologic and molecular remission in patients (pts) with APL treated with frontline ATRA and arsenic trioxide (ATO). *Journal of Clinical Oncology* 28(15S):498s (#6548), 5/2010.
371. Pemmaraju N, Kantarjian H, Faderl S, Garcia-Manero G, Kadia TM, Borthakur G, Cortes JE, Ravandi Kashani F. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). *Journal of Clinical Oncology* 28(15S):513s (#6605), 5/2010.
372. Pemmaraju N, Kantarjian H, Faderl S, Garcia-Manero G, Kadia TM, Borthakur G, Cortes JE, Ravandi Kashani F. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). *Journal of Clinical Oncology* 28(15S):513s (#6605), 5/2010.
373. Chen Y, Kantarjian H, Garcia-Manero G, Estrov Z, Konopleva M, Jabbour E, Kadia TM, Williams B, George S, Borthakur G. Phase II study of decitabine and gemtuzumab

- ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). *Journal of Clinical Oncology* 28(15S):503s (#6566), 5/2010.
374. Fullmer A, Borthakur G, Kadia TM, Garcia-Manero G, Jabbour E. Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine. *Journal of Clinical Oncology* 28(15S):504s (#6571), 5/2010.
 375. Ravandi Kashani F, Jorgensen J, Faderl S, Issa J, Autry J, Garcia-Manero G, Borthakur G, Huang X, Cortes JE, Kantarjian H. Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR). *Journal of Clinical Oncology* 28(15S):493s (#6527), 5/2010.
 376. Garcia-Manero G, Thomas DA, Rytting ME, O'Brien S, Franklin ARK, Borthakur G, Kwari M, Dara S, Yang H, Kantarjian H. Final Report of a Phase I Trial of Decitabine with or without hyperCVAD In Relapsed Acute Lymphocytic Leukemia (ALL). *Blood* 116(21) (#867), 11/2010.
 377. Wei Y, Chen R, Bueso-Ramos C, Yang H, Jia Y, Fang Z, Garcia-Manero G. Use of genome-wide CHIP-Seq analysis allows identification of deregulated molecular pathways in myelodysplastic syndromes (MDS). *CPRIT Innovations in Cancer Prevention and Research Conference:31* (#120), 11/2010.
 378. Jabbour E, Garcia-Manero G, Ghanem HA, Ravandi F, Faderl S, Cortes J, Reyes AS, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Kantarjian HM. A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). *Blood* (#2188), 12/2010.
 379. Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Altman JK, Claxton DF, Strickland SA Jr, Foran JM, Goldberg SL, Chiao J, Kantarjian HM. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents. *Blood* (#1857), 12/2010.
 380. Wei Y, Calin G, Jia Y, Zheng H, McCay S, Yang H, Fang Z, Garcia-Manero G. Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 In MDS CD34+ Hematopoietic Cells. *Blood* (#609), 12/2010.
 381. Jabbour E, Kantarjian H, Cornelison M, Kadia T, Welch M-A, Abruzzo LV, Burger JA, Ferrajoli A, Garcia-Manero G, Cortes JE. Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML). *Blood* (#1232), 12/2010.
 382. Kadia T, Borthakur G, Faderl S, Ravandi F, Cortes JE, O'Brien S, Jabbour E, Dong XQ, Pierce SA, Kantarjian HM, Garcia-Manero G. Clinical Characterization, Prognostic Implications, and Response to Therapy In Patients with Myelodysplastic Syndrome (MDS) and Chromosome 17 Abnormality: A Single Institutional Experience. *Blood* (#2930), 12/2010.
 383. Naqvi K, Suarez-Almazor ME, Sardesai S, Oh J, Vigil C, Pierce S, Lei X, Kantarjian HM, Garcia-Manero G. Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index. *Blood* (#605), 12/2010.
 384. Li L, Jabbour E, Borthakur G, Faderl S, Kadia T, Ravandi F, Pierce SA, Wierda WG, Abruzzo LV, Kantarjian H, Garcia-Manero G. Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis. *Blood* (#2941), 12/2010.
 385. Mattiuzzi G, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Faderl S, Kadia T, Estrov Z, Iliescu G, Pierce SA, Cortes JE. Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem? *Blood* (#2710), 12/2010.
 386. Cornelison M, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Borthakur G, Brandt M, Jabbour EJ. Decitabine (DAC) Can Be Safely Reduced After Achievement of Best Response in Patients (pts) with Myelodysplastic Syndrome (MDS). *Blood*, 12/2010.

387. Jabbour E, Kantarjian HM, Ravandi F, Cornelison AM, Kadia T, Borthakur G, Cortes JE, Garcia-Manero G. Decitabine Is Effective and Safe In Patients with Chronic Myelomonocytic Leukemia. *Blood* (#4032), 12/2010.
388. Jabbour E, Kantarjian H, Kadia T, Borthakur G, Cortes JE, Cornelison, AM, Ravandi F, Garcia-Manero G. Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy. *Blood* (#2936), 12/2010.
389. Kantarjian HM, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Cortes JE, Faderl S, Garcia-Manero G, Borthakur G. Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML). *Blood* (#672), 12/2010.
390. Naqvi K, Garcia-Manero G, Bueso-Ramos CE, Pierce S, Kadia T, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian HM, Jabbour E. Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC). *Blood* (#1870), 12/2010.
391. Garcia-Manero G, Gore SD, Cogle CR, Jabbour EJ, Ward MR, MacBeth KJ, Laille E, Giordano H, Kantarjian HM, Skikne BS. Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study. *Blood* (#603), 12/2010.
392. Garcia-Manero G, Tambaro FP, Bekele N, Jabbour E, Borthakur G, Ravandi F, Konopleva M, Kadia T, Cortes JE, Yang H, Brandt M, Pierce SA, Newsome WM, Kantarjian H. Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS). *Blood* (#2189), 12/2010.
393. Faderl S, Ravandi F, Garcia-Manero G, Huang X, Jabbour E, Kadia T, Ferrajoli A, Estrov Z, Feliu J, Schroeder H, Kwari M, Kantarjian HM. Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine. *Blood* (#336), 12/2010.
394. Al-Kali A, Luthra R, Bueso-Ramos CE, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of RAS Mutations In Myelodysplastic Syndrome (MDS). *Blood* (#2926), 12/2010.
395. Eghtedar A, Faderl S, Kantarjian H, O'Brien S, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce SA, Shan J, Cortes JE, Ravandi F. Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO). *Blood* (#1085), 12/2010.
396. Dayyani F, Mougalian SS, Naqvi K, Ravandi F, Cortes J, Jabbour E, Faderl S, Wierda WG, Thomas DA, O'Brien S, Pierce SA, Kantarjian HM, Garcia-Manero G. Intracranial Hemorrhage (ICH) In Patients (Pts) Presenting with Myeloid Leukemia to a Tertiary Care Center. *Blood* (#2170), 12/2010.
397. Yang H, Fang Z, Wei Y, Hu Y, Calin G, Kantarjian HM, Garcia-Manero G. Levels of Mir-29b or Mir-101 Do Not Predict Response In Patients (pts) with Acute Myelogenous Leukemia (AML) Treated with the Combination of 5-Azacytidine, Valproic Acid and ATRA. *Blood* (#1701), 12/2010.
398. Tambaro FP, Vigil C, Hu Y, Yang H, Fang Z, Jia JY, Zheng H, Wei Y, Kantarjian HM, Altucci L, Ferrara F, Garcia-Manero G. Levels of Nrf2 and Keap1 Are Associated with Poor Prognostic Features In Myelodysplastic Syndromes (MDS). *Blood* (#1874), 12/2010.
399. Thomas DA, Faderl S, O'Brien S, Wierda WG, Garcia-Manero G, Verstovsek S, Konopleva M, Kadia T, Kornblau SM, Fayad L, Romaguera J, Cortes JE, Kantarjian H. Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants. *Blood* (#2831), 12/2010.
400. Thomas DA, O'Brien S, Cortes JE, Faderl S, Wierda WG, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Burger JA, Garris R, Romaguera J, Hagemeister F, Kantarjian H. Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab. *Blood* (#1781), 12/2010.

401. Heinrichs S, Conover L, Bueso-Ramos CE, Kilpivaara O, Levine R, Stevenson K, Neuberg D, Bejar R, Ebert BL, Garcia-Manero G, Kantarjian HM, Look AT. MYBL2 Is a Candidate Tumor Suppressor Gene In MDS. *Blood* (#1865), 12/2010.
402. Eghtedar A, Kantarjian HM, Jabbour E, O'Brien S, Quintas-Cardama A, Burton E, Garcia-Manero G, Verstovsek S, Konopleva M, Cortes JE. Outcome After Failure to Second Generation Tyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP). *Blood* (#3442), 12/2010.
403. Garcia-Manero G, Chuah C, Wilding G, Chang J, Verstovsek S, Faderl S, Kantarjian HM, Ethirajulu K, Zhu J. Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies. *Blood* (#3292), 12/2010.
404. Pemmaraju N, Kantarjian HM, Garcia-Manero G, Faderl S, Ferrajoli A, Borthakur G, Kadia T, Cortes JE. Phase I Study Results of Gimatecan In the Treatment of Myelodysplastic Syndrome (MDS). *Blood* (#1883), 12/2010.
405. Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour E, Owen K, Stockman P, Oliver S. Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML). *Blood*, 12/2010.
406. Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Liu JS, Kornblau SM, Grable M, Hwang I-R, Borthakur G, Mankin A, Bivins C, Garcia-Manero G, Kadia T, Harris D, Ravandi F, Andreeff M, Cortes JE, Niecestro R, Bergstein I, Kantarjian HM, Frankel AE. Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses in Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. *Blood* (#3298), 12/2010.
407. Garcia-Manero G, Estey EH, Jabbour E, Kadia T, Estrov Z, Cortes J, Boone PA, Kantarjian HM. Phase II Study of 5-Azacytidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other Comorbidities. *Blood* (#604), 12/2010.
408. Ravandi F, Estey EH, Cortes JE, O'Brien S, Pierce SA, Brandt M, Ferrajoli Alessandra, Borthakur G, Konopleva M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian HM. Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab Ozogamycin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL). *Blood* (#1080), 12/2010.
409. Bejar R, Stevenson K, Abdel-Wahab O, McKonkey M, Lin K, McAuley JR, Cheung K, Galili N, Garcia-Manero G, Kantarjian HM, Raza A, Levine R, Neuberg D, Ebert BL. Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival. *Blood* (#300), 12/2010.
410. Ravandi F, Patel KP, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau SM, Garcia-Manero G, Cortes JE, Kantarjian HM. Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction. *Blood* (#2706), 12/2010.
411. Kornblau SM, Qiu YH, Zhang N, Coombes KR, Graber D, Garcia-Manero G, Kantarjian HM. Proteomic Profiling In CD34+CD38- Stem Cells and CD34+ Cells From 185 Myelodysplasia Patients Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications. *Blood* (#2126), 12/2010.
412. Pemmaraju N, Kantarjian HM, O'Brien S, Verstovsek S, Jabbour E, Quintas-Cardama A, Garcia-Manero G, Borthakur G, Ravandi F, Shan J, Cortes JE. Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg vs. 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML). *Blood* (#3438), 12/2010.
413. Jabbour E, Kantarjian HM, Shan J, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cortes J. The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2nd) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS). *Blood* (#2289), 12/2010.
414. Jabbour E, Kantarjian HM, Shan J, O'Brien S, Kadia T, Borthakur G, Quintas-Cardama A, Garcia-Manero G, Ravandi F, Cortes J. The Achievement of An Early Complete Cytogenetic

- Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). *Blood* (#3429), 12/2010.
415. Tung S, Decker W, Robinson S, Shah N, Klumpp S, Clifton S, Konopleva M, Garcia-Manero G, Cooper L, Shpall EJ, Parmar S. Third Party Umbilical Cord Blood Regulatory T Cells Prevents Graft Versus Host Disease In a Xenogenic Murine Model. *Blood* (#3737), 12/2010.
 416. Kadia T, Ravandi F, Garcia-Manero G, Jabbour E, Borthakur G, Estrov Z, Pierce SA, York S, Kantarjian HM. Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS). *Blood* (#2920), 12/2010.
 417. Ghanem H, Kantarjian H, Garcia-Manero G, Ravandi F, Faderl S, Cortes JE, Reyes A, O'Brien SM, Borthakur G, Kadia TM, Burger JA, Konopleva M, Jabbour E. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). *Journal of Clinical Oncology* 29 (#6568), 6/2011.
 418. Vigil CE, Tan W, Wilding GE, Garcia-Manero G, Wang ES, Wetzler M, List AF. Comparison of outcome in erythroleukemia patients treated with standard chemotherapy regimens or hypomethylating agents. *Journal of Clinical Oncology* 29 (#6630), 6/2011.
 419. Cotto M, Cabanillas F, Garcia-Manero G, Yang H, Bruno M, Pavia OA, Rivera E, Liboy I, Tirado-Gomez M. Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/relapsed non-Hodgkin Lymphoma (NHL) and Hodgkin disease. *Journal of Clinical Oncology* 29 (#8056), 6/2011.
 420. Quintas-Cardama A, Cortes JE, Jabbour E, O'Brien SM, Garcia-Manero G, Shan J, Ravandi F, Faderl S, Kadia TM, Borthakur G, Kantarjian H. Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. *Journal of Clinical Oncology* 29 (#6557), 6/2011.
 421. Jabbour E, O'Brien SM, Thomas DA, Ravandi F, York S, Kwari M, Faderl S, Kadia TM, Wilson C, Tarnai R, Advani AS, Garcia-Manero G, Cortes JE, Kantarjian H. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). *Journal of Clinical Oncology* 29 (#6507), 6/2011.
 422. Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia TM, Borthakur G, Wierda WG, Chiao JH, Kantarjian H. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. *Journal of Clinical Oncology* 29 (#6587), 6/2011.
 423. Cornelison M, Garcia-Manero G, Cortes JE, Ravandi F, Kantarjian H, Stein K, Teng A, Jabbour E. Retrospective analysis of effects of dose modification and myelosuppression on response to decitabine and overall survival in patients with myelodysplastic syndromes. *Journal of Clinical Oncology* 29 (#6600), 6/2011.
 424. Kadia TM, Garcia-Manero G, Kantarjian H, Pemmaraju N, Stein K, Teng A, Cortes JE. Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. *Journal of Clinical Oncology* 29 (#6617), 6/2011.
 425. Malik A, Garcia-Manero G, Welch M, Kantarjian H, Stein K, Teng A, Jabbour E. Retrospective analysis of prognostic factors associated with response and overall survival in patients with RAEB-t MDS treated with decitabine. *Journal of Clinical Oncology* 29 (#6598), 6/2011.
 426. Lyons RM, Marek BJ, Sharma S, Paley C, Esposito J, Garbo L, DiBella N, Garcia-Manero G. 24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients. *Blood* (ASH Annual Meeting Abstracts) 118(21) (#2800), 11/2011.
 427. Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Greenberg PL, Tallman MS, DiPersio JF, Bunjes D, Weisdorf DJ, Cutler CS. A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early

- Transplantation Offers Survival Benefit in Higher-Risk MDS. Blood (ASH Annual Meeting Abstracts) 118(21) (#115), 11/2011.
428. Mistry B, Jones MM, Kubiak P, Garcia-Manero G, Litzow MR, Mesa RA, Rifkin R, Tarassoff P, Cortes JE. A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 118(21) (#3801), 11/2011.
 429. Quintas-Cardama A, Kim H, Shan J, Jabbour E, Faderl S, Wierda WG, Ravandi F, Kadia T, Wang SA, Pierce S, Kantarjian HM, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 118(21) (#967), 11/2011.
 430. Jabbour E, Kantarjian HM, Wang X, Abruzzo LV, Cornelison AM, O'Brien S, Ravandi F, Kadia T, Borthakur G, Estrov Z, Cortes JE, Garcia-Manero G. Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 118(21) (#3802), 11/2011.
 431. Nazha A, Cortes JE, Faderl S, Pierce S, Garcia-Manero G, O'Brien S, Ferrajoli A, Kadia T, Borthakur G, Luthra R, Kantarjian HM, Ravandi F. Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 118(21) (#3557), 11/2011.
 432. Tambaro FP, Garcia-Manero G, Faderl S, O'Brien S, Ferrajoli A, Burger JA, Trinh LX, Lerner S, Kantarjian HM, Keating MJ, Wierda WG. Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC). Blood (ASH Annual Meeting Abstracts) 118(21) (#981), 11/2011.
 433. Tanaka MF, Jabbour E, Kantarjian HM, Pierce S, Champlin R, Lima MD, Garcia-Manero G. Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus Hypomethylating Agents (HMA) in Patients (pts) with Myelodysplastic Syndrome (MDS): A Case-Control Study. Blood (ASH Annual Meeting Abstracts) 118(21) (#1707), 11/2011.
 434. Daver N, Kantarjian HM, Garcia-Manero G, Borthakur G, Ravandi F, Kadia T, Estrov Z, Konopleva M, Faderl S, Cortes JE. AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood (ASH Annual Meeting Abstracts) 118(21) (#3820), 11/2011.
 435. Shoukier M, Kantarjian HM, Jabbour E, Quintas-Cardama A, Estrov Z, Kadia T, Borthakur G, Garcia-Manero G, Kornblau SM, Burton EM, O'Brien S, Cortes JE. Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML). Blood (ASH Annual Meeting Abstracts) 118(21) (#4443), 11/2011.
 436. Mathisen MS, Kantarjian HM, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintas-Cardama A. Clofarabine Does Not Impact Negatively the Outcomes of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Stem Cell Transplantation and Is Not Associated with Higher Liver Toxicity Rates Compared with Standard Chemotherapy. Blood (ASH Annual Meeting Abstracts) 118(21) (#1489), 11/2011.
 437. Nazha A, Ravandi F, Kantarjian HM, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts) 118(21) (#3557), 11/2011.
 438. Mathisen MS, Kantarjian HM, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintas-Cardama A. Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts) 118(21) (#4256), 11/2011.
 439. Ottmann OG, DeAngelo DJ, Garcia-Manero G, Lubbert M, Jillella A, Sekeres MA, Zahlten A, Squier M, Acharyya S, Winiger IJ, Fenaux P. Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 118(21) (#459), 11/2011.

440. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Brandt M, Pierce S, Borthakur G, Cortes JE. Early Clearance of Peripheral Blood Blasts but Not White Blood Cells Is a Powerful Prognostic marker for complete Response and Overall Survival in Patients with Acute Myeloid Leukemia (AML) receiving Induction Chemotherapy. Blood (ASH Annual Meeting Abstracts) 118(21) (#1553), 11/2011.
441. Quintas-Cardama A, Kantarjian HM, Luthra R, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Garcia-Manero G, Faderl S, Konopleva M, Wierda WG, Burton E, Cortes JE. Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP). Blood (ASH Annual Meeting Abstracts) 118(21) (#454), 11/2011.
442. ter Elst A, Kampen KR, Diks SH, Kornblau SM, Garcia-Manero G, De Bont ES. EphrinB1 Activation As a Potential New Treatment Option in AML. Blood (ASH Annual Meeting Abstracts) 118(21) (#5235), 11/2011.
443. Nazha A, Jabbour E, Cortes JE, O'Brien S, Shan J, Garcia-Manero G, Quintas-Cardama A, Kantarjian HM. EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC). Blood (ASH Annual Meeting Abstracts) 118(21) (#3769), 11/2011.
444. Garcia-Manero G, Estey EH, Jabbour E, Borthakur G, Kadia T, Naqvi K, Levine RL, Estrov Z, Quintas-Cardama A, Konopleva M, Faderl S, Tanaka M, Yang H, Ravandi F, Wierda WG, Cortes JE, Boone PA, Kantarjian HM. Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. Blood (ASH Annual Meeting Abstracts) 118(21) (#608), 11/2011.
445. Garcia-Manero G, Tambaro FP, Bekele N, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia T, Konopleva M, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce S, DeLima M, Kantarjian HM. Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 118(21) (#763), 11/2011.
446. Boubamer Y, Issa J-P, Jorgensen JL, Faderl S, Castoro RJ, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes JE, Kantarjian HM, Ravandi F. Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). Blood (ASH Annual Meeting Abstracts) 118(21) (#1530), 11/2011.
447. Alvarado Y, Kantarjian HM, Ravandi F, Luthra R, Borthakur G, Garcia Manero G, Faderl S, Konopleva M, Estrov Z, Andreeff M, Cortes JE. FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations. Blood (ASH Annual Meeting Abstracts) 118(21) (#1493), 11/2011.
448. Takahashi K, Kantarjian HM, Pemmaraju N, Borthakur G, Faderl S, Garcia-Manero G, Andreeff M, Pierce S, Ravandi F, Cortes JE. FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations. Blood (ASH Annual Meeting Abstracts) 118(21) (#3623), 11/2011.
449. Ohanian M, Kantarjian HM, Quintas-Cardama A, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton EM, Trinh LX, Ferrajoli A, Jabbour E, Kadia T, Cortes JE. Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP). Blood (ASH Annual Meeting Abstracts) 118(21) (#3779), 11/2011.
450. Borthakur G, Andreeff M, Coombes KR, Qiu YH, Duvvuri S, Zhang N, Ruvolo V, Konopleva M, Garcia-Manero G, Ruvolo PP, Cortes JE, Kantarjian HM, Kornblau SM. High Expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukemia-Time to Target Autophagy to Improve Therapy Outcomes? Blood (ASH Annual Meeting Abstracts) 118(21) (#2513), 11/2011.

451. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Jabbour E, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad L, Romaguera JE, Garriss R, Cortes JE, O'Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#2698), 11/2011.
452. Quintas-Cardama A, Kantarjian HM, Garcia-Manero G, Brandt M, Faderl S, Pierce S, Borthakur G, Ravandi F, Cortes JE. Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The MD Anderson Cancer Center Experience. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#1539), 11/2011.
453. Quintas-Cardama A, Kantarjian HM, Garcia-Manero G, Ravandi F, Brandt M, Faderl S, Pierce S, Borthakur G, Cortes JE. Impact of Epigenetic Therapy Versus Conventional Chemotherapy on Survival of Elderly Patients with Acute Myeloid Leukemia. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#1494), 11/2011.
454. Quintas-Cardama A, Kantarjian HM, Garcia-Manero G, Ravandi F, Brandt M, Pierce S, Borthakur G, Cortes JE. Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#3594), 11/2011.
455. Lee H, Cortes JE, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Kantarjian HM. Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introduction of Imatinib Therapy - A Single Institution Historical Experience. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#2750), 11/2011.
456. Kadia T, Ravandi F, Borthakur G, Jabbour E, Pierce S, Garcia-Manero G, Faderl S, Cortes JE, Kantarjian HM. Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#2522), 11/2011.
457. Popat U, Bassett R, de Padua Silva L, Alousi AM, Anderlini P, Hosing CM, Jones R, Kebriaei P, Khouri I, Shpall EJ, Qazilbash MH, Garcia-Manero G, Andersson BS, Champlin R, de Lima MJ. Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#4531), 11/2011.
458. Gore SD, Cogle CR, Skikne B, Laille E, Shi T, MacBeth KJ, Giordano H, Garcia-Manero G. Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML). *Blood (ASH Annual Meeting Abstracts)* 118(21) (#1546), 11/2011.
459. Lee HJ, O'Brien S, Kantarjian HM, Ravandi F, Faderl S, Koller C, Konopleva M, Verstovsek S, Kadia T, Garcia-Manero G, Borthakur G, Wierda WG, Burger JA, Thomas DA, Cortes JE. Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#1518), 11/2011.
460. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau SM, Andreeff M, Garriss R, Cortes JE, O'Brien S. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. *Blood (ASH Annual Meeting Abstracts)* 118(21) (#1524), 11/2011.
461. Quintas-Cardama A, Kantarjian H, Ravandi F, Garcia-Manero G, Faderl S, Sherry P, Brandt M, Borthakur G, Keating M, Freireich E, Cortes JE. Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At MD Anderson Cancer Center. *Blood (ASH Annual Meeting Abstracts)* 21 (#2606), 118, 11/2011.
462. Naqvi K, Tanaka M, Garcia-Manero G, Pierce S, Kantarjian HM, Verstovsek S. Patients' Comorbidities and Overall Survival in Primary Myelofibrosis (PMF). *Blood (ASH Annual Meeting Abstracts)* 118(21) (#5164), 11/2011.
463. Komrokji RS, List AF, Khoury HJ, Lancet JE, Jabbour E, Foudray MC, Winski SL, Bell S, Rush SA, Maloney L, Ptaszynski AM, Kantarjian HM, Garcia-Manero G. Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS

- Low/Int-1 Risk Myelodysplastic Syndromes. Blood (ASH Annual Meeting Abstracts) 118(21) (#118), 11/2011.
464. Raza A, Galili N, Mulford D, Smith SE, Brown G, Meng L, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra(R), TLK199) in Combination with Lenalidomide (Revlimid(R)) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 118(21) (#2778), 11/2011.
 465. Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia T, Borthakur G, Wierda WG, Wetzler M, Venugopal P, Chiao J, Kantarjian HM. Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML. Blood (ASH Annual Meeting Abstracts) 118(21) (#3630), 11/2011.
 466. Garcia-Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda WG, Estrov Z, Faderl S, Kadia T, Rey K, Cheung C, Kantarjian HM. Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood (ASH Annual Meeting Abstracts) 118(21) (#2613), 11/2011.
 467. Holkova B, Tombes MB, Shrader E, Cooke SS, Wan W, Sankala H, Kmiecik M, Roberts JD, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis. Blood (ASH Annual Meeting Abstracts) 118(21) (#2598), 11/2011.
 468. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly MA, Pierce S, Kantarjian HM, Garcia-Manero G. Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 118(21) (#1731), 11/2011.
 469. Ravandi F, Faderl S, Pierce S, Garcia-Manero G, Brandt M, Shan J, Kadia T, Borthakur G, Estrov Z, O'Brien S, Cortes JE, Kantarjian HM. Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse. Blood (ASH Annual Meeting Abstracts) 118(21) (#3569), 11/2011.
 470. Wierda WG, O'Brien S, Ferrajoli A, Koller CA, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Lerner S, Keating MJ. Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclophosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL. Blood (ASH Annual Meeting Abstracts) 118(21) (#3902), 11/2011.
 471. Nazha A, Bhatt VR, Noguera-Gonzalez G, Kadia T, Cortes JE, Daver N, Garcia-Manero G, Kantarjian HM, Borthakur G. Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics. Blood (ASH Annual Meeting Abstracts) 118(21) (#1495), 11/2011.
 472. Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Godley L, Gabrail NY, Berdeja JG, Nadeem A, Stein K, Noble Y, Kassalow L, Kantarjian HM. Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes. Blood (ASH Annual Meeting Abstracts) 118(21) (#3812), 11/2011.
 473. Tambaro FP, Wierda WG, Pierce S, Yang H, Wei Y, Fang Z, Kantarjian HM, Garcia-Manero G. ROS Activation Independent From Iron Overload in MDS. Blood (ASH Annual Meeting Abstracts) 118(21) (#2798), 11/2011.
 474. Shoukier M, Kantarjian HM, Jabbour E, Quintas-Cardama A, Estrov Z, Kadia T, Borthakur G, Garcia-Manero G, Kornblau SM, Burton EM, O'Brien S, Cortes JE. Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts). Blood (ASH Annual Meeting Abstracts) 218(21) (#2764), 11/2011.
 475. Cortes JE, Garcia-Manero G, Ravandi F, Andreeff M, Borthakur G, Jabbour E, Konopleva M, O'Brien S, Quintas-Cardama A, Verstovsek S, Wierda WG, Kantarjian HM. Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic

- Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 118(21) (#3639), 11/2011.
476. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Al-Kali A, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. Blood (ASH Annual Meeting Abstracts) 118(21) (#460), 11/2011.
 477. Daver N, Kantarjian HM, Garcia-Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Brandt M, Huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 118(21) (#3629), 11/2011.
 478. Sekeres MA, Elson P, Tiu RV, Sauntharajah Y, Advani AS, Paulic K, Chan J, Pierce S, Jabbour E, Kantarjian HM, Maciejewski JP, Garcia-Manero G. Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes. Blood (ASH Annual Meeting Abstracts) 118(21) (#1720), 11/2011.
 479. Bejar R, Stevenson K, Caughey B, Abdel-Wahab O, Galili N, Garcia-Manero G, Kantarjian HM, Raza A, Steensma DP, Levine RL, Neuberg D, Ebert BL. Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples. Blood (ASH Annual Meeting Abstracts) 118(21) (#969), 11/2011.
 480. Alattar ML, Cortes JE, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Kantarjian HM. Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy. Blood (ASH Annual Meeting Abstracts) 118(21):460 (#2749), 11/2011.
 481. Faderl S, Garcia-Manero G, Kadia T, Borthakur G, Jabbour E, Ravandi F, Estrov Z, Cortes J, Autry J, Kantarjian H. A randomized study of decitabine alternating with clofarabine versus decitabine alone in patients with higher-risk myelodysplastic syndrome (MDS). Haematologica 97(supplement 1):369 (#0894), 6/2012.
 482. Cornelison M, Daver N, De Lima M, Kantarjian H, Ravandi F, Pierce S, Khouri I, Giralt S, Oran B, Garcia-Manero G, Jabbour E. Allogeneic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy. Haematologica 97(supplement no. 1):34 (#0086), 6/2012.
 483. Garcia-Manero G, Komrokji R, Winski S, Garrus J, Cable L, Kilz D, Chantry D, Hogeland G, Bell S, Rush S, Ptaszynski M, List A, Houry H. Clinical evaluation of Arry-615, a dual P38/TIE2 inhibitor for patients with myelodysplastic syndromes, identifies unique disease-related and drug-related biomarkers. Haematologica 97(supplement 1):367 (#0888), 6/2012.
 484. Quintas-Cardama A, Cortes J, Liu-Dumlao T, Ravandi F, Brandt M, Faderl S, Pierce, Borthakur G, Garcia-Manero G, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in elderly patients with newly diagnosed acute myeloid leukemia. Haematologica 97(supplement 1):446 (#1091C), 6/2012.
 485. Naqvi K, Tanaka M, Garcia-Manero G, Pierce S, Cortes J, Quintas-Cardama A, Borthakur G, Estrov Z, Kantarjian H, Verstovsek S. Patients' comorbidities and overall survival in primary myelofibrosis (PMF). Haematologica 97(supplement 1):632 (#1607), 6/2012.
 486. Nazha A, Kantarjian HM, Borthakur G, Garcia-Manero G, Kadia TM, Faderl S, Estrov Z, Jabbour E, Quintas-Cardama A, Ravandi F, Cortes JE. A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). ASH Annual Meeting Abstracts 120(21):3587, 11/2012.
 487. Tambaro FP, Garcia-Manero G, Qiao W, Pierce SA, Ripaldi M, Faderl S, Kantarjian HM, Wierda WG, Cortes JE. A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC. ASH Annual Meeting Abstracts 120(21):131, 11/2012.

488. Faderl S, Garcia-Manero G, Ravandi F, Cortes JE, Estrov Z, Borthakur G, O'Brien SM, Kadia TM, Konopleva M, Daver N, Brandt M, Schroeder H, Kantarjian HM. A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily x 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS). ASH Annual Meeting Abstracts 120(21):3851, 11/2012.
489. Pemmaraju N, Thomas D, Kantarjian HM, Cortes JE, Manning JT, Medeiros LJ, O'Brien S, Daver NG, Nazha A, Pierce SA, Garcia-Manero G, Jabbour EJ, Faderl S. Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. ASH Annual Meeting Abstracts 120(21):3554, 11/2012.
490. Strati P, Kantarjian HM, Cortes JE, Ravandi F, Pemmaraju N, Garcia-Manero G, Kadia TM, Jabbour EJ, Nazha A, Borthakur G, Faderl S, Quintas-Cardama A, Daver NG. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. ASH Annual Meeting Abstracts 120(21):1488, 11/2012.
491. Falchi L, Kantarjian H., Quintas-Cardama A, O'Brien S, Jabbour EJ, Ravandi F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia. ASH Annual Meeting Abstracts 120(21):164, 11/2012.
492. Nazha A, Ravandi F, Kantarjian HM, Huang X, Choi S, Garcia-Manero G, Jabbour EJ, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Estrov Z, Daver NG, Pemmaraju N, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). ASH Annual Meeting Abstracts 120(21):43, 11/2012.
493. Ravandi F, Alattar ML, Levis MJ, Garcia-Manero G, Richie MA, Daver NG, Faderl S, Andreeff M, Borthakur G, Burger JA, Kadia TM, Grunwald MR, Dellasala SE, Cortes JE, Kantarjian HM. Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. ASH Annual Meeting Abstracts 120(21):1519, 11/2012.
494. Jabbour EJ, Kantarjian HM, Oran B, Ravandi F, Ghanem H, Khouri I, Garcia-Manero G, Mathisen MS, Bashir Q, Saliba RM, Khouri M, Pierce SA, Brandt M, Champlin RE, De Lima M. Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities. ASH Annual Meeting Abstracts 120(21):2029, 11/2012.
495. Arana Yi CY, Kantarjian HM, Garcia-Manero G, Wierda WG, Borthakur G, Quintas-Cardama A, Konopleva M, Faderl S, Pierce SA, Andreeff M, Ravandi F, Cortes JE. Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies. ASH Annual Meeting Abstracts 120(21):3557, <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/3557>, 11/2012.
496. Pemmaraju N, Kantarjian HM, Tran KM, Kazmi SM, Kadia TM, Borthakur G, Verstovsek S, O'Brien S, Garcia-Manero G, Estrov Z, Faderl S, Ravandi F, Pierce SA, Cortes JE, Quintas-Cardama A. Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML). ASH Annual Meeting Abstracts 120(21):2592, 11/2012.
497. Kazmi SM, Kantarjian HM, Tran KM, Cortes JE, Ravandi F, Borthakur G, Jabbour EJ, Faderl S, Garcia-Manero G, Kadia TM, Daver N, Pierce SA, Nazha A, Quintas-Cardama A, Pemmaraju N. Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia. ASH Annual Meeting Abstracts 120(21):2587, 11/2012.
498. Daver N, Kantarjian HM, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, O'Brien S, Ferrajoli A, Verstovsek S, Kadia TM, Jabbour EJ, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce SA, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. ASH Annual Meeting Abstracts 120(21):3619, 11/2012.
499. Wei Y, Chen R, Dimicoli S, Bueso-Ramos CE, Neuberg DS, Pierce SA, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Fernandez M, Wang SA, Kantarjian HM, Garcia-Manero G.

- Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). ASH Annual Meeting Abstracts 120(21):1700, 11/2012.
500. Bejar R, Stevenson KE, Stojanov P, Zaneveld JE, Bar-Natan M, Caughey B, Wang H, Garcia-Manero G, Kantarjian HM, Cutler C, Ritz J, Cibulskis K, Getz G, Steensma DP, Stone RM, Chen R, Neuberg DS, Ebert BL. Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. ASH Annual Meeting Abstracts 120(21):311, 11/2012.
501. Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber J, Dennison B, Sekeres MA. Disparity in Perceptions of Disease, Treatment Effectiveness and Treatment Adherence Between Physicians and Patients with Myelodysplastic Syndromes (MDS). ASH Annual Meeting Abstracts 120(21):4949, 11/2012.
502. Benton CB, Qiu P, Ravandi F, Kantarjian HM, Garcia-Manero G, Pierce SA, Borthakur A, Konopleva M, Cortes JE, Andreeff M, Quintas-Cardama A. Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy. ASH Annual Meeting Abstracts 120(21):1417, 11/2012.
503. Jabbour EJ, Kantarjian HM, Cameron Y, Ravandi F, Cortes JE, Garcia-Manero G, Ghanem H, Kadia TM, Faderl S, O'Brien S, Mathisen MS, Brandt M, Pemmaraju N, Thomas DA, Bass J, Borthakur G. Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) With Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen. ASH Annual Meeting Abstracts 120(21):1609, 11/2012.
504. Yang H, Bueso-Ramos CE, Pierce SA, Wei Y, Fang Z, Nguyen M, Fernandez M, Cardenas-Turanzas M, Kantarjian HM, Garcia-Manero G. Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients. ASH Annual Meeting Abstracts 120(21):3845, 11/2012.
505. Laille E, Shi T, Garcia-Manero G, Cogle CR, Gore SD, Kumar KJ, Skikne BS, MacBeth KJ. Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule. ASH Annual Meeting Abstracts 120(21):1337, 11/2012.
506. Yi CYA, Cortes J, Faderl S, Garcia-Manero G, Konopleva M, Estrov Z, O'Brien S, Borthakur G, Levis MJ, Thomas DA, Pierce SA, Brandt M, Pratz KW, Luthra R, Andreeff M, Kantarjian HM, Ravandi F. Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. ASH Annual Meeting Abstracts 120(21):1516, 11/2012.
507. Alattar ML, Kantarjian HM, Cortes JE, Kadia TM, Borthakur G, Ohanian M, Ravandi F, Garcia-Manero G, Quintas-Cardamas A, Jabbour E, Daver N, Pierce SA, Brandt M, Faderl S, Pemmaraju N. Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). ASH Annual Meeting Abstracts 120(21):1456, 11/2012.
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/1456>, 11/2012.
508. Takahashi K, Kantarjian HM, Abruzzo LV, Borthakur G, Garcia-Manero G, O'Brien S, Faderl S, Luthra R, Wierda WG, Ferrajoli A, Pierce SA, Ravandi F, Cortes JE. Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis. ASH Annual Meeting Abstracts 120(21):2562, 11/2012.
509. Yang H, Bueso-Ramos CE, Parmar S, Wei Y, Fang Z, Nguyen M, Fernandez M, Pierce SA, Geng Q, Kantarjian HM, Cortes JE, Garcia-Manero G. Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to HMAs. ASH Annual Meeting Abstracts 120(21):3810, 11/2012.
510. Mathisen MS, Kantarjian HM, Jabbour EJ, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintas-Cardama A. Infectious Complications in Patients with Relapsed Acute Myeloid Leukemia (AML) Receiving Clofarabine Versus Fludarabine-Containing Salvage Chemotherapy Regimens. ASH Annual Meeting Abstracts 120(21):4322, 11/2012.

511. Ravandi F, Patel KP, Luthra R, Pierce SA, Borthakur G, Jabbour EJ, Kadia TM, Pemmaraju N, Daver N, Konopleva M, Faderl S, Garcia-Manero G, Cortes JE, Kantarjian HM. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents ({+/-} Histone Deacetylase Inhibitors). ASH Annual Meeting Abstracts 120(21):2483, 11/2012.
512. de Lima M, Parmar S, Chen JJ, Giralt SA, Rondon G, Popat UR, Alousi AM, Lee HC, Woodworth GG, Hosing CM, Shpall EJ, Kebriaei P, Garcia-Manero G, Champlin RE, Saliba RM. Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). ASH Annual Meeting Abstracts 120(21):742, 11/2012.
513. Attieh Y, Wei Y, Yang H, Jia Y, Zheng H, Fang Z, Kantarjian HM, Garcia-Manero G. Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS). ASH Annual Meeting Abstracts 120(21):3844, 11/2012.
514. Jain P, Kantarjian HM, Faderl S, Patel KP, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia TM, Daver NG, Nazha A, Luthra R, Pierce SA, Cortes JE, Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. ASH Annual Meeting Abstracts 120(21):2484, 11/2012.
515. Quintas-Cardama A, Kantarjian HM, O'Brien S, Jabbour EJ, Garcia-Manero G, Koller C, Pierce SA, Talpaz M, Cortes JE. Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center. ASH Annual Meeting Abstracts 120(21):918, 11/2012.
516. Takahashi K, Kantarjian HM, Ghanem H, Ravandi F, Cortes JE, Kadia TM, O'Brien S, Pierce SA, Jain N, Garcia-Manero G, Jabbour EJ. Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure. ASH Annual Meeting Abstracts 120(21):2627, 11/2012.
517. Ghanem H, Kantarjian HM, Garcia-Manero G, Ravandi F, Cortes JE, Takahashi K, O'Brien SM, Pierce SA, Kadia TM, Jabbour EJ. Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethylating Agents (HMA) Failure. ASH Annual Meeting Abstracts 120(21):3600, 11/2012.
518. Jabbour EJ, Daver NG, Dong T, Kadia TM, O'Brien S, Cortes JE, Ravandi F, Pemmaraju N, Ghanem H, Faderl S, Borthakur G, Kantarjian HM, Garcia-Manero G. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. ASH Annual Meeting Abstracts 120(21):2824, 11/2012.
519. Nazha A, Kantarjian HM, Cortes JE, Faderl S, Pierce SA, Daver NG, Pemmaraju N, Ravandi F, Borthakur G, Kadia TM, Quintas-Cardama A, Garcia-Manero G. Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy. ASH Annual Meeting Abstracts 120(21):4928, 11/2012.
520. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Borthakur G, Burger JA, Verstovsek S, Ferrajoli A, Wierda WG, Kornblau SM, Andreeff M, Garri R, Wang SA, Estrov Z, Cortes JE, O'Brien S. Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. ASH Annual Meeting Abstracts 120(21):3572, 11/2012.
521. Ghanem H, Garcia-Manero G, Faderl S, Takahashi K, Ravandi F, Cortes JE, O'Brien S, Daver NG, Katragadda L, Pemmaraju N, Pierce SA, Quintas-Cardama A, Kadia TM, Kantarjian HM, Jabbour EJ. Outcomes of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure. ASH Annual Meeting Abstracts 120(21):1722, 11/2012.
522. Benjamini O, Kantarjian HM, Rios MB, Jabbour E, O'Brien S, Jain P, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes JE. Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Phase Chronic Myeloid

- Leukemia (CML) - Single Institution Experience. ASH Annual Meeting Abstracts 120(21):3783, 11/2012.
523. Garcia-Manero G, Tibes R, Chiu YL, Xiong H, Qin Q, Ansell P, Albert DH, Tse C, Oliver B, Sajwani K, McKee MD, Ricker JL, Khoury HJ. Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies. ASH Annual Meeting Abstracts 120(21):2617, 11/2012.
 524. Holkova B, Bose P, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmiecik M, Roberts JD, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update. ASH Annual Meeting Abstracts 120(21):3588, 11/2012.
 525. Borthakur G, Popplewell L, Boyiadzis M, Foran JM, Platzbecker U, Vey N, Roland WB, Olin RL, Raza A, Giagounidis A, Ottmann OG, Al-Kali A, Jabbour EJ, Kadia TM, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Zhu JZ, Wissel P, Kantarjian HM. Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. ASH Annual Meeting Abstracts 120(21):677, 11/2012.
 526. Katragadda L, Kantarjian HM, Garcia-Manero G, Kadia TM, Ferrajoli A, Jabbour EJ, Quintas-Cardama A, Konopleva M, Maniar M, Wilhelm F, Ravandi F, Cortes JE. Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms. ASH Annual Meeting Abstracts 120(21):3606, 11/2012.
 527. Ghanem H, Kantarjian HM, Faderl S, Jabbour EJ, Daver N, Pierce SA, Brandt M, Quintas-Cardama A, Luthra R, Garcia-Manero G, Cortes JE, Ravandi F. Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO). ASH Annual Meeting Abstracts 120(21):2623, 11/2012.
 528. Takahashi K, Pemmaraju N, Beran M, Quintas-Cardama A, Cortes JE, Ravandi F, Faderl S, Verstovsek S, Kadia TM, Borthakur G, Jabbour EJ, Daver N, Estrov Z, Pierce SA, Garcia-Manero G. Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). ASH Annual Meeting Abstracts 120(21):3797, 11/2012.
 529. Lyons RM, Marek BJ, Paley C, Esposito J, Garbo L, DiBella N, Garcia-Manero G. Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months. ASH Annual Meeting Abstracts 120(21):3800, 11/2012.
 530. Kantarjian HM, Roboz GJ, Rizzieri DA, Stock W, O'Connell CL, Griffiths EA, Yee K, Tibes R, Garcia-Manero G, Ravandi F, Walsh K, Feldman E, Ritchie E, Rao A, Decastro C, Schimmer AD, Mesa RA, Syed I, Choy G, Oganessian A, Taverna P, Azab M, Chung W, Issa JP. Results From the Dose Escalation Phase of a Randomized Phase 1-2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. ASH Annual Meeting Abstracts 120(21):414, 11/2012.
 531. Pemmaraju N, Kantarjian HM, O'Brien S, Kadia TM, Cortes JE, Borthakur G, Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Quintas-Cardama A, Jabbour EJ, Koller CA, Dellasala SE, Pierce SA, Burton EM, Verstovsek S. Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. ASH Annual Meeting Abstracts 120(21):3617, 11/2012.
 532. Winski SL, Cable L, Hogeland G, Brown S, Weaver D, Garrus J, Rhodes S, Maloney L, Ptaszynski AM, Khoury HJ, Sekeres MA, Komrokji RS, Garcia-Manero G, Chantry D. Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614. ASH Annual Meeting Abstracts 120(21):2825, 11/2012.
 533. Garcia-Manero G, Gore SD, Kambhampati S, Scott BL, Tefferi A, Cogle CR, Edenfield W, Hetzer J, Kumar K, Skikne BS. Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. ASH Annual Meeting Abstracts 120(21):424, 11/2012.

534. Wei Y, Bueso-Ramos CE, Yang H, Jia Y, Zheng H, Colla S, Nguyen M, Fernandez M, Kantarjian HM, Garcia-Manero G. Serum Amyloid Protein A 1 (hSAA1) Is Overexpressed in Myelodysplastic Syndromes and Potentially Mediates Toll-Like Receptor 2 Innate Immunity Signaling in CD34+ Hematopoietic Stem Cells. *ASH Annual Meeting Abstracts* 120(21):1703, 11/2012.
535. Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Kadia TM, Ravandi F, Andreeff M, Cortes JE, Hoberman K, Szarek M, Rowinsky E, Bergstein I, Kantarjian HM, Frankel AE. SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. *ASH Annual Meeting Abstracts* 120(21):3625, 11/2012.
536. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour EJ, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Ferrajoli A, Kadia TM, O'Brien S, Cortes JE. The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP). *ASH Annual Meeting Abstracts* 120(21):72, 11/2012.
537. Yilmaz M, Kantarjian HM, Jabbour EJ, O'Brien SM, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger JA, Pierce SA, Quintas-Cardama A, Cortes JE. The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution. *ASH Annual Meeting Abstracts* 120(21):1693, 11/2012.
538. Dimicoli S, Wei Y, Chen R, Bueso-Ramos CE, Pierce SA, Yang H, Jia Y, Zheng H, Fang Z, Ganon-Gomez I, Nguyen M, Fernandez M, Kantarjian HM, Garcia-Manero G. Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). *ASH Annual Meeting Abstracts* 120(21):556, 11/2012.
539. Ghanem H, Kantarjian HM, Ravandi F, Cortes JE, Pemmaraju N, Faderl S, Dellasala SE, O'Brien SM, Burger JA, Borthakur G, Kadia TM, Quintas-Cardama A, Brandt M, Pierce SA, Garcia-Manero G, Jabbour EJ. Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP). *ASH Annual Meeting Abstracts* 120(21):4939, 11/2012.
540. Mathisen MS, Kantarjian HM, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes JE, O'Brien S, Quintas-Cardama A, Ghanem H, Daver NG, Pierce SA, Lira C, Faderl S, Jabbour E. Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). *ASH Annual Meeting Abstracts* 120(21):3610, 11/2012.
541. Yang H, Bueso-Ramos CE, Pierce SA, Wei Y, Fang Z, Nguyen M, Fernandez M, Cardenas-Turanzas M, Kantarjian HM, Garcia-Manero G. Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). *ASH Annual Meeting Abstracts* 120(21):2827, 11/2012.
542. Takahashi K, Jabbour EJ, Wang X, Ghanem H, Pemmaraju N, Ravandi F, Cortes JE, Faderl S, Kadia TM, Borthakur G, Wierda WG, Pierce SA, Estrov Z, Kantarjian HM, Garcia-Manero G. Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. *ASH Annual Meeting Abstracts* 120(21):3802, 11/2012.
543. Quintas-Cardama A, Kantarjian HM, Ravandi F, Foudray C, Pemmaraju N, Kadia TM, Borthakur G, Daver NG, Faderl S, Jabbour E, Cortes JE, Garcia-Manero G. Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. *ASH Annual Meeting Abstracts* 120(21):3821, 11/2012.
544. Lyons RM, Marek BJ, Paley CS, Esposito J, McNamara K, Garbo L, DiBella N, Garcia-Manero G. 48-Month Update on Survival and AML Transformation in a 600-Patient Registry of Lower-Risk MDS Patients. *Blood* 122(21):2775, 11/2013.
545. DiNardo CD, Kantarjian HM, Ravandi F, Konopleva M, Kadia TM, Borthakur G, Daver NG, Durand M, Rivera S, Quintas-Cardama A, Garcia-Manero G, Cortes JE. A Phase I/II Study of

- Cytarabine or Azacitidine in Combination with Tosedostat in Older Patients with AML or High-Risk MDS. *Blood* 122(21):2698, 11/2013.
546. Takahashi K, Jabbour E, Ravandi F, Borthakur G, Cortes JE, Kadia T, O'Brien S, Thomas DA, Faderl S, Bass J, Wierda WG, Daver N, DiNardo CD, Pierce S, Brandt M, Kantarjian HM, Garcia-Manero G. A Phase II Expansion Study of Vorinostat in Combination with Idarubicin and Cytarabine for Patients with Acute Myelogenous Leukemia (AML) with FLT3 Molecular Alterations. *Blood* 122(21):2684, 11/2013.
 547. Garcia-Manero G, Kadia TM, Daver N, Jabbour E, Jain N, Cortes JE, Estrov Z, Borthakur G, Dong XQ, Kumar VJ, Kantarjian HM. A Phase II Study of the Combination of Azacitidine and Lenalidomide In Patients (pts) with Higher Risk Myelodysplastic Syndromes (MDS). *Blood* 122(21):2751, 11/2013.
 548. Garcia-Manero G, Luger SM, Goldberg S, Altman JK, Arellano M, Wetzler M, Seiter K, Chiao J, Kantarjian HM. A Randomized Phase II Study of Sapacitabine in MDS Refractory to Hypomethylating Agents. *Blood* 122(21):2752, 11/2013.
 549. Wei Y, Jia Y, Zheng H, Yang H, Chen R, Wang H, Wang X, Garcia-Manero G. Assessment of EZH2 Expression in CD34+ Bone Marrow Progenitor Cells of Patients of Myelodysplastic Syndromes (MDS). *Blood* 122(21):2805, 11/2013.
 550. Pemmaraju N, Shah D, Kantarjian HM, Wagner V, Orlowski RZ, Garcia-Manero G, Ravandi F, Pierce S, Takahashi K, Daver NG, Nazha A, Verstovsek S, Jabbour EJ, de Lima MJ, Champlin RE, Cortes JE, Qazo;basj MH. Characteristics and Outcomes of Patients (pts) with Multiple Myeloma (MM) who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), or t-Acute Myeloid Leukemia (AML). *Blood* 122(21):1424, 11/2013.
 551. Daver N, Kantarjian HM, Faderl SH, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing CM, Kadia TM, Cortes JE, Ravandi F, Anderlini P. Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis. *Blood* 122(21):1343, 11/2013.
 552. Nazha A, Garcia-Manero G, Kantarjian HM, Ravandi F, Borthakur G, Kadia TM, Jabbour E, Pemmaraju N, Daver NG, DiNardo CD, Miller D, Faderl SH. Clofarabine plus Low-Dose Cytarabine for the Treatment of Patients with higher-Risk Myelodysplastic Syndrome (MDS) who have been Relapsing after, or are Refractory to, Hypomethylator Agent Therapy. *Blood* 122(21):1525, 11/2013.
 553. Garcia-Manero G, Luger S, Klimek V, Cooper M, Besa EC, Rossetti JM, Chao R, Humphrey R, Silverman LR. Combination Therapy with Mocetinostat, an Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azacitidine: Indication of Clinical Activity in MDS. *Blood* 122(21):1550, 11/2013.
 554. Komrokji RS, Wang XF, Ali NHA, Garcia-Mnaero G, Steensma DP, Roboz GJ, Gore SD, Hobson S, Zimmerman C, Padron E, Maciejewski JP, List A, Sekeres MA. Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium. *Blood* 122(21):1505, 11/2013.
 555. Benton CB, Gu L, Kantarjian HM, Qiu P, Ravandi F, Garcia-Manero G, Pierce S, Brandt M, Konopleva M, Cortes JE, Andreeff M, Quintas-Cardama A. Differential Prognostic Impact of Peripheral Blood Blast Clearance in AML Based on Type of Therapy and FLT3 Mutation Status. *Blood* 122(21):2584, 11/2013.
 556. Fang J, Liu X, Barker B, Bolanos L, Wei Y, Garcia-Manero G, Starczynowski D. Disease-Relevant Expression of TRAF6 in Mouse HSC Results in an MDS-Like Disease. *Blood* 122(21):101, 11/2013.
 557. Roboz GJ, Issa JP, Rizzieri D, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Feldman EJ, Ritchie E, Rao AV, Larson RA, Garcia-Manero G, Ravandi F, Jabbour E, Cortes JE, Schimmer A, Mesa RA, Blum W, Chung W, Naim S, Taverna P, Hao Y, Choy G, Azab M, Kantarjian HM. DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. *Blood* 122(21):1548, 11/2013.

558. Wei Y, Jia Y, Zheng H, Yang H, Fang Z, Colla S, Garcia-Manero G. Down-Regulated Expression of Protection of Telomeres 1 (POT1) Gene in Bone Marrow Hematopoietic Progenitor Cell Compartment has Prognostic Value in Myelodysplastic Syndromes (MDS). *Blood* 122(21):1511, 11/2013.
559. Strati P, Kantarjian HM, Nazha A, Borthakur G, Daver NG, Kadia TM, Estrov Z, Garcia-Manero G, Rajkhowa T, Ravandi F, Durand M, Levis M, Cortes JE. Early Results of a Phase I/II Trial of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for Patients (Pts) with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood* 122(21):3949, 11/2013.
560. Daver NG, Naqvi K, Kadia TM, DiNardo CD, Ravandi F, Nazha A, Borthakur G, Pemmaraju N, Brandt M, O'Brien S, Garcia-Mnaeor G, Pierce SR, Jabbour E, Cortes JE, Kantarjian HM. Effect of Comorbidities in Myelodysplastic Syndrome by Revised-IPSS and Age. *Blood* 122(21):1530, 11/2013.
561. Kampen KR, Scherpen FJG, Garcia-Manero G, Yang H, Kornblau SM, de Bont ESJM. EphB1 Downregulation in Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System. *Blood* 122(21):2484, 11/2013.
562. Yang H, Bueso-Ramos CE, DiNardo CD, Estecio MR, Davanlou M, Geng Q, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes HJ, Kantarjian HM, Garcia-Manero G. Expression of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict for Prognosis and Resistance to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS). *Blood* 122(21):2767, 11/2013.
563. Ohanian M, Levis M, Faderl SH, Garcia-Manero G, Jabbour E, Daver HG, Dellasala SA, Pierce S, Burger JA, Cortes JE, Kantarjian HM, Ravandi F. Final Report of Phase II Study of Sorafenib and 5-Azacytidine in Patients with Relapsed or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. *Blood* 122(21):3934, 11/2013.
564. Kantarjian HM, Jabbour E, Yee K, Kropf P, O'Connell C, Stock W, Tibes R, Rizzieri D, Walsh K, Griffiths EA, Roboz GJ, Savona M, Ervin T, Podoltsev NA, Pemmaraju N, Daver N, Garcia-Manero G, Borthakur G, Wierda WG, Ravandi F, Cortes JE, Brandwein JM, Odenike O, Feldman EJ, Chung W, Naim S, Choy G, Taverna P, Hao Y, Dimitrov G, Azab M, Issa JP. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). *Blood* 122(21):497, 11/2013.
565. Takahashi K, Garcia-Manero G, Cortes J, Ravandi F, Faderl S, O'Brien S, Kantarjian HM, Borthakur G. Fludarabine and Cytarabine Based Induction Therapy is Associated with High Response Rate and Durable Remission with Low Treatment Related Mortality in Elderly Patients with Core-Binding Factor AML (CBF-AML). *Blood* 122(21):3945, 11/2013.
566. Xiaoying L, Tung S, Setoyama T, D'Abundo L, Simon R, Yang H, Yvon E, Shah N, Yang H, Garcia-Manero G, McNiece IK, Rezvani K, Calin G, Shpall EJ, Parmar S. FOXP3 is a Direct Target of miR15a/16 in Umbilical Cord Blood Regulatory T Cells. *Blood* 122(21):3261, 11/2013.
567. Garcia-Manero G, Szvona M, Gore SD, Cogle CR, Conkling P, Beach CL, Hetzer J, Dong Z, Skikne BS. Hematologic Response To Oral Azacitidine (CC-486) In Subjects with WHO-Defined RAEB-1 or RAEB-2 Myelodysplastic Syndromes (MDS). *Blood* 122(21):1554, 11/2013.
568. Jabbour E, Kantarjian HM, Ziao W, Strati P, Khan NF, Cortes JE, Hoehn D, Hu J, O'Brien S, Bryan J, Prescott H, DiNardo CD, Daver N, Kadia TM, Garcia-Manero G. Impact of the Achievement of a Complete Cytogenetic Response (CCyR) on Outcome In Patients (pts) with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA). *Blood* 122(21):2801, 11/2013.
569. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl SH, Cortes JE, Pierce SR, Kantarjian HM, Estrov Z. Incidence of and Risk Factors for Acute Myeloid Leukemia Involvement of the Central Nervous System. *Blood* 122(21):3883, 11/2013.
570. Jain P, Kantarjian HM, Patel KP, Jabbour E, Daver N, Pierce S, Benjamini O, Borthakur G, DiNardo CD, Faderl SH, Ravandi F, Cortes JE, Garcia-Manero G, Kadia TM. Incidence, Clinical Characteristics, and Prognostic Relevance of Clonal T-Cell Receptor Positive (TCR+) Populations in Patients with Myelodysplastic Syndrome (MDS). *Blood* 122(21):5231, 11/2013.

571. Jain P, Kantarjian HM, Cortes JE, Jabbour EJ, Faderl SH, Wierda WG, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad L, Romaguera J, Garris R, Ravandi F, O'Brien S, Thomas D. Long Term Follow-Up of De Novo or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) after Frontline Therapy per the Hyper-CVAD Regimen with or without Rituximab: 20-Year Cumulative Experience. *Blood* 122(21):3917, 11/2013.
572. Nazha A, Kantarjian HM, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brandt M, Faderl SH. Longer Follow-Up of the Combination of Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients Younger than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood* 122(21):1451, 11/2013.
573. Kongtim P, Popat UR, de Lima M, Garcia-Manero G, Jabbour EJ, Chen J, Rondon G, Abruzzo JV, Ciurea SO, Shpall EJ, Champlin RE, Oran B. MD Anderson Scoring System (MDACC) Predicts Outcomes after Hematopoietic Stem Cell Transplantation (HSCT) Better than other Prognostic Classifications in MDS. *Blood* 122(21):3340, 11/2013.
574. DiNardo CD, Daver NG, Jain N, Pemmaraju N, Bueso-Ramos CE, Yin C, Pierce SR, Jabbour E, Quintas-Cardama A, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome by Therapeutic Approach. *Blood* 122(21):2825, 11/2013.
575. Jabbour E, Garcia-Manero G, Xiao L, Najla AA, Mishra A, Padron E, Lancet JE, Bryan J, Prescott H, Steensma DP, Sekeres MA, Roboz GJ, List A, Kantarjian HM, Komrokji RS. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) after Hypomethylating Agent (HMA) Failure. *Blood* 122(21):388, 11/2013.
576. Jabbour E, Kantarjian HM, Garcia-Manero G, Quintas-Cardama A, Cardena-Turanzas M, O'Brien S, Cortes JE, Jain N, Ravandi F, Kadia TM, Brandt M, Verstovsek S. Outcome of Patients (pts) with Myelofibrosis (MF) after Ruxolitinib (Rux) Therapy. *Blood* 122(21):1584, 11/2013.
577. Nazha A, Kantarjian HM, Jabbour E, DiNardo CD, Borthakur G, Daver NG, Faderl SH, Ning J, Qiao W, Ravandi F, Kadia TM, Pierce SR, Cortes JE, Garcia-Manero G. Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow Blasts between 10-30% Treated with Hypomethylating Agents versus Intensive Chemotherapy. *Blood* 122(21):2788, 11/2013.
578. Ganon-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G. Overexpression of Mir-125a in Bone Marrow CD34+ cells of Patients with Myelodysplastic Syndrome is Correlated to a Poor Prognosis and may Contribute to the Pathogenesis of the Disease through the Modulation of NF-Kb Activation and Enhancement of Differentiation Arrest. *Blood* 122(21):5206, 11/2013.
579. Garcia-Manero G, Sekeres MA, List AF, Khoury J, Advani A, Jabbour E, Kantarjian HM, Lancet JE, Cable LA, Guthrie K, Hogeland G, Ptaszynski M, Maloney L, Corson D, Komrokji RS. Phase 1 Dose-Escalation/Expansion Study of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes. *Blood* 122(21):387, 11/2013.
580. Jabbour E, Kantarjian HM, Thomas DA, Ravandi F, Cortes JE, Faderl SH, Pemmaraju V, Kadia TM, Prescott H, Garcia-Manero G, Borthakur G, Wierda WG, O'Brien S. Phase II Study of Combination of Hyper-CVAD with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). *Blood* 122(21):2663, 11/2013.
581. Jabbour E, Kantarjian HM, Thomas D, Garcia-Manero G, Hoehn D, Garris R, Faderl SH, Cortes JE, Kadia TM, Ravandi F, Verstovsek S, O'Brien S. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab as Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). *Blood* 122(21):2664, 11/2013.
582. Kadia TM, Borthakur G, Ferrajoli A, Jain P, Jabbour E, Verstovsek S, Pemmaraju N, Faderl S, Ravandi F, Konopleva M, Tuttle C, Brandt M, Wang X, Garcia-Manero G, Kantarjian HM, Cortes JE. Phase II Trial of Cladribine and Low-Dose AraC (LDAC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). *Blood* 122(21):5011, 11/2013.
583. Badar T, Mattiuzzi G, Kantarjian HM, Ravandi F, Daver NG, Garcia-Manero G, Kadia TM, Jabbour EJ, Borthakur G, Cortes JE. Phase II, Open Label, Randomized Comparative Trial

- of Ondansetron alone versus the Combination of Ondansetron plus Aprepitant for the Prevention of Nausea and Vomiting in Patients (Pts) with Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine. *Blood* 122(21):3887, 11/2013.
584. Oran B, Kongtim P, de Lima M, Popat UR, Garcia-Manero G, Jabbour EJ, Abruzzo LV, Chen J, Rondon G, Andersson BS, Alousi A, Ciurea SO, Shpall EJ, Champlin RE. Prior Hypomethylating Agents or Chemotherapy does not Improve the Outcome of Allogeneic Hematopoietic Transplantation for High Risk MDS. *Blood* 122(21):305, 11/2013.
 585. Jabbour E, Kantarjian HM, Ning J, Garcia-Manero G, Kadia TM, O'Brien S, Cortes JE, Hoehn D, Bryan J, Ravandi F, Verstovsek S. Prognostic Factors for Outcome in Patients (pts) with Myelofibrosis (MF) Treated with Ruxolitinib (Rux). *Blood* 122(21):4050, 11/2013.
 586. Kornblau SM, Hu CW, Qiu Y, Young Yoo S, Zhang N, Ravandi F, Garcia-Manero G, Qutub AA, Coombes KR. Recurrent Patterns of Histone Methylation and Acetylation Regulating Protein Expression in Acute Myelogenous Leukemia (AML). *Blood* 122(21):3733, 11/2013.
 587. Borthakur G, Cortes JE, Ravandi F, Gonzalez GN, Luthra R, Jabbour E, Garcia-Manero G, Kadia TM, Bass J, Brandt M, Kantarjian HM. Replacing Gemtuzumab Ozogamicin with Idarubicin in Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does not Compromise Outcome in Core Binding Factor Acute Myelogenous Leukemia. *Blood* 122(21):3971, 11/2013.
 588. Ohanian M, Kantarjian HM, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, O'Brien S, Quintas-Cardama A, Somer BG, Tari A, Verstovsek S, Wierda WG, Cortes JE. Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). *Blood* 122(21):2679, 11/2013.
 589. Shah SS, Kantarjian HM, Ravandi F, O'Brien S, Garcia-Manero G, Andreeff M, Konopleva M, Jabbour E, Pierce SR, Borthakur G, Cortes JE. Survival Outcomes in Relapsed/Refractory Acute Myeloid Leukemia Patients who Achieve Less-Than-Complete Response after Salvage Therapy. *Blood* 122(21):2654, 11/2013.
 590. Shetty A, Kantarjian HM, Champlin RE, Borthakur G, Badar T, Garcia-Manero G, Andersson BS, Oran B, Ciurea SO, Konopleva M, Andreeff M, Kornblau SM, Wierda WG, Pierce S, Ravandi F, Cortes JE. Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years. *Blood* 122(21):3886, 11/2013.
 591. Williams LA, Ault PS, Kantarjian HM, Garcia-Manero G, Quintas-Cardama A, Borthakur G, Faderl SH, Jabbour EJ, Cleeland CS, Cortes JE. Symptom Burden in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood* 122(21):2988, 11/2013.
 592. Pfeilstöcker M, Tüchler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian HM, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, LeBeau M, Slovak ML, Krieger O, Luebbert M, Maciejewski JP, Magalhaes Silvia MM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL. Time Changes in Predictive Power of MDS Prognostic Scores – Effects on Revised Scores such as the IPSS-R, Impact of Age. *Blood* 122(21):1544, 11/2013.
 593. Nazha A, Kantarjian HM, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia TM, Ferrajoli A, Konopleva M, Borthakur G, Burger JA, Feliu J, Faderl SH. Clofarabine plus Low-Dose Cytarabine Induction Followed by Clofarabine plus Low-Dose Cytarabine Alternating with Decitabine Consolidation in Acute Myeloid Leukemia Frontline Therapy for Older Patients. *Blood* 122(21):3948, 12/2013.
 594. Lyons RM, Marek BJ, Paley CS, Esposito J, Garbo LE, DiBella NJ, Garcia-Manero G. A 36-month analysis of treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes from a prospective observational study. *Journal of Clinical Oncology* 31(suppl) (#7122), 2013.
 595. Luger SM, O'Connell CL, Klimek V, Cooper MA, Besa EC, Rossetti JM, Reid GK, Humphrey R, Martell RE, Garcia-Manero G. A phase II study of mocetinostat, an oral isotype-selective

- histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS). *Journal of Clinical Oncology* 31(suppl) (#7116), 2013.
596. Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Ravandi F, Kadia TM, Andreeff M, Cortes JE, Hoberman K, Szarek M, Bergstein I, Kantarjian HM, Rowinsky EK. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. *Journal of Clinical Oncology* 31(suppl) (#7029), 2013.
 597. Jimenez AM, De Lima M, Popat UR, Borthakur G, Abruzzo L, Andersson B, Garcia-Manero G, Jabbour E, Chen J, Bashir Q, Ciurea SO, Kebriaei P, Ahmed S, Khouri IF, Kongtim P, Qazilbash MH, Rondon G, Shpall EJ, Champlin RE, Oran B. Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). *Journal of Clinical Oncology* 31(suppl) (#7010), 2013.
 598. Jabbour E, Kantarjian HM, Thomas DA, Ravandi F, Cortes JE, Faderl S, Pemmaraju N, Kadia TM, Garriss RS, Garcia-Manero G, Borthakur G, Wierda WG, O'Brien SM. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). *Journal of Clinical Oncology* 31(Suppl) (#7024), 2013.
 599. Borthakur G, Yi CYA, Cortes JE, Qiao W, Kadia TM, Ravandi F, Faderl S, Garcia-Manero G, Brandt M, Kantarjian HM. Prognostic impact of trisomy 8 cytogenetic abnormality in acute myelogenous leukemia: Analysis of a large cohort (N=2187) of newly diagnosed patients. *Journal of Clinical Oncology* 31(suppl) (#7089), 2013.
 600. Garcia-Manero G, Huang X, Cabrero M, DiNardo CD, Pemmaraju N, Daver NG, Borthakur G, Wierda WG, Kadia T, Alvarado Y, Cortes JE, Jain N, Ravandi F, Jabbour E, Brandt M, Sneed T, Sukholutsky V, Pierce S, Bohannon Z, Kantarjian HM. A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. *Blood* 124(21):3277, 12/2014.
 601. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Wei Y, Wierda WC, Bueso-Ramos CE, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). *Blood* 124(21):164, 12/2014.
 602. Colla S, Ong D, Ogoti Y, Marchesini M, Mistry N, Clise-Dwyer K, Storti P, Viale A, Giuliani N, Yang H, D'Anca M, Estecio MR, Liang H, Kantarjian HM, Wang AY, Chin L, Bueso-Ramos CE, Garcia-Manero G, DePinho R. A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome. *Blood* 124(21):523, 12/2014.
 603. Borthakur G, Foran JM, Wang ES, Rakkar A, Hager S, Frey NV, Andreeff M, Garcia-Manero G, Kadia TM, Carter BZ, Minderman H, Russell L, Tibes R. A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitidine: a Preliminary Analysis. *Blood* 124(21):3263, 12/2014.
 604. Navada SC, Garcia-Manero G, Wilhelm F, Hearn K, Odchimar-Reissig R, Demakos EP, Alvarado Y, Daver N, DiNardo CD, Konopleva M, Borthakur G, Azarnia N, Silverman LR. A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). *Blood* 124(21):3252, 12/2014.
 605. DiNardo CD, Aung FM, Martinez F, Daver N, Kadia T, Jain N, Jabbour E, Pemmaraju N, Reddy VM, Garcia-Manero G, Cortes JE, Ravandi F, Kantarjian HM, Lichtiger B, Freireich EJ. A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy. *Blood* 124(21):1564, 12/2014.
 606. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali MH, Thompson Z, Lee JH, Colla S, Feneaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates

- Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. *Blood* 124(21):530, 12/2014.
607. Komrokji RS, Garcia-Manero G, Ades L, Laadem A, Vo B, Prebet T, Stamatoullas A, Boyd G, Delaunay J, Steensma DP, Sekeres MA, Beyne-Rauzy O, Zou J, Attie K, Sherman ML, Fenaux P, List AF. An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. *Blood* 124(21):3251, 12/2014.
 608. Wei Y, Cabrero M, Jia Y, Zheng H, Yang H, Fang Z, Bohannan Z, Chen R, Wang H, Colla S, Wang X, Garcia-Manero G. Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes. *Blood* 124(21):3241, 12/2014.
 609. Wei Y, Verma A, Cabrero M, Jia Y, Zheng H, Fang Z, Yu Y, Colla S, Bohannan Z, Bowman TV, Boultonwood J, Garcia-Manero G. Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes. *Blood* 124(21):4663, 12/2014.
 610. Estecio MR, Maddipati S, DiNardo CD, Yang H, Stevenson WS, Bueso-Ramos CE, Pierce SR, Wei Y, Garcia-Manero G. Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype. *Blood* 124(21):3548, 12/2014.
 611. Alvarado Y, Keating MJ, O'Brien S, Kantarjian HM, Wierda WG, Sneed T, Jain N, Garcia-Manero G. Azacytidine and Vorinostat in Patients with Chronic Lymphocytic Leukemia (CLL) Diagnosed with Therapy-Related Myelodysplastic Syndromes/Acute Myeloid Leukemia (t-MDS/AML). *Blood* 124(21):5627, 12/2014.
 612. Badar T, Kantarjian HM, O'Brien S, Garcia-Manero G, Jabbour E, Garriss R, Pemmaraju N, Daver N, Ravandi F, Cortes JE, Thomas DA. Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia (MLL) Gene Rearrangements. *Blood* 124(21):5342, 12/2014.
 613. Jabbour E, Sasaki K, Daver N, Pemmaraju N, Jain N, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Faderl SH, O'Brien S, Cortes J, Kantarjian HM, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. *Blood* 124(21):534, 12/2014.
 614. Cabrero M, Garcia-Manero G, Sasaki K, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukolitsky V, Ravandi F, Pierce S, Kadia TM, Pemmaraju N, Oran B, Champlin RE, Kantarjian HM, Jabbour E. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. *Blood* 124(21):4666, 12/2014.
 615. Kim HR, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Maiti S, Cooper LJN, Medeiros LJ, Zuo Z. Comparison of Risk Models for Patients with Lower Risk Myelodysplastic Syndromes. *Blood* 124(21):1919, 12/2014.
 616. Williams LA, Ahaneku H, Cortes JE, Garcia-Manero G, Kantarjian HM, Shi Q, Lin HK, Limaye AR, Cleeland CS. Comparison of Symptom Burden in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood* 124(21):2652, 12/2014.
 617. Cabrero M, Jabbour E, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholitsky V, Ravandi F, Pierce S, Kadia T, Pemmaraju N, Kantarjian HM, Garcia-Manero G. Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. *Blood* 124(21):4664, 12/2014.
 618. Gerds AT, Dennison B, Latsko J, Houk A, Chisolm S, Huber JM, Stone RM, Maciejewski JP, Komrokji RS, Garcia-Manero G, Steensma DP, Sekeres MA. Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression. *Blood* 124(21):2642, 12/2014.
 619. Garcia-Manero G, Ritchie EK, Walsh K, Savona M, Kropf P, O'Connell C, Tibes R, Daver NG, Jabbour E, Lunin S, Rosenblatt TL, Yee K, Stock W, Griffiths EA, Mace JR, Podoltsev NA, Berdeja JG, Issa JP, Chung W, Naim S, Taverna P, Hao Y, Azab M, Kantarjian HM, Roboz GJ. First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with

- Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood* 124(21):529, 12/2014.
620. Daver N, Kantarjian HM, O'Brien S, Jabbour E, Pierce S, Lim Miranda, Borthakur G, Pemmaraju N, Konopleva M, DiNardo CD, Ravandi F, Garcia-Manero G, Cortes JE. Frequency and Impact of Molecular Response's with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). *Blood* 124(21):3156, 12/2014.
 621. Marchesini M, Storti P, Ogoti Y, D'Anca M, Nezi L, Wei Y, Yang H, Ong D, Neri A, Giuliani N, Garcia-Manero G, DePinho R, Coilla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. *Blood* 124(21):30, 12/2014.
 622. Badar T, Kantarjian HM, Borthakur G, Garcia-Mnaero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Ravandi F, Cortes JE. Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade. *Blood* 124(21):949, 12/2014.
 623. Thomas DA, O'Brien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, Estrov Z, Garcia-Manero G, Burger JA, Wierda W, Konopleva M, Andreeff M, Kornblau SM, Verstovsek S, Borthakur G, Kadia T, Garriss R, Pemmaraju N, Daver N, Jain N, Cortes J, Kantajrian HM. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). *Blood* 124(21):940, 12/2014.
 624. Jabbour E, Sasaki K, Daver N, Pemmaraju N, DiNardo CD, Kadia T, Miller D, Sukholutsky V, Huang X, Borthakur G, Estrov Z, Kantarjian HM, Garcia-Manero G. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). *Blood* 124(21):4640, 12/2014.
 625. Jabbour E, O'Brien S, Thomas DA, Sasaki K, Garcia-Manero G, Ravandi F, Borthakur G, York S, Garriss R, Cortes JE, Kantarjian HM. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (≥ 60 years) with Acute Lymphoblastic Leukemia (ALL). *Blood* 124(21):794, 12/2014.
 626. Jabbour E, O'Brien S, Thomas DA, Sasaki K, Garcia-Manero G, Kadia T, Jain N, York S, Garriss R, Cortes JE, Kantarjian HM. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). *Blood* 124(21):964, 12/2014.
 627. Gerds AT, Dennison B, Latsko J, Howk A, Chisolm S, Huber JM, Stone RM, Maciejewski JP, Komrokji RS, Garcia-Manero G, Steensma DP, Sekers MA. Knowledge That the Myelodysplastic Syndromes (MDS) Are a Type of Cancer Does Not Influence Patient Perception of Treatment Discontinuation. *Blood* 124(21):6015, 12/2014.
 628. Diaz Duque A, Cabrero M, Ravandi F, Pemmaraju N, Borthakur G, Kantarjian HM, Cortes JE, Kadia TM, Daver NH, Jabbour E, Garcia-Manero G, Sasaki K. Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. *Blood* 124(21):1924, 12/2014.
 629. Jabbour E, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Daver NG, Pemmaraju N, Kadia TM, DiNardo CD, Wang X, Nogueras-Gonzalez G, Borthakur G, Estrov Z, Kantarjian HM, Garcia-Manero G. Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. *Blood* 124(21):4641, 12/2014.
 630. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Jabbour E, Borthakur G, Garriss R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Kadia T, Jain N, Wang SA, Kebriaei P, Champlin RE, Estrov Z, Cortes JE, Kantarjian HM. Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL). *Blood* 124(21):1079, 12/2014.
 631. Patel K, Routbort M, Noguera-Gonzalez G, Kantarjian HM, Jabbour E, Borethakur G, DiNardo CD, Estrov Z, Daver NG, Wierda WG, Jain N, O'Brien S, Konopleva M, Cortes JE, Pemmaraju N, Alvarado Y, Bueso-Ramos CE, Luthra R, Singh R, Pierce S, Medeiros J, Bohannon Z, Huang X, Garcia-Manero G. Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. *Blood* 124(21):4658, 12/2014.

632. Mufti GJ, Best S, Lea N, Silverman LR, Garcia-Manero G, Azarnia N, Wilhelm F, Goehring G. Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy. *Blood* 124(21):3258, 12/2014.
633. Ohanian M, Rozovski U, Kantarjian HM, Loghavi S, Huh YO, Abruzzo L, Garcia-Manero G, Ravandi F, Andreeff M, Kornblau SM, Borthakur G, Nguyen M, Stingo F, Hu P, Fox P, Medeiros LJ, Estrov Z, Bueso-Ramos CE, Cortes JE. MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. *Blood* 124(21):5334, 12/2014.
634. Sasaki K, Jabbour E, Kantarjian HM, Cortes JE, Garcia-Manero G, Borthakur G, Pierce SR, Pemmaraju N, O'Brien S, Ravandi F. Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. *Blood* 124(21):2273, 12/2014.
635. Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour E, Greenberg MD, Lee S, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS. Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). *Blood* 124(21):3273, 12/2014.
636. Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekers MA, Roboz GJ, Caidano G, Scott BL, Greenberg PL, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Collins R, Atallah E, Wilhelm F, Wilhelm IE, Azarnia N, Maniar M, Silverman LR. Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). *Blood* 124(21):163, 12/2014.
637. Pinnamaneni P, Jorgensen JL, Kantarjian HM, Jabbour E, Pierce SR, Brandt M, Wang SA, Konoplev S, Konopleva M, Kornblau SM, Kadia T, DiNardo CD, Pemmaraju N, Andreeff M, Estrov Z, Garcia-Manero G, Cortes JE, Ravandi F. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. *Blood* 124(21):1015, 12/2014.
638. Daver N, Kantarjian HM, Garcia-Manero G, Pemmaraju N, Kadia TM, DiNardo CD, Jain N, Borthakur G, Jabbour E, Konopleva M, Cortes JE, Craig A, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). *Blood* 124(21):385, 12/2014.
639. Pemmaraju N, Kantarjian HM, O'Brien S, Borthakur G, Ravandi F, Verstovsek S, Daver NG, Garcia-Manero G, DiNardo CD, Skinner J, Konopleva M, Pierce S, Jabbour E, Cortes JE. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). *Blood* 124(21):4565, 12/2014.
640. Kadia T, Borthakur G, Ferrajoli A, Daver N, Jabbour E, Pemmaraju N, Verstovsek S, Burger JA, Wierda WG, Konopleva M, DiNardo CD, Jain N, Brandt M, Tuttle C, Wang X, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). *Blood* 124(21):3671, 12/2014.
641. Jabbour E, Kantarjian HM, Thomas DA, Sasaki K, Ravandi F, Cortes JE, Pemmaraju N, Kadia T, Garriss R, Garcia-Manero G, Borthakur G, Wierda WG, O'Brien S. Phase II Study of Combination of Hyper-CVAD with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). *Blood* 124(21):2289, 12/2014.
642. Randhawa JK, Jabbar KJ, Kadia T, Borthakur G, Pemmaraju N, Daver N, Kantarjian HM, Cortes JE, Hearn K, Bueso-Ramos CE, Garcia-Manero G. Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF- κ B Activation. *Blood* 124(21):1930, 12/2014.

643. Jabbour E, Kantarjian HM, Thomas DA, Sasaki K, Garcia-Manero G, Garris R, Cortes JE, Kadia TM, Ravandi F, Verstovsek S, O'Brien S. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab As Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). *Blood* 124(21):5277, 12/2014.
644. Jain N, Ravandi F, Garcia-Mnaero G, Borthakur G, Kadia T, Jabbour E, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Pike A, Bivins C, Pierce S, O'Brien S, Cortes JE, Kantarjian HM. Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML). *Blood* 124(21):5283, 12/2014.
645. Garcia-Manero G, Atallah E, Odenike L, Medeiros BC, Cortes JE, Esquibel V, Cha S, Khaled SK. Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). *Blood* 124(21):947, 12/2014.
646. Sasaki K, Jabbour E, Pemmaraju N, Daver NG, Kadia TM, DiNardo CD, Pierce S, Borthakur G, Kantarjian HM, Garcia-Manero G. Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). *Blood* 124(21):1922, 12/2014.
647. Jabbour E, O'Brien S, Sasaki K, Huang X, Thomas DA, Rytting ME, Garcia-Manero G, Cortes JE, Pierce S, Kadia TM, Kantarjian HM. Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. *Blood* 124(21):2288, 12/2014.
648. Lyons RM, Marek BJ, Paley c, Esposito J, McNamara K, Garbo L, DiBella N, Garcia-Manero G. Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years. *Blood* 124(21):1350, 12/2014.
649. Silverman LR, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Caidano G, Scott BL, Greenberg PL, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Collins R, Atallah E, Navada SC, Wilhelm F, Azarnia N, Garcia-Manero G. Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). *Blood* 124(21):3259, 12/2014.
650. George B, Jabbour E, Cabrero M, Jain N, Daver N, Ravandi F, Borthakur G, Bohannan Z, Cortes JE, Keating MJ, O'Brien S, Kantarjian HM, Garcia-Manero G. Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents. *Blood* 124(21):2278, 12/2014.
651. George G, Williams L, Shi Q, Badar T, O'Brien S, Jabbour E, Garcia-Manero G, Jain N, Ravandi F, Borthakur G, Wierda W, Cleeland CS, Kantarjian HM, Cortes JE. Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase. *Blood* 124(21):4548, 12/2014.
652. Shetty AV, Ravandi F, Alapati N, Borthakur G, Garcia-Manero G, Kadia TM, Wierda W, Estrov Z, Pierce S, O'Brien S, Kantarjian HM, Cortes JE. Survivorship in APL- Outcomes of Acute Promyelocytic Leukemia (APL) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years. *Blood* 124(21):954, 12/2014.
653. Badar T, Thompson PA, George B, Daver N, Borthakur G, Cortes JE, Konopleva M, Kadia TM, Bohannan Z, Pierce S, Jabbour E, Ravandi F, Kantarjian HM, Patel KP, Luthra R, Sukholutsky V, Garcia-Manero G. Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications. *Blood* 124(21):4631, 12/2014.
654. Borthakur G, Kantarjian HM, O'Brien S, Garcia-Manero G, Jabbour E, Daver N, Kadia TM, Gborogen R, Konopleva M, Andreeff M, Ravandi F, Cortes JE. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. *Blood* 124(21):388, 12/2014.
655. Stein EM, Garcia-Manero G, Rizzieri DA, Savona M, Tibes R, Altman JK, Jongen-Lavrencic M, Döhner H, Armstrong S, Pollock RM, Waters NJ, Legler M, Thomson B, Daigle S,

- McDonald A, Campbell C, Olhova E, Hedrick EE, Lowenberg B, Copeland RA, Tallman MS. The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia. *Blood* 124(21):387, 12/2014.
656. Nazha A, Komrokji R, Garcia-Manero G, Barnard J, Zimmerman C, Najla AA, Roboz GJ, Steensma DP, DeZern AE, Jabbour E, Lee S, Greenberg MD, List AF, Kantarjian HM, Maciejewski JP, Sekeres MA. The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. *Blood* 124(21):3275, 12/2014.
 657. Zeidan AM, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Zimmerman C, Roboz GJ, Steensma DP, DeZern AE, Jabbour E, Kantarjian HM, Zell K, Wang Q, Gore SD, Nazha A, Maciejewski JP, List AF, Komrokji RS. The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA). *Blood* 124(21):1935, 12/2014.
 658. Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez R, Kantarjian HM, Michal M, Albarracin C, Tang G, Strom SS, Reuben JM, Khoury JD. Therapy-Related Myeloid Neoplasms in Breast Cancer Patients: A Single-Institution Report of 150 Cases. *Blood* 124(21):962, 12/2014.
 659. Bejar R, Papaemmanuil E, Haferlach T, Garcia-Manero G, Maciejewski JP, Sekeres MA, Walter MJ, Graubert TA, Cazzola M, Malcovati L, Campbell PJ, Ogawa S, Boultonwood J, Bowen D, Tauro S, Groves MJ, Fontenay M, Shih LY, Tüchler H, Stevenson KE, Neuberg D, Greenberg PL, Ebert BL. TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. *Blood* 124(21):532, 12/2014.
 660. Garcia-Manero G, Martinelli G, Zeidner JF, Avigan D, Anderson KC, Ribrag V, Moskowitz C, Zinzani PL, Wu D, Emancipator K, Dolled-Filhart M, Gause C, Brown H, Geschwindt RD, Iannone R, Rose S, Armand P. A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies. *Journal of Clinical Oncology* 32(5s) (#TPS3116), 2014.
 661. Pemmaraju N, Thomas DA, Kantarjian HM, Cortes JE, Khoury J, Manning JT, Medeiros LJ, O'Brien SM, Daver NG, Pierce S, Garcia-Manero G, Jabbour E, Jain N, Qazilbash MH, Faderl S, Frankel AE, Konopleva M. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes. *Journal of Clinical Oncology* 32(5s) (#7118), 2014.
 662. Ohanian M, Kantarjian HM, Rozovski U, Loghavi S, Huh Y, Abruzzo L, Garcia-Manero G, Ravandi F, Borthakur G, Stingo F, Hu P, Nguyen MH, Fox PS, Medeiros LJ, Estrov Z, Bueso-Ramos CE, Cortes JE. Clinical significance of MYC expression in acute myeloid leukemia. *Journal of Clinical Oncology* 32(5s) (#7094), 2014.
 663. Steensma DP, Abedi M, Attar EC, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Ma X, Maciejewski JP, Pollyea DA, Roboz GJ, Savona M, Scott BL, Sekeres MA, Thompson MA, Zernovak O, Sugrue MM, Swern AS, Nifenecker M, Erba HP. Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. *Journal of Clinical Oncology* 32(5s) (#TPS7126), 2014.
 664. Griffiths EA, Kantarjian HM, Roboz GJ, Kropf PL, O'Connell CL, Yee KWL, Garcia-Manero G, Jabbour E, Feldman EJ, Walsh KJ, Rizzieri D, Stock W, Lunin SD, Naim S, Choy GS, Taberna P, Hao Y, Azab M, Chung W, Issa JPJ. First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML). *Journal of Clinical Oncology* 32(5s) (#7030), 2014.
 665. Aad SA, Daver NG, Strati P, Cortes JE, Garcia-Manero G, Mathisen M, Ravandi F, Kadia TM, O'Brien SM, Bivins C, Pierce S, Kantarjian HM, Jabbour E. High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse. *Journal of Clinical Oncology* 32(5s) (#7074), 2014.
 666. Shetty A, Cortes JE, Ravandi F, Kadia TM, Garcia-Manero G, Pemmaraju N, Pierce S, Kantarjian HM, Borthakur G. Hyperdiploidy in AML: Outcomes of acute myelogenous leukemia (AML) patients (pts) with a hyperdiploid karyotype. *Journal of Clinical Oncology* 32(5s) (#7088), 2014.

667. Jabbour E, O'Brien SM, Jain N, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, York S, Garriss R, Cortes JE, Kantarjian HM. Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL). *Journal of Clinical Oncology* 32(5s) (#7019), 2014.
668. Takahashi K, Kantarjian HM, Garcia-Manero G, Stevens RJ, DiNardo CD, Allen J, Hardeman E, Carrier S, Powers C, Keane P, Pierce S, Routbort M, Nguyen KT, Smith B, Frey J, Perry K, Frenzel JC, High R, Futreal A, Chin L. MD Anderson's Oncology Expert Advisor powered by IBM Watson: A Web-based cognitive clinical decision support tool. *Journal of Clinical Oncology* 32(5s) (#6506), 2014.
669. Andreeff M, Borthakur G, Zeng Z, Kelly MA, Wang RY, McQueen TJ, Qiu Y, Mak D, Burger JA, Daver NG, Pemmaraju N, Kadia TM, Jabbour E, Pierce S, Ravandi F, Garcia-Manero G, O'Brien SM, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. *Journal of Clinical Oncology* 32(5s) (#7033), 2014.
670. Daver NG, Kantarjian HM, Pierce S, Brandt M, DiNardo CD, Pemmaraju N, Vaughan K, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Cortes JE, Craig A, Ravandi F. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). *Journal of Clinical Oncology* 32(5s) (#7098), 2014.
671. O'Brien SM, Jabbour E, Thomas DA, Ravandi F, Cortes JE, Pemmaraju N, Kadia TM, Garriss R, Jeanis V, Garcia-Manero G, Borthakur G, Wierda WG, Kantarjian HM. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). *Journal of Clinical Oncology* 32(5s) (#7064), 2014.
672. Jabbour E, Kantarjian HM, Thomas DA, Garcia-Manero G, Aad SA, Garriss R, Cortes JE, Kadia TM, Ravandi F, Verstovsek S, O'Brien SM. Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL. *Journal of Clinical Oncology* 32(5s) (#7065), 2014.
673. Kadia TM, Cortes JE, Borthakur G, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Ravandi F, Pemmaraju N, Daver NG, Konopleva M, Wang X, Kantarjian HM. Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML. *Journal of Clinical Oncology* 32(5s) (#7031), 2014.
674. Takahashi K, Kantarjian HM, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, DiNardo CD, Jabbour E, Konopleva M, Andreeff M, Cortes JE. Propensity score matched comparison of intermediate-intensity chemotherapy induction versus intensive chemotherapy induction in elderly patients (age ≥ 60) with acute myeloid leukemia (AML). *Journal of Clinical Oncology* 32(5s) (#7097), 2014.
675. Savona MR, Gore SD, Kolibaba KS, Ukrainskyj SM, Kumar K, Dong Q, Hetzer J, Skikne B, Garcia-Manero G. CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML). *Blood* 126(23):452, 11/2015.
676. Jabbour E, O'Brien S, Sasaki K, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, Jain N, Konopleva M, Jacob J, Garriss R, Cortes JE, Kantarjian HM. Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). *Blood* 126(23):83, 11/2015.
677. Short NJ, Garcia-Manero G, Bravo GM, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Gautam Borthakur G, DiNardo CD, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian HM, Jabbour E. Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. *Blood* 126(23):94, 11/2015.
678. Fang J, Bolanos L, Choi KM, Liu S, Christie S, Akunuru S, Kumar R, Greis K, Peter Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch M, Salomonis N, Geiger H, Zheng Y, Starczynowski D. Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links

- Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia. *Blood* 126(23):143, 11/2015.
679. Garcia-Manero G, Atallah E, Khaled SK, Arellano M, Patnaik MM, Butler TA, Ashby C, Medeiros BC. Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). *Blood* 126(23):453, 12/2015.
680. Williams LA, Garcia-Gonzalez A, Ahaneku H, Cortes JE, Garcia-Manero G, Kantarjian HM, Shi Q, Borthakur G, Burger JA, Jabbour E, Takahashi K, Lin HK, Limaye A, Cleeland CS. A patient-reported outcome measure for symptoms of AML/MDS. *Journal of Clinical Oncology* 33(suppl) (#e17648), 2015.
681. Daher M, Sobieski C, Marin D, Sekine T, Shpall EJ, Champlin RE, Kantarjian HM, Garcia-Manero G, Rezvani K. Association between KIR genes and risk of MDS. *Journal of Clinical Oncology* 33(suppl) (#7001), 2015.
682. Silverman LR, Fenaux P, Greenberg P, Demakos EP, Santini V, Seymour JF, Navada SC, Petrone ME, Snyder BR, Azamia N, Garcia-Manero G. Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome. *Journal of Clinical Oncology* 33(suppl) (#7017), 2015.
683. Chae YK, Dimou A, Takahashi K, Benton CB, Jabbour E, Ravandi F, Borthakur G, Cortes JE, Kadia TM, Thomas DA, Wierda WG, Daver NG, DiNardo CD, Kantarjian HM, Garcia-Manero G. Effect of vorinostat use on survival in patients with acute myeloid leukemia (AML) with FLT3 ITD mutations. *Journal of Clinical Oncology* 33(suppl) (#e18019), 2015.
684. Sanford D, Blum WG, Ravandi F, Klisovic RB, Borthakur G, Walker AR, Garcia-Manero G, Marcucci G, Wierda WG, Whitman SP, Kantarjian HM, Cortes JE. Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia. *Journal of Clinical Oncology* 33(suppl) (#7059), 2015.
685. Kantarjian HM, Jabbour E, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Izuka K, Jin C, Plunkett W. First report of a phase I/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia. *Journal of Clinical Oncology* 33(suppl) (#7077), 2015.
686. Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Silverman LR, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kreuzer KA, Godley LA, Collins R, Atallah EL, Azamia N, Garcia-Manero G. Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. *Journal of Clinical Oncology* 33(suppl) (#e18079), 2015.
687. Garcia-Manero G, Schiffer CA, Godley LA, Paquette R, Platzbecker U, Robbins PB, Norton J, Karakunnel JJ, Lindsley RC. Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents. *Journal of Clinical Oncology* 33(suppl) (#TPS7103), 2015.
688. Silverman LR, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kreuzer KA, Godley LA, Collins R, Atallah EL, Azamia N, Garcia-Manero G. Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. *Journal of Clinical Oncology* 33(suppl) (#7092), 2015.
689. Short NJ, Benton CB, Noguera-Gonzalez GM, Hokanson J, Gu L, Ravandi F, Garcia-Manero G, Brandt M, Pierce S, Konopleva M, Cortes JE, Kantarjian HM, Quintas-Cardama A, Andreeff M. Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction chemotherapy. *Journal of Clinical Oncology* 33(suppl) (#e18045), 2015.
690. Sasaki K, Kantarjian HM, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver NG, Jain P, Pierce S, Rios MB, Cortes JE. Propensity score analysis: Frontline therapy with high-dose (HD) imatinib vs. 2nd generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase. *Journal of Clinical Oncology* 33(suppl) (#7022), 2015.

691. Badar T, Cortes JE, Jabbour E, Borthakur G, Konopleva M, Kadia TM, Bohannon Z, Pierce S, Ravandi F, Patel K, Luthra R, Kantarjian HM, Garcia-Manero G. RAS mutation acquisition at transformation from myelodysplastic syndrome to acute myeloid leukemia to predict poor outcome. *Journal of Clinical Oncology* 33(suppl) (#7052), 2015.
692. Naqvi K, Pierce S, Zhou L, Garcia-Mnaero G, Cortes JE, Kantarjian HM, Verstovsek S. Role of ruxolitinib in patients (pts) with myeloproliferative neoplasms (MPNs) treated off clinical trial. *Journal of Clinical Oncology* 33(suppl) (#e18076), 2015.
693. Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Hui Yang, Yue Wei, Yesid Alvarado, Courtney D. DiNardo, Naval G. Daver, Marina Konopleva, Katherine P. Hearn, Robert Miller, Sarah Arbe-Barnes, Peter Mc Guirk, Tara Kearney, Brian Keogh, Hagop M. Kantarjian and Mary Reilly. A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. *Blood* 128(22):227, 2016.
694. Guillermo Garcia-Manero, Ehab Atallah, Samer K Khaled, Martha Arellano, Mrinal M Patnaik, Olatoyosi Odenike, Hamid Sayar, Mohan Tummala, Prapti A. Patel, Richard G. Ghalie and Bruno C. Medeiros. A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. *Blood* 128(22):100, 2016.
695. Guillermo Montalban-Bravo, Xuelin Huang, Elias J. Jabbour, Gautam Borthakur, Courtney D. DiNardo, Naveen Pemmaraju, Jorge E. Cortes, Srdan Verstovsek, Tapan M. Kadia, Naval G. Daver, William G. Wierda, Yesid Alvarado, Marina Konopleva, Farhad Ravandi, Zeev Estrov, Nitin Jain, Ana Alfonso Pierola, Mark Brandt, Troy Sneed, Hsiang-Chun Chen, Hui Yang, Carlos E Bueso-Ramos, Sherry Pierce, Elihu H. Estey, Zachary S. Bohannon, Hagop M. Kantarjian and Guillermo Garcia-Manero. A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials. *Blood* 128(22):1999, 2016.
696. Nicholas J. Short, Guillermo Garcia-Manero, Kiran Naqvi, Steven M. Kornblau, Abhishek Maiti, Marina Konopleva, Courtney D DiNardo, Koichi Takahashi, Yesid Alvarado, Maro Ohanian, Zeev Estrov, Prithviraj Bose, Michael Andreeff, Rabiul Islam, Xiao Dong, Jorge E. Cortes, Hagop M. Kantarjian, and Elias J. Jabbour. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. *Blood* 128(4328), 2016.
697. Rashmi Kanagal-Shamanna, Juliana E. Hidalgo Lopez, Hye Ryouon Kim, Zhuang Zuo, Michelle Janania Martinez, Chong Zhao, Denái R. Milton, Francesco Stingo, John Lee, Raja Luthra, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, L. Jeffrey Medeiros, and Carlos E Bueso-Ramos. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. *Blood* 128(4319), 2016.
698. Yasmin Abaza, Hagop M. Kantarjian, Gautam Borthakur, Guillermo Garcia-Manero, Naval Daver, Farhad Ravandi, Srdan Verstovsek, Jan A. Burger, Zeev Estrov, Maro Ohanian, Miranda Lim, Rita Assi, Elias J. Jabbour, and Jorge E. Cortes. An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). *Blood* 128(5433), 2016.
699. Hui Yang, Zachary S. Bohannon, Zhihong Fang, Irene Gañán-Gómez, Yue Wei, Linda J. Paradiso, Hiroyuki Iwamura and Guillermo Garcia-Manero. Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia. *Blood* 128(22):2756, 2016.
700. Guillermo Garcia-Manero, Michael R. Savona, Steven D. Gore, Bart L. Scott, Christopher R. Cogle, Thomas Boyd, Paul Conkling, Joel Hetzer, Qian Dong, Keshava Kumar, Stacey M. Ukrainskyj, and Barry S. Skikne. CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. *Blood* 128(905), 2016.
701. Prajwal Chaitanya Boddu, Hagop M. Kantarjian, Guillermo Garcia-Manero, Srdan Verstovsek, Farhad Ravandi, Elias J. Jabbour, Koichi Takahashi, Kapil N. Bhalla, Marina Konopleva, Courtney D DiNardo, Maro Ohanian, Naveen Pemmaraju, Nitin Jain, Sherry Pierce, William G. Wierda, Jorge E. Cortes, and Tapan M. Kadia. Characteristics and

- Outcomes of Older Patients with Secondary AML According to Treatment Approach. *Blood* 128(2788), 2016.
702. Koji Sasaki, Hagop M. Kantarjian, Elias J. Jabbour, Susan O'Brien, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William G. Wierda, Naval Daver, Koichi Takahashi, Preetesh Jain, Jeffrey Skinner, Mary Beth Rios, Sherry Pierce, Guillermo Garcia-Manero, and Jorge E. Cortes. Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. *Blood* 128(940), 2016.
 703. Preetesh Jain, Hagop M. Kantarjian, Elias J. Jabbour, Rashmi Kanagal-Shamanna, Keyur P. Patel, Sara Emogene DellaSala, Sherry Pierce, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Susan M. O'Brien, and Jorge E. Cortes. Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML). *Blood* 128(5436), 2016.
 704. Koichi Takahashi, Feng Wang, Hagop M. Kantarjian, Doss Denaha, Kanhav Khann, Keyur P. Patel, Sattva S. Neelapu, Curtis Gumbs, Carlos E Bueso-Ramos, Courtney D. DiNardo, Simona Colla, Farhad Ravandi, Jianhua Zhang, Xifeng Wu, Felipe Samaniego, Guillermo Garcia-Manero, and Andrew Futreal. Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms. *Blood* 128(38), 2016.
 705. Shyamala C. Navada, Guillermo Garcia-Manero, Katherine P. Hearn, Rosalie Odchimar-Reissig, Erin P. Demakos, Yesid Alvarado, Naval Daver, Courtney D DiNardo, Marina Konopleva, Gautam Borthakur, Pierre Fenaux, Michael E. Petrone, Patrick Simon Zbyszewski, Steven M. Fruchtman, and Lewis R. Silverman. Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study. *Blood* 128(3167), 2016.
 706. Megan Othus, Mikkael A Sekeres, Sucha Nand, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, and Elihu H. Estey. Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. *Blood* 128(1613), 2016.
 707. Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Shyamala C. Navada, Maria R. Baer, Azra Raza, Peter Greenberg, Karl-Anton Kreuzer, Devendra K Hiwase, Gail J. Roboz, Valeria Santini, Uwe Platzbecker, Michael E. Petrone, Bernard Brownstein, Patrick Simon Zbyszewski, Manoj Maniar and Lewis R. Silverman. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). *Blood* 128(22):2011, 2016.
 708. Guillermo Garcia-Manero, Michael E. Petrone, Steven M. Fruchtman, Bernard Brownstein, Hannes Loferer, Nozar Azarnia, Shireen Vali, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi and Lewis R. Silverman. Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response. *Blood* 128(22):4324, 2016.
 709. Rita Assi, Hagop M. Kantarjian, Srdan Verstovsek, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Courtney D DiNardo, Tapan M. Kadia, Naval Daver, Elias J. Jabbour, Rosilyn A. Gborogen, Kamal Chamoun, William G. Wierda, Gautam Borthakur, and Jorge E. Cortes. CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. *Blood* 128(4047), 2016.
 710. Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Tapan M. Kadia, Elias J. Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D DiNardo, Marina Konopleva, Yesid Alvarado, Koichi Takahashi, Christopher B. Benton, Allison Pike, Sherry Pierce, Jorge E. Cortes, and Hagop M. Kantarjian. Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). *Blood* 128(2817), 2016.
 711. Alfonso A, Montalban-Bravo G, Garcia-Manero G. Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). *Blood* 128(2900), 2016.
 712. Guillermo Garcia-Manero, Valeria Santini, Antonio Almeida, Pierre Fenaux, Norbert Gatterman, Keiya Ozawa, Stuart L. Goldberg, Jerry Weaver and Mary M. Sugrue. Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). *Blood* 128(22):3190, 2016.

713. Abdallah Abou Zahr, Jorge E. Cortes, Srdan Verstovsek, Jairo Matthews, Nitin Jain, Elias J. Jabbour, Guillermo Garcia-Manero, Michael Andreef, Kiran Naqvi, Hagop M. Kantarjian, and Gautam Borthakur. Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis. *Blood* 128(3062), 2016.
714. Abhishek Maiti, Hagop M. Kantarjian, Alessandra Ferrajoli, Zeev Estrov, Gautam Borthakur, Guillermo Garcia-Manero, Elias J. Jabbour, Farhad Ravandi, Susan M. O'Brien, and Jorge E. Cortes. Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML). *Blood* 128(5449), 2016.
715. Abhishek Maiti, Hagop M. Kantarjian, Alessandra Ferrajoli, Zeev Estrov, Gautam Borthakur, Guillermo Garcia-Manero, Elias J. Jabbour, Farhad Ravandi, Susan M. O'Brien, and Jorge E. Cortes. Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML). *Blood* 128(5449), 2016.
716. Matteo Marchesini, Yamini Ogoti, Elena Fiorini, Marianna D'anca, Paola Storti, Luigi Nezi, Mehmet K. Samur, Irene Gañán-Gómez, Mariateresa Fulcinitti, Zachary S. Bohannon, Karen Clise-Dwyer, Nicola Giuliani, Nikhil C Munshi, Robert Z. Orlowski, Guillermo Garcia-Manero, Ronald A. DePinho, and Simona Colla. ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. *Blood* 128(359), 2016.
717. Guillermo Montalban-Bravo, Koichi Takahashi, Ana Alfonso Pierola, Feng Wang, Song Xingzhi, Elias J. Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney D DiNardo, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Carlos E. Bueso-Ramos, Andrew Futreal, Hagop M. Kantarjian and Guillermo Garcia-Manero. Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System. *Blood* 128(22):4317, 2016.
718. Ana Alfonso Pierola, Guillermo Montalban-Bravo, Ali N. Chamseddine, Koichi Takahashi, Feng Wang, Song Xingzhi, Elias J. Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney D. DiNardo, Naval G. Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Carlos E Bueso-Ramos, Keyur Patel, Andrew Futreal, Sherry Pierce, Hagop M. Kantarjian and Guillermo Garcia-Manero. Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome. *Blood* 128(22):4340, 2016.
719. Aziz Nazha, Rami S. Komrokji, John Barnard, Najla H Al Ali, Gail J. Roboz, David P. Steensma, Amy E. DeZern, Jaime Fensterl, Guillermo Garcia-Manero, Alan F List, Jaroslaw P Maciejewski, and Mikkael A. Sekeres. Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). *Blood* 128(4332), 2016.
720. Koji Sasaki, Elias J. Jabbour, Susan M. O'Brien, Farhad Ravandi, Deborah A Thomas, Guillermo Garcia-Manero, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Nicholas J. Short, Naveen Pemmaraju, Yesid Alvarado, Jovitta Jacob, Rebecca Garriss, Philip A Thompson, Jorge E. Cortes, and Hagop M. Kantarjian. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. *Blood* 128(588), 2016.
721. May Daher, David Marin, Catherine Sobieski, Hila Shaim, Rafet Basar, Mayela Carolina Mendt Vilchez, Elif Gokdemir, Li Li, Nobuhiko Imahashi, Muharrem Muftuoglu, Richard E. Champlin, Elizabeth J. Shpall, Hagop M. Kantarjian, Guillermo Garcia-Manero, and Katayoun Rezvani. KIR Gene Haplotype: An Independent Predictor of Clinical Outcome in MDS Patients. *Blood* 128(4330), 2016.
722. Prajwal Chaitanya Boddu, Hagop M. Kantarjian, Abdul Rashid Shah, Gautam Borthakur, Srdan Verstovsek, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Farhad Ravandi, Nitin Jain, Ahmad Alhurairi, Jan Burger, Steven M. Kornblau, Sara Emogene Dellasala, Sherry Pierce, Elias J. Jabbour, and Jorge E. Cortes. Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. *Blood* 128(3073), 2016.

723. Ana Alfonso Pierola, Guillermo Montalban-Bravo, Koichi Takahashi, Elias J. Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney D. DiNardo, Naval G. Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Carlos E. Bueso-Ramos, Sherry Pierce, Hagop M. Kantarjian, and Guillermo Garcia-Manero. Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia. *Blood* 128(111), 2016.
724. Yogin B Patel, Kelsey N Voit, Koji Sasaki, Farhad Ravandi, Deborah A Thomas, Susan M. O'Brien, Gautam Borthakur, Guillermo Garcia-Manero, Jorge E. Cortes, Marina Konopleva, Nitin Jain, Maro Ohanian, Rebecca Garriss, Jovitta Jacob, Hagop M. Kantarjian, and Elias J. Jabbour. Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. *Blood* 128(5194), 2016.
725. Guillermo Montalban-Bravo, Ana Alfonso Pierola, Koichi Takahashi, Elias J. Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney D. DiNardo, Naval G. Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Sherry Pierce, Carlos E Bueso-Ramos, Keyur Patel, Hagop M. Kantarjian and Guillermo Garcia-Manero. Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. *Blood* 1128(22):3171, 2016.
726. Rami S. Komrokji, Mikkael A. Sekeres, John Barnard, Najla Alali, Amy E. DeZern, Eric Padron, David Sallman, Jeffrey E. Lancet, Gail J. Roboz, Jaime Fensterl, Guillermo Garcia-Manero, David P. Steensma, and Alan F List. Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. *Blood* 128(4322), 2016.
727. Nicholas J. Short, Elias J. Jabbour, Heidi Ko, Farhad Ravandi, Deborah A Thomas, Guillermo Garcia-Manero, Rita B. Khouri, Jorge E. Cortes, William G. Wierda, Srdan Verstovsek, Zeev Estrov, Alessandra Ferrajoli, Philip A Thompson, Sherry Pierce, and Hagop M. Kantarjian. Outcomes of Adult Patients with Relapsed/Refractory Burkitt or Burkitt-like Leukemia/Lymphoma. *Blood* 128(5150), 2016.
728. Yue Wei, Hong Zheng, Yu Jia, Naran Bao, Shan Jiang, Simona Colla, Carlos E Bueso-Ramos, Joseph D Khoury, Zachary S. Bohannon and Guillermo Garcia-Manero. Overexpression of KDM6B, an Epigenetic and Innate Immune Regulator, Results in Hematopoietic Alterations of Mice Including Changes in Hematopoietic Stem Cells. *Blood* 128(22):3149, 2016.
729. Nicholas J. Short, Farhad Ravandi, Jorge E. Cortes, Rebecca Garriss, Susan M. O'Brien, Keyur P. Patel, Jeffrey L. Jorgensen, Joseph D Khoury, Guillermo Garcia-Manero, Deborah A Thomas, Hagop M. Kantarjian, and Elias J. Jabbour. Patterns of Relapse in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Achieve Complete Molecular Response with Chemotherapy Plus a Tyrosine Kinase Inhibitor. *Blood* 128(3977), 2016.
730. Guillermo Garcia-Manero, Martin S. Tallman, Giovanni Martinelli, Vincent Ribrag, Hui Yang, Arun Balakumaran, Sabine Chlosta, Yayan Zhang and B. Douglas Smith. Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. *Blood* 128(22):345, 2016.
731. Guillermo Garcia-Manero, Hui Yang, Zhihong Fang, Hagop M. Kantarjian, Courtney D. DiNardo, Elias J. Jabbour, Naveen Pemmaraju, Naval Daver, Ricardo Delumpa, Christopher Loiselle, Silvia Rivera, Kristin Anderson, Brittany Yearby, Susan Denton, Whitney Smith, Kathleen Tiefenwerth, Hiroyuki Iwamura, Teletha Gipson, Michele Rosner, Thomas J. Myers and Linda J. Paradise. Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. *Blood* 128(22):1640, 2016.
732. Yasmin Abaza, Elias J. Jabbour, Srdan Verstovsek, Zeev Estrov, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Naval Daver, Courtney D DiNardo, Carlos E. Bueso-Ramos, Juliana E. Hidalgo, Heather Schneider, Guillermo Montalban Bravo, Ana Alfonso, Yue Wei, Hagop M. Kantarjian and Guillermo Garcia-Manero. Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. *Blood* 128(22):4318, 2016.

733. Hagop M. Kantarjian, Elias J. Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia, Courtney D. DiNardo, Naval G. Daver, Gautam Borthakur, Nitin Jain, Jane Waukau, Monica Kwari, Barry Douglas Anderson, Kenzo Iizuka, Cheng Jin, Chun Zhang, Farhad Ravandi, and William Plunkett. Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study. *Blood* 128(2822), 2016.
734. Alfonso A, Montalban-Bravo G, Garcia-Manero G. Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). *Blood* 128(1224), 2016.
735. Ahmad Alhurairi, Hagop M. Kantarjian, Elias J. Jabbour, Prajwal Chaitanya Boddu, Farhad Ravandi, Gautam Borthakur, Courtney D DiNardo, Naval Daver, Tapan M. Kadia, Naveen Pemmaraju, Sherry Pierce, Guillermo Garcia-Manero, and Jorge E. Cortes. Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors. *Blood* 128(3064), 2016.
736. Naveen Pemmaraju, Bing Z Carter, Hagop M. Kantarjian, Jorge E. Cortes, Tapan M. Kadia, Guillermo Garcia-Manero, Courtney D DiNardo, Prithviraj Bose, Sherry Pierce, Lingsha Zhou, Zeev Estrov, Carla Kay Tuttle, Karina Salinas, Po Yee Mak, and Srdan Verstovsek. Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). *Blood* 128(3105), 2016.
737. Rami S. Komrokji, John Barnard, David P Steensma, Amy E. DeZern, Gail J. Roboz, Najla Alali, Jaime Fensterl, Guillermo Garcia-Manero, and Mikkael A. Sekeres. Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC). *Blood* 128(4321), 2016.
738. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF). *Blood* 128(1127), 2016.
739. Abhishek Maiti, Hagop M. Kantarjian, Alessandra Ferrajoli, Zeev Estrov, Gautam Borthakur, Guillermo Garcia-Manero, Elias J. Jabbour, Farhad Ravandi, Susan M. O'Brien, and Jorge E. Cortes. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). *Blood* 128(4246), 2016.
740. Guillermo Montalban-Bravo, Koichi Takahashi, Ana Alfonso Pierola, Feng Wang, Song Xingzhi, Elias J. Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney D DiNardo, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Carlos E. Bueso-Ramos, Andrew Futreal, Hagop M. Kantarjian and Guillermo Garcia-Manero. STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes. *Blood* 128(22):3182, 2016.
741. Guillermo Garcia-Manero, Olatoyosi Odenike, Philip C. Amrein, David P. Steensma, Amy E. DeZern, Laura C. Michaelis, Stefan Faderl, Hagop M. Kantarjian, James N. Lowder, Pietro Taverna, Aram Oganessian, Xiaoping Zhang, Mohammad Azab, and Michael R. Savona. Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study. *Blood* 128(114), 2016.
742. Ana Alfonso Pierola, Matteo Marchesini, Koichi Takahashi, Irene Gañán-Gómez, Elena Fiorini, Yamini Ogoti, Esperanza Irlés, Guillermo Montalban-Bravo, Silver Sofia, Karen C. Dwyer, Guillermo Garcia-Manero, and Simona Colla. The Role of Chip-Related DNA Damage Response Dysfunction in Therapy-Related Myeloid Neoplasms. *Blood* 128(958), 2016.
743. May Daher, Juliana Elisa Hidalgo Lopez, Jasleen K. Randhawa, Kausar Jabeen Jabbar, Naveen Pemmaraju, Gautam Borthakur, Tapan M. Kadia, Marina Konopleva, Hagop M. Kantarjian, Jorge E. Cortes, Katherine P. Hearn, Steven R. Reyes, Carlos E. Bueso-Ramos and Guillermo Garcia-Manero. Updated Phase II Study of Targeted Subcutaneous (SC)

- Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF- κ B Activation. *Blood* 128(22):3191, 2016.
744. Irene Gañán-Gómez, Ana Alfonso, Yamini Ogoti, Hui Yang, Guillermo Montalban-Bravo, Abraham C Yu, Matteo Marchesini, Carlos E Bueso-Ramos, Koichi Takahashi, Karen Clise-Dwyer, Guillermo Garcia-Manero, and Simona Colla. You have access Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes. *Blood* 128(4310), 2016.

Book Chapters

1. Garcia-Manero G, Martinez J. Principles of hemostasis and thrombosis. In: Management and Prevention and of Thrombosis in Primary Care, 2001.
2. Garcia-Manero G, Kantarjian H. New approaches to the management of patients with the myelodysplastic syndrome. In: The myelodysplastic syndromes. Pathobiology and Clinical Management. Marcel Dekker, 2002.
3. Garcia-Manero G, Kantarjian H, Schiffer C. Adult acute lymphocytic leukemia. In: Cancer Medicine 6. BC Decker, Inc., 2003.
4. Garcia-Manero G, Talpaz M, Faderl S, Kantarjian H. Chronic myelogenous leukemia. In: Blood: Principles and Practice of Hematology. Lippincott, Williams & Wilkins, 433, 2003.
5. Garcia-Manero G, Issa JP. The role of DNA hypomethylating agents in cancer treatment. In: Progress In Oncology 2004. 6, 131-158, 2004.
6. Atallah E, Garcia-Manero G. Epigenetic Drugs (DNA Demethylating Agents). In: Epigenetics in Biology and Medicine. Ed(s) M Estellar. CRC Press: Boca Raton, FL, 27-48, 2009.
7. Garcia-Manero G, List A, Kantarjian H, Cortes JE. Myelodysplastic Syndromes. In: Cancer Management: A Multidisciplinary Approach, 12. Ed(s) R Pazdur, LD Wagman, KA Camphausen, WJ Hoskins. CMP Healthcare Media LLC: Norwalk, CT, 841-857, 2009. PMID: 9781891483639.
8. Garcia-Manero G, List A, Kantarjian H, Cortes J. Myelodysplastic syndromes. In: Cancer Management: A Multidisciplinary Approach, 13. Ed(s) R Pazdur, LD Wagman, KA Camphausen, WJ Hoskins. UBM Medica LLC: Norwalk, 887-903, 2010.
9. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer Network. Myelodysplastic syndromes. In: J Natl Compr Canc Netw. 9, 13. Ed(s) R Pazdur, LD Wagman, KA Camphausen, WJ Hoskins. CMP Medica: Lawrence, Kansas, USA, 887-903, 1/2011. PMID: PMC3768131.
10. Stevenson W, Garcia-Manero G. Myelodysplastic Syndromes. In: Leukemias: Principles and Practice of Therapy, 1. Ed(s) S Faderl, H Kantarjian. Blackwell Publishing Ltd.: Oxford, United Kingdom, 99-114, 2011.
11. Faderl SH, Garcia-Manero G, Kantarjian HM. Myelodysplastic syndromes (MDS). In: Management of Hematologic Malignancies. Ed(s) S O'Brien, JM Vose, HM Kantarjian. Cambridge University Press: Cambridge, United Kingdom, 103-115, 2011.
12. Stevenson WS, Bueso-Ramos C, Garcia-Manero G. Myelodysplastic Syndromes: The MD Anderson Cancer Center Approach. In: The MD Anderson Manual of Medical Oncology, 2nd. Ed(s) HM Kantarjian, RA Wolff, CA Koller. McGraw-Hill Companies, Inc.: China, 75-95, 2011. PMID: 978-0-07-170106-8.
13. Fabio Santos, Garcia-Manero, G. Targeted Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndromes. In: Cancer Etiology, Diagnosis and Treatments: Targeted Therapy for Solid Tumors and Hematologic Malignancies. Ed(s) A Quintas-Cardama, DL Gibbons, V Cataldo. Nova Science Publishers, Inc.: New York, 75-103, 2011. PMID: 978-1-61761-854-3.
14. Bumber Y, Garcia-Manero G. The Myelodysplastic Syndromes. In: Emerging Cancer Therapeutics: Leukemia. 2. Ed(s) U Popat. Demos Medical Publishing: New York, 283-306, 2011. PMID: 978-1-933864-68-6.
15. Garcia-Manero G. Therapeutic Modalities. In: The Myelodysplastic Syndromes. Ed(s) J Varkonyi. Springer: London, New York, 219-238, 2011. PMID: 978-94-007-0439-8.

16. Stevenson W, Garcia-Manero G. Epigenetics of leukemia. In: Childhood Leukemias, 3rd. Ed(s) Ching-Hon Pui. Cambridge University Press: United Kingdom, 239-236, 2012.
17. Garcia-Manero, G. Prognostic Models for Patients with Myelodysplastic Syndromes. In: Myelodysplastic Syndromes, 2. Ed(s) HJ Deeg, DT Bowen, SD Gore, T Haferlach, MM Le Beau, C Niemeyer. Springer: Wurzburg, 153-167, 2013. PMID: 978-3-642-36228-6.
18. Guillermo Montalban-Bravo, Guillermo Garcia-Manero. The Myelodysplastic Syndromes. In: Wintrobe's Clinical Hematology,, 14e: 9781496347428. Carlisle Publishing Services: India, 2018.

Books (edited and written)

N/A

Letters to the Editor

1. Garcia-Manero G. Chromosomal abnormalities in chronic lymphocytic leukemia. N Engl J Med 344(16):1254, 4/2001. PMID: 11314693.
2. Garcia-Manero G. In reply to 'Improving the prognostic evaluation of patients with lower-risk myelodysplastic syndromes' by Kuendgen et al. Leukemia 23:185, 2009. e-Pub 6/2008. PMID: 18548096.

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Member, Archives of Medical Science, 2007-2008
Associate Editor for MDS, Clinical Leukemia, 2007-2008
Section Editor MDS, Leukemia, 2007-present
Associate Editor, Clinical Lymphoma & Myeloma, 2009-present
Member, American Journal of Hematology, 2012-2015
Associate Editor, Leukemia, 2015-present
Member, Reviewer, Blood Cancer Journal, Springer Nature, 2017-present
Board Member, Clinical Advances in Hematology & Oncology, 2020-present

Member of Editorial Review Board

Board Member, Blood Cancer Journal, 2018-present
Associate Editor, Cancer.Net, 2018-present

Journal Reviewer

Reviewer, Cancer, 2000-present
Reviewer, Hematology, 2000-present
Editorial Board member, Hematologica, 2002-2018
Reviewer, British Journal of Cancer, 2002-present
Reviewer, British Journal of Hematology, 2002-present
Reviewer, Clinical Cancer Research, 2002-present
Reviewer, American Journal of Hematology, 2003-present
Reviewer, Blood, 2003-present
Reviewer, Cancer Chemotherapy and Pharmacology, 2003-present
Reviewer, Cancer Letters, 2003-present

Reviewer, Cancer Research, 2003-present
Reviewer, Neoplasia, 2003-present
Reviewer, Acta Haematologica, 2004-present
Reviewer, Carcinogenesis, 2005-present
Reviewer, Journal of Clinical Oncology, 2005-present
Reviewer, Leukemia Research, 2005-present
Reviewer, Oncogene, 2005-present
Reviewer, Pediatric Blood and Cancer, 2005-present
Reviewer, Journal of Pediatric Hematology/Oncology, 2006-present
Reviewer, The Lancet, 2006-present
Reviewer, The Open Hematology Journal, 2007-2008
Reviewer, Biochemistry, 2007-present
Reviewer, Cancer Investigation, 2007-present
Reviewer, Cancer Science, 2007-present
Reviewer, Clinical Leukemia, 2007-present
Reviewer, Clinical Lymphoma and Myeloma, 2007-present
Reviewer, New England Journal of Medicine, 2008-present
Reviewer, Proceedings of the National Academy of Sciences U.S.A, 2009-present
Reviewer, The European Journal of Clinical & Medical Oncology (EJCMO), San Lucas Medical, 2009-present
Reviewer, Epigenetics, Landes Bioscience, 2010-present
Reviewer, Genes, Chromosomes and Cancer, 2010-present
Reviewer, Nature Medicine, 2010-present
Reviewer, Revista de Investigación Clínica, 2010-present
Reviewer, International Journal of Cancer, 2011-present
Reviewer, Mayo Clinic Proceedings, 2011-present
Reviewer, PLoS ONE, 2011-present
Reviewer, BMC Medicine, 2012-present
Reviewer, Journal of Clinical Investigation, 2013-present
Reviewer, Leukaemia & Lymphoma Research, 2013-present
Reviewer, Annals of Medicine, 2014-present
Reviewer, Nature, 2016
Reviewer, Oncotarget, 2016
Reviewer, Blood Advances, 2018-present
Reviewer, Bone Marrow Transplantation, 2018-present
Reviewer, Nature, Springer, 2018-present
Reviewer, Blood Advances, 2019-present
Reviewer, HemaSphere, 2019-present
Reviewer, Nature Communications, 2020-present

Other Editorial and Review Activities

Reviewer, Annals of Hematology, 2018-present

Reviewer, American Society of Hematology Education Program, 2021

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

Lecturer, Mechanisms in Cancer Therapeutics, GSBS, Course Number: GS04 1213,
Course Hours: 2

Spring, 2005

Spring, 2006

Lecturer, Principles in Neoplastic Hematology, GSBS, Course Number: GS04 1033,
Course Hours: 1

Spring, 2007

Lecturer, Advances in MDS

4/2009

Lecturer, MDS

2/2010

Lecturer, Seminar in Clinical Cancer Research, GSBS, Course Number: GS21 1011,
Course Hours: 1

Spring, 2010

Fall, 2011

Lecturer, Translational Sciences: Bedside to Bench and Back, GSBS, Course Number:
GS21 1232, Course Hours: 2

Spring, 2010

Fall, 2011

Lecturer, Update on MDS Program

4/2013

Lecturer to Hematology-Oncology Fellows, Myelodysplastic Syndrome

9/2013

Lecturer, Update on MDS

8/2014

Training Programs

N/A

Other Formal Teaching

Lecturer, MDS Update

8/2016

MDS 2017

11/2017

Myelodysplastic Syndromes

11/2017

Lecturer for Leukemia Fellow Lecture Series, MDS Biology, CMML and MDS/MPN

12/2017

Supervisory Teaching

Committees

Advisory Committees

GSBS, Andres Soriano, M.S., 8/2006-6/2007

Committee Member, GSBS, Gerald Falchook, M.S., 8/2007-12/2007

Committee Member, GSBS, Fadi Braiteh, Ph.D., 3/2008-4/2009

Committee Chair, GSBS, Tapan Kadia, M.D., M.S., 9/2008-2009

Shu-Hong Lin, PhD, 3/2016-2016

Research Mentor, Nicholas Short, Cancer Medicine Fellowship Program, 6/2016-2017

Committee Member, Shu-Hong Lin

Supervisory Committees

Committee Member, GSBS, Gerald Falchook, M.S., 12/2007-8/2009

Committee Member, GSBS, Fadi Braiteh, M.S., 4/2009-9/2011

Research Mentor, UT MD Anderson Cancer Center, Shawn George, High School Student, 12/2014-5/2015

Examining Committees

Committee Member, GSBS, Taichun Qin, 4/2005-2005

Committee Member, GSBS, Jingmin Shu, 9/2006-2006

Direct Supervision

Undergraduate and Allied Health Students

Jason Williamson, 11/1999-6/2001

Jerry Daniels, 1/2000-7/2001

Andreia Canalli, 2/2003-12/2003

Maja Kuppurajan, 2/2004-5/2004

Claritza Santos, 6/2004-8/2004

Matthew Lee, 6/2005-8/2006

Andres Quezada, 8/2005-5/2006

Jonathan Clavell Hernandez, 6/2006-8/2006

Research Mentor, Emilio Andres Gonzales Cervantes, Contact Hours: 240, 11/2008-12/2008

Zhou Joe Fang, 2010-2011

Newsha Nikzad, 6/2015-8/2015

Medical Students

Shylendra Sreenvisappa, 12/2005-1/2006

Mari Teresa Sanchez, 2/2007-3/2007

Sebastian Bruera, MD, 6/2011-8/2011

Noelia Valdez-Fernandez, 4/2012-2012

Maria Vahi, 4/2012-5/2012

Seung Tae Lee, 2/2013-2013

Clinical Rotation, UT MD Anderson Cancer Center, LaQuisa Hill, 8/2014-9/2014

Sofia Silver, 10/2016-1/2017

Graduate Students

Graduate School of Biomedical Sciences, Ivey Denham, 1/2005-3/2005

Hugo Henriquez Luzardo, 11/2005-2/2006

Graduate School of Biomedical Sciences, Hussein Abbas, 9/2006-1/2007

Maita Rodriguez, 4/2007-5/2007

Graduate School of Biomedical Sciences, Gonzalo Lopez, 6/2007-8/2007
Isabel Rivas, 10/2009-12/2009
Graduate School of Biomedical Sciences, Mayur Arvind Gadhikar, 1/2010-3/2010
Graduate School of Biomedical Sciences, Deeksha Vishwamitra, 1/2010-4/2010
Irene Ganan-Gomez, 2010-2012
Carolina Miranda, 3/2011-4/2011
Anny Jaramillo, 4/2011-6/2011
Gabriela Rodriguez-Macias, 9/2011-10/2011
Raisa Camacho Guerrero, 1/2012-2/2012
Karem Humala, 1/2012-3/2012
Daniela Mora Ortiz, 2/2012-3/2012
Rafael Del Orbe, 4/2012-2012
Ana Alicia Lopez-Iglesias, 5/2012-6/2012
Luke Zhu, 8/2012-2012
Veronica Saavedra Campuzano, 6/2013-7/2013
Wei Wang, 7/2013-8/2013
Mayline Zhong, 8/2013-2013
Miguel Villanueva, 9/2013-10/2013
Guillermo Montalban Bravo, 9/2013-11/2013
Brayan Merchan, 10/2013-11/2013

Postdoctoral Research Fellows

Ruoping Wang, PhD, PhD, 1/2000-1/2001
Rajan Mannari, MD, 10/2000-9/2003
Koyu Hoshino, MD, 8/2002-8/2004
Blanca Sanchez-Gonzalez, PhD, 7/2004-5/2005
Marta Eugenia Cuadros, PhD, 8/2004-1/2005
Kang Li Luo, 9/2004-4/2005
Patricia Pardo, PhD, 11/2004-3/2005
Weigang Tong, MD, 5/2005-6/2009
Hui Yang, MD, PhD, 8/2006-7/2007
Leandro De Padua Silva, MD, 11/2006-7/2009
Zhi Hong Fang, 1/2007-2009
Sirisha C. Maddipoti, MD, 5/2007-7/2008
Onur Emiroglu, 7/2007-6/2008
William Stevenson, MD, 7/2007-6/2008
Ana Esther Kerguelen Fuentes, 9/2007-11/2007
Research Mentor, Nominator, The Kimberly Patterson Fellowship in Leukemia
Research recipient, Yumin Hu, PhD, PhD, 2008-2011
Francesco Paolo Tambaro, 7/2008-7/2010
Yiyi Yan, PhD, 2010-2011

Sophie Dimicoli-Salazar, 11/2010-10/2011
Research Mentor, Koichi Takahashi, MD, 2012-2014
Research Mentor, UT MD Anderson Cancer Center, Itxaso Portero, 1/2014-2/2014
Research Mentor, Monica Cabrero, Postdoctoral Fellowship, 2/2014-6/2015
Research mentor, Ana Pierola Alfonso (winner of 2016 ASH achievement award),
PhD, 11/2015-10/2017
Esperanza Irlles, 5/2016-5/2017
Irene Ganan Gomez, 5/2016-5/2018
Alexandra Pedraza Navarrete, PhD, 2/2017-3/2017
Marta Garcia Recio, 9/2017-11/2017
Darwin Roman, 2018-2019

Clinical Residents and Fellows

Magdalena Sierra, MD, 1/2000-3/2000
Jorge Medina, MD, 5/2001-11/2002
Begona Grana, MD, 4/2002-6/2002
Lina Cassol, MD, 8/2002-9/2002
Miguel Blanquer, MD, 3/2003-5/2003
Elias Jabbour, MD, 9/2003-6/2008
Jose Falantes, MD, 3/2005-6/2005
Matias Diaz, MD, 4/2005-7/2005
Roselle Villar, MD, 2/2007-3/2007
UT MD Anderson Cancer Center, Anthony Conley, MD, 4/2007-5/2007
Carmella Bingcang, MD, 5/2007-6/2007
UT MD Anderson Cancer Center, Baby Rochelle de Vega Casino, MD, 11/2007-
12/2007
Hussam Ghoti, MD, 7/2008-6/2009
Adriana Rossi, MD, 8/2008-9/2008
Valentin Garcia-Gutierrez, MD, 10/2008-12/2008
Ubaldo Martinez Outschoorn, MD, 2/2009-12/2009
Ana T Fernandes, MD, 6/2009-2009
Fatima Miras, MD, 6/2009-2009
Mohamad Ayoubi, MD, 6/2009-5/2010
Carlos Vigil, MD, 6/2009-6/2010
Taida Martin Santos, MD, 9/2009-11/2009
Josephine Tolentino, MD, 10/2009-11/2009
Mohsen Arani, MD, 2/2010-2010
Klaus Wolfgang Wagner, MD, 6/2010-2010
Alaa Al Tahan, MD, 7/2010-2010
Margaret Van Meter, 3/2011-2011
Naval Daver, MD, 4/2011-2011

Rashmi K Murthy, MD, 1/2012
Gabriela Simona Ene, MD, 3/2012-4/2012
Pedro Giovanni Medina Alfonso, MD, 8/2012-10/2012
Marcio Andrade, MD, 9/2012-10/2012
Marianna Criscuolo, MD, 9/2012-11/2012
Research Mentor, Leukemia, Anaïd Hernández Sánchez, MD, MD, 4/2013-2013
Isabel Goyanes, MD, 1/2017-3/2017
Eran Tallis, MD, 2017-2019
Fevzi Firat Yalniz, MD, 2017-2019
Iman Abou Dalle, MD, 2017-2019
Mahesh Swaminathan, MD, 2017-2019
Mansour Alfayez, MD, 2017-2019
Maria Lucia Fuentes, MD, 4/2017
Gustavo Pinto, 9/2017-11/2017
Silvia Martin-Batista, MD, 9/2017-11/2017
Amelia Martinez Marin, MD, 10/2017-12/2017
Yamil Michelen, MD, 2018-2019
Guillaume Richard-Carpentier, MD, 2018-2020
Veronica Guerra, MD, 2018-2020
Ahmad Alotaibi, MD, 2019-2020
Arrvind Raghunath, MD, 2019-2020
Bachar Samra, MD, 2019-2020
Hycienth Ahaneku, MD, 2019-2020
Omar Shahin, MD, 2019-2020
Danielle Hammond, MD, 2019-2021
Jorge Ramos-Perez, MD, 2019-2021
Kiyomi Morita, MD, 2019-2021
Yasmin Alwash, MD, 2019-2021
Research Mentor, Sara Caceres hernandez, MD, 2/2019-3/2019
Shehab Mohamed, MD, 2020-2021
Daniel Rivera Delgado, MD, 2020-2022
Fadi Haddad, MD, 2020-2022
Sangeetha Venugopal, MD, 2020-2022
DoCM Heme/Onc Fellow, Kunhwa Kim, MD, 2020-2023
Alexandre Bazinet, MD, 2021-2023
Rodrick Babakhanlou, MD, 2021-2023
Sai Prasad Desikan, MD, 2021-2023
Tareq Abu Asab, MD, 2021-2023

Other Supervisory Teaching

Mentor, Shao-Qing Kuang, Assistant Professor, 6/2004-6/2009

Research Mentor, Yue Wei, Ph.D., Instructor, 2007-2011

High School Student, UT MD Anderson Cancer Center, Newsha Nikzad, High School Student, 7/2014-8/2014

Observership, UT MD Anderson Cancer Center, Fernanda Ibanez Camacho, 10/2014-11/2014

Clinician, Observership, UT MD Anderson Cancer Center, Javier Alexander Fonseca, 10/2014-11/2014

Observership, UT MD Anderson Cancer Center, Tamara Torrado, 10/2014-12/2014

Observership, UT MD Anderson Cancer Center, Maria Cynthia Fuentes Lacouture, 1/2015-2/2015

Observership, UT MD Anderson Cancer Center, Alfonso Fernandez, 4/2015-5/2015

Observership, UT MD Anderson Cancer Center, Xuehong Ran, 9/2015-10/2015

Observership, Angelina Carneade, 9/2015-11/2015

Observership, UT MD Anderson Cancer Center, Fe Serra, 9/2015-11/2015

Observership, UT MD Anderson Cancer Center, Pilar Paredes, 10/2015-11/2015

UTMDACC, Maria Josee-Fundaleu, 4/2017-5/2017

Teaching Outside Current Institution

Formal Teaching

Courses Taught

Instructor, Annual Internal Medicine Course for Third Year Medical Students: Introduction to Hematology, Thomas Jefferson University
1996-1999

Introduction to Hematological Malignancies, The University of Texas-Houston Medical School
2001-2003

Lecturer to BCM Oncology Fellows Group, Myelodysplastic Syndrome, Baylor College of Medicine
4/2013

Lecturer, Personalization of Therapy for MDS: The Role of Biology, Risk Stratification, and Evolving Therapies, UT Houston Medical School
9/2014

Training Programs

N/A

Other Formal Teaching

Lecturer, Medical Oncology, The University of Texas Houston Medical School
8/2016

Lecturer, Memorial Sloan Kettering Cancer Center
11/2017

Supervisory Teaching

Committees

Advisory Committees

Co-Director, Thesis, Universidad de Alcala, Irene Ganan-Gomez, PhD, 2012-2013

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

Thomas Jefferson University, Medical Oncology Monday Conference, Philadelphia, PA, Coordinator, 1998

Thomas Jefferson University, Cardeza Foundation Grand Rounds, Philadelphia, PA, Coordinator, 1999

American Society of Clinical Oncology, ASCO Annual Meeting: Leukemia, Myelodysplasia and Transplantation Poster Presentation, Atlanta, GA, Co-Chairman, 6/2007

American Society of Hematology, 49th Annual Meeting of American Society of Hematology, Atlanta, GA, Moderator, 12/2007

The University of Texas MD Anderson Cancer Center, 3rd Annual MDS Symposium, Houston, TX, Chair, 4/2008

Spanish Association of Myelodysplastic Syndromes, Annual Meeting, Palma de Mallorca, Spain, Chair, 6/2008

The University of Texas MD Anderson Cancer Center, 4th Annual MDS and MPN Symposium, Houston, TX, Chair, 4/2009

American Society of Clinical Oncology, 2009 Annual Meeting, Chairman Educational Session on Myelodysplastic Syndromes, Orlando, FL, Chair, 5/2009

European School of Haematology, International Conference on Myelodysplastic Syndromes: Non-curative treatment of high-risk MDS, Mandelieu, France, Chair, 10/2009

University of Minnesota and KnowledgeOncology, 5th Annual Houston Conference on MDS and MPN, Houston, TX, Chair, 4/2010

Aplastic Anemia & MDS International Foundation, Living with Myelodysplastic Syndromes (MDS), Houston, TX, Chair, 5/2010

The University of Texas MD Anderson Cancer Center, 6th Annual Conference: Advancing Knowledge in the Biology and Therapeutic Approach to MDS and MPN, Houston, TX, Chair, 5/2011

The University of Texas MD Anderson Cancer Center and University of Barcelona, Hospital Clinic, First Workshop on Collaborative Actions, Barcelona, Spain, Chair, 6/2011

Aplastic Anemia & MDS International Foundation, Aplastic Anemia & MDS International Foundation Bone Marrow Failure Disease Scientific Symposium, Member of Planning Committee, 3/2012

The University of Texas MD Anderson Cancer Center, Eighth Annual Hematologic Malignancies 2012 Conference, Houston, TX, Co-Chair of Sessions IV, X and XI, 10/2012

New Perspectives in Hematological Malignancies, PETHEMA and MD Anderson, Seville, Spain, Chair, 10/2013

Society of Hematologic Oncology, Houston, TX, Chair and Education Committee Member, 9/2014

Asociacion Mexicana de Sindrome Mielodisplasico, A.C., Simposio Iberoamericano de Sindrome Mielodisplasico, Puerto Vallarta, Mexico, Honorary Members, 10/2014

10th Global Iron Summit, Excerpta Medica, Berlin, Germany, Chair, 3/2015

ASCO Annual Meeting, Chicago, IL, Scientific Program Committee: Hem Malignancies, 2016

U.S. Focus on MPN & MDS Myeloproliferative Neoplasms and Myelodysplastic Syndromes, MDS Foundation and AA and MDS International Foundation, Alexandria, VA, Chair, 8/2016

Society of Hematologic Oncology, Houston, TX, Chair of MDS Session, 2017

International Association for Comparative Research on Leukemia and Related Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, Chair of Panel on Myelodysplastic Syndromes, 10/2017

ASCO Annual Meeting, Chicago, IL, Educational Committee Member, Hematologic Malignancies-Leukemia, MDS, and Allotransplant, 2018

Society of Hematologic Oncology, Houston, TX, Member of Education Committee, 2018

AA MDS International Foundation, Houston, TX, Organizer, 4/2018

Presentations at National or International Conferences

Invited

Compounds that induce FRA16B modify the in vitro behavior of DNA-topoisomerase II, XVII Congress of the European Society of Medical Oncology, Lyon, France, 11/1/1992

Appropriate prescribing for hispanic patients, The Pennsylvania Medical Society/MSA-MEDNET, Harrisburg, PA, 10/28/1994

Appropriate prescribing for hispanic patients., Cycle of conferences in Camp Hill, The Pennsylvania Medical Society/MSA-MEDNET, Pittsburg, PA, 3/1/1996

New treatment strategies for acute myelogenous leukemia, XVIII Meeting of Castellano-Leones Society of Hematology, Salamanca, Spain, 1/21/2000

Clinical development of HDAC inhibitor and demethylating agents, Workshop on Clinical Translation of Gene Re-express, Johns Hopkins University, Baltimore, MD, 1/17/2003

Novel treatment strategies for hematological malignancies: Epigenetic therapy of leukemia, I International Oncology Symposium, Madrid, Spain, 3/7/2003

Development of Decitabine in AML, Myeloma, and Hemoglobinopathies - AML, Sonoma, CA, 3/20/2003

Treatment of chronic myelogenous leukemia with imatinib mesylate, IV Symposium of the Hematology Society of the Canary Islands (ACAHM), La Palma, Spain, 4/24/2003

Tratamiento de la LMC con Imatinib, IV Congreso De La Asociacion Canaria De Hematologia, La Palma, Canary Islands, Spain, 4/25/2003

Advances in Chronic myelogenous leukemia, XVIII Peruvian Congress of Oncology, Lima, Peru, 9/24/2003

Metastatic disease in the leptomeninges: from treatment to prevention, 2003 Society of NeuroOncology (SNO) Meeting, Keystone, CO, 11/15/2003

Advances in the treatments of leukemia, II Simposio Avances y Nuevas Perspectivas en Linfomas, Valencia, Spain, 3/11/2004

Results of a Phase I/II Study of the Combination of 5-aza-2-deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia, 2004 American Society of Hematology Annual Meeting, 12/6/2004

Results of a phase 1 study of oral SAHA in leukemia, Johns Hopkins Clinical Targeting of Epigenetic Changes, Johns Hopkins University, Charleston, SC, 1/15/2005

Advances in the treatment of leukemia and MDS, Oklahoma City Oncology Society Annual Meeting, Oklahoma City, OK, 1/29/2005

Advances in the treatment of Chronic Myelogenous Leukemia, XXII Reunion de la Sociedad Castellano Leonesa de Hematologia y Hemoterapia, Leon, Spain, 4/8/2005

Advances in the treatment of Chronic Myelogenous Leukemia, V Congreso Association Canaria de Hematologica, La Gomera, Canary Islands, 4/22/2005

What are consequences of epigenetic therapy, Horizon Symposium, Portland, ME, 5/7/2005

Results of a phase I/II study of the combination of 5-aza-2'-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome, American Society of Clinical Oncology Annual Meeting, Orlando, FL, 5/16/2005

Clinical experience with hypomethylating agents, ASCO MGI Industry Sponsored Satellite Symposium, Atlanta, GA, 6/2/2005

Epigenetic information for the treatment and prognostication of cancer, Moving Biosensors to Point-of-Care Cancer Diagnostics, National Cancer Institute, Rockville, MD, 6/8/2005

Targeting DNA Hypomethylation, International Congress of Myeloproliferative Diseases and Myelodysplastic Syndrome, Washington, DC, 10/27/2005

MDS/decitabine: new data from the Phase III trial, Chemotherapy Foundation Symposium XXIII, New York, NY, 11/2/2005

Current Topics in Myelodysplastic Syndromes, ONS Learning Institution, Phoenix, AZ, 11/12/2005

Effective use of hypomethylating agents: future directions, 47th Annual Meeting of the American Society of Hematology, Corporate Friday Symposium, Atlanta, GA, 12/9/2005

Aberrant DNA methylation of a cell cycle regulatory pathway composed of p73, p15, and P57kip2 is associated with poor prognosis in adult patients with philadelphia chromosome negative acute lymphocytic leukemia, 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, 12/12/2005

Emerging Agents for MDS, Current Trends in Leukemia, Lymphoma, and Myeloma, Physicians' Education Resource, Kansas, MO, 1/28/2006

Papel de las terapias blanco en leucemias, 1er congreso Nacional de Terapias Biologicas en Mexico, Mexico, 4/8/2006

Disrupting chromatin topology: models for future clinical trails, Annual Meeting European Hematology Association, Amsterdam, Netherlands, 6/15/2006

Breakthrough in the management of myelodysplastic syndrome, 36th Annual Meeting of the Philippine Society of Hematology and Blood Transfusion, Mandaluyong, Philippines, 9/6/2006

Targeted Therapy for AML, Recent Advances in AML Biology and Treatment, Barcelona, Spain, 9/27/2006

New strategies for MDS: epigenetic-modulating drugs, Satellite Symposium at ACCP Meeting, St. Louis, MO, 10/26/2006

Update on the treatment of MDS, 32nd Meeting of the Turkish Hematology Association and 1st Meeting of the Balkan Hematology Society, Antalya, Turkey, 11/7/2006

Treatment of MDS, Portuguese Society of Hematology 2006, Lisbon, Portugal, 11/16/2006

Epigenetic therapy of leukemia, CNIO Symposium on Molecular Markers in Cancer Therapy, Madrid, Spain, 11/28/2006

Using combination therapy to improve control: DNA methylation and HDAC inhibition, 48th Annual Meeting of the American society of Hematology, Friday Satellite Symposium, Orlando, FL, 12/8/2006

MGCD 0103: The first class-selective HDAC-i?, Johns Hopkins Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics, Phoenix, AZ, 1/12/2007

Advances in the treatment of AML, First Haematology/Oncology Symposium, Magaliesburg, South Africa, 1/26/2007

Combination epigenetic therapy in leukemia and MDS, European Hematology Association Scientific Workshop: The Role of Epigenetics in Hematological Malignancies, Mandelieu, France, 2/9/2007

Desarrollo de Epigenetica en Cáncer, 2do Congreso Internacional de Terapias Biológicas en México, Tequesquitengo, Morelos, Mexico, 4/27/2007

Combination epigenetic therapy, The Ninth International Symposium on Myelodysplastic Syndromes, Florence, Italy, 5/16/2007

New Strategies in the Treatment of MDS, New developments in Hematologic Malignancies, ASCO Annual Meeting, Chicago, IL, 6/2/2007

Leukemia Module, Instituto Nacional de Cancerologia de Mexico and Sociedad Latinoamericana y del Caribe de Oncologia Medica (SLACOM), Cancun, Mexico, 9/7/2007

Epigenetics and Cancer Therapy, Piedmont Oncology Association 28th Annual Symposium, Myrtle Beach, SC, 10/1/2007

Update on Treatment Options in MDS and AML, Chemotherapy Foundation Symposium XXV, New York, NY, 11/7/2007

Epigenetic Alterations in Leukaemia, CNIO Conference, The European School of Oncology, Madrid, Spain, 11/29/2007

Clinical and Molecular Implications of Epigenetic Alterations in Human Leukemia, American Association of Cancer Research Meeting, Philadelphia, PA, 12/6/2007

i3 CME Satellite Symposia - The Hematology Circle - Rebalancing Molecular Profiles in Hematologic Malignancies: New Technologies for Targeting Silenced and Overexpressed Genes, Friday Satellite Symposium, 49th American Society of Hematology Annual Meeting, Atlanta, GA, 12/7/2007

Myelodysplastic Syndromes: Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia, Friday Satellite Symposium, 49th American Society of Hematology Annual Meeting, Atlanta, GA, 12/8/2007

Update on methyltransferase inhibitors, 4th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies, Moffitt Cancer Center, Lake Buena Vista, FL, 1/19/2008

Myeloid Leukemias and MDS, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, ASH 2007 Highlights, Washington Cancer Institute at Washington Hospital Cancer Center, Tysons Corner, VA, 3/8/2008

Hypomethylating Agents in MDS, State of the Art in Myeloid Malignancies Conference, The University of Texas MD Anderson Cancer Center, Madrid, Spain, 3/12/2008

Epigenetic Therapy of Leukemia, University of California, San Francisco, Gladstone Cancer Center, San Francisco, CA, 4/11/2008

Advances in MDS, XLIX Congress of the Mexican Society of Hematology, Plenary Session, Dr. Guillermo Ruiz Reyes Lecture, Monterrey, Mexico, 5/2/2008

Use of HDAC inhibitors alone and in combination with hypomethylating agents, European School of Haematology, Myelodysplastic Syndromes and Bone Marrow Failure International Conference, Albufeira, Portugal, 5/17/2008

Practical Case: Treatment Options for a Patient with Acute Myeloid Leukemia in First Remission, 44th ASCO Annual Meeting, Chicago, IL, 5/30/2008

Advances In MDS, Spanish Association of Myelodysplastic Syndromes, Palma de Mallorca, Spain, 6/15/2008

Estado actual del manejo de los SMD de alto riesgo, Evidencia y practica en sindromes mielodisplasias, Barcelona, Spain, 6/21/2008

Making Combination Therapy Reality, 50th Meeting American Society of Hematology Friday Satellite Symposium Integrating New Developments in MDS in Clinical Practice, CA, 12/5/2008

Myelodysplastic syndromes: risk factors, classification--when to treat, 5th Annual Clinical Breakthroughs & Challenges in Hematological Malignancies, Moffitt Cancer Center, Orlando, FL, 1/17/2009

Tratamiento De Los Sindromes Mielodisplasicos En El 2009, Programa de la XXVII Reunion Anual de la Asociacion Castellano-Leonesa de Hematologia y Hemoterapia, Asociacion Castellano-Hematologia, Carrion de los Condes, Spain, 3/27/2009

Standard-of-Care approaches for myelodysplastic syndromes, ASCO 2009 Annual Meeting, Orlando, FL, 5/28/2009

Clinical Relevance of Epigenetic Agents in Hematology, Spanish Department of Health, Madrid, Spain, 6/25/2009

New Algorithms in the Prognosis and Treatment of MDS, II Annual Meetings of the Andalucia Society of Hematology, Malaga, Spain, 6/26/2009

Improving Outcomes in Myelodysplastic Syndromes, Current Status and Future of Anti-Cancer Targeted Therapies, InterAmerican Oncology Conferences, Buenos Aires, Argentina, 10/2/2009

Management and treatment of thrombocytopenia, International Conference on Myelodysplastic Syndromes, European School of Haematology, Mandelieu, France, 10/24/2009

High-risk MDS: HIDACi and ongoing trials at clinical trials.gov, International Conference on Myelodysplastic Syndromes, European School of Haematology, Mandelieu, France, 10/25/2009

Current treatment of MDS, The HematOncology Conference, Rivera Maya, Quintana Roo, Mexico, 10/30/2009

Advances in MDS, LI Reunion Nacional AEHH 25 Congreso Nacional SETH, Barcelona, Spain, 11/13/2009

Emerging Strategies for the Treatment of AML and MDS: Progress and Challenges, 51st Meeting American Society of Hematology, A Friday Satellite Symposium, New Orleans, LA, 12/4/2009

Managing Higher-Risk Disease: Hypomethylating Agents and Beyond, USF Health, Moffitt Cancer Center, MD Anderson Cancer, 6th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies, Lake Buena Vista, FL, 1/16/2010

Myelodysplastic Syndromes, prIME Oncology, Hematologic Malignancies Demystified: A critical appraisal from 2009 and ASH, New York, NY, 1/23/2010

Myelodysplastic Syndromes, Hematology 2010: Advances in Science, Emerging Data, and Novel Therapeutics, San Francisco, CA, 1/30/2010

HDAC Inhibitor and Combination Therapy in MDS, Aplastic Anemia and MDS International Foundation, Bethesda, MD, 3/12/2010

New Approaches in the Treatment and Management of MDS and AML, Excel Continuing Education, Post Ash Review: Translating Today's Science into Tomorrow's Practice, New Orleans, LA, 3/20/2010

Clinical and Prognostic Features in MDS, Classifications, Risk Models, MD Anderson Cancer Center Symposium: Breakthroughs in Hematological Malignancies, Lebanese Society of Hematology and Blood Transfusion, Beirut, Lebanon, 4/17/2010

Treatment of High Risk MDS and Novel Strategies, MD Anderson Cancer Center Symposium: Breakthroughs in Hematological Malignancies, Lebanese Society of Hematology and Blood Transfusion, Beirut, Lebanon, 4/17/2010

Lenalidomide is not the best choice for most deletion 5q patients, Imedex, Great Debates and Updates in Hematologic Malignancies, New York, NY, 5/1/2010

Novel and Evolving Therapeutic Strategies for MDS, Imedex, Great Debates and Updates in Hematologic Malignancies, New York, NY, 5/1/2010

Evolving strategies for the treatment of MDS, NIH, Hematology IACC Workshop: Myelodysplastic Syndromes, Bethesda, MD, 5/10/2010

Prognostic models in MDS, ASCO 2010 Annual Meeting, Myelodysplastic Syndromes and Elderly Acute Myeloid Leukemia, Chicago, IL, 6/6/2010

Leucemia mieloide aguda en el anciano y otras leucemias "dificiles," Celgene, Vall d'Hebron Hospital, Barcelona, Spain, 10/1/2010

Updates on Biology and Therapy of MDS, Hematologic Malignancies Houston 2010, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/13/2010

Debate: Role of Allogeneic SCT in MDS--Minimal Benefit in MDS, Hematologic Malignancies Houston 2010, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/14/2010

New Perspectives in Hematological Malignancies, Genzyme, Las Palmas, Spain, 10/30/2010

Advances in the Management of Patients with Myeloid Neoplasms, University of Nebraska Medical Center, Neoplastic Hematopathology Update: New Insights into Old Questions, Hollywood, FL, 11/11/2010

Prognosis in Myelodysplastic Syndromes, 52nd ASH Annual Meeting, American Society of Hematology, Orlando, FL, 12/4/2010

Myelodysplastic Syndromes, Seventh Annual Hematology Conference: An Update on Selected ASH Topics, The University of Tennessee Graduate School of Medicine, Knoxville, TN, 1/22/2011

Myelodysplastic Syndromes, prIME Oncology, Hematologic Malignancies Demystified: The Series, Houston, TX, 2/12/2011

Treatment of MDS, BMT Tandem Meetings, Center for Blood and Marrow Transplant Research, Honolulu, HI, 2/17/2011

Bases moleculares y geneticas del SMD; Nueva clasificacion SMD; Factores pronosticos en SMD, SMD III Simposio Latino-Americano, Asociacion Colombiana de Hematologia y Oncologia, Cartagena, Colombia, 3/3/2011

Manejo de Mielodisplasico con Hipometilantes, SMD III Simposio Latino-Americano, Asociacion Colombiana de Hematologia y Oncologia, Cartagena, Colombia, 3/4/2011

Leucemia mieloide aguda en el anciano, Congreso de la Asociacion Madrilenia de Hematologia y Hemoterapia, Asociacion madrilenia de hematologia y hemoterapia, Madrid, Spain, 4/8/2011

Síndromes Mielodisplásicos: nuevos abordajes terapéuticos, III Congreso Nacional de Hematología, Sociedad Panameña de Hematología, Panama City, Panama, 4/28/2011

Nucleoside Analogues, MDS 2011, Edinburgh, Scotland, 5/21/2011

Treatment of MDS, 16th Congress of the European Hematology Association (EHA), London, United Kingdom, 6/10/2011

Garcia-Manero G. Myelodysplastic Syndrome in 2011, University of Minnesota and Association of VA Hematology/Oncology, 7th Annual Meeting: Association of VA Hematology/Oncology, Kansas City, MO, 10/15/2011

Garcia-Manero G. Subcomisión de Hematólogos Jóvenes. Leucemia Mieloblástica Aguda: Manejo de Diferentes Situaciones Clínicas, XX Congreso Argentino de Hematología, Buenos Aires, Argentina, 10/20/2011

Garcia-Manero G. ¿Cómo tomar Decisiones en el Tratamiento de los Síndromes Mielodisplásicos?, XX Congreso Argentino de Hematología, Buenos Aires, Argentina, 10/21/2011

Garcia-Manero G. Síndromes mielodisplásicos, Reunión Nacional de la SEHH; XXVII Congreso Nacional de la SETH, Zaragoza, Spain, 10/27/2011

Epigenetic and molecular changes in SMD; Algorithm for MDS treatment; Specific characteristics and treatment of AML in the elderly, Janssen Pharmaceutical Companies of Johnson & Johnson, Hospital Brigadeiro, Sao Paulo, Brazil, 3/24/2012

New experimental drugs; Combination drug therapy, International Conference on Myelodysplastic Syndromes, European School of Haematology, Dublin, Ireland, 5/26/2012

Quintas-Cardama A, Cortes J, Liu-Dumlao T, Ravandi F, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in elderly patients with newly diagnosed acute myeloid leukemia, 17th Congress of the European Hematology Association, European Hematology Association, Amsterdam, Netherlands, 6/16/2012

Diagnosis and management of low risk MDS: molecular markers and cytogenetic profile, Asofarma, The Hemato Oncology Conference, Cancun, Mexico, 8/31/2012

Current Treatment of Myelodysplastic Syndrome RAEB type II and acute myeloid leukemia secondary to myelodysplasia, Asofarma, The Hemato Oncology Conference, Cancun, Mexico, 9/1/2012

Advances in Treatment of MDS, II Curso Internacional de Hematopatología, Lima, Peru, 9/7/2012

Actualización en Síndrome Mielodisplásico, Organiza Sociedad Chilena Hematología, XVIII Congreso Chileno Hematología / VIII Congreso Medicina Transfusional, Santiago, Chile, 10/5/2012

Garcia-Manero G. Therapy of MDS, The University of Texas MD Anderson Cancer Center, Eighth Annual Hematologic Malignancies 2012 Conference, Houston, TX, 10/10/2012

Garcia-Manero G. New MDS Strategies, The University of Texas MD Anderson Cancer Center, Eighth Annual Hematologic Malignancies 2012 Conference, Houston, TX, 10/11/2012

Garcia-Manero G. Treatment of Lower Risk MDS, The University of Texas MD Anderson Cancer Center, Eighth Annual Hematologic Malignancies 2012 Conference, Houston, TX, 10/11/2012

Garcia-Manero G. Progress in MDS, The University of Texas MD Anderson Cancer Center, Eighth Annual Hematologic Malignancies 2012 Conference, Houston, TX, 10/12/2012

Garcia-Manero G. S1203, "A Randomized Phase III Study of Standard Cytarabine plus Daunomycin (7 + 3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without

Vorinostat in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).," SWOG (formerly the Southwest Oncology Group), Chicago, IL, 10/19/2012

"Direcciones Futuras en SMD" and "Nuevos enfoques fisiopatogenicos en SMD," AMSM Iberoamerican MDS Simposio, Puerto Vallarta, Mexico, 11/16/2012

"What is next for MDS?" poster discussant, ASCO, Chicago, IL, 5/2013

Update on MDS, Washington Cancer Institute, Berlin, Germany, 5/17/2013

"Novel Strategies in MDS" meet the professor session, Society of Hematologic Oncology, Houston, TX, 9/18/2013

"Myelodysplastic Syndromes" session chair, Society of Hematologic Oncology, Houston, TX, 9/19/2013

Novel Therapeutics in MDS, Society of Hematologic Oncology, Houston, TX, 9/19/2013

S1203, "A Randomized Phase III Study of Standard CytarabineS1203, "A Randomized Phase III Study of Standard Cytarabine plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML), SWOG Fall 2013 Group Meeting, Chicago, IL, 10/11/2013

Controversies in MDS and Optimizing the Management of AML patients (MD Anderson Cancer Center perspective), Joint Meeting PETHMA and MD Anderson Cancer Center, Seville, Spain, 10/16/2013

Advances in the Treatment of MDS, Medical Oncology and Hematology 2013: Multidisciplinary Approaches that Improve Coordination of Care, Houston, TX, 10/19/2013

Moderator and Speaker--Myelodysplastic syndrome: research and treatment, MDS Symposium, Bogota, Colombia, 11/7/2013

How I Treat: Bringing Science to Clinical Dilemmas, American Society of Hematology, New Orleans, LA, 12/8/2013

MDS Update, Instituto Nacional de Cancerología (INCAN), Mexico City, Mexico, 3/27/2014

What is new in MDS?, Eurasion Hematology Forum, Istanbul, Turkey, 4/23/2014

"The management of older patients with AML" and "Optimal frontline therapies for patients with MDS," MEMA 2014 Updates: Focus on Hematological Malignancies, MD Anderson Cancer Center Global Academic Programs and King Hussein Cancer Center, Jordan, Beirut, Lebanon, 4/25/2014

Update on MDS, Lebanese Society of Medical Oncology National Forum, Beirut, Lebanon, 4/25/2014

Hacia la cura de los sindromes mielodisplasicos y de la leukemia mieloide aguda, Instituto de Espana Academia Asociada, Palma, Mallorca, Spain, 7/1/2014

Advances in MDS Disease Management, Janssen, Hematologic Malignancies Summit, Beijing, China, 8/16/2014

Treatment of Lower Risk MDS that has Failed HMA and Lenalidomide, Houston, TX, 9/18/2014

Beyond Diagnosis of MDS: How to Improve Survival?, Celgene, The 2nd MENA Hematology Meeting, Istanbul, Turkey, 4/10/2015

MDS/AML in Young Patients: Clinical Cases, Celgene, The 2nd Annual MENA Hematology Meeting, Istanbul, Turkey, 4/11/2015

How do I treat elderly AML patients?, Janssen, India, Bridging the Gap in the Management of Elderly AML Patients, India, 4/18/2015

Myelodysplastic Syndrome-Molecular Novelty, Therapy and Immunotherapy in 2015, Hematology Specialists Association, Eurasian Hematology Summit Program, Istanbul, Turkey, 4/25/2015

Update on MDS, EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY, European Cancer Congress, Vienna, Austria, 7/27/2015

Molecular Basis of MDS and Current Strategies in Patients with MDS who are not Transplant Candidates, Congreso Venezolano de Hematología, Caracas, Venezuela, 8/10/2015

Update on MDS, Imedex, US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Alexandria, VA, 8/28/2015

What's New in MPN?, Saint George Hospital University Medical Center, Hematologic Oncology Meeting, Beirut, Lebanon, 10/16/2015

Epigenetics in clinical practice: SPOTLIGHT on decitabine in myelodysplasia and acute myeloid leukemia, HAEMATOCON 2015: 56th Annual Meeting of Indian Society of Haematology and Blood Transfusion, Bangalore, India, 11/4/2015

Myelodysplastic Syndromes, prIME Oncology, Hematologic Malignancies Demystified--The Series: A Critical Appraisal of Data from 2015, New York, NY, 1/23/2016

Myelodysplastic Syndromes, prIME Oncology, Hematologic Malignancies Demystified--The Series: A Critical Appraisal of Data from 2015, Chicago, IL, 1/30/2016

Myelodysplastic Syndromes, prIME Oncology, Hematologic Malignancies Demystified: The Series 2016, Houston, TX, 2/20/2016

Myelodysplastic Syndromes, prIME Oncology, Hematologic Malignancies Demystified--The Series: A Critical Appraisal of Data from 2015, San Francisco, CA, 2/27/2016

How I treat MDS, Congres d'Oncologie Francophone & The Middle East, Beirut, Lebanon, 4/19/2016

MDS Overview and Focus on Immunotherapy, Eurasian Hematology Summit, Istanbul, Turkey, 4/23/2016

The goals of first-line and salvage therapies for MDS by risk group in practice, and how well current established (what should be used as the control arm?) and investigational treatments are meeting those goals, FDA, MDS Mini-Symposium, Silver Springs, MD, 8/10/2016

Factors affecting prognostication and assessment of Minimal Residual Disease in MDS, Argentinian Society of Hematology, Buenos Aires, Argentina, 8/24/2016

Manejo de los Síndromes Mielodisplásicos. La visión de un experto, Jornada Latino Americana de la Sociedad Argentina de Hematología, Buenos Aires, Argentina, 8/25/2016

Hypomethylating Agents in Acute Myeloblastic Leukemia, Present and Future, MD Anderson Madrid, Spain, Acute Leukemia Update, Madrid, Spain, 9/30/2016

Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD, Hui Yang, MD, PhD, Yue Wei, PhD, Yesid Alvarado, MD, Courtney D. DiNardo, MD, MSCE, Naval G. Daver, MD, Marina Konopleva, MD, PhD, Katherine P. Hearn, BSN, RN, Robert Miller, Sarah Arber-Barnes, Peter Mc Guirk, Tara Kearney, Brian Keogh, Hagop M. Kantarjian, MD and Mary Reilly. A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy, Ash Annual Meeting, San Diego, CA, 12/3/2016

Guillermo Garcia Manero, Ehab Atallah, MD, Samer K Khaled, MD, Martha Arellano, MD, Mrinal M Patnaik, MBBS, Olatoyosi Odenike, MD, Hamid Sayar, MD, Mohan Tummala, Prapti A. Patel, MD, Richard G. Ghalie, MD and Bruno C. Medeiros, MD. A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit, Ash Annual Meeting, San Diego, CA, 12/3/2016

Guillermo Garcia-Manero, MD, Pierre Fenaux, MD, PhD, Aref Al-Kali, MD, Shyamala C. Navada, MD, Maria R. Baer, MD, Azra Raza, MD, Peter Greenberg, MD, Karl-Anton Kreuzer, MD, Devendra K Hiwase, MBBS, MD, FRACP, FRCPA, PhD, Gail J. Roboz, Valeria Santini, MD, Uwe Platzbecker, MD, Michael E. Petrone, MD, MPH, Bernard Brownstein, MD, Patrick Simon Zbyszewski, MBA, Manoj Maniar, PhD and Lewis R. Silverman, MD. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML), ASH Annual Meeting, San Diego, CA, 12/3/2016

Guillermo Garcia-Manero, Hui Yang, Zhihong Fang, Hagop M. Kantarjian, Courtney D. DiNardo, Elias J. Jabbour, Naveen Pemmaraju, Naval Daver, Ricardo Delumpo, Christopher Loiselle, Silvia Rivera, Kristin Anderson, Brittany Yearby, Susan Denton, Whitney Smith, Kathleen Tiefenwerth, Hiroyuki Iwamura, Teletha Gipson, Michele Rosner, Thomas J. Myers, Linda J. Paradiso. Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures, Ash Annual Meeting, San Diego, CA, 12/3/2016

Guillermo Garcia-Manero, MD1, Olatoyosi Odenike, MD2, Philip C. Amrein, MD3, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Laura C. Michaelis, MD, Stefan Faderl, MD, Hagop M. Kantarjian, MD, James N. Lowder, MD, Pietro Taverna, PhD, Aram Oganessian, PhD., Xiaoping Zhang, PhD*, Mohammad Azab, MD and Michael R. Savona, MD. Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study, Ash Annual Meeting, San Diego, CA, 12/3/2016

Guillermo Garcia-Manero, MD, Naval G. Daver, MD, Guillermo Montalban-Bravo, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MD, MSCE, Steven M. Kornblau, MD, Prithviraj Bose, MD, Yesid Alvarado, MD, Maro Ohanian, DO, Gautam Borthakur, MD, Jorge E. Cortes, MD, Kiran Naqvi, MD, Naveen Pemmaraju, MD, Xuelin Huang, PhD, Graciela M. Nogueras-Gonzalez, Carlos E Bueso-Ramos, MD, PhD, Yvonne Gasior, Virginia R Bayer, RN, Sherry Pierce, BSN, BA, Hui Yang, MD, PhD, Simona Colla, PhD and Hagop M. Kantarjian, MD. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS), Ash Annual Meeting, San Diego, CA, 12/4/2016

Guillermo Garcia-Manero, MD, Valeria Santini, MD, Antonio Almeida, MD, PhD, Pierre Fenaux, MD, PhD, Norbert Gatterman, MD, PhD, Keiya Ozawa, MD, PhD, Stuart L. Goldberg, MD, Jerry Weaver, PhD and Mary M. Sugrue, MD, PhD. Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS), Ash Annual Meeting, San Diego, CA, 12/4/2016

Guillermo Garcia-Manero, MD, Martin S. Tallman, MD, Giovanni Martinelli, MD, Vincent Ribrag, MD, Hui Yang, MD, PhD, Arun Balakumaran, MD, PhD, SM, Sabine Chlosta, MD, Yayan Zhang, PhD and B. Douglas Smith, MD. Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment, Ash Annual Meeting, San Diego, CA, 12/4/2016

Guillermo Garcia-Manero, MD1, Michael R. Savona, MD2,3, Steven D. Gore, MD4*, Bart L. Scott, MD5, Christopher R. Cogle, MD6, Thomas Boyd, MD, Paul Conkling, Joel Hetzer, PhD, Qian Dong, MS, Keshava Kumar, PhD, Stacey M. Ukrainskyj, BSN and Barry S. Skikne, MD. CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies, Ash Annual Meeting, San Diego, CA, 12/5/2016

Guillermo Garcia-Manero, MD, Michael E. Petrone, MD, MPH, Steven M. Fruchtman, MD, Bernard Brownstein, MD, Hannes Loferer, PhD, Nozar Azarnia, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi and Lewis R. Silverman, MD. Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of

Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response, Ash Annual Meeting, San Diego, CA, 12/5/2016

Guillermo Garcia-Manero, MD, Megan Othus, John M. Pagel, MD PhD, Jerald P. Radich, Min Fang, David A Rizzieri, MD, Guido Marcucci, MD, Stephen A. Strickland, Mark Litzow, MD, Mary Lynn Savoie, MD, Bruno C. Medeiros, MD, Mikkael A. Sekeres, MD, MS., Tara L. Lin, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard A. Larson, MD, Richard M. Stone, MD, David F. Claxton, MD, James Essell, MD, Selina Luger, MD, Sanjay R. Mohan, MD, Anna Moseley, Frederick R. Appelbaum, MD and Harry P. Erba, MD, PhD. SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML), Ash Annual Meeting, San Diego, CA, 12/5/2016

How I treat Azacitidine Failures, British Society for Haematology, UK MS Forum, Brighton Centre, Brighton, United Kingdom, 3/28/2017

AML: Challenges and Overview, New Approaches in AML Management, and Recent Updates in MDS, Celgene, 4th Hematology MENA Meeting, Rome, Italy, 4/8/2017

New options and treatment strategies in MDS, 14th Valencia MDS Symposium, Valencia, Spain, 5/5/2017

Myelodysplastic Syndrome: Management Beyond Hypomethylating Agent, University of Nebraska Medical Center, Bone Marrow Failure Disease Symposium, Omaha, NE, 5/9/2017

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant, Best of ASCO, New Orleans, LA, 7/28/2017

Harnessing Immunotherapeutics for the Treatment of MDS, Society of Hematologic Oncology, Houston, TX, 9/13/2017

The NLRP3 Inflammasome As Driver of the MDS Phenotype, Society of Hematologic Oncology, Houston, TX, 9/13/2017

How I Treat MDS and Myelodysplastic Syndromes, International Association for Comparative Research on Leukemia and Related Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/31/2017

Hematology Demystified: Update on MDS, prIME Oncology, Chicago, 1/13/2018

Hematology Demystified: Update on MDS, prIME Oncology, New York, 1/20/2018

Hematology Demystified: Update on MDS, prIME Oncology, Atlanta, 1/27/2018

NGS in Hematologic Neoplasms, Clinician View, NEO Genomics, Dana Point, CA, 2/24/2018

High Risk MDS, Miami, FL, 3/10/2018

Optimizing TKi in CML, Miami, FL, 3/10/2018

Does Dose/Schedule Matter for HMA Based Therapy?, AA MDS International Foundation, Rockville, MD, 3/23/2018

Biology of MDS and Prognostic systems, Hikma Cancer Network, Dead Sea, Jordan, 4/12/2018

AML: Understanding your Disease and Treatment Options, AAMDS, Houston, TX, 4/21/2018

MDS: Understanding your Disease and Treatment Options, AAMDS, Houston, TX, 4/21/2018

Current and Future Treatments of MDS, AAMDS, Puerto Vallarta, Mexico, 4/25/2018

Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant, ASCO, Chicago, IL, 6/3/2018

A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME, EHA, Sweden, Sweden, 6/17/2018

Guillermo Garcia-Manero. Treatment of acute myeloblastic leukemia: whats new?, Latinoamericano de Hematologia, Cartagena de Indias, Colombia, Colombia, 8/3/2018

Guillermo Garcia-Manero. Update on the diagnosis and treatment of MDS, Latinoamericano de Hematologia, Cartagena de Indias, Columbia, Colombia, 8/3/2018

Clonal hematopoiesis, FUNDALEU, Buenos Aires, Argentina, 9/6/2018

Integrating molecular profile in AML ad MDS, FUNDALEU, Buenos Aires, Argentina, 9/6/2018

Minimal Residual Disease: What method? When and how to interpret results?, FUNDALEU, Buenos Aires, Argentina, 9/6/2018

New drugs and applications in MDS and AML, FUNDALEU, Buenos Aires, Argentina, 9/6/2018

Current and future therapy of MDS, Argentinian Society of Hematology, Buenos Aires, Argentina, 9/7/2018

Guillermo Garcia-Manero. Problems Ahead in MDS: What is Next?, Society of Hematologic Oncology, Houston, TX, 9/12/2018

Immunotherapy in AML, Doctaforum Medical Events, Madrid, Spain, 9/28/2018

Acute Myeloid Leukemia, Lebanese Society of Hematology and Blood Transfusion, Beirut, Lebanon, 10/6/2018

Kim ST, Tayar JH, Lu H, Suarez-Almazor M, Wang J, Gibbons, DL, Garcia-Manero G, Hwu P, Diab A, Nurieva R. Poster Presentation: Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients immune related arthritis, SITC, Washington, DC, 11/9/2018

Guillermo Garcia-Manero. Hematologia, ASOFARMA, Miami, FL, 3/23/2019

Biology and staging systems, Hikma Cancer Network, Lisbon, Portugal, 4/11/2019

Management of Lower-risk MDS, Hikma Cancer Network, Lisbon, Portugal, 4/11/2019

Biology and Staging Systems, Eurasian Hematology and Oncology Summit, Istanbul, Turkey, 4/13/2019

Management of Lower-risk MDS, Eurasian Hematology Oncology Summit, Istanbul, Turkey, 4/13/2019

Combining Hypomethylation Drugs and Immune Check Point Inhibitors, MDS Foundation, Copenhagen, Denmark, 5/10/2019

Long Term Survival Results and prognostic Factors of Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) Treated with Guadecitabine, MDS Foundation, Copenhagen, Denmark, 5/11/2019

Do We Know How to Use Hypomethylating Agents in Myeloid Disorders?, 2019 ASCO Annual Meeting, Chicago, IL, 5/31/2019

Incorporating immunotherapy in AML, FUNDALEU, Buenos Aires, Argentina, 6/6/2019

New genetic and molecular markers for the diagnosis and prognosis of AML, FUNDALEU, Buenos Aires, Argentina, 6/6/2019

Treatment directed at AML: Induction, consolidation, and maintenance, FUNDALEU, Buenos Aires, Argentina, 6/6/2019

Relevance of Measurable Residual Disease. What's the chosen method in 2019?, FUNDALEU, Buenos Aires, Argentina, 6/7/2019

Emerging Utility of immune Checkpoint Inhibitors in Myelodysplastic Syndromes, 24th Congress of the European Hematology Association, Amsterdam, Netherlands, 6/13/2019

Data on Treatment Options of Myelodysplastic Syndromes, AmerisourceBergen, Xcenda, Las Vegas, NV, 6/22/2019

MDS State of the Art Update: Emerging Targeted Therapeutics for MDS, Society of Hemtologic Oncology, Houston, TX, 9/12/2019

Next Questions: Myelodysplastic Syndromes, Society of Hematologic Oncology, Houston, TX, 9/14/2019

Clinical development of epigenetic modifiers in human leukemia, Josep Carreras Leukemia Research Institute, Barcelona, Spain, 9/20/2019

Update on AML Management in 2019, The Regional Academy for Clinical Hematology, Beirut, Lebanon, 9/21/2019

State of the art Updatein MDACC: Emerging Targeted Therapeutics for MDS, Society of Hematologic Oncology, Rome, Italy, 9/25/2019

Breakfast with the Expert: State of the art of MDS in MDACC, Society of Hematologic Oncology, Rome, Italy, 9/26/2019

Targeting apoptosis in Melodisplastic sindromes, MD Anderson Cancer Center Madrid, MD Anderson Cancer Center Fundacion Espana, Madrid, Spain, 10/4/2019

Breaking Myelodysplastic Syndrome, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz, Madrid, Spain, 11/21/2019

NPM1 mutations define a specific subgroup of MD and MDS/MPN patients with favorable outcomes and intensive chemotherapy, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz, Madrid, Spain, 11/21/2019

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine, 61st American Society of Hematology Annual Meeting, Orlando, FL, 12/9/2019

Myelodysplastic Syndromes, Hematologic Malignancies Demystified, prIME Oncology and Medscape, LLC, Chicago, IL, 1/11/2020

Myelodysplastic Syndromes, Hematologic Malignancies Demystified, prIME Oncology and Medscape, LLC, New York, NY, 1/18/2020

Myelodysplastic Syndromes, Hematologic Malignancies Demystified, prIME Oncology and Medscape, LLC, Atlanta, GA, 1/25/2020

Myelodysplastic Syndromes, Hematologic Malignancies Demystified, prIME Oncology and Medscape, LLC, Houston, TX, 2/1/2020

MDS KOL Case Study Workshop, Bristol-Myers Squibb, Maimi, FL, 2/26/2020

Reblozyl MDS General Session, Bristol-Myers Squibb, Miami, FL, 2/26/2020

What's in the pipeline?, MDS Foundation, Tel Aviv, Israel, 3/5/2020

Personalized Treatment in MDS, European School of Oncology, 6/5/2020

Novel Treatments for MDS I, Medco, EHA, 6/18/2020

Tratamiento contemporáneo de los síndromes mielodisplásicos, Agrupación Mexicana para el Estudio de la Hematología A.C., 6/24/2020

Acute Leukemia Webinar I, FUNDALEU, 6/25/2020

Biology and Staging Systems, Eurasian Hematology Oncology Group, 6/27/2020

Management of Lower-Risk MDS, Eurasian Hematology Oncology Group, 6/27/2020

Treatment of Higher-Risk MDS, Novartis, Aptitude Health, 7/13/2020

Treatment of Lower-Risk MDS and Role of Inflammation, Novartis, Aptitude Health, 7/13/2020

Therapies to bring resistant acute leukemia into HSCT, European Society for Blood and Marrow Transplantation, 8/29/2020

Future of MDS, Le 11ème Congrès d'Oncologie Francophone & the 8th Lebanese Gynecologic Oncologic Group, 8/31/2020

Development of Oral HMAs For MDS, SOHO, Houston, TX, 9/9/2020

Next Questions: Myelodysplastic Syndromes, SOHO, Houston, TX, 9/12/2020

Myelodysplastic Syndromes: State of the art in USA - Emerging frontline HMA based regimens, SOHO - 2nd Italian Conference, 9/24/2020

Oral Therapies in MDS, DoctaForum and MD Anderson Cancer Center Madrid, MD Anderson Cancer Center Fundacion Espana, 9/24/2020

Immunotherapy approaches in MDS, DoctaForum and MD Anderson Cancer Center Madrid, MD Anderson Cancer Center Fundacion Espana, 9/25/2020

COVID 19 Session Presentation, DoctaForum and MD Anderson Cancer Center Madrid, MD Anderson Cancer Center Fundacion Espana, 9/26/2020

Advanced therapy in MDS, Japanese Society of Hematology, 10/11/2020

SOHO Updates on AML, Eurasian Hematology Oncology Group, 10/23/2020

SOHO Updates on MDS, Eurasian Hematology Oncology Group, 10/23/2020

Myelodysplastic syndrome Current treatment first line and refractory to hypomethylating, National Cancer Institute - Mexico, 10/28/2020

State of the Art & Next Questions: Myelodysplastic Syndromes, Society of Hematologic Oncology, 10/28/2020

Deconstructing MDS @ The Inaugural Edward P. Evans Seminar in MDS, Dana-Farber Cancer Institute & The Jimmy Fund, 11/19/2020

Treatment of MDS in 2021 - An ASH Update, Hematologic Malignancies Demystified 2021, Medscape Oncology, 1/30/2021

Clinical Update In Myelodysplastic Syndromes, 25th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas, 2/28/2021

Treatment in Patient Refractory to Hypomethylants, Grupo Espanol de Sindromes Mielodisplasicos, XI Reunion anual GESMD, 3/4/2021

The Best of ASH in Myelodysplastic Syndromes, Agrupación Mexicana para el Estudio de la Hematología A.C., 3/10/2021

Update Treatment MDS: New Agents, Puerto Rico Hematology and Medical Oncology Association, 3/14/2021

Update Treatment MDS: New Agents, Puerto Rico Hematology and Medical Oncology Association, 3/14/2021

MDS Panel, NCCN Myelodysplastic Syndromes Panel, National Comprehensive Cancer Network (NCCN), 4/5/2021

Advances in MDS, Mumbai Hematology Group, 5/8/2021

The future treatments for MDS patients, Sheba City of Health, Israeli Society of Hematology, 5/26/2021

A PHASE 1, DOSE ESCALATION TRIAL WITH NOVEL ORAL IRAK4 INHIBITOR CA-4948 IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELOYDYSPLASTIC SYNDROME – INTERIM REPORT, European Hematology Association (EHA), 6/11/2021

Novel targets in MDS, European Hematology Association (EHA), 6/16/2021

How I Treat MDS, Infomed, 10th Hematology Course, 7/2/2021

Therapeutic Progress in MDS and AML, 9th InterAmerican Oncology Conference, 7/10/2021

MDS/AML: Current treatment options for elderly patients, Philippine College of Hematology and Transfusion Medicine, 9/7/2021

MDS/AML: Maintenance therapy in AML, Philippine College of Hematology and Transfusion Medicine, 9/7/2021

Session II: Myelodysplastic Syndromes, SOHO, 9/8/2021

Use of Oral Hypomethylating Agents in MDS, SOHO, 9/8/2021

Next Questions: Myelodysplastic Syndromes, SOHO, 9/11/2021

Molecular Target in AML, ASH-SAH Joint Symposium, 9/24/2021

Debate: Personalized therapy Is ready for prime time in MDS, 16th International Congress on Myelodysplastic Syndromes (MDS 2021), 9/25/2021

Personalized therapy is ready for prime time in MDS, MDS 2021 Symposium, 9/25/2021

Immunotherapy in Myelodysplastic Syndromes, MD Anderson Madrid, 9/30/2021

1º Curso Práctico Manejo de los nuevos agentes en LMA (Plazas limitadas) - Moderator, MD Anderson Madrid Acute Leukemia Meeting, 10/1/2021

Incorporación de inhibidores de Bcl-2 en los SMD, MD Anderson Madrid Acute Leukemia Meeting, 10/1/2021

Nuevas opciones terapéuticas en los pacientes de alto riesgo, ¿es el momento de las terapias combinadas?, 63rd Annual Meeting of the Spanish Society of Hematology and Haemotherapy and 37th National Congress of the Spanish Society of Thrombosis and Haemostasis, 10/16/2021

Maintenance Therapy in AML, Bristol Myers Squibb - Chile, 10/26/2021

Therapeutic alternatives in high-risk myelodysplasia, XXV Argentine Congress of Hematology, 10/27/2021

Hypomethylating agents in AML, National Congress of Hematology, Mexican Group for the Study of Hematology, 10/29/2021

New challenges in therapeutic approach of High Risk Myelodysplastic Syndromes: therapies in combination and targeting molecular targets, Andalusian Group Myelodysplastic Syndromes, 11/19/2021

Myelodysplasia Syndrome, Mumbai Hematology Group, 1/25/2022

Impact of Cytopenias in Low-Risk Myelodysplastic Syndromes, XII Reunion Anual GESMD, Spanish Group of Myelodysplastic Syndromes, Madrid, Spain, 5/5/2022

Other, Including Scientific Exhibitions

DNA-Topoisomerase II In Hematological Malignancies, The Cardeza Foundation For Hematologic Research, Thomas Jefferson Medical University, Philadelphia, PA, 10/12/1993

Approach to the Treatment of AML, The Cardeza Foundation For Hematologic Research,, Thomas Jefferson Medical University, Philadelphia, PA, 6/11/1997

Treatment of AML, The Cardeza Foundation For Hematologic Research, Thomas Jefferson Medical University, Philadelphia, PA, 10/20/1998

Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The MD Anderson Cancer Center experience, ASCO 2009 Annual Meeting, Orlando, FL, 5/28/2009

Verma D, Kantarjian H, Jones D, Borthakur G, Garcia-Manero G, Thomas DA, Verstovsek S, Rios M, Cortes J. Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance, ASCO 2009 Annual Meeting, Orlando, FL, 5/28/2009

Naqvi K, Oh J, Garcia-Manero G, Pierce S, Suarez-Almazor ME. Comorbidities and prognosis of myelodysplastic syndromes, ASCO 2009 Meeting Annual, Orlando, FL, 5/28/2009

Batty G, Kantarjian H, Issa JJ, Garcia-Manero G, Pierce S, O'Brien S, Jabbour E, Cortes J, Ravandi F. Feasibility of hypomethylating therapy in patients with renal insufficiency, ASCO 2009 Annual Meeting, Orlando, FL, 5/28/2009

Ravandi-Kashani F, Cortes J, Faderl S, Jones D, Byrd A, Brandt M, Garcia-Manero G, Levis M, Andreeff M, Kantarjian H. Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML), ASCO 2009 Annual Meeting, Orlando, FL, 5/28/2009

Jabbour E, Faderl S, Ravandi F, Konopleva M, Verstovsek S, Cortes J, Wierda W, Newsome WM, Yang H, Kantarjian H, Garcia-Manero G. Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), ASCO 2009 Annual Meeting, Orlando, FL, 5/28/2009

Sampat KR, Garcia-Gutierrez V, Rossi A, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia, ASCO 2009 Annual Meeting, Orlando, FL, 5/28/2009

E. Laille, R. Ward, A. Nasser, M. Stoltz, C. Cogle, S. Gore, B.S. Skikne, G. Garcia-Manero. The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML), ASCO 2009 Annual Meeting, Orlando, FL, 5/28/2009

How Do I Approach MDS?, Hematology/Oncology Education Conference, Mayo Clinic, Scottsdale, AZ, 3/24/2011

What to Make of All the MDS Prognostic Systems, Aplastic Anemia and MDS International Foundation, Third Bone Marrow Failure Disease Scientific Symposium, Bethesda, MD, 3/22/2012

Personalization of Therapy for MDS: The Role of Biology, Risk Stratification, and Evolving Therapies, NCCN 7th Annual Congress: Hematologic Malignancies, New York, NY, 9/14/2012

How I treat higher-risk MDS, Hikma Cancer Network, Dead Sea, Jordan, 4/12/2013

Actualizacion en el manejo de la lma del anciano, Sociedad Espanola de Hematologia y Hemoterapia, Madrid, Spain, 6/25/2014

How Cardeza helped me focus on MDS and AML, Cardeza 75th Anniversary, Thomas Jefferson University, Philadelphia, PA, 9/18/2014

Update on MDS Research, MDS Research Summit, The Edward P. Evans Foundation, Philadelphia, PA, 9/20/2014

Manejo actual en Mielodisplasia. Revision & MESA REDONDA: Eleccion Terapeutica en SMD: Como, Cuando y A quien?, Asociacion Mexicana de Sindrome Mielodisplasico, A.C., Simposio Iberoamericanode Sindrome Mielodisplasico, Puerto Vallarta, Mexico, 10/30/2014

Hematology Demystified: Update on MDS, prIME Oncology, Houston, 2/3/2018

International Bone Marrow Failure Disease Scientific Symposium, Aplastic Anemia and MDS International Foundation, Rockville, MD, 3/2018

How I treat higher-risk MDS, Hikma Cancer Network, Dead Sea, Jordan, 4/12/2018

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant, ASCO, Chicago, IL, 6/3/2018

Meaningful Patient-Reported Outcomes – how to learn from real-life experience in clinical research, EHA, Stockholm, Sweden, Sweden, 6/16/2018

Myelodysplastic Syndromes, Lebanese Society of Hematology and Blood Transfusion, Beirut, Lebanon, 10/6/2018

Updates in MDS and AML, 9th Annual Clinical Update in Hematology, Abu Dhabi, United Arab Emirates, 11/17/2018

Hematologic Malignancies Demystified: Myelodysplastic Syndromes, prIME Oncology, Atlanta, GA, 1/26/2019

Hematologic Malignancies Demystified: Myelodysplastic Syndromes, prIME Oncology, Houston, TX, 2/2/2019

New questions in MDS, Global Academic Programs Conference: Innovation & Collaboration to Transform Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/30/2019

Development of an Oral Hypomethylating Agent (ASTX727) as a Fixed Dose Combination (FDC) of Decitabine and CDA Inhibitor Cedazuridine, MDS Foundation, Copenhagen, Denmark, 5/9/2019

Clinical Case Reviews Acute Leukemias: Unusual cases and rare leukemias, MD Anderson Cancer Center Madrid, MD Anderson Cancer Center Fundacion Espana, Madrid, Spain, 10/5/2019

Landscape of MDS Therapy, Novartis, Aptitude Health, 7/13/2020

Seminar Invitations from Other Institutions

Acute myelogenous leukemia. Immunotherapy and Cytoprotection, Wake Forest University School of Medicine, Winston-Salem, NC, 11/1/1998

Treatment alternatives for patients with chronic phase CML, Thomas Jefferson University, Philadelphia, PA, 3/13/2001

DNA methylation in acute lymphocytic leukemia, Thomas Jefferson University, Philadelphia, PA, 3/14/2001

Advances in Leukemia, INTEGRIS Bass Baptist Health Center, Enid, OK, 10/1/2002

DNA methylation in hematological malignancies: clinical implications, Hospital Universitario Son Dureta, Palma de Mallorca, Spain, 12/19/2002

Epigenetic therapy of leukemia, University of Navarra, Pamplona, Spain, 3/5/2003

Epigenetic alterations in leukemia, Hospital del Mar, Center for Genomic Regulation, Barcelona, Spain, 6/16/2003

Advances in the Treatment of Chronic Myelogenous Leukemia, INTEGRIS Bass Baptist Health Center, Enid, OK, 11/7/2003

New Advances in the Treatment of CML, New Mexico Oncology Hematology, Albuquerque, NM, 2/24/2004

An approach to the patient with MDS, West Palm Beach VA Hospital, West Palm Beach, FL, 11/4/2004

Advances in Acute Lymphocytic Leukemia, St. Vincent Hospital Cancer Center, Santa Fe, NM, 11/30/2004

New approaches to the treatment of the acute lymphocytic leukemia, Duke University, Department of Hematology/Medical Oncology, Durham, NC, 1/18/2005

Advances in Chronic Myelogenous Leukemia, West Palm Beach VA Medical Center, West Palm Beach, FL, 2/10/2005

New approaches to the treatment of the acute lymphocytic leukemia, Medical University of South Carolina, Charleston, SC, 2/11/2005

New approaches to the treatment of the acute lymphocytic leukemia, Northside Hospital, Atlanta, GA, 2/15/2005

Implementing epigenetic information in the treatment and prognosis of patients with leukemia, St. Luke's Episcopal Hospital, Milwaukee, WI, 8/11/2005

Treatment of myelodysplastic syndrome, Cook County Hospitals, Chicago, IL, 11/10/2005

Implications of epigenetic information in leukemia, Rush University, Chicago, IL, 1/26/2006

The role of epigenetic therapeutics in hematological malignancies, Marquette General Hospital, Marquette, MI, 4/7/2006

Epigenetic alterations in leukemia: prognostic and therapeutic implications, Ingalls Hospital, Harvey, IL, 4/17/2006

Implications of aberrant DNA methylation in acute lymphocytic leukemia, Central Baptist Hospital Weekly Tumor Board, Lexington, KY, 6/23/2006

Advances in the Treatment of MDS, Kansas City Round Table of Hematology/Oncology, Kansas City, MO, 8/28/2006

Current treatment options for myelodysplastic syndromes, West Virginia University School of Medicine, Charleston, WV, 8/28/2006

Epigenetic Therapy of Leukemia/MDS, Washington University at St. Louis School of Medicine, St. Louis, MO, 9/16/2006

Update on MDS, Presbyterian Hospital of Dallas, Dallas, TX, 11/21/2006

Update on myelodysplastic syndrome, LBJ Hospital, Houston, TX, 12/21/2006

Epigenetic Therapy of Leukemia, Hollings Cancer Center Seminar, Medical University of South Carolina, Charleston, SC, 1/19/2007

Advances in MDS, St. Mary's Health Center, St. Louis, MO, 2/1/2007

Advances in MDS, Washington University School of Medicine, St. Louis, MO, 2/1/2007

Clinical development of histone deacetylase inhibitors, Janssen Pharmaceutica NV Headquarters, Antwerp, Belgium, 2/12/2007

Advances in the Treatment of MDS, University of Kentucky, Lexington, KY, 2/23/2007

Current treatment options for myelodysplastic syndromes, University of Louisville, Louisville, KY, 2/23/2007

Advances in the treatment of MDS, John B. Amos Cancer Center, Georgia Cancer Foundation, Columbus, GA, 3/20/2007

Treatment update on MDS, Central Utah Clinic, Provo, UT, 4/5/2007

Treatment update on MDS, Colorado Hematology Oncology, Englewood, CO, 4/13/2007

Estado actual del tratamiento de los síndromes mielodisplásicos, Hospital Universitario, Son Dureta Palma Mallorca, Spain, 7/13/2007

Current Treatments for MDS, University of New Mexico, Cancer Research and Treatment Center, Albuquerque, NM, 9/13/2007

MDS Updates, Virginia Mason Medical Center, Hematology/Oncology Group, Seattle, WA, 9/27/2007

Current Treatments for MDS, University of Arizona Medical School, Arizona Cancer Center, Tucson, AZ, 10/12/2007

Update on treatment of MDS and CML management, Hahnemann University, Philadelphia, PA, 10/24/2007

Update on MDS at The University of Texas MD Anderson Cancer Center, University of Sevilla, Hospital Virgen del Rocio, Sevilla, Spain, 11/29/2007

Epigenetic therapy of leukemia, Hematology Oncology Grand Rounds, University of Maryland, Baltimore, MD, 12/17/2007

Advances in MDS, Southern Cancer Center, Mobile, AL, 1/28/2008

Advances in MDS, MD Anderson Cancer Center, Orlando, FL, 2/21/2008

Targeting Chromatin in Hematologic Malignancies, Emory University, Winship Cancer Institute, Atlanta, GA, 3/20/2008

Update on MDS, Ochsner Clinic Foundation, New Orleans, LA, 4/22/2008

Incorporating epigenetic information in leukemia care, Moffitt Cancer Center, Tampa, FL, 5/5/2008

Progress in MDS, Comanche Hospital, Lawson, OK, 9/9/2008

Using Epigenetic Information in Leukemia, Hematology Oncology Grand Rounds, University of Colorado, Aurora, CO, 9/30/2008

Progress in MDS, Hematology Oncology Grand Rounds, Tufts University, Boston, MA, 10/15/2008

Progress in MDS, Tumor Board, St. Lukes Hospital, Hematology Oncology, Milwaukee, WI, 11/7/2008

Progress in MDS, Medical College of Wisconsin Cancer Center Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 11/8/2008

Update in MDS, Medical College of Vizcaya, Bilbao, Spain, 3/27/2009

MDS: Classification, Genetics and Chromatin, Memorial Sloan-Kettering Cancer Center, Hematology/Oncology Grand Rounds, New York, NY, 6/30/2009

Enhancing (Incorporating) HDACi in leukemia, Northwestern University, Barnes-Jewish Hospital Siteman Cancer Center, St. Louis, MO, 8/27/2009

MDS: Tailoring Treatment to Optimize Patient Outcomes, CHRISTUS, Clinical Care Options, Spohn Cancer Center, Corpus Christi, TX, 10/6/2010

The Latest Therapies for MDS, Cancer Institute Grand Rounds, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, 9/23/2011

Introduction to MDS, University of Texas, Houston, Medical School, Oncology Student Association, Houston, TX, 1/6/2016

Breaking MDS, Memorial Sloan Kettering Cancer Center, New York, NY, 9/18/2018

Pursuing a Career in Oncology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 1/28/2019

Update on Myelodysplastic Syndromes, Mayo Clinic, Division of Hematology & Oncology, Scottsdale, AZ, 2/15/2019

Fellows' Visiting Professor for 2019 - Deconstructing MDS, Mayo Clinic Rochester, Division of Hematology, Rochester, MN, 4/25/2019

Breaking MDS, NIH, National Heart, Lung, and Blood Institute's Fellowship Hematology Conference, Bethesda, MD, 9/4/2019

Epigenetic malignant modification, is this reversible?, Baylor St. Luke's Medical Center, Houston, TX, 11/2/2019

NGS vs flow cytometry, or both? For MRD, Baylor St. Luke's Medical Center, Houston, TX, 11/2/2019

Progress in MDS, The University of Texas MD Anderson Cancer Center, Leukemia, Houston, TX, 2/19/2020

Basic Concepts of MDS, Yale University, 6/2/2020

Future Approaches to Treatment of MDS, Yale University, 6/2/2020

High Risk Hematology Conference Series: MDS, Baylor College of Medicine, 11/3/2020

Case based lecture on Novel agents for LR-MDS, Third Annual DLDDCC/BSLMC Hematologic Malignancies Symposium, Baylor College of Medicine, 3/13/2021

Myelodysplastic Syndromes, Advances in Hematology: 2021 Evidence Updates program, Georgia Cancer Specialists, 3/20/2021

Update on the MDS-AML Moon Shot, The University of Texas MD Anderson Cancer Center, Leukemia, Houston, 8/4/2021

Lectureships and Visiting Professorships

Cancer of the Prostate, UT Houston Health Science Center, Houston, TX, 10/20/2000

An Overview of Breast Cancer from the Oncologist's Perspective, UT Houston Health Science Center, Houston, TX, 10/31/2000

Aberrant DNA methylation in pediatric and adult ALL, Grand Rounds, UT MD Anderson Cancer Center, Pediatrics, Houston, TX, 4/2/2001

Aberrant methylation in acute leukemia: Therapeutic implications, UT MD Anderson Cancer Center, Sarcoma, Houston, TX, 4/10/2001

DNA-methylation in lymphoid malignancies, First Myeloma Retreat, UT MD Anderson Cancer Center, Blood and Marrow Transplantation, Houston, TX, 9/22/2001

Aberrant methylation in acute leukemia: Therapeutic implications, UT MD Anderson Cancer Center, Sarcoma, Houston, TX, 10/9/2001

Leukemia, lymphoma and multiple myeloma, UT Houston Health Science Center, Houston, TX, 1/31/2002

Phase I Study of Dose Escalation Idarubicin with Amifostine and High-Dose ara-C, Mortality Conference, UT MD Anderson Cancer Center, Hematology, Houston, TX, 2/13/2002

Phase I Study of Dose Escalation Idarubicin with Amifostine and High-Dose ara-C, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 4/13/2002

Molecular Epigenetics of Leukemia: clinical implications, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 11/5/2002

Mortality Cases, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 3/26/2003

Epigenetic alterations in leukemia: clinical implications, BIT Clinical Meeting, UT MD Anderson Cancer Center, Houston, TX, 5/2/2003

Epigenetic Alterations in Leukemia: Prognostic and Therapeutic Implications, Division of Cancer Medicine Grand Rounds, UT MD Anderson Cancer Center, Houston, TX, 5/6/2003

Hypomethylating agents, Advanced Leukemia Practitioner Journal Club, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 6/1/2003

Azacitidine, Advanced Leukemia Practitioner Journal Club, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 6/5/2003

Epigenetic therapy in leukemia, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 6/2/2004

Epigenetic Alterations in Leukemia: Prognostic and Therapeutic Implications, Grand Rounds, Memorial Sloan Kettering Cancer Center, Hematology and Medical Oncology, New York, NY, 6/14/2004

Acetylation Properties of Valproic Acid, Phase I Program Weekly Meeting for Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX, 8/30/2004

Molecular pathogenesis of ALL, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 10/8/2004

p57KIP2 expression as a prognostic marker in adult ALL, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 10/14/2004

An epigenetic approach to the treatment and prognosis of patients with leukemia, Grand Rounds, Thomas Jefferson University, Cardeza Foundation Hematology, Philadelphia, PA, 11/9/2004

JunB expression in CML, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 11/11/2004

Use of 5-azacytidine in myelodysplastic syndrome, Grand Rounds, Christus- Schrumper Hospital, Hematology Oncology, Shreveport, LA, 5/9/2005

Implementing epigenetic information in the treatment and prognosis of patients with leukemia, Grand Rounds, University of Wisconsin, Hematology/Oncology, Madison, WI, 8/10/2005

Integrating epigenetic information in the prognosis and treatment of patients with leukemia, Hematology Grand Rounds, UT MD Anderson Cancer Center, Houston, TX, 8/31/2005

Introduction to MDS, UT Houston Medical School, Internal Medicine Program, Houston, TX, 12/19/2005

Epigenetic Therapy, Hematology Grand Rounds, UT MD Anderson Cancer Center, Houston, TX, 2/22/2006

HDAC's and leukemia, Institutional Grand Rounds, UT MD Anderson Cancer Center, Houston, TX, 2/24/2006

Clinical experience with hypomethylating agents, The Johns Hopkins University School of Medicine, Baltimore, MD, 6/2/2006

Epigenetic changes in leukemia, Relapsed Leukemia in Adolescents/Young Adults: Advancing Therapy, UT MD Anderson Cancer Center, Houston, TX, 10/24/2006

Update on myelodysplastic syndrome, UT Medical School at Houston, Houston, TX, 12/20/2006

The anti-leukemic activity of acetyl transferase inhibitors, Hematology Grand Rounds, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 1/3/2007

Epigenetic therapy of leukemia, Grand Rounds, Duke University Medical Center, Hematology/Oncology, Durham, NC, 1/5/2007

Treatment of MDS, Baylor College of Medicine, Houston, TX, 3/2/2007

Update in the management of myelodysplastic syndrome, Christus Spohn Cancer Center Lectureship Series, Texas A & M Health Science Center Coastal Bend Health Education Center, Corpus Christi, TX, 6/12/2007

Update in the management of myelodysplastic syndrome, Texas A & M Health Science Center, Coastal Bend Health Education Center, Corpus Christi, TX, 6/27/2007

The MDS Program, Leukemia, UT MD Anderson Cancer Center, Houston, TX, 8/1/2007

Myelodysplastic Syndrome, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 9/19/2007

Manipulating epigenetic repression in leukemia, Institutional Grand Rounds, UT MD Anderson Cancer Center, Houston, TX, 9/21/2007

Current Treatments for MDS, The University of Texas Southwestern, Simmons Cancer Center, Dallas, TX, 10/4/2007

Update on Treatment of MDS, Grand Rounds, Thomas Jefferson University, Cardeza Foundation Hematology, Philadelphia, PA, 10/23/2007

Myelodysplastic Syndromes, UT MD Anderson Cancer Center, Houston, TX, 1/12/2008

An approach to the treatment of MDS, Grand Rounds, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, 2/6/2008

Using epigenetic information in leukemia, Hematology Grand Rounds, UT MD Anderson Cancer Center, Biochemistry and Molecular Biology Center for Epigenetics Research, Houston, TX, 3/28/2008

Some more on the epigenetics of leukemia, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 4/9/2008

Combination Epigenetic Therapy, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 4/18/2008

Management of Myelodysplasia at MD Anderson, Global Academic Programs Conference, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 6/5/2008

Progress in MDS, Division of Cancer Medicine Grand Rounds, UT MD Anderson Cancer Center, Houston, TX, 7/15/2008

Progress and problems in MDS, Hematology Grand Rounds, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 3/11/2009

Hematology Lecture on MDS for DoCM Fellows, UT MD Anderson Cancer Center, Houston, TX, 6/10/2009

Hematology/Oncology Educational Series, Baylor College of Medicine, Hematology/Oncology, Houston, TX, 6/19/2009

Working Groups in Chronic Myelogenous Leukemia: Key Issues in Primary Treatment, Evaluation, and Second-Line Therapy, CML Workshops, Clinical Care Options and Oncology Today, 2010

Update on MDS from ASH '09, Research Meeting, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 1/20/2010

MDS, Hematology Lecture Series, UT MD Anderson Cancer Center, Houston, TX, 2/3/2010

Myelodysplastic Syndromes, Washington Cancer Institute Oncology Grand Rounds, Washington Hospital Center, Washington, DC, 5/7/2010

Highlights from ASH (American Society of Hematology) 2010, Advances in Oncology Institutional Grand Rounds, UT MD Anderson Cancer Center, Leukemia, Houston, TX, 12/10/2010

An update on "epigenetic" therapy at MDACC, Center for Cancer Epigenetics, UT MD Anderson Cancer Center, Houston, TX, 6/17/2011

Molecular Alterations in Myelodysplastic Syndromes, Seminar Series, UT MD Anderson Cancer Center, Dept of Molecular & Cellular Oncology and Center for Biological Pathways, Houston, TX, 9/14/2011

Use of Epigenetic Information in Leukemia, Translational Science: From Bench to Bedside and Back, UT MD Anderson Cancer Center, Investigational Cancer Therapeutics, Houston, TX, 9/28/2011

Advances in Myelodysplastic Syndromes, Advances in Oncology Institutional Grand Rounds, UT MD Anderson Cancer Center, Houston, TX, 10/7/2011

Advances in Therapy of MDS, Grand Rounds, Massachusetts General Hospital, Cancer Center, Boston, MA, 12/19/2011

Innate immunity alterations in MDS, Grand Rounds, Albert Einstein College Medicine, Cancer Center, New York, NY, 3/7/2012

Innate Immunity Alterations of MDS, Hematology Fellowship Conference, NIH, NHLBI, Bethesda, MD, 8/15/2012

Update on MDS, The University of Texas Southwestern, Hematologic Malignancies, Dallas, TX, 2/5/2014

Leukemia Case Studies, MD Anderson Physicians Network, The University of Texas
MD Anderson Cancer Center, Provider Relations, Houston, TX, 2/18/2014

A Total Approach to Myelodysplastic Syndromes, Grand Rounds, The University of Texas
MD Anderson Cancer Center, Division of Cancer Medicine, Houston, TX, 1/6/2015

An Integrated Approach to MDS, Emil J Freireich Hematology Grand Rounds, UT MD Anderson
Cancer Center, Leukemia, Lymphoma/Myeloma, and Stem Cell Transplantation, Houston, TX,
3/9/2016

Treatment of MDS: An update from ASH 2016, Leukemia Research Meeting, UT MD Anderson
Cancer Center, Leukemia, Houston, TX, 3/23/2016

Molecular Bases Moleculares del Cáncer, Molecular Bases Moleculares del Cáncer, CENTRO DE
ESTUDIOS BIOSANITARIOS SL, Madrid, Spain, Spain, 1/9/2018

Review of MDS clinical trial portfolio at MDACC, Review of MDS clinical trial portfolio at MDACC,
MD Anderson Cancer Center, TX, 1/31/2018

Update on Treatment of Low Risk MDS, The Zeev Estrov Leukemia Research Meeting, The
University of Texas MD Anderson Cancer Center, Houston, TX, 11/7/2018

Myelodysplastic Syndromes, Grand Rounds, Taiho Oncology, Princeton, NJ, 9/10/2019

Other Presentations at State and Local Conferences

Treatment of Breast Cancer, Clinical Pathological Conference, UT-Houston Medical School,
Houston, TX, 5/7/2001

Acute Myeloid Leukemia, International Conference of Hematology and Medical Oncology, UT
MD Anderson Cancer Center, Houston, TX, 5/17/2001

Chronic Lymphocytic Leukemia, International Conference of Hematology and Medical Oncology,
UT MD Anderson Cancer Center, Houston, TX, 5/17/2001

Leukemia: Clinical Trials, Windsor Village Cancer Symposium, Windsor Village, Houston, TX,
9/28/2002

New Advances in the Treatment of CML, Christus St. Elizabeth Hospital, Beaumont, TX,
1/27/2004

An epigenetic approach to the treatment of leukemia and myelodysplastic syndromes,
Hematology Oncology Grand Rounds, The Methodist Hospital, Houston, TX, 9/29/2004

Use of 5-azacytidine in myelodysplastic syndrome, TOPA, El Paso Cancer Treatment Center, El
Paso, TX, 10/13/2005

Valley Baptist Hospital Tumor Board Conference, Valley Baptist Hospital, Harlingen, TX,
2/28/2006

Updates on the Treatments in Myelodysplastic Syndromes, Tumor Board, Texas
Hematology/Oncology Center, PA, McKinney, TX, 5/19/2006

Updates on the treatments of myelodysplastic syndromes, Medical Center of McKinney,
McKinney, TX, 5/19/2006

Novel agents for management of MDS, Annual Meeting of the TOPA, Dallas, TX, 3/31/2007

Advances in MDS, Bayshore Hospital, Pasadena, TX, 4/19/2007

Update on MDS, Memorial Hospital Oncology Consultants, Houston, TX, 10/15/2007

Progress in MDS, Annual Meeting of the TOPA, Dallas, TX, 8/23/2008

Progress in MDS, Victoria Hospital, Victoria, TX, 11/12/2008

Problems in MDS, Michael E DeBakey VA Medical Center, Hematology Round, Houston, TX,
3/13/2009

MDS, Michael E. DeBakey VA Medical Center, Houston, TX, 3/2/2010

Risk Stratification and Treatment of Principles in AML, FHCRC Clinical Research Division Seminar, Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, 3/28/2011

Treatment of Myelodysplastic Syndromes (MDS) – Dacogen® (decitabine) for Injection, Eisai Dacogen® Speakers Bureau Meeting, Eisai, Eisai Dacogen® Speakers Bureau Program, Houston, TX, 8/8/2011

Translational implications of epigenetic information in leukemia, Center for Cancer Epigenetics Retreat, The University of Texas MD Anderson Cancer Center, Round Top, TX, 4/14/2012

Innate immunity alterations in MDS, Grand Rounds, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston, TX, 7/31/2012

Garcia-Manero G. Treatment of Myelodysplastic Syndromes (MDS), 2nd annual Physician Relations' Conference: "Medical Oncology and Hematology: Clinical and Scientific Approaches that Enhance Patient Outcomes," The University of Texas MD Anderson Cancer Center, Physician Relations, Houston, TX, 10/20/2012

Garcia-Manero, Guillermo. Innate Immunity Alterations in Myelodysplastic Syndrome (MDS), The Department of Experimental Therapeutics Seminar Series, The Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Experimental Therapeutics, Houston, TX, 11/28/2012

MDS-AML Moon Shot, Global Academic Programs 2013, UT MD Anderson Cancer Center, Houston, TX, 4/3/2013

Myelodysplastic Syndromes, Malignant Hematology Session, The 2014 Baylor College of Medicine/MD Anderson Cancer Center Hematology and Medical Oncology Board Review, Houston, TX, 9/12/2014

Oral presentations from ASH 2016, Emil J Freireich Hematology Grand Rounds, The University of Texas MD Anderson Cancer Center, 12/14/2016

What did I learn on MDS at ASH 2016, Emil J Freireich Hematology Grand Rounds, The University of Texas MD Anderson Cancer Center, 2/1/2017

Update on MDS clinical trials at MDACC, Leukemia Research Meeting, The University of Texas MD Anderson Cancer Center, 2/8/2017

Toward a Cure for Myelodysplastic Syndromes (MDS), The Division of Cancer Medicine Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/21/2017

MDS/AML Moon Shot: A Molecular Immunotherapy-Targeted Program, Advances in Oncology Institutional Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/31/2017

What is new and exciting in MDS, Global Academic Programs (GAP) 2019 Conference: Innovation & Collaboration to Transform Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/30/2018

Assessment and Management of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia, Leukemia Master Class, BioMedical Learning Institute, Dallas, TX, 10/19/2018

Management of Higher-risk Myelodysplastic Syndrome, Leukemia Master Class, BioMedical Learning Institute, Dallas, TX, 10/20/2018

Staging and Scoring Systems for Myelodysplastic Syndrome, Leukemia Master Class, BioMedical Learning Institute, Dallas, TX, 10/20/2018

Translational research in myelodysplastic syndromes, GSBS - Translational Sciences From Bedside to Bench and, The University of Texas MD Anderson Cancer Center, GI Medical Oncology, Houston, TX, 10/31/2018

Case based lecture on Novel therapies for low-risk MDS, First Baylor St. Luke's Medical Center Hematologic Malignancies Symposium, Baylor College of Medicine, Houston, TX, 11/3/2018

Deconstructing MDS, The Zeev Estrov Leukemia Research Meeting, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/19/2018

Deconstructing MDS, Leukemia Fellow Series, The University of Texas MD Anderson Cancer Center, Leukemia, Houston, TX, 1/9/2019

Breaking MDS, The Division of Cancer Medicine and Department of leukemia Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/15/2019

Myelodysplastic Syndromes, Hematological Malignancies Demystified, prIME Oncology, Houston, New York, Atlanta, 2/2019

High risk MDS/AML: A New Entity, Disease Area Educational Course on Acute Myeloid Leukemia, Hematology Oncology Learning Institute, Aptitude Health, Houston, TX, 3/20/2019

Understanding of Time-based Response Milestones and Monitoring in Patients with CML, New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia, CancerNet, LLC, Houston, TX, 4/27/2019

ASH MDS Update, Zeev Estrov Leukemia Research Meeting at MD Anderson Cancer Center, MD Anderson Cancer Center, Leukemia, Houston, TX, 12/18/2019

Therapies and Patient Treatment Options, MDS Patient & Family Forum, MDS Foundation, Houston, TX, 2/22/2020

Incorporating New Prognostic Scores in MDS into Clinical Trials, Acute Leukemias & Myeloproliferative Neoplasms, Dava Oncology, Dallas, TX, 2/29/2020

Progress in the treatment of MDS at MD Anderson Cancer Center, EnjoyScience Webinar Series, MD Anderson Cancer Center, 6/12/2020

MDS, Leukemia Fellow Lecture Series, MD Anderson Cancer Center, Leukemia, Houston, 9/23/2020

MDS Part 2, Leukemia Fellows Lecture Series, MD Anderson Cancer Center, Leukemia, Houston, 9/30/2020

Treatment of MDS in 2021 - An ASH Update, Emil J Freireich Hematology Grand Rounds, MD Anderson Cancer Center, Department of Leukemia, Lymphoma/Myeloma and Stem Cell Transplant, Houston, TX, 2/3/2021

Update on MDS, BCM Heme-Onc Fellows Program, Baylor College of Medicine, 2/11/2022

MDS at MDACC 2022, Hematology Grand Rounds, MD Anderson Cancer Center, 3/2/2022

Hematologic Malignancies Demystified: A Critical Appraisal of Data from 2017, prIME Oncology, prIME Oncology,

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

London Goodenough Trust, London, United Kingdom
Life Member, 1990-present

American Association for the Advancement of Science
Member, 1993-present

American Society of Hematology, Washington, DC
Member, 1997-present

Abstract Reviewer for Annual meeting, 2011

Manuscript Reviewer for ASH Education Program, 2013

Chair, Oral Abstract Session "Innate Immunity and Bone Marrow Failure States", 2015

Chair, Poster Walk 2, 2015

American Society of Clinical Oncology

Member, 1998-present

Jefferson Medical College Alumni Association

Member, 2000-present

American Association of Cancer Research

Member, 2001-present

Chair, Scientific Review Committee, 1/2009-present

Peruvian Society of Oncology

Honorary Member, 10/2003-present

The Aplastic Anemia and International Myelodysplastic Syndromes Foundation, NJ

Member, Steering Committee, 2007-present

Medical Advisory Board, 2010-present

American Medical Association (AMA) Foundation, Chicago, IL

Selection Committee, 1/2010-present

Society of Hematologic Oncology, Houston, TX

Educational Committee, 8/2013-8/2023

Institute of Health Research Palma, Palma, Mallorca, Spain

External Scientific Committee, 11/2014

European Hematology Association

Abstract Reviewer, 2015

Harvard Medical School Promotion Committee

Committee member, 11/2018-present

Society of Hematologic Oncology

President-Elect, 9/2023-8/2024

President, 9/2024-9/2025

Local/State

N/A

UNIQUE ACTIVITIES

1. Leader: Leukemia Activity for the Royal House of Abu Dhabi

2. Race Governor, Seabrook Sailing Club, Seabrook, TX

DATE OF LAST CV UPDATE

3/28/2022